

SECURITIES AND EXCHANGE COMMISSION

FORM 10-K

Annual report pursuant to section 13 and 15(d)

Filing Date: **2021-02-26** | Period of Report: **2020-12-31**  
SEC Accession No. [0001628908-21-000026](#)

[\(HTML Version on secdatabase.com\)](#)

FILER

**Evolut Health, Inc.**

CIK: **1628908** | IRS No.: **320454912** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
Type: **10-K** | Act: **34** | File No.: **001-37415** | Film No.: **21682328**  
SIC: **8741** Management services

Mailing Address  
800 NORTH GLEBE RD,  
SUITE 500  
ARLINGTON VA 22203

Business Address  
800 NORTH GLEBE RD,  
SUITE 500  
ARLINGTON VA 22203  
571-389-6000

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-K**

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the fiscal year ended December 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-37415

**Evolent Health, Inc.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or other jurisdiction of incorporation or organization)	<u>32-0454912</u> (I.R.S. Employer Identification No.)
<u>800 N. Glebe Road , Suite 500 , Arlington , Virginia</u> (Address of principal executive offices)	<u>22203</u> (Zip Code)

(571) 389-6000

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock of Evolent Health, Inc., par value \$0.01 per share	EVH	New York Stock Exchange

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  S

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No  S

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (based on the closing price of the shares on the New York Stock Exchange on such date) as of the last business day of the registrant's most recently completed second fiscal quarter was \$540.0 million.

As of February 22, 2021, there were 86,091,822 shares of the registrant's Class A common stock outstanding.

#### **Documents Incorporated by Reference**

Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for June 10, 2021, have been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2020.

**Evolent Health, Inc.**  
**Table of Contents**

<b><u>Item</u></b>	<b><u>Page</u></b>
<b><u>PART I</u></b>	
1. <a href="#">Business</a>	<a href="#">1</a>
1A. <a href="#">Risk Factors</a>	<a href="#">18</a>
1B. <a href="#">Unresolved Staff Comments</a>	<a href="#">41</a>
2. <a href="#">Properties</a>	<a href="#">41</a>
3. <a href="#">Legal Proceedings</a>	<a href="#">42</a>
4. <a href="#">Mine Safety Disclosures</a>	<a href="#">42</a>
<b><u>PART II</u></b>	
5. <a href="#">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a>	<a href="#">43</a>
6. <a href="#">Selected Financial Data</a>	<a href="#">44</a>
7. <a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	<a href="#">44</a>
7A. <a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	<a href="#">64</a>
8. <a href="#">Financial Statements and Supplementary Data</a>	<a href="#">65</a>
9. <a href="#">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a>	<a href="#">127</a>
9A. <a href="#">Controls and Procedures</a>	<a href="#">127</a>
9B. <a href="#">Other Information</a>	<a href="#">130</a>
<b><u>PART III</u></b>	
10. <a href="#">Directors, Executive Officers and Corporate Governance</a>	<a href="#">131</a>
11. <a href="#">Executive Compensation</a>	<a href="#">131</a>
12. <a href="#">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a>	<a href="#">131</a>
13. <a href="#">Certain Relationships and Related Transactions, and Director Independence</a>	<a href="#">131</a>
14. <a href="#">Principal Accounting Fees and Services</a>	<a href="#">131</a>
<b><u>PART IV</u></b>	
15. <a href="#">Exhibits, Financial Statement Schedules</a>	<a href="#">132</a>
16. <a href="#">Form 10-K Summary</a>	<a href="#">136</a>
<a href="#">Signatures</a>	<a href="#">137</a>

## Explanatory Note

In this Annual Report on 10-K, unless the context otherwise requires, “Evotent,” the “Company,” “we,” “our” and “us” refer to Evotent Health, Inc. and its consolidated subsidiaries. Evotent Health LLC, a subsidiary of Evotent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evotent Health, Inc. is a holding company.

As used in this Annual Report on Form 10-K:

- “ACA” means the Patient Protection and Affordable Care Act;
- “Accordion” means Accordion Health, Inc.;
- “accountable care organizations,” or “ACOs,” means organizations of groups of doctors, hospitals and other health care providers which have come together voluntarily to provide coordinated care to their Medicare patients;
- “ASO” means administrative services only, which refers to contracts with our partners wherein Evotent provides certain services on a fee-basis but does not assume responsibility for the cost of care;
- “Aldera” means Aldera Holdings, Inc.;
- “capitated arrangements” means health care payment arrangements whereby providers are paid a fixed amount of money per patient during a given period of time rather than on a per-service or per-procedure basis;
- “CMS” means the Centers for Medicare and Medicaid Services;
- “DGCL” means General Corporation Law of the State of Delaware;
- “EMR” means electronic medical records;
- “Evotent Health Holdings” means Evotent Health Holdings, Inc., the predecessor to Evotent Health, Inc.;
- “EVH Passport” means Justify Holdings, Inc., a subsidiary of the Company;
- “Exchange Act” means the Securities Exchange Act of 1934, as amended;
- “founders” means the Advisory Board Company (“The Advisory Board”), and the University of Pittsburgh Medical Center (“UPMC”);
- “FTC” means the United States Federal Trade Commission;
- “GAAP” means United States of America generally accepted accounting principles;
- “health insurance exchanges” means organizations that provide a marketplace for individuals to purchase standardized and government regulated health insurance policies;
- “HIPAA” means The Health Insurance Portability and Accountability Act;
- “HITECH Act” means The Health Information Technology for Economic and Clinical Health Act;
- “IPO” means our initial public offering of 13.2 million shares of our Class A common stock at a public offering price of \$17.00 per share in June 2015;
- “New Century Health” means NCIS Holdings, Inc.;
- “NMHC” means New Mexico Health Connections;
- “NYSE” means the New York Stock Exchange;
- “Offering Reorganization” means the reorganization undertaken in 2015 prior to our IPO where our predecessor, Evotent Health Holdings, Inc. merged with and into Evotent Health, Inc.;
- “partners” means our customers, unless we indicate otherwise or the context otherwise implies;
- “performance-based” means risk-based contracts with our partners wherein Evotent assumes financial responsibility for the cost of care, which may range from upside and downside gain share to all, or substantially all, of the responsibility for the cost of care within a defined scope subject to Evotent management controls and contractual protections;
- “pharmacy benefit management,” or “PBM,” means the administration of prescription drug programs, including developing and maintaining a list of medications that are approved to be prescribed, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers and processing prescription drug claim payments;

- “population health” means an approach to health care that seeks to improve the health of an entire human population;
- “SEC” means the Securities and Exchange Commission;
- “Securities Act” means the Securities Act of 1933, as amended;
- “third-party administration,” or “TPA,” means the processing of insurance claims or the administration of certain aspects of employee benefit plans for a separate entity;
- “True Health” means True Health New Mexico, Inc., a wholly-owned subsidiary of Evolent Health, Inc.;
- “TPG” means TPG Global, LLC and its affiliates including one or both of TPG Growth II BDH, LP and TPG Eagle Holdings, L.P.;
- “TRA” means the Income Tax Receivables Agreement. See “Part II – Item 8. Financial Statements and Supplementary Data - Note 14” for further details of the Tax Receivables Agreement;
- “UHC” means University Health Care, Inc d/b/a Passport Health Plan;
- “Valence Health” means Valence Health, Inc., excluding Cicerone Health Solutions, Inc.;

- “value-based care” means a health care management strategy that is focused on high-quality and cost-effective care with the goals of promoting a healthy lifestyle, enhancing the patient experience and reducing preventable hospital admissions and emergency visits; and
- “VIE” means variable interest entities.



## FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE

Certain statements made in this report and in other written or oral statements made by us or on our behalf are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: “believe,” “anticipate,” “expect,” “estimate,” “aim,” “predict,” “potential,” “continue,” “plan,” “project,” “will,” “should,” “shall,” “may,” “might” and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, trends in our businesses, prospective services, future performance or financial results and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.

These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements. Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:

- the significant portion of revenue we derive from our largest partners, and the potential loss, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;
- evolution in the market for value-based care;
- uncertainty in the health care regulatory framework, including the potential impact of policy changes;
- our ability to offer new and innovative products and services;
- risks related to completed and future acquisitions, investments, alliances and joint ventures, including the acquisition of assets from New Mexico Health Connections, and the acquisitions of Valence Health Inc., excluding Cicerone Health Solutions, Inc., Aldera Holdings, Inc., New Century Health, and Passport, which may be difficult to integrate, divert management resources, or result in unanticipated costs or dilute our stockholders;
- the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized;
- the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners’ plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;
- risks relating to our ability to maintain profitability for our total cost of care and New Century Health’s performance-based contracts and products, including capitation and risk-bearing contracts;
- our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;
- the potential negative impact of the COVID-19 pandemic and other public health emergencies;
- our ability to recover the significant upfront costs in our partner relationships;
- our ability to attract new partners and successfully capture new growth opportunities;
- the increasing number of risk-sharing arrangements we enter into with our partners;
- our ability to estimate the size of our target markets;
- our ability to maintain and enhance our reputation and brand recognition;
- consolidation in the health care industry;
- competition which could limit our ability to maintain or expand market share within our industry;
- risks related to governmental payer audits and actions, including whistleblower claims;
- our ability to partner with providers due to exclusivity provisions in our contracts;
- risks related to our offshore operations;

- our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;
- our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;
- the impact of additional goodwill and intangible asset impairments on our results of operations;
- our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing;
- our ability to achieve profitability in the future;
- the impact of litigation, including the ongoing class action lawsuit;
- additional material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;
- restrictions and penalties as a result of privacy and data protection laws;
- data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;
- restrictions and penalties as a result of privacy and data protection laws;
- adequate protection of our intellectual property, including trademarks;
- any alleged infringement, misappropriation or violation of third-party proprietary rights;

- our use of “open source” software;
- our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;
- our reliance on third parties and licensed technologies;
- our ability to use, disclose, de-identify or license data and to integrate third-party technologies;
- our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;
- our reliance on third-party vendors to host and maintain our technology platform;
- our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;
- our ability to utilize benefits under the tax receivables agreement described herein;
- our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;
- the terms of agreements between us and certain of our pre-IPO investors;
- the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash;
- the impact of the accounting method for convertible debt securities that may be settled in cash;
- the potential volatility of our Class A common stock price;
- the potential impact of our securities class action litigation;
- the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale;
- provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;
- the ability of certain of our investors to compete with us without restrictions;
- provisions in our second amended and restated certificate of incorporation which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and
- our intention not to pay cash dividends on our Class A common stock.

The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. More information on potential factors that could affect our businesses and financial performance is included in “Forward Looking Statements - Cautionary Language,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” or similarly captioned sections of this Annual Report and the other period and current filings we make from time to time with the SEC. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.

Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this report.

## **Market Data and Industry Forecasts and Projections**

We use market data and industry forecasts and projections throughout this Annual Report on Form 10-K, and in particular in “Part I - Item 1. - Business.” We have obtained the market data from certain publicly available sources of information, including publicly available independent industry publications and other third-party sources. Unless otherwise indicated, statements in this Annual Report on Form 10-K concerning our industry and the markets in which we operate, including our general expectations and competitive position, business opportunity and market size, growth and share, are based on information from independent industry organizations and other third-party

sources (including industry publications, surveys and forecasts), data from our internal research and management estimates. We believe the data that third parties have compiled is reliable, but we have not independently verified the accuracy of this information and there is no assurance that any of the forecasted amounts will be achieved. Any forecasts are based on data (including third-party data), models and experience of various professionals and are based on various assumptions, all of which are subject to change without notice. While we are not aware of any misstatements regarding the industry data presented herein, forecasts, assumptions, expectations, beliefs, estimates and projections involve risks and uncertainties and are subject to change based on various factors, including those described under the heading “Forward-Looking Statements - Cautionary Language” and in “Part I - Item 1A. Risk Factors.”

## PART I - FINANCIAL INFORMATION

### Item 1. Business

#### Market Opportunity

We are a market leader in the new era of value-based care, in which leading health systems and physician organizations, which we refer to as providers, as well as health plans, which we refer to as payers, are moving their business models from traditional fee-for-service (“FFS”) reimbursement to an increasingly integrated clinical and financial responsibility for populations. We refer to our provider and payer customers as partners. We consider this integration of health care delivery and financial responsibility with the aim of lowering cost, enhancing quality, and improving satisfaction, to be the core of value-based care. We believe the pace of this integration is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and innovation in data and technology.

The U.S. health care market is projected to approach \$4 trillion in spending during 2020, with less than half of payments tied to value-based care models. We believe the shift to value-based care is accelerating, driven by price pressure in traditional FFS health care, a policy and market environment that is incentivizing value-based care models and innovation in data and technology. We believe that the transition to value-based care is impacting the business models of both providers and payers in all segments of the market, including Medicare, Medicaid, and Commercial lines of business.

We believe providers are well-positioned to lead this transition to value-based care because of their control over large portions of health care delivery costs, their primary position with consumers, and their strong local brands. Providers operating successfully in value-based arrangements can diversify their revenue streams, capture superior economics, and improve the quality of care they provide.

We also believe payers who successfully evolve their business model from that of FFS reimbursement towards value-based care can gain meaningful competitive advantages. Payers who successfully integrate care delivery and financing with providers stand to gain market advantage as medical expenses for their populations are lowered while also quality of care is improved.

The transformation of provider and payer business models from FFS to value-based care requires infrastructure that performs two functions: (i) the ability to create clinical value, which is typically defined as lowering the cost of care while maintaining or improving quality, that is superior to FFS, and (ii) an administrative platform on which to operate the value-based business. In addition to this infrastructure, we believe that participants in value-based arrangements also need sustainable contractual mechanisms to enable each party to capture clinical value that is created and sufficient lives in value-based arrangements to provide a return on infrastructure investments.

#### Our Business

##### *Our History*

Evolent was founded in 2011 by members of our management team, UPMC, an integrated delivery system in Pittsburgh, Pennsylvania, and The Advisory Board Company, to enable providers to pursue a value-based business model and evolve their competitive position and market opportunity. Since that time, we have grown both organically and through acquisitions. On February 1, 2016, the Company entered into a strategic alliance with UHC. In October 2016, we acquired Valence Health. Valence Health, based in Chicago, Illinois, was founded in 1996 and provides TPA services, value-based administration, population health and advisory services with a particular focus on the Medicaid and pediatric markets. On November 1, 2016, the Company completed the acquisition of Aldera, a key vendor and the primary software provider for the Valence Health TPA platform. In January 2018, we acquired a commercial health plan in New Mexico

that focuses on small and large businesses, True Health. In October 2018, we acquired New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under performance-based arrangements, focused primarily on oncology and cardiovascular care.

On December 30, 2019, we closed a transaction whereby EVH Passport acquired substantially all of the assets and assumed substantially all of the liabilities of UHC (the “Passport Closing”), including UHC’s Medicaid contract (the “Passport Medicaid Contract”) with the Kentucky Cabinet for Health and Family Services (“CHFS”). UHC was our largest partner in terms of revenue in 2019 and 2018, representing 18.7% and 17.5% of our revenues for such years, respectively. In connection with the Passport Closing, EVH Passport issued a 30% equity interest in EVH Passport, in the aggregate, to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the “Sponsors”).

On July 16, 2020, EVH Passport and Evolent Health LLC entered into an Asset Purchase Agreement (the “Molina APA”) with Molina Healthcare, Inc. (“Molina”), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s rights under the Passport Medicaid Contract with CHFS. On September 1, 2020, EVH Passport and Molina completed the closing of the transactions contemplated by the Molina APA (the “Molina Closing”), and the Passport Medicaid Contract was novated to Molina. Following the Molina Closing, EVH Passport redeemed the Sponsors’ equity interests in EVH Passport in accordance with the terms of EVH Passport’s Stockholders’ Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company. In addition, following the Molina Closing, EVH Passport began to wind down its business.

On January 11, 2021, Evolent Health LLC, EH Holding Company, Inc. (“EH Holdings”) and True Health, each wholly owned subsidiaries of the Company, agreed to sell True Health to Bright Health Management, Inc. Though we cannot predict the certainty or timing of closing, we expect the transaction to close in the first half of 2021, subject to satisfaction of customary closing conditions, including regulatory approvals.

During 2020, we managed our operations and allocated resources across two reportable segments, our Services segment and our True Health segment. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company will bifurcate its Services segment into two reportable segments as follows:

- Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and
- Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands.

### *Services Overview*

Our services segment includes clinical and administrative solutions designed to help our customers manage and administer patient health in a more cost-effective manner. We have two clinical solutions: (i) total cost of care management, and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one type of solution, or multiple types of solutions, depending on specific needs.

Core elements of our total cost of care management services include: (i) Identifi®, our proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients, (ii) population health performance, which supports the delivery of patient-centric cost effective care and (iii) delivery network alignment, comprising the development of high performance delivery networks.

Our specialty care management services support a broad range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics. We focus on the oncology and cardiology markets with the objective of helping providers and payers deliver higher quality, more affordable care and we provide comprehensive quality management for oncology and cardiology patients.

Our comprehensive health plan administration services help payers and providers assemble the infrastructure required to operate, manage and capitalize on a variety of financial and administrative management services, such as health plan services, risk management, analytics and reporting and leadership and management.

The majority of our services revenue is derived from recurring multi-year contracts, which we refer to as platform and operations. Platform and operations services accounted for 87.3% and 77.9% of our consolidated revenue for the years ended December 31, 2020 and 2019, respectively. We believe the recurring, multi-year nature of our platform and operations contracts enables us to have strong visibility into future revenue. The amount of revenue in a given platform and operations contract is typically driven by: (i) the number of members that Evolent is contracted to manage, (ii) the population types being served (e.g., Medicare, Medicaid, Commercial), and (iii) the depth and breadth of the services and technology applications that our partners utilize from us. In situations involving clinical solutions, we typically elect to: (iv) participate alongside or co-own risk-sharing arrangements with our partners whereby we share in a portion of the upside and downside clinical performance, or by owning a portion of the underwriting results. We believe performance-based contracts align our partners' incentives with our own and enables us to capture greater value from our contracts. We believe we are in the early stages of capitalizing on these aligned operating partnerships. We believe the current value-based care arrangements of our payer and provider partners represent a relatively small portion of their overall total opportunity.

Our services business model benefits from scale, as we leverage our purpose-built technology-enabled solutions and centralized resources in conjunction with the growth of our partners' membership base. While our absolute investment in our centralized



resources and technologies may increase over time, we expect it will decrease as a percentage of revenue as we are able to scale this investment across a broader group of partners. We expect to grow with current partners as they increase membership in their existing value-based operations, through expanding the number of services we provide to our existing partners, by adding new partners and by capturing value through risk-sharing arrangements.

The other portion of our services revenue, which we call transformation is typically composed of implementation services associated with our recurring revenue relationships. Due to the nature of recurring multi-year contracts, as we have added additional partners, transformation revenue has decreased to approximately 1% of total revenues.

### *Clinical Solutions*

We have two clinical solutions: total cost of care management and specialty care management services. We manage both of these solutions in our services segment.

#### Total Cost of Care Management Solution

Our total cost of care management solution was developed based on the intellectual property contributions of UPMC at our founding. Since then, we have continued to invest in the solution to broaden, deepen and scale its capabilities.

Our total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or ACO contracts with CMS. This solution seeks to reduce the total cost of care for a given population by identifying and managing high cost patients with targeted interventions managed and coordinated through primary care physicians. The economic model of our total cost of care management solution is primarily performance-based, which we believe enhances our ability to influence provider behavior by aligning our incentives with our partners. We estimate the total addressable market size of our total cost of care management solution to be approximately \$60 billion. We use, and may continue to use, different go-to-market brand names for various solution packages, depending on the markets we seek to address. These go-to-market brand names include: (i) Value Based Services, wherein we support primarily health systems in their value-based operations, and (ii) Evolent Care Partners, wherein we offer physicians the opportunity to join Evolent's proprietary payer contracting vehicles, scaled risk pools, and operating model.

We refer to the offerings within this solution as value-based care services. Core elements of our value-based care services include: (i) Identifi<sup>®</sup>, our proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients, (ii) population health performance, which supports the delivery of patient-centric cost effective care and (iii) delivery network alignment, comprising the development of high performance delivery networks. We integrate change management processes and ongoing physician-led transformation into all value-based services to build engagement, integration and alignment within our partners to successfully deliver value-based care and sustain performance. We have standardized the processes described below and are able to leverage our expertise across our partner base. Through the technological and clinical integration we achieve, our solutions are delivered as engrained components of our partners' core operations rather than as add-on solutions.

#### (i) Identifi<sup>®</sup>

Identifi<sup>®</sup> is our proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients. Identifi<sup>®</sup> links our processes with those of our partners and other third parties to create a connected clinical delivery ecosystem, stratify patient populations, standardize clinical work flows and enable high-quality, cost-effective care. The configurable nature and broad capabilities of Identifi<sup>®</sup> help enhance the benefits our partners receive from our value-based care services and increase the effectiveness of our partners' existing technology architecture. Highlights of the capabilities of Identifi<sup>®</sup> include the following:

- *Data and integration services:* Data from disparate sources, such as EMRs, and lab and pharmacy data, is collected, assembled, integrated and maintained to provide health care professionals with a holistic view of the patient.
- *Clinical and business content:* Clinical and business content is applied to the integrated data to create actionable information to optimize clinical and financial performance.
- *EMR integration:* Data and clinical insights from Identifi® are fed back into partner EMRs to improve both provider and patient satisfaction, create workflow efficiencies, promote clinical documentation and coding and provide clinical support at the point-of-care.
- *Applications:* A suite of cloud-based applications manages the clinical, financial and operational aspects of the value-based model. Our applications scale with the clinical, financial and administrative needs of our provider partners. As additional capabilities are required by our partners, they are often deployed as applications through Identifi®.

## (ii) Population Health Performance

Population Health Performance is an integrated suite of technology-enabled solutions that supports the delivery of quality care in an environment where a provider's need to manage health has significantly expanded. These solutions include:

- *Clinical programs*: Care processes and ongoing clinical innovation that enables providers to target the right intervention at the right time for a given patient.
- *Specialized care team*: Multi-disciplinary team that is deployed telephonically from a centralized location or throughout a local market to operate clinical programs, engage patients and support physicians.
- *Patient engagement*: Integrated technologies and processes that enable outreach to engage patients in their own care process.
- *Quality and risk coding*: Engagement of physicians to identify opportunities to close gaps in care and improve clinical documentation efforts.

## (iii) Delivery Network Alignment

We help our partners build the capabilities that are required to develop and maintain a coordinated and financially-aligned provider network that can deliver high-quality care necessary for value-based contracts. These capabilities include:

- *High-performance network*: Supporting the capabilities needed to build, maintain and optimize provider- and clinically-integrated networks.
- *Value compensation models*: Developing and supporting physician incentive payment programs that are linked to quality outcomes, payer shared savings arrangements and health plan performance.
- *Integrated specialty partnerships*: Supporting the technology-enabled strategies, analytics and staff needed to optimize network referral patterns.

## Specialty Care Management Services Solution

The foundation for our specialty care management services solution was derived through our acquisition in 2018 of New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under performance-based and administrative services arrangements. Since then, we have continued to invest in the solution to broaden, deepen, and scale its capabilities.

Since its founding in 2002, New Century Health has focused on the oncology and cardiology markets. Using clinical data analytics, predictive modeling and decision support tools, New Century Health has developed proprietary clinical pathways in these markets. Managed through its proprietary specialty care management platform, New Century combines high performance networks of specialists and enhanced clinical pathways to deliver higher quality and more affordable care, which we consider to be hallmarks of value-based care, to patients, providers and payers. Historically, New Century Health focused on the Medicare market and offered performance-based contracts, as well as ASO arrangements, primarily to payers in the Medicare HMO segment of the overall Medicare market. More recently, New Century Health has entered into performance-based contracts with Medicaid health plans. We estimate the total addressable market for New Century Health to be \$50 billion.

New Century Health provides a differentiated approach designed to meet market challenges based on (i) networks of high-performance providers, (ii) design of evidence-based clinical pathways and (iii) leveraging our proprietary specialty care management technology.

### (1) High performance provider networks

We develop high-performance provider networks with tools, capabilities and incentives to align and support physicians. We develop and manage comprehensive specialty networks, provide physician engagement and support and identify provider financial incentive alignment. Key features include:

- ***Direct contracts with specialists*** facilitates ease of care.
- ***Comprehensive specialty networks*** include multiple downstream subspecialists.
- ***Incentivize financial payment*** for quality and cost efficient utilization
- ***Minimize “buy and bill” incentives*** through shared savings methodologies
- ***Dedicated provider operations*** provide staff to support practices.
- ***Clinical response team*** provides clinical education on-site to practice staff.
- ***Dedicated central call center*** facilitates referrals and helps to resolve claims issues.
- ***Established system*** of ongoing provider education and training.

## (2) Design evidence-based clinical pathways

We design high-quality evidence-based clinical pathways to drive provider behavior towards improved quality of care at a lower cost. The transparent pathway development process for our specialty population health focal areas, oncology and cardiology, is designed to achieve the following objectives:

- **Reduce** unnecessary clinical variation.
- **Support** physician clinical decision making of evidence-based therapies.
- **Facilitate** total cost-of-care management.

Our clinical pathways are based on national guidelines with independent scientific advisory boards, in-house clinical expertise with original publications and presentations at national congress. We employ a collaborative review process that is not based on denials, which includes customized clinical review based on tier 1-5 drugs and proactive monitoring response to therapy. We employ quality metrics and clinical benchmarking to continually improve our pathways. We incentivize financial payment for quality by minimizing “buy and bill” incentives and through a shared savings methodology.

## (3) Leverage proprietary specialty care management technology

We leverage a custom specialty care management workflow platform, CarePro™, to provide clinical decision support and manage providers to high-quality care, while aiming to achieve significant cost savings. Our technology consists of a clinical decision support portal that provides oversight of individual treatment plans for pathway adherence. Our platform integrates clinical analytics and protocols, pharmacy management, physician engagement, network management and claims payment to drive improved outcomes for partners.

- **Decision support portal** delivers specialty specific clinical experience based on assigned roles (e.g. cardiologist vs. oncologist).
- **Custom-built rules engine** allows flexibility for multiple specialties and automated decisions based on clinical relevance, considering, for example, rigor levels based on specified payers and providers.
- **Workflow capability** facilitates a seamless collaboration within and across organizations, connecting payers and clearing houses for systematic data exchange.
- **Nurse triage system** leverages proprietary technology infrastructure.
- **Overall flexibility** enables a new business launch of existing specialty within 60 days.

### *Administrative Solution: Comprehensive Health Plan Administration Services*

The foundation for our comprehensive health plan administrative services solution was derived through our acquisitions in 2015 of Valence Health and Aldera. Since the time of these acquisitions, we have invested to upgrade the platform and integrate it with Identifi® and our clinical solutions to create an integrated value-based care platform.

Our comprehensive health plan administrative services help providers and regional payers assemble the complete infrastructure required to operate and manage value-based care and health plan businesses. The economic model of this solution is primarily ASO or fee-based with defined service-level agreements around key operating metrics. We estimate the total addressable market for our comprehensive health plan administrative services solution to be \$23 billion. These services include:

- **Health plan services:** A comprehensive suite of services including third-party administration, enrollment and billing support, medical and utilization management, third-party payment and program integrity support and provider network contracting services. Other health plan related services include sales and marketing, product development, actuarial, and regulatory and compliance.
- **Pharmacy benefit management:** Our team of professionals support the drug component of providers' plan offerings and bring national buying power and dedicated resources that are tightly integrated with the care delivery model. Differentiated from what we consider to be traditional PBMs, our solution is integrated into patient care and engages population health levers including generic utilization, provider management, and utilization management to reduce unit pharmacy costs.
- **Risk management:** The capabilities needed to successfully manage risk for payers, including analysis, data and operational integration with payer processes, and ongoing performance management.
- **Analytics and reporting:** The ongoing and ad hoc analytic teams and reports required to measure, inform and improve performance, including population health analytics, market analytics, network evaluation, staffing models, physician effectiveness, clinical delivery optimization and patient engagement.

- **Leadership and management:** Our local and national talent assist our partners in effectively managing the performance of their value-based operations.

### *True Health*

On January 2, 2018, Evolent acquired certain assets from New Mexico Health Connections, one of the first consumer operated and oriented plans established following the implementation of the ACA-including a commercial plan and health plan management services organization. The acquired assets were contributed to a new entity, True Health, a wholly-owned subsidiary of Evolent. True Health is a physician led health plan offering individual, small group, large group, ASO and Federal Employee Health Benefit health insurance products to New Mexico consumers.

True Health accounted for 11.5% and 20.3% of our consolidated revenue for the years ended December 31, 2020 and 2019, respectively.

The core elements of True Health include:

- **A statewide network** of primary care and specialty providers, with an emphasis on primary care coordination.
- **Extensive care management and prevention capabilities** leveraging diagnostic and actuarial analysis to drive care and health metrics.
- **Focus on community partnerships**, both medical and socioeconomic, to improve individual and population health status and promote trusted collaborations with clinicians in facilitating access to care and working through insurance issues.
- **Advanced analytics** aim to avoid costly interventions and complications in the future by focusing on preventative care.

Our True Health segment derives revenue from premiums earned over the terms of the related insurance policies. As of December 31, 2020, True Health served approximately 24,000 members, consisting principally of large group and off-exchange small group members. True Health provides an opportunity for us to leverage our services offerings to support True Health and transform the health plan into a value-based provider-centric model of care.

During the fourth quarter of 2017, we entered into a \$10.0 million capital-only reinsurance agreement with NMHC, which expired on December 31, 2018. The purpose of the capital-only reinsurance was to provide balance sheet support to NMHC. There was no uncertainty to the outcome of the arrangement as there was no transfer of underwriting risk to Evolent or True Health, and neither Evolent nor True Health was at risk for any cash payments on behalf of NMHC. As a result, this arrangement did not qualify for reinsurance accounting and we recorded the fees received under the deposit-only reinsurance agreement as non-operating income on our consolidated statements of operations and comprehensive income (loss).

During the fourth quarter of 2018, the Company terminated its prior reinsurance agreement with NMHC and entered into an updated 15-month quota-share reinsurance agreement with NMHC. As a result of certain changes in terms as compared to the prior reinsurance agreement, the new reinsurance agreement qualified for reinsurance accounting due to the deemed risk transfer and, as such, the Company began recording the full amount of the gross reinsurance premiums and claims assumed by the Company on its Consolidated Statements of Operations and Comprehensive Income (Loss) from its legal effective date. Under the terms of the new reinsurance agreement, NMHC ceded 90% of its gross premiums to the Company and the Company indemnified NMHC for 90% of its claims liability. The maximum amount of insurance risk to the Company was capped at 105% of premiums ceded to the Company by NMHC. During the third quarter of 2019, the Company terminated the new reinsurance agreement with NMHC effective in the fourth quarter of 2019, approximately one and a half months prior to its scheduled end. In 2020, True Health launched a product on the individual exchange. Refer to “Part II - Item 8. Financial Statements and Supplementary Data - Note 10” for additional discussion regarding the reinsurance agreement. Refer to “Part II - Item 8. Financial Statements - Note 26” for additional discussion regarding the True Health sale.

### *Significant Activities*

In August 2020, the Company issued \$117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the “2024 Notes”) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued \$84.2 million aggregate principal amount of 2024 Notes in exchange for \$84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of \$2.5 million, and issued \$32.8 million aggregate principal amount of New Notes for cash at par. We incurred \$3.0 million of debt issuance costs in connection with the 2024 Notes. Refer to “Part II - Item 8. Financial Statements - Note 9” for additional discussion regarding the Company’s 2024 Notes.

On July 16, 2020, EVH Passport, Evolent Health LLC and Molina entered into the Molina APA, which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina completed the Molina Closing, and the Passport



Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, Molina deposited \$20.0 million in cash in escrow, which was subsequently released to the Company in January, 2021. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting. As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company's consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors' equity interests in EVH Passport for \$20.0 million in cash in accordance with the terms of EVH Passport's Stockholders' Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company. The Company expects a return of capital from EVH Passport, expected to be between \$130 million and \$170 million in total, which is subject to regulatory approval from the Kentucky Department of Insurance. Refer to "Part II - Item 8. Financial Statements - Note 4" for additional discussion regarding the Passport transactions.

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was \$98.6 million, which included \$9.7 million for the make-whole premium as well as \$0.2 million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for \$13.7 million. Refer to "Part II - Item 8. Financial Statements - Note 26" for additional discussion regarding the Credit Agreement repayment.

On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the "True Health SPA") with Bright Health Management, Inc. ("Bright HealthCare"), pursuant to which EH Holdings expects to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of \$22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the closing of the transactions contemplated by the True Health SPA (the "True Health Closing") based in part on actual medical claims experience. Refer to "Part II - Item 8. Financial Statements - Note 26" for additional discussion regarding the True Health sale.

### *Financing Strategy*

Our capital structure is designed to offer an efficient complement of funding sources to maintain appropriate liquidity to support our business and meet our financial obligations. To maintain our desired capital profile, we utilize a mix of debt and equity funding. Debt funding may include convertible debt, lines of credit, long-term credit agreements or other liabilities. Equity capital primarily consists of issuing common stock. As of December 31, 2020, we had \$263.3 million of long-term debt, net of discount outstanding.

### **Competitive Strengths**

We believe we are well-positioned to benefit from the transformations occurring in health care payment and delivery described above. We believe this environment that rewards the better use of information to drive patient outcomes aligns with our business model, recent investments and other competitive strengths.

### *Early Innovator*

We believe we are an innovator in the delivery of comprehensive value-based care solutions. We were founded in 2011, ahead of the implementation of the ACA and before the rapid expansion of programs, such as Medicare ACOs or Medicare Bundled Payment Initiatives. Since our inception, we have invested a significant amount in expanding our offerings.

### *Differentiated Offering in High Cost Oncology and Cardiology Markets*

Cardiovascular disease and cancer accounted for approximately 25% of total U.S. health expenditures in 2014 to 2015. One of the major cost drivers is spending on oncology drugs which rose 50% from \$38 billion in 2013 to \$57 billion in 2018. We offer a comprehensive performance based solution that we believe delivers meaningful savings to customers relative to historical spend. Our specialty care management solution manages over 3.6 million lives in Medicare, Medicaid and Commercial markets as of December 31, 2020 and we believe our solution is one of the most comprehensive in the market today.

### *Comprehensive End-to-End Solutions*

We provide end-to-end, built-for-purpose, technology-enabled solutions for our partners to succeed in value-based payment models. We believe that offering comprehensive and integrated solutions which bring together clinical and administrative management allows payers and providers to accelerate their path to adoption of value-based care.

### *Depth of Market Experience*

With experience across Medicare, Medicaid and commercial markets, our depth and variety of expertise allows us to serve a variety of customer types in the broad health care marketplace including health systems, providers, physicians, health plans, ACOs, delegated arrangements and other payers.

### *Proprietary Technology*

Our integrated proprietary technology, Identifi®, allows us to deliver a connected delivery ecosystem, implement replicable clinical processes, scale our value-based services and capitalize on multiple types of value-based payment relationships.

We leverage a custom specialty care management workflow platform, CarePro™, to provide clinical decision support and manage providers to high-quality care, while aiming to achieve significant cost savings. Our technology consists of a clinical decision support portal that provides oversight of individual treatment plans for pathway adherence. Our platform integrates clinical analytics and protocols, pharmacy management, physician engagement, network management and claims payment to drive improved outcomes for partners.

We believe we are creating scaled benefits for our partners in areas such as data analytics, administrative services and care management. We expect Identifi® and CarePro™ to enable us to deliver increasing levels of efficiency to our partners.

### *Provider-Heritage Brand Identity*

We believe our provider-heritage brand identity and origins differentiate us from our competitors in the value-based care services area. We believe our solutions resonate with potential partners seeking proven solutions that work with providers in a non-abrasive way. Our analytical and clinical solutions are rooted in UPMC's experience in growing a provider-led, integrated delivery network over the 15 years prior to the founding of Evolent Health, Inc., and growing to become one of the largest provider-owned health plans in the country. Our unique position allows for the sharing of data across multiple payers and care delivery integration regardless of payer, which we believe is not possible with traditional, payer-siloed solutions.

### *Partnership-Driven Business Model*

Our business model is predicated on strategic partnerships with leading providers and payers that are attempting to evolve two of their most critical business functions: how they deliver care and how they are compensated for it. The partnership model enables cultural alignment, integration into the provider care delivery and payment work flow, contractual relationships and a cycle of clinical and cost improvement with shared financial benefit. In certain cases, we also agree to participate alongside our partners in risk-sharing or other support arrangements to increase our alignment of interests via performance-based relationships.

### *Proven Leadership Team*

We have made a significant investment in building an industry-leading management team. Our senior leadership team has extensive experience in the health care industry and a track record of delivering measurable clinical, financial and operational improvement for health care providers and payers. Our Chief Executive Officer, Seth Blackley, had served as our President since August 2011. Prior to co-founding the company, Mr. Blackley was the Executive Director of Corporate Development and Strategic Planning at The Advisory Board from June 2007 to August 2011.

## **Growth Opportunities**

### *Multiple Avenues for Growth with Our Existing, Embedded Partner Base*

We have established a multi-year partnership model with multiple drivers of embedded growth through the following avenues:

- growth in lives in existing covered populations;
- partners expanding into new lines of value-based care to capture growth in new profit pools;
- cross-selling additional solutions to existing partners; and
- capturing value created through a variety of value-based arrangements by participating alongside our partners in upside risk sharing arrangements.

In addition to growth within our existing partner base, we also evaluate and consider pursuing opportunities to expand into businesses related to the services we currently provide.

### *Significant Market Potential for Specialty Care Management Solution*

As of December 31, 2020, our specialty care management solution is managing less than 5% of lives in the Medicare market and less than 1% of lives in the Medicaid and Commercial markets. Oncology and Cardiology spend is increasing as a percentage of total health care spend and both markets are experiencing periods of significant advancements in treatment options and pharmacy solutions, thus presenting a challenge to payers to manage spend. We offer a comprehensive, performance-based solution and believe we have significant growth potential in this market.

### *Early Stages of a Rapidly Growing Transformational Addressable Market*

We believe that our existing partners represent a small fraction of providers and payers that could benefit from our solutions. The transformation of the care delivery and payment model in the United States has been rapid, but it is still in the early stages. Approximately 50% of health care payments were paid through value-based care programs in 2018 and it is estimated that this number will continue to grow.

We believe there is significant market opportunity in our total cost of care solution. As of December 31, 2020, our solution served less than 1% of the Medicare Shared Savings Program ACO-assignable population. Furthermore, we believe that populations covered by CMS ACOs will continue to grow, and also that the solution will be relevant to private payer value-based arrangements.

We believe there is a significant market opportunity in our specialty care management services solution. As of December 31, 2020, New Century Health served approximately 1.6 million Medicaid Managed Care and Medicare HMO patients out of total population of approximately 69 million. This represents a market share of roughly 2% of this total population. We believe that the adoption of this solution in oncology and cardiology by payers serving the Medicare HMO market is very low but is likely to increase as the growth in spending in these specialties is higher than the growth in overall health care spending. Furthermore, we believe that our specialty care management solution is scalable to Medicaid and other lines of business.

### *Capitalize on Growth in Select Government-Driven Programs*

The number of people managed by government-driven programs in the United States has seen significant growth since 2016. Specifically, the number of Medicare beneficiaries reached 62 million in 2019, an 11% increase from 2016. The nature of our variable fee economic model enables us to benefit from this growth in government-managed lives. A significant portion of our revenues are attributable to government-driven programs, primarily comprised of Medicaid and, to a less significant extent, Medicare.

### *Ability to Capture Additional Value through Delivering Clinical Results*

We are capturing only a portion of the addressable clinical and administrative dollars in the market through our current solutions. We believe there is a significant opportunity to capture an increasing portion of the medical dollar over time, namely the remainder of the premium dollar which goes to medical expenses, and we have begun to do so in certain performance-based relationships. We believe business models that allow us to participate in the medical savings through a variety of risk-sharing arrangements that align incentives to reduce costs and improve quality outcomes will enable us to grow and differentiate ourselves from other vendors.

### *Expand Offerings to Meet Evolving Market Needs*

There are multiple business offerings that our partners may require to operate in a value-based care environment that we do not currently provide, including but not limited to:

- PBM expansion to include additional specialty pharmacy management capabilities;
- additional specialty lines of business beyond oncology and cardiology, including kidney, maternity and end-of-life care;
- physician employment;
- on-site or specialty clinic services; and
- consumer engagement and digital outreach.

*Selectively Pursue Strategic Acquisitions and Investments*

We believe that the nature of our competitive landscape provides meaningful acquisition and investment opportunities. Our industry is in the early stages of its life cycle and there are multiple firms attempting to capitalize on the transformation of the care delivery model and the various forms of new profit pools. We believe that our partners will require an end-to-end solution and we believe we are well positioned to meet this demand by expanding the breadth of our offerings through not only organic growth, but also the acquisition of niche vendors and non-core portions of larger enterprises. From time to time, we may also pursue acquisition and investment

opportunities of businesses related to services we currently provide or that are complementary to our technical capabilities. As an example of executing on our strategy, on October 1, 2018, we completed the acquisition of New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under risk-based, capitated relationships. Our acquisition of New Century Health opened a direct sales channel to the payer market.

## Sales and Marketing

We market and sell our services to payers and providers throughout the United States. Our sales team works closely with our leadership team and subject matter experts to foster long-term relationships with our partners' leadership and board of directors given the nature of our partnerships. Our dedicated business development team works closely with our partners to identify additional service opportunities on a continuous basis.

## Services Partner Relationships

Our services business is predicated on strategic partnerships with leading payers and providers that are attempting to evolve two of their most critical business functions: how they deliver care and how they are compensated for it. The partnership model enables cultural alignment, integration into the care delivery and payment work flow, contractual relationships and a cycle of clinical and cost improvement with shared financial benefit.

We have sought to partner with leading payers and providers in sizable markets, which we believe creates a growth cycle that benefits from the secular transition to value-based care.

As of December 31, 2020, we had contractual relationships with over 37 operating partners. The following table summarizes those customers of our services segment who represented at least 10.0% of our consolidated revenue for the periods presented:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Cook County Health and Hospitals System	20.3 %	*	*
Passport <sup>(1)</sup>	16.8 %	18.7 %	17.5 %
New Mexico Health Connections	*	10.9 %	*

<sup>1</sup>. Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 8.8% of our consolidated revenues for the year ended December 31, 2020.

\* Represents less than 10.0% of the respective balance.

As of December 31, 2020, our average contractual relationship with our operating partners was approximately 5.1 years, with an average of 1.8 years of performance remaining per contract. The contracts of New Century Health typically run for one-year terms, with year-to-year renewal provisions.

Our contracts governing the relationships with our operating partners include key terms which may include the period of performance, revenue rates, advanced billing terms, service level agreements, termination clauses, exclusivity clauses and right of first refusal clauses. Typically, these contracts provide for a monthly payment calculated based on a specified rate multiplied by the number of members that our partners are managing. The specified rate varies depending on which market-facing solutions the partner has adopted and the number of services and technology applications they are utilizing. In some cases, we are responsible for paying for all, or substantially all, of the cost of care for a defined scope of health care services out of the revenue we receive. Some of our contracts allow for advance billing of our partners. In some of our contracts, a defined portion of the revenue is at risk and can be refunded to the partner if certain service

levels are not attained. We monitor our compliance with the service levels to determine whether a refund will be provided and record an estimate of these refunds. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health typically run for one year terms. While they typically contain year-to-year renewal provisions, we cannot assure you any or all of these contracts will be renewed in any particular year.

Although the revenue from our contracts is not guaranteed because certain of our contracts are terminable for convenience by our partners after a notice period has passed, certain partners would be required to pay us a termination fee in certain circumstances. Termination fees and the related notice period in certain of our contracts are determined based on the scope of the market-facing solutions that the partner has adopted and the duration of the contract. Most of our contracts include cure periods for certain breaches, during which time we may attempt to resolve any issues that would trigger a partner's ability to terminate the contract. However, certain of our contracts are also terminable immediately on the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging



from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. The loss, termination or renegotiation of any contract could negatively impact our results. In addition, as our partners' businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, we expect that certain of our partners will, from time to time, seek to restructure their agreements with us.

The contracts often contain exclusivity or other restrictive provisions, which may limit our ability to partner with or provide services to other providers or purchase services from other vendors within certain time periods and in certain geographic areas. The exclusivity and other restrictive provisions are negotiated on an individual basis and vary depending on many factors, including the term and scope of the contract. The time limit on these exclusivity and other restrictive provisions typically corresponds to the term of the contract. These exclusivity or other restrictive provisions often apply to specific competitors of our health system partners or specific geographic areas within a particular state or an entire state, subject to certain exceptions, including, for example, exceptions for employer plan entities that have operations in the restricted geographic areas but that are headquartered elsewhere. Accordingly, these exclusivity clauses may prevent us from entering into relationships with certain potential partners.

The contracts with our partners impose other obligations on us. For example, we typically agree that all services provided under the partner contract and all employees providing such services will comply with our partner's policies and procedures. In addition, in most instances, we have agreed to indemnify our partners against certain third-party claims, which may include claims that our services infringe the intellectual property rights of such third parties.

## **Competition**

The market for our solutions is fragmented, competitive and characterized by rapidly evolving technology standards, customer needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities. Our partners may also choose to insource Solution functions from us in part or in whole. Our services solutions compete based on several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement using products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. We also compete based on price and aligned performance relationships.

Our health plan, True Health, also competes with local and regional health care benefits plans, health care benefits and other plans sponsored by large commercial health care benefit insurance companies, health system owned health plans, new entrants into the marketplace and numerous for-profit and not-for-profit organizations.

## **Health Care and Insurance Laws and Regulations**

Our business is subject to extensive, complex and rapidly changing federal and state laws and regulations. Various federal and state agencies have discretion to issue regulations and interpret and enforce health care laws. While we believe we comply in all material respects with applicable health care and insurance laws and regulations, these regulations can vary significantly from jurisdiction to jurisdiction, and interpretation of existing laws and regulations may change periodically. Federal and state legislatures also may enact various legislative proposals that could materially impact certain aspects of our business. The following are summaries of key federal and state laws and regulations that impact our operations:

## *Health Care Reform*

In March 2010, the ACA and the Health Care and Education Reconciliation Act of 2010, which we refer to, collectively, as health care reform, was signed into law. Health care reform contains provisions that have changed and will continue to change the health insurance industry in substantial ways. For example, health care reform includes a mandate that employers with over 50 employees offer their employees group health insurance coverage or face tax penalties; prohibitions against insurance companies that offer Individual Major Medical plans using pre-existing health conditions as a reason to deny an application for health insurance; medical loss ratio requirements that require each health insurance carrier to spend a certain percentage of their premium revenue on reimbursement for clinical services and activities that improve health care quality; establishment of health insurance exchanges to facilitate access to, and the purchase of, health insurance; and subsidies and cost-sharing credits to make health insurance more affordable for those below certain income levels.

Health care reform amended various provisions in many federal laws, including the Code, the Employee Retirement Income Security Act of 1974 and the Public Health Services Act. Health care reform is being implemented by the Department of Health and Human

Services, the Department of Labor and the Department of Treasury. Most of the ACA regulations became effective on January 1, 2014.

During 2017, several attempts were made to amend the ACA, although no amendment proposal gained the requisite support from the U.S. Senate to pass a repeal bill. As a result, in October 2017, former President Trump issued an executive order relating to the ACA titled “Promoting Healthcare Choice and Competition Across the United States,” which further directs federal agencies to modify how the ACA is implemented, and soon after announced the termination of the cost-sharing subsidies that reimburse insurers under the ACA. It is expected that the Biden administration will repeal the Executive Order, but it is not known what other changes the new administration will implement through Congress or future executive orders, and how those may impact our partners and our business. Because of the continued uncertainty about the ACA, including the timing of and potential for further legal challenges, repeal or amendment of that legislation and future of the health insurance exchanges, we cannot quantify or predict with any certainty the likely impact of the ACA on our business, financial condition, operating results and prospects. In addition, Congress, state legislatures and third-party payers may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system, including with respect to Medicare and Medicaid programs. We cannot assure you as to the ultimate content, timing, or effect of any changes, nor is it possible at this time to estimate the impact of any such potential legislation or changes. Health care reform has resulted in profound changes to the individual health insurance market and our business, and we expect these changes to continue.

#### *Stark Law*

We are subject to federal and state “self-referral” laws. The Stark Law is a federal statute that prohibits physicians from referring patients for items covered by Medicare or Medicaid to entities with which the physician has a financial relationship, unless that relationship falls within a specified exception. The Stark Law is a strict liability statute and is violated even if the parties did not have an improper intent to induce physician referrals. The Stark Law is relevant to our business because we frequently organize arrangements of various kinds under which (a) physicians and hospitals jointly invest in and own ACOs, clinically integrated networks and other entities that engage in value-based contracting with third-party payers or (b) physicians are paid by hospitals or hospital affiliates for care management, medical or other services related to value-based contracts. We evaluate when these investment and compensation arrangements create financial relationships under the Stark Law and design structures that are intended to satisfy exceptions under the Stark Law or Medicare Shared Savings Program waiver.

#### *Anti-kickback Laws*

In the United States, there are federal and state anti-kickback laws that generally prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business. The United States federal health care programs’ Anti-Kickback Statute makes it unlawful for individuals or entities knowingly and willfully to solicit, offer, receive or pay any kickback, bribe or other remuneration, directly or indirectly, in exchange for or to induce the referral of an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a federal health care program or the purchase, lease or order, or arranging for or recommending purchasing, leasing or ordering, any good, facility, service, or item for which payment may be made in whole or in part under a federal health care program. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from federal health care programs. The Anti-Kickback Statute raises similar compliance issues as the Stark Law. While there are safe harbors under the Anti-Kickback Statute, they differ from the Stark Law exceptions in that compliance with a safe harbor is not mandatory. If an arrangement falls outside the safe harbors, it must be evaluated on its specific facts to assess whether regulatory authorities might take the position that one purpose of the arrangement is to induce referrals of federal health care program business. Our business arrangements implicate the Anti-Kickback Statute for the same reasons they raise Stark Law issues. We evaluate whether investment and compensation arrangements being developed by us on behalf of hospital partners fall within one of the safe harbors or Medicare Shared Savings Program waiver. If not, we consider the factors that

regulatory authorities are likely to consider in attempting to identify the intent behind such arrangements. We also design business models that reduce the risk that any such arrangements might be viewed as abusive and trigger Anti-Kickback Statute claims.

### *Antitrust Laws*

The antitrust laws are designed to prevent competitors from jointly fixing prices. However, competitors often work collaboratively to reduce the cost of health care and improve quality. To balance these competing goals, antitrust enforcement agencies have established a regulatory framework under which claims of per se price fixing can be avoided if a network of competitors (such as an ACO or clinically integrated network) is financially or clinically integrated. In this context, we evaluate the tests for financial and clinical integration that would be applied to the provider networks that we are helping to create and support, including the nature and extent of any financial risk that must be assumed to be deemed financially integrated and the types of programs that must be implemented to achieve clinical integration. However, even if a network is integrated, it is still subject to a “rule of reason” test to determine whether

its activities are, on balance, pro-competitive. The key factors in the rule of reason analysis are market share and exclusivity. We focus on network size, composition and contracting policies to strengthen our partners' position that their networks meet the rule of reason test.

#### *Federal Civil False Claims Act and State False Claims Laws*

The federal civil False Claims Act imposes liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. The "qui tam" or "whistleblower" provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. Our activities relating to the way we sell and market our services, including our provider-led risk adjustment solution, may be subject to scrutiny under these laws.

#### *HIPAA, Privacy and Data Security Regulations*

By processing data on behalf of our partners, we are subject to specific compliance obligations under privacy and data security-related laws, including HIPAA, the HITECH Act and related state laws. We are also subject to federal and state security breach notification laws, as well as state laws regulating the processing of protected personal information, including laws governing the collection, use and disclosure of social security numbers and related identifiers.

The regulations that implement HIPAA and the HITECH Act establish uniform standards governing the conduct of certain electronic health care transactions and protecting the security and privacy of individually identifiable health information maintained or transmitted by health care providers, health plans and health care clearinghouses, all of which are referred to as "covered entities," and their "business associates" (which includes anyone who performs a service on behalf of a covered entity involving the use or disclosure of protected health information and is not a member of the covered entity's workforce). Our partners' health plans generally will be covered entities, and, as their business associate, they may ask us to contractually comply with certain aspects of these standards by entering into requisite business associate agreements.

#### *HIPAA Health Care Fraud Standards*

The HIPAA health care fraud statute created a class of federal crimes, including health care fraud and false statements relating to health care matters, known as the "federal health care offenses." The HIPAA health care fraud statute prohibits, among other things, executing a scheme to defraud any health care benefit program, while the HIPAA false statements statute prohibits, among other things, concealing a material fact or making a materially false statement in connection with the payment for health care benefits, items or services. Entities that are found to have aided or abetted in a violation of the HIPAA federal health care offenses are deemed by statute to have committed the offense and are punishable as a principal.

#### *Medicare and Medicaid*

Medicare is a federal program that provides hospital and medical insurance benefits to persons age 65 and over, as well as certain other individuals. Medicaid programs are jointly funded by federal and state governments and are administered by states under an approved plan that provides hospital and other health care benefits to qualifying individuals. As we increase our exposure to Medicare and Medicaid businesses through new and existing partners, we increase our exposure to changes in government policy with respect to and regulation of the Medicaid and Medicare programs in which we and our partners participate. We are subject to regulation by both CMS and state agencies in respect of certain services we provide relating to Medicaid and Medicare programs.

Because some of our partners are participants in governmental programs, our services have in the past and may again in the future be subject to periodic surveys and audits by governmental entities or contractors for compliance with Medicare and other standards and

requirements. As a result of surveys or audits, CMS may seek premium and other refunds, prohibit us from continuing to market or enroll members in plans, exclude us from participating in one or more programs or institute other sanctions against us if we fail to comply with CMS regulations or Medicare contractual requirements.

The regulations and requirements applicable to us and other participants in Medicaid and Medicare programs are complex and subject to change. In January 2020, CMS announced a new demonstration program that will allow states to adopt a block grant, capped-funding approach to Medicaid. We cannot quantify or predict with any certainty the likely impact of the demonstration program, other changes in the law or new interpretations of existing laws on our business, financial condition, operating results and prospects.

Following recent elections, Congress and state and local legislatures may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes with respect to Medicare and Medicaid programs. Such changes in the law, or new interpretations of existing laws, may have a significant impact on our methods and costs of doing business. Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS and

Congress to continue to closely scrutinize each component of the Medicare program as well as modify the terms and requirements of the program. It is not possible to predict the outcome of this Congressional or regulatory activity, either of which could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.

#### *Consumer Protection Laws*

Federal and state consumer protection laws are being applied increasingly by the FTC, Federal Communications Commission and states' attorneys general to regulate the collection, use, storage and disclosure of personal or patient information, through websites or otherwise, and to regulate the presentation of website content and to regulate direct marketing, including telemarketing and telephonic communication. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access.

#### *State Privacy Laws*

In addition to federal regulations issued under HIPAA, some states have enacted privacy and security statutes or regulations, which we refer to as state privacy laws, that govern the use and disclosure of a person's medical information or records and, in some cases, are more stringent than those issued under HIPAA. These state privacy laws include regulation of health insurance providers and agents, regulation of organizations that perform certain administrative functions, such as UR, or TPA, issuance of notices of privacy practices and reporting and providing access to law enforcement authorities. In those cases, it may be necessary to modify our operations and procedures to comply with these more stringent state privacy laws. If we fail to comply with applicable state privacy laws, we could be subject to additional sanctions.

#### *Other State Laws*

State insurance laws require licenses for certain health plan administrative activities, including TPA licenses for the processing, handling and adjudication of health insurance claims and UR agent licenses for providing medical management services. Given the nature and scope of services that we provide to certain partners, we are required to maintain TPA and UR agent licenses and ensure that such licenses are in good standing on an annual basis. In addition, laws in many states govern prompt payment obligations for health care services. These laws generally define claims payment processes and set specific time frames for submission, payment, and appeal steps. Failure to meet these requirements and time frames may result in rejection, delay of claims and possible interest and regulatory penalties. The Company has also established a captive insurance company under the laws of the State of Vermont and is subject to the captive insurance laws of that state.

Insurance subsidiaries and investees must be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. For example, True Health is regulated under specific New Mexico laws and regulations and indirectly affected by other health care-related laws and regulations and EVH Passport is regulated under specific Kentucky laws and regulations and indirectly affected by other health care-related laws and regulations. State regulations mandate minimum capital or restricted cash reserve requirements.

### **Intellectual Property**

Our continued growth and success depend, in part, on our ability to protect our intellectual property and proprietary technology, including our Identifi® software and CarePro™ platform. We primarily protect our intellectual property through a combination of copyrights, trademarks and trade secrets, intellectual property licenses and other contractual rights (including confidentiality, non-

disclosure and assignment-of-invention agreements with our employees, independent contractors, consultants and companies with which we conduct business).

However, these intellectual property rights and procedures may not prevent others from creating a competitive online presence or otherwise competing with us. We may be unable to obtain, maintain and enforce the intellectual property rights on which our business depends, and assertions by third parties that we violate their intellectual property rights could have a material adverse effect on our business, financial condition and results of operations. For additional information related to our intellectual property position see “Part I - Item 1A. Risk Factors - Risks relating to our business and industry.”



## **Research and Development**

Our research and development expenditures primarily consist of our strategic investment in enhancing the functionality and usability of our software, Identifi® and developing programs and processes to maximize care delivery efficiency and effectiveness. We also capitalize software development costs related to Identifi®. Our research and development expenditures and capitalized software development costs also include the suite of products developed by New Century Health, Accordion, Valence Health and Aldera.

## **Human Capital Management**

We believe our commitment to and investment in human capital enables our continued efforts to dramatically reduce the total cost of care, improve clinical quality and simplify administration. As of December 31, 2020, we had approximately 2,900 global employees. None of our employees are represented by a labor union, and we are not a party to any collective bargaining agreements. We focus on the following key measures and objectives in managing our business in order to deploy and develop our human capital strategy:

- Employee Compensation and Incentives
- Employee Training and Career Development
- Employee Well Being
- Diversity, Equity and Inclusion

### *Employee Compensation and Incentives*

We aim to attract and retain the highest caliber of health care talent. We believe in pay for performance and structure our compensation to annually incent & reward exceptional performance at all levels in the organization. Ensuring that our employees are compensated fairly and have the appropriate incentives in place to meet and exceed their potential is an integral part of our human capital management. We annually conduct pay equity assessments and compensation reviews, and we continue to actively work to reduce unconscious bias in our hiring practices, performance reviews and promotion opportunities that may contribute to pay inequities.

### *Employee Training and Career Development*

We believe that the continued edification and development of our talent is important in continuing to maintain growth as a company as well as the growth of our individual talent. Training programs are available to all employees through our company portal that is managed by our learning and development team. Our learning and development portal enables employees to find on-demand content, view and attend live learning sessions. Additionally, during 2020 we launched our internal mobility initiative. The initiative gives employees the visibility and opportunity to apply for positions within their current teams as well as company-wide. We feel that this initiative will also help with transparency of opportunities and talent across the organization as well as focus on increasing the diversity of our senior levels within the company over time by growing our current diverse workforce.

### *Employee Well-Being*

We believe that we have a responsibility to help maintain the health and well-being of our employees. We provide our employees with comprehensive benefits including: competitive medical insurance, dental, vision, PTO and 401k plan. In addition, we offer 100% paid maternity leave, parental leave, fertility support, diabetes and hypertension program offerings. In response to the COVID-19 pandemic we have also implemented 100% work from home across our employee population, additional mental health offerings, work from home office set-up support, regular employee feedback surveys, holistic wellness initiatives that include yoga, cooking sessions, meditation and wellness challenges.

## *Diversity, Equity and Inclusion*

We believe that Evolent is a stronger company with diverse employees and encourage hiring and retention practices that focus on top performing talent regardless of gender, national origin, ethnicity or other protected class. In 2020, we refocused on additional diversity, equity and inclusion initiatives to continue to create a more equitable workspace. This initiative included additional training for leadership in diversity, equity and inclusion throughout the organization and the hiring of a Head of Diversity, Equity, and Inclusion to focus on diversity as well as an internal organization review that focused around pay, job descriptions, recruiting, career pathing and development. We feel this renewed commitment to diversity, equity and inclusion enables us to attract, develop and retain the highest caliber talent in health care.

Overall, we believe our culture, along with our internal programs and initiatives, allow us to effectively execute our human capital strategy.

## Information about our Executive Officers

Our executive officers as of February 25, 2021, were as follows:

Name	Age	Position
Seth Blackley	42	Chief Executive Officer
John Johnson	37	Chief Financial Officer
Steve Tutewohl	48	Chief Operating Officer
Jonathan Weinberg	53	General Counsel
Aammaad Shams	37	Principal Accounting Officer and Corporate Controller
Frank Williams	54	Executive Chairman

**Seth Blackley** is our co-founder and has served as our Chief Executive Officer since October 2020. Prior to serving as our Chief Executive Officer, Mr. Blackley served as our President from the Company's founding in August 2011. Prior to co-founding the company, Mr. Blackley was the Executive Director of Corporate Development and Strategic Planning at The Advisory Board from June 2007 to August 2011. Mr. Blackley began his career as an analyst in the Washington, D.C. office of McKinsey & Company. Mr. Blackley holds a Bachelor of Arts degree in business from The University of North Carolina at Chapel Hill, and a master of business administration from Harvard Business School.

**John Johnson** has served as our Chief Financial Officer since July 2019. Prior to his role as Chief Financial Officer, Mr. Johnson was acting Chief Financial Officer for New Century Health from March 2019 to June 2019. Prior to his New Century Health role, Mr. Johnson was Senior Vice President, Corporate Performance at Evolent Health from January 2018 to March 2019 and Vice President, Corporate Performance at Evolent Health from April 2016 to December 2017. Prior to joining the Company, Mr. Johnson was the Managing Partner at Riverbend Analytics, LLC from December 2015 until April 2016 and the Vice President of Strategy at PSA Healthcare from February 2013 until November 2015. Mr. Johnson holds a Bachelor of Arts degree in Physics from Cornell University.

**Steve Tutewohl** has served as our Chief Operating Officer since June 2020. Mr. Tutewohl has also served as the Chief Executive Officer of Evolent Health Services, since January 2018. Mr. Tutewohl previously served as the Chief Actuary of the Company from January 2017 until December 2017. Prior to the Company's acquisition of Valence Health, Mr. Tutewohl was the Strategic Accounts Officer of Valence Health from October 1996 - January 2017. Mr. Tutewohl received his B.S. in risk management, math and actuarial science from the University of Wisconsin.

**Jonathan Weinberg** has served as our General Counsel since January 2014. Prior to joining Evolent, Mr. Weinberg was a Senior Vice President and Deputy General Counsel for Coventry Health Care, Inc. (Aetna Inc.) from 1999 to 2013, and was in charge of the day-to-day management of the legal department as well as the company's risk management department. Prior to joining Coventry, Mr. Weinberg was an associate and then partner at Epstein Becker and Green, P.C. in the firm's health care practice, specializing in managed care issues from 1992 to 2002. Mr. Weinberg received his Bachelor of Arts in history and political science from the University of Wisconsin-Madison and his juris doctorate from the Catholic University of America.

**Aammaad Shams** has served as our Controller since June 2020. Prior to his role as Controller, Mr. Shams was the Company's Assistant Corporate Controller from January 2020 to June 2020. Mr. Shams also served as Senior Director of Technical Accounting from April 2018 to June 2019, and Senior Director of Accounting from July 2019 until December 2019. Prior to joining the Company, Mr. Shams

was a Director in KPMG, LLP's Accounting Advisory Services practice from June 2015 until March 2018. Mr. Shams is a Certified Public Accountant in the Commonwealth of Virginia.

**Frank Williams** is our co-founder and has served as our Executive Chairman since October 2020. Prior to serving as our Executive Chairman, Mr. Williams served as our Chief Executive Officer from the Company's founding in August 2011. Prior to Evolent, Mr. Williams served as the Chief Executive Officer of The Advisory Board from June 2001 to September 2008, and as its Chairman from September 2008 to August 2011. Previously, Mr. Williams also served as President of MedAmerica OnCall, President of Vivra Orthopedics and as a management consultant for Bain & Co. Mr. Williams holds a bachelor of arts with high honors in political economies of industrial societies from the University of California, Berkeley, and a master of business administration from Harvard Business School.

## **Corporate Information**

Evolent began business operations in August 2011. Evolent Health, Inc., the registrant, was incorporated in the State of Delaware in December 2014. We completed our IPO in June 2015 and our Class A common stock is listed on the NYSE under the symbol “EVH.” Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries and the financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

## **Website to Access Our Reports**

Our internet website address is [www.evolenthealth.com](http://www.evolenthealth.com). In addition to the information about us and our subsidiaries contained in this Annual Report on Form 10-K, information about us can be found on our website including information on our corporate governance principles and practices. Our Investor Relations website at [ir.evolenthealth.com](http://ir.evolenthealth.com) contains a significant amount of information about us, including financial and other information for investors. We encourage investors to visit our website, as we frequently update and post new information about our company on our website and it is possible that this information could be deemed to be material information. Our website and information included in or linked to our website are not part of this Annual Report on Form 10-K.

We make available, free of charge, on or through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

## Item 1A. Risk Factors

The following summary highlights some of the principal risks that could adversely affect our business, financial condition or results of operations. This summary is not complete and the risks summarized below are not the only risks we face. These risks are discussed more fully further below. These risks include, but are not limited to, the following:

- The loss, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate, could negatively impact our results.
- Evolution in the market for value-based care makes it difficult to forecast demand for our services.
- The health care regulatory and political framework is uncertain and evolving.
- If we are unable to offer new and innovative products and services, our partners may terminate or fail to renew their relationships with us.
- Acquisitions, investments, alliances and joint ventures, may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.
- The financial benefits we expect to receive as a result of our sale of assets of Passport may not be realized.
- We depend on the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control.
- Failure to accurately underwrite performance-based contracts could result in a reduction in profitability.
- If we fail to effectively manage our growth and cost structure, our results of operations could be harmed.
- Public health emergencies such as the COVID-19 pandemic could, adversely affect our business.
- If we are unable to develop or grow partner relationships over time, we are unlikely to recover upfront costs and our operating results may suffer.
- If we do not attract new partners and capture new opportunities, we may not achieve our revenue projections.
- An increasing number and variety of risk sharing arrangements may impact our revenues and profitability.
- If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted.
- If we are not able to maintain and enhance our reputation and brand recognition, our results will be harmed.
- Consolidation in the health care industry could have a material adverse effect on our business..
- Competition could limit our ability to maintain or expand market share.
- Audits by CMS, other governmental payers and whistleblower claims could impact our business.
- Exclusivity and right of first refusal clauses in some of our contracts may restrict us.
- Offshore support services may be difficult to manage or may not allow us to reach our cost reduction goals.
- Our inability to contain health care costs relating to our health plan business, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements may adversely affect our business and profitability.
- Loss of one or more of our executive officers or key employees could adversely affect our business.
- We may never realize the full value of our goodwill and other intangible assets.
- We may need to obtain additional financing which may not be available.
- We have experienced net losses in the past and we may not achieve profitability in the future.
- Litigation, government inquiries, reviews, audits or investigations could adversely affect our business.
- Future material weaknesses may impact our ability produce timely and accurate financial statements.
- Privacy and data protection laws may impose restrictions and subject us to penalties.
- Data loss or corruption may adversely affect our reputation and relationships with existing partners.
- Failure to safeguard data may result in significant liabilities, and business and reputational harm.
- Failure to maintain and protect intellectual property may adversely affect our products and technology.

- If our trademarks and trade names are not adequately protected, our business may be adversely affected.
- Third party claims that we are violating their intellectual property rights could have a material adverse effect on our business.
- Our use of “open source” software could affect our ability to offer our services and subject us to litigation.
- Failure to protect our proprietary information could impact the value of our technology and products.
- Our dependence on licensed technologies could prevent us from developing and commercializing products.
- Restrictions on our use of third-party technologies could have a material adverse effect on our business.
- Interruption in technology services provided by third parties or our own systems could adversely impact our brand and our business.
- We rely on third-party vendors to host and maintain our technology platform.
- We are required to pay certain of our pre-IPO investors for certain tax benefits we may claim in the future.
- We will not be reimbursed for any payments made under the TRA if any tax benefits are disallowed.
- We may not be able to realize all or a portion of the tax benefits that resulted from the exchanges of Class B common units for our Class A common stock from the utilization of NOLs.

- Payments by us under the TRA may be accelerated or exceed the tax benefits we realize.
- Agreements between us and certain pre-IPO investors contain different terms than comparable agreements with unaffiliated third parties.
- The conditional conversion feature of the 2025 Notes may adversely affect our financial condition.
- The accounting method for convertible debt securities that may be settled in cash could have a material effect on our reported financial results.
- We expect that our stock price will be volatile and may fluctuate or decline significantly.
- We are subject to class action litigation and an adverse outcome could have an adverse effect on us.
- The market price of our stock could decline due to the large number of shares issuable upon conversion of our convertible notes, or by sales or issuances of substantial amounts of our Class A common stock.
- Some provisions of Delaware law and our charter documents may deter third parties from acquiring us.
- Our charter contains provisions renouncing our interest and expectation to participate in certain corporate opportunities identified by or presented to certain of our pre-IPO investors.
- Our charter designates Delaware courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders.
- We do not anticipate paying any cash dividends in the foreseeable future.

Our business, operations and financial position are subject to various risks. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including the audited annual financial statements and notes thereto included elsewhere in this Form 10-K, when evaluating your investment in our securities. The risks and uncertainties described below are those that we currently believe may materially affect the Company. Additional risks and uncertainties of which we are unaware or that we currently deem immaterial also may become important factors that affect the Company. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our securities could decline, and you could lose part or all of your investment. Some statements in this Form 10-K, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled “Forward-Looking Statements - Cautionary Language.”

### **Risks relating to our business and industry**

*We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with a significant partner, or multiple partners in the aggregate, could negatively impact our results.*

Historically, we have relied on a limited number of partners for a substantial portion of our total revenue and accounts receivable. Our largest partner in terms of both revenue and accounts receivable, Cook County Health and Hospitals System, comprised 20.3% of our revenue and 61.5% of our accounts receivable for 2020. The unexpected loss of Cook County or any other significant partner, or the renegotiation of any of our significant partner contracts, could adversely affect our results. We cannot assure that similar facts will not occur with a different partner in the future.

In the ordinary course of business, we engage in active discussions and renegotiations with our partners in respect of the services we provide and the terms of our partner agreements, including our fees. As our partners’ businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, certain of our partners have renegotiated or terminated, and we expect that in the future additional partners will, from time to time, seek to renegotiate or terminate their agreements with us. These discussions and future discussions have resulted and could result in reductions to the fees and changes to the scope of services contemplated by our original partner contracts and consequently have and could negatively impact our revenues, business and prospects.



Because we rely on a limited number of partners for a significant portion of our revenues, we depend on the creditworthiness of these partners. Our partners are subject to a number of risks including reductions in payment rates from governmental payers, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations, such as plans established under the ACA and Aged, Blind and Disabled Medicaid. If the financial condition of our partners declines, our credit risk could increase. Should one or more of our significant partners (including Cook County) declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, the collectability of our accounts receivable and affect our bad debt reserves and net income (loss).

Although we have long-term contracts with many partners, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of these contracts are terminable for convenience by our partners after a notice period has passed and the partner has paid a termination fee. Certain of our contracts are terminable immediately upon the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified

period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. In addition, certain of our contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any of our contracts with our partners is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health typically run for one-year terms. While they typically contain year-to-year renewal provisions, we cannot assure that any or all of these contracts will be renewed in any particular year. We expect that future contracts will contain similar provisions to those described in this paragraph.

*The market for value-based health care in the United States continues to evolve, which makes it difficult to forecast demand for our products and services.*

The market for value-based health care in the United States is rapidly evolving. Our future financial performance will depend in part on growth in this market and on our ability to adapt to emerging demands of this market. It is difficult to predict with any precision the future growth rate and size of our target markets.

The rapidly evolving nature of the markets in which we operate, as well as other factors that are beyond our control, reduce our ability to accurately evaluate our long-term outlook and forecast annual performance. We believe that demand for our products and services has been driven in large part by price pressure in traditional FFS health care, a regulatory environment that is incentivizing value-based care models, a rapid expansion of retail insurance, broader use of the Internet and advances in technology. Widespread acceptance of the value-based care model is critical to our future growth and success. A reduction in demand for our products and services caused by lack of acceptance, technological challenges, competing offerings or other factors would result in a lower revenue growth rate or decreased revenue, either of which could negatively impact our business and results of operations. For example, a large portion of New Century Health's revenue is derived from customers in the managed care industry, including risk bearing providers and national and regional managed care companies. Changes in this industry's business practices could negatively impact New Century Health. For example, if New Century Health's managed care customers seek to provide services directly to their subscribers instead of contracting with New Century Health for such services, New Century Health could be adversely affected.

*The health care regulatory and political framework is uncertain and evolving.*

Health care laws and regulations are rapidly evolving and may change significantly in the future, including as a result of the new Biden administration, which could adversely affect our financial condition and results of operations. For example, in March 2010, the ACA was adopted, which is a health care reform measure that aims to increase the number of Americans with health insurance and reduce health care related costs. The ACA includes a variety of health care reform provisions and requirements, which became effective at varying times through 2018 and substantially changed the way health care is financed by both governmental and private insurers, which may significantly impact our industry and our business. During 2017, several attempts were made to amend the ACA, although no amendment proposal gained the requisite support from the U.S. Senate to pass a repeal bill. As a result, in October 2017, former President Trump issued an executive order relating to the ACA titled "Promoting Healthcare Choice and Competition Across the United States," which further directs federal agencies to modify how the ACA is implemented, and soon after announced the termination of the cost-sharing subsidies that reimburse insurers under the ACA. It is expected that the Biden administration will repeal the Executive Order, but it is not known what other changes the new administration will implement through Congress or future executive orders, and how those may impact our partners and our business. Because of the continued uncertainty about the ACA, including the timing of and potential for

further legal challenges, repeal or amendment of that legislation and future of the health insurance exchanges, we cannot quantify or predict with any certainty the likely impact of the ACA on our business, financial condition, operating results and prospects.

In addition, Congress, state legislatures and third-party payers may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system, including with respect to Medicare and Medicaid programs. In January 2020, CMS announced a new demonstration program that will allow states to adopt a block grant, capped-funding approach to Medicaid. We cannot quantify or predict with any certainty the likely impact of the demonstration program, other changes in the law or new interpretations of existing laws, on our methods and costs of doing business.

Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS and Congress to continue to closely scrutinize each component of the Medicare program as well as modify the terms and requirements of the program. It is not possible to predict the outcome of this Congressional or regulatory activity, either of which

could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the health care delivery system, including Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.

In addition to these health care laws and regulations, we are subject to various other laws and regulations, including, among others, other aspects of state insurance laws, the Stark Law relating to self-referrals, the whistleblower provisions of the False Claims Act, anti-kickback laws, antitrust laws and the privacy and data protection laws. We have identified instances of noncompliance in the past and cannot guarantee that we will not identify other instances in the future, or the outcome of any regulatory investigation into any non-compliance. See “Part I-Item 1. Business-Health Care Laws and Regulations” for additional information. If we were to become subject to litigation, liabilities or penalties under these or other laws or as part of a governmental review or audit, our business could be adversely affected.

*If we are unable to offer new and innovative products and services or our products and services fail to keep pace with advances in industry standards, technology and our partners’ needs, our partners may terminate or fail to renew their relationships with us and our revenue and results of operations may suffer.*

Our success depends on providing high-quality products and services that health care providers use to improve clinical, financial and operational performance. If we cannot adapt to rapidly evolving industry standards, technology and increasingly sophisticated and varied partner needs, our existing technology could become undesirable or obsolete, which could harm our reputation. We must continue to invest significant resources in our personnel and technology in a timely and cost-effective manner in order to enhance our existing products and services and introduce new high-quality products and services that existing partners and potential new partners will want. Our operating results would also suffer if our innovations are not responsive to the needs of our existing partners or potential new partners, are not appropriately timed with market opportunity, are not effectively brought to market or significantly increase our operating costs. If our new or modified product and service innovations are not responsive to partner preferences, emerging industry standards or regulatory changes, are not appropriately timed with market opportunity or are not effectively brought to market, we may lose existing partners or be unable to obtain new partners and our results of operations may suffer. In addition, should any of our partners terminate their relationship with us after implementation has begun, we would not only lose our time, effort and resources invested in that implementation, but we would also have lost the opportunity to leverage those resources to build a relationship with other partners over that same period of time. In some cases, we price our services based on expectations of long-term relationships and when the partner terminates the relationship earlier than we had expected, we lose the resources invested in that relationship as well as the upside benefits we had anticipated.

We also engage third-party vendors to develop, maintain and enhance our technology solutions, and our ability to develop and implement new technologies is therefore dependent on our ability to engage suitable vendors. We may also need to license software or technology from third parties in order to maintain, expand or modify our technology-enabled services platform. However, there is no guarantee we will be able to enter into such agreements on acceptable terms or at all. The functionality of our services platforms depend, in part, on our ability to integrate with third-party applications and data management systems that our partners use and from which they obtain data. These third parties may terminate their relationships with us, change the features of their applications and platforms, restrict our access to their applications and platforms or alter the terms governing use of their applications, data management systems and application programming interfaces and access to those applications and platforms in an adverse manner.

*We have made and entered, and may in the future make and enter acquisitions, investments and alliances and joint ventures, which may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.*

As our business continues to grow, we may continue to acquire or invest in companies, businesses, products or technologies that complement our current products and services, enhance our market coverage or technical capabilities or offer growth opportunities. This may include acquiring or investing in companies, businesses, products or technologies that are tangential to our current business and

in which we have limited or no prior operating experience. That and other acquisitions, investments, alliances or joint ventures, have resulted and could result in new, material risks to our results of operations, financial condition, business and prospects. These new risks could include increased variability in revenues and prospects associated with various risk sharing arrangements. In addition, the market price for our Class A common stock could also be affected, following the consummation of any other transaction, by factors that have not historically affected the market price for our Class A common stock.

We continuously evaluate potential acquisition targets and investments. However, there can be no assurance that any of these potential acquisitions or investments will be consummated. Acquisitions, investments and alliances could numerous risks to our business which could negatively impact and our financial condition and results of operations, including:

- difficulty converting platforms or integrating the purchased operations, products or technologies;
- substantial unanticipated integration costs, delays and challenges that may arise in integration;
- the loss of key customers who are in turn subject to risks and financial dislocation in their businesses;

- the loss of key employees, particularly those of the acquired operations;
- difficulty retaining or developing the acquired business' customers;
- adverse effects on our existing business relationships with customers, suppliers, other partners, standing with regulators;
- challenges related to the integration and operation of businesses that operate in new geographic areas and new markets or lines of business;
- challenges related to the integration and operation of businesses that operate in new geographic areas and new markets or lines of business;
- unanticipated financial losses in the acquired business, including the risk of higher than expected health care costs;
- failure to realize the potential cost savings or other financial benefits or the strategic benefits of the acquisitions, including failure to consummate any proposed or contemplated transaction; and
- liabilities, including acquired litigation, and expenses from the acquired businesses for contractual disputes with customers and other third parties, infringement of intellectual property rights, data privacy violations or other claims and failure to obtain indemnification for such liabilities or claims, and distraction of our personnel in connection with any related proceedings.

We may be unable to integrate the operations, products, technologies or personnel gained through acquisitions or investments or integrate or complete any other such transaction without a material adverse effect on our business, financial condition and results of operations. Transaction agreements may impose limitations on our ability, or the ability of the business to be acquired, to conduct business. Events outside our control, including operating changes or regulatory changes, could also adversely affect our ability to realize anticipated revenues, synergies, benefits and cost savings. In addition, revenues of acquired businesses or companies, prior to and after consummation of a transaction, may be less than expected. Counterparties in transactions may have contracts with customers and other business partners which may require consents from these parties in connection with a transaction. If these consents cannot be obtained, the Company may suffer a loss of potential future revenue and may lose rights that are material to its business and the business of any combined company. Any such disruptions could limit our ability to achieve the anticipated benefits of the transaction. Any integration may be unpredictable, or subject to delays or changed circumstances, and we and any targets may not perform in accordance with our expectations.

We have also entered into a number of joint ventures. Conflicts or disagreements between us and any joint venture partner may negatively impact the benefits expected to be achieved by the joint venture or may ultimately threaten the ability of such joint venture to continue. We are also subject to additional risks and uncertainties because we may be dependent upon and subject to the liability, losses or reputational damage relating to joint venture partners that are not entirely under our control.

In connection with these acquisitions, investments, alliances or joint ventures, we could incur significant costs, debt, amortization expenses related to intangible assets or large and immediate write-offs or other impairments or charges (as was the case with the \$47.1 million impairment charge we incurred in connection with our investment in GlobalHealth during the year ended December 31, 2020, which represented the total value of our investment), assume liabilities or issue stock (as we have done in prior transactions) that would dilute our current stockholders' ownership.

*The financial benefits we expect to receive as a result of our sale of certain assets of Passport to Molina may not be realized.*

On September 1, 2020, EVH Passport and Molina consummated the Molina Closing and the Passport Medicaid Contract was novated to Molina. In the event certain conditions are not fulfilled, we may not realize the economic benefits we expect to derive from the transaction. The amount of cash we ultimately receive in connection with the transactions consummated by the Molina APA, the wind down of EVH Passport and related transactions could be adversely affected by a number of factors including litigation from third parties, the outcome of ongoing protests against the Kentucky Medicaid awards for 2021 and the results of litigation related thereto, the performance of Passport through 2020 and the results of Medicaid open enrollment in the Commonwealth of Kentucky. In addition, our

return of capital from EVH Passport, which is expected to be between \$130 million and \$170 million in total, is subject to regulatory approval from the Kentucky Department of Insurance, and we cannot control or predict the timing of such capital return.

*Our revenues and the growth of our business rely, in part, on the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes.*

We enter into agreements with our partners under which a significant portion of our fees are variable, including fees which are dependent upon the number of members that are covered by our partners' health care plans each month, expansion of our partners and the services that we provide, as well as performance-based metrics. The number of members covered by a partner's health care plan is often impacted by factors outside of our control, such as the actions of our partner or third parties. In addition, ongoing payment of fees by our partners could be negatively impacted by the general financial condition of our partners. Accordingly, revenue under these agreements is unpredictable. If the number of members covered by one or more of our partners' plans were to be reduced by a material amount, or if member enrollment numbers in new plans are lower than expected, which was the case with our Florida Medicaid

partners, such decrease would lead to a decrease in our expected revenue, which could harm our business, financial condition and results of operations. In addition, growth forecasts of our partners are subject to significant uncertainty and are based on assumptions and estimates that may prove to be inaccurate. Even if the markets in which our partners compete meet the size estimates and growth forecasted, their health plan membership could fail to grow at similar rates, if at all. In addition, a portion of the revenue under certain of our service contracts is tied to the partners' continued participation in specified payer programs over which we have no control. If a partner ceases to participate or is disqualified from participation in any such program, this would lead to a decrease in our expected revenue under the relevant contract.

In addition, the transition to value-based care may be challenging for our partners. For example, fully capitated or other provider risk arrangements have had a history of financial challenges for providers. Our partners may also have difficulty in value-based care if premium pricing is under pressure or if they incur selection bias in the health plans under which they assume risk and in so doing the premium, capitation amount or other risk-sharing arrangement they undertake does not adequately reflect the health status of the membership. Our partners may choose not to continue to capitalize affiliated health plans or subsidize losses to their reimbursement rates. Furthermore, revenue under our partner contracts may differ from our projections because of the termination of the contract for cause or at specified life cycle events, or because of fee reductions that are occasionally agreed to after the contract is initially signed.

Our partners derive a substantial portion of their revenue from third-party private and federal and state governmental payers, including Medicaid programs. Revenue under certain of our agreements could be negatively impacted as a result of governmental funding reductions impacting government-sponsored programs, changes in reimbursement rates, and premium pricing reductions, as well as the inability of our partners to control and, if necessary, reduce health care costs, all of which are out of our control. Because certain of our partners' revenues are highly reliant on third-party payer reimbursement funding rates and mechanisms, overall reductions of rates from such payers could adversely impact the liquidity of our partners, resulting in their inability to make payments to us on agreed payment terms. These risks may be heightened by the COVID-19 pandemic. See "Risk factors-The health care regulatory and political framework is uncertain and evolving" for additional information.

*Failure to accurately underwrite performance-based contracts could result in a reduction in profitability for our Specialty Care Management solution.*

New Century Health, the brand name we use for our specialty care management solution, derives a portion of its revenue from arrangements under which it assumes responsibility for a portion of the total cost of treatments (for oncology and cardiology patients) in exchange for a fixed fee. These are typically referred to as "performance-based contracts". If the Company is unable to accurately underwrite the health care cost risk for New Century Health and control associated costs, the Company's profitability could decline. Moreover, costs of providing cancer care are very hard to predict, in part as a result of rapidly changing utilization of new and existing drugs and changing diagnostic and therapeutic protocols. The competitive environment for New Century Health's performance-based products could result in pricing pressures which could cause New Century Health to reduce its rates. In addition, customer demands or expectations as to margin levels could cause New Century Health to reduce its rates. A reduction in performance-based contract rates which are not accompanied by a reduction in covered services or expected underlying care trend could result in a decrease of New Century Health's operating margins.

*If we fail to effectively manage our growth and cost structure, our business and results of operations could be harmed.*

We have expanded our operations significantly since our inception, organically as well as through acquisitions. If we do not effectively manage our growth and maintain an efficient cost structure as we continue to expand, the quality of our products and services could suffer. Our growth to date has increased the significant demands on our management, our operational and financial systems and infrastructure and other resources. In order to successfully expand our business, we must effectively recruit, integrate and motivate new employees, while maintaining the beneficial aspects of our corporate culture. We may not be able to hire new employees quickly enough to meet



our needs. If we fail to effectively manage our hiring needs and successfully integrate our new employees, our efficiency and ability to meet our forecasts and our employee morale, productivity and retention could suffer, and our business and results of operations could be harmed. We must also continue to improve our existing systems for operational and financial management, including our reporting systems, procedures and controls. These improvements require significant capital expenditures and place increasing demands on our management. We may not be successful in managing or expanding our operations or in maintaining adequate financial and operating systems and controls. If we do not successfully manage these processes, including the timely processing of claims on behalf of our partners, our business and results of operations could be harmed.

*Public health emergencies such as the COVID-19 pandemic have adversely affected, and could in the future, adversely affect our business and the business of our customers and suppliers.*

An epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could significantly disrupt or prevent us from operating our business in the ordinary course for an extended period, and thereby, and/or

along with any associated economic and/or social instability or distress, have a material adverse impact on our results of operations, cash flows and financial condition.

To date, due to the nature of the services we provide, market dynamics in our end markets and with our significant customers, our operations have not been materially affected by the ongoing global COVID-19 pandemic and the resulting volatility and uncertainty it has caused in the U.S. and international markets. The extent to which COVID-19 ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Factors that may determine the severity of the impact include the duration of the outbreak, new information which may emerge concerning the severity of COVID-19, employee mobility and productivity and the actions to contain COVID-19 or treat its impact (including federal, state and local directives to remain at home or forced business closures), among others.

The COVID-19 pandemic may impact our business, financial condition, cash flows, or results of operations in a number of ways, including the following:

- State Medicaid agencies may experience budget pressures as a result of the pandemic which could negatively impact payments to certain of our Medicaid health plan customers and potentially cause us to incur additional bad debt expense.
- The impact of the pandemic on certain partners could result in delayed or reduced payments to us.
- As our employees and our partners' employees work from home and access our system remotely, we may be subject to heightened security and privacy risks, including the risks of cyberattacks and privacy incidents.
- Volatility in the capital markets could have a negative impact on our ability to access those markets on acceptable terms, or at all.
- Any benefits to our business as a result of increased Medicaid membership or lower utilization may not be sustained in or through future periods.

The inherent uncertainty surrounding COVID-19, due in part to rapidly changing governmental directives, public health challenges and progress, and market reactions thereto, also makes it more challenging for our management to estimate the potential impact and the future performance of our business. We cannot at this time predict the impact of the COVID-19 pandemic, but it could materially adversely affect our business, including our financial position, results of operations and/or cash flows.

*Our offshore support and professional services may prove difficult to manage or may not allow us to realize our cost reduction goals.*

We use certain offshore resources to provide certain support and professional services, which requires technical and logistical coordination. If we are unable to maintain acceptable standards of quality in support and professional services, our attempts to reduce costs and drive growth through margin improvements in technical support and professional services may be negatively impacted, which would adversely affect our results of operations. Our offshore resources, and their ability to provide support and professional services to our domestic operations, are subject to domestic regulation at the federal, state and local levels. In certain cases, those regulations restrict or prohibit us from using our offshore resources. As a result, we may not be able to reduce costs for our domestic operations or fully realize our margin improvement goals.

*While we continue to own a health plan, our inability to contain health care costs relating to our health plan business, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements may adversely affect our business and profitability.*

We have entered into an agreement to sell True Health, our health plan business, to Bright HealthCare. Closing of the transaction is subject to customary closing conditions, and while we expect the transaction to close in the first half of 2021, we cannot assure you that

the closing will take place on that timeframe or at all. In the event that the transaction does not close, we will remain subject to the risks described in this risk factor, and a significant reduction in enrollment in our health plan could materially impact our results.

The profitability of our health plan businesses, which includes our wholly owned True Health business, depends in large part on accurately predicting health care costs, coding and risk adjustment and on our ability to manage future health care costs through medical management, product design, negotiation of favorable provider contracts and underwriting criteria. Government-imposed limitations on Medicare and Medicaid reimbursement have also caused the private sector to bear a greater share of increasing health care costs. Changes in health care practices, demographic characteristics, inflation, new technologies, the cost of prescription drugs, clusters of high cost cases, changes in the regulatory environment and numerous other factors affecting the cost of health care may adversely affect our ability to predict and manage health care costs, as well as our business, financial condition and results of operations.

In addition to the challenge of managing health care costs, we face pressure to contain premium rates. Our customers may renegotiate their contracts to seek to contain their costs or may move to a competitor to obtain more favorable premiums. Further, federal and state regulatory agencies may restrict our ability to implement changes in premium rates. Fiscal concerns regarding the continued viability

of programs such as Medicare and Medicaid may cause declines in membership and eligibility, decreasing reimbursement rates, including retroactive decreases in Medicaid reimbursement rates, and/or retrospective changes in membership and associated financial responsibility, delays in premium payments or a lack of sufficient increase in reimbursement rates for government-sponsored programs in which we participate. A limitation on our ability to increase or maintain our premium or reimbursement levels or a significant loss of membership resulting from our need to increase or maintain premium or reimbursement levels could adversely affect our business, cash flows, financial condition and results of operations.

The reserves that we establish for health insurance policy benefits and other contractual rights and benefits are based upon assumptions concerning a number of factors, including trends in health care costs, expenses, general economic conditions and other factors. In addition, claims reserves reflect estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. To the extent the actual claims experience is unfavorable as compared to our underlying assumptions, our incurred losses would increase and future earnings could be adversely affected. Our health plan businesses are required to maintain regulatory capital levels and if our actual claims experience is unfavorable compared to our assumptions we may be required to increase our regulatory capital levels. In addition, our health plans may enter new lines of business. For example, in 2020, True Health launched a product on the individual exchange. Our assumptions and expectations around the costs of entering and operating any such new lines of business may prove to be materially different from our expectations.

The profitability of our health plan business is dependent in part upon our ability to contract on favorable terms with hospitals, physicians, claims processing service providers and other health care providers. Physicians, hospitals and other health care providers may refuse to contract with us, and the failure to secure or maintain cost-effective health care provider contracts on competitive terms may result in a loss of membership or higher medical costs, which could adversely affect our business. In addition, consolidation among health care providers, ACO practice management companies, which aggregate physician practices for administrative efficiency and marketing leverage, and other organizational structures that physicians, hospitals and other care providers choose may change the way that these providers interact with us and may change the competitive landscape. Such organizations or groups of physicians may compete directly with us, which may impact our relationship with these providers or affect the way that we price our products and estimate our costs and may require us to incur costs to change our operations, and our business, cash flows, financial condition and results of operations could be adversely affected.

Our inability to contract with providers, or if providers attempt to use their market position to negotiate more favorable contracts or place us at a competitive disadvantage, or the inability of providers to provide adequate care, could adversely affect our business. In addition, we do not have contracts with all providers that render services to our members and, as a result, do not have a pre-established agreement about the amount of compensation those out-of-network providers will accept for the services they render, which can result in significant litigation or arbitration proceedings, or provider attempts to obtain payment from our members for the difference between the amount we have paid and the amount they have charged.

*We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.*

Our success depends largely upon the continued services of our key executive officers and recruitment of additional highly skilled employees. From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives, which could disrupt our business. Hiring executives with needed skills or the replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.

In addition, competition for qualified management in our industry is intense. Many of the companies with which we compete for management personnel have greater financial and other resources than we do. We have not entered into employment agreements with our executive officers. All of our employees are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason and without notice. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. In addition, volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart. If we are not able to retain any of our key management personnel, our business could be harmed.

*We have recorded a significant amount of goodwill, and we may never realize the full value of our intangible assets, causing us to record impairments that may negatively affect our results of operations.*

The Company has four reporting units. Our total assets include substantial goodwill. At December 31, 2020, we had \$354.7 million of goodwill on our consolidated balance sheets. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors.

While our annual goodwill impairment test is conducted at October 31, we have processes to monitor for interim triggering events. Under GAAP, we review our goodwill for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our goodwill may not be recoverable include macroeconomic conditions, industry and market considerations, our overall financial performance including an analysis of our current and projected cash flows, revenue and earnings, a sustained decrease in our share price and other relevant entity-specific events including changes in strategy, customers or litigation.

A detailed discussion of our impairment testing is included in “Part II - Item 8. Financial Statements and Supplementary Data - Note 8.”

The Company recorded goodwill of \$762.4 million as of December 31, 2018 in its Services segment and subsequently recorded impairment charges of \$199.8 million and \$215.1 million during the three months ended December 31, 2019 and June 30, 2020, respectively, as a result of factors relating to the Company’s investment in Passport. When other indications of goodwill impairment exist, we may be required to recognize additional impairments in the future as a result of market conditions or other factors related to our performance, including changes in our forecasted results, investment strategy, interest rates or assumptions used as part of the goodwill impairment analysis. Any further impairment charges that we may record in the future could be material to our results of operations.

*We may need to obtain additional financing which may not be available or, if it is available, may result in a reduction in the ownership of our stockholders.*

We may need to raise additional funds in order to:

- finance unanticipated working capital requirements;
- develop or enhance our technological infrastructure and our existing products and services;
- fund strategic relationships, including joint ventures and co-investments;
- fund additional implementation engagements; and
- acquire complementary businesses, technologies, products or services.

Additional financing may not be available on terms favorable to us, or at all. If adequate funds are unavailable or are unavailable on acceptable terms, our ability to fund our expansion strategy, take advantage of unanticipated opportunities, develop or enhance technology or services or otherwise respond to competitive pressures could be significantly limited. If we raise additional funds by issuing equity or convertible debt securities, the ownership of our then-existing stockholders may be reduced, and holders of these securities may have rights, preferences or privileges senior to those of our then-existing stockholders. In addition, any indebtedness we incur and restrictive covenants contained in the agreements related thereto could:

- make it difficult for us to satisfy our obligations, including interest payments on any debt obligations;
- limit our ability to obtain additional financing to operate our business;
- require us to dedicate a substantial portion of our cash flow to payments on our debt, reducing our ability to use our cash flow to fund capital expenditures and working capital and other general operational requirements;
- limit our flexibility to plan for and react to changes in our business and the health care industry;
- place us at a competitive disadvantage relative to our competitors;
- limit our ability to pursue acquisitions; and

- increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy.

The occurrence of any one of these events could cause a significant decrease in our liquidity and impair our ability to pay amounts due on any indebtedness, and could have a material adverse effect on our business, financial condition and results of operations.

*We have experienced net losses in the past and we may not achieve profitability in the future.*

We have incurred significant net losses in the past and our operating expenses may increase in the future as we continue to invest to grow our business and build relationships with partners, develop our platforms and develop new solutions. These efforts may prove to be more expensive than we currently anticipate, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. In addition, as we continue to increase our partner base, we could incur increased losses due to mis-forecasted underwriting in performance-based contracts or because significant costs associated with entering into partner agreements are generally incurred up

front, while revenue under certain of our partner agreements is recognized each period in the month in which the services are delivered. As a result, we may need to raise additional capital through equity and debt financings in order to fund our operations. We may also fail to improve the gross margins of our business as anticipated. If we are unable to effectively manage these risks and difficulties as we encounter them, our business, financial condition and results of operations may suffer.

*We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations which could have a material adverse effect on our business, financial condition and results of operations.*

We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations in the future, including potential claims against us by our partners, with or without merit. For example, on August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer and Steven Wigginton seeking unspecified remedies under the Securities Exchange Act of 1934. A second amended complaint, which was substantially similar to the amended complaint, was filed on June 8, 2020. The Company filed a motion to dismiss in response on June 22, 2020 and the briefing was completed on July 17, 2020; the parties are now waiting for the court's decision. Some of these matters and claims may result in significant defense costs and potentially significant judgments against us, some of which we are not, or cannot be, insured against. We generally intend to defend ourselves vigorously; however, we cannot be certain of the ultimate outcomes of any claims or other matters that may arise in the future. Resolution of these types of matters against us may result in our having to pay significant fines, judgments or settlements, which, if uninsured, or if the fines, judgments and settlements exceed insured levels, could adversely impact our earnings and cash flows, thereby having a material adverse effect on our business, financial condition, results of operations, cash flow and per share trading price of our Class A common stock. Certain litigation, proceedings, government inquiries, reviews, audits or investigations or the resolution of such matters may affect the availability or cost of some of our insurance coverage, which could adversely impact our results of operations and cash flows, expose us to increased risks that would be uninsured and adversely impact our ability to attract directors and officers.

### **Risks Related to Data Protection Privacy, Cybersecurity, Intellectual Property and Technology**

*We typically incur significant upfront costs in our partner relationships, and if we are unable to develop or grow these partner relationships over time, we are unlikely to recover these costs and our operating results may suffer.*

We devote significant resources to establish relationships with our partners. Some of our partners undertake a significant and prolonged evaluation process, often to determine whether our products and services meet their unique health system needs, which has in the past resulted in extended periods of time to establish a partner relationship. Our efforts involve educating our partners about the use, technical capabilities and benefits of our products and services. Accordingly, our operating results will depend in substantial part on our ability to deliver a successful partner experience and persuade our partners to grow their relationship with us over time. There is no guarantee that we will be able to successfully convert a customer of our transformation services into a partner of our platform and operations services. If we are unable to sell additional products and services to existing partners, enter into and maintain favorable relationships with new partners or sufficiently grow our partners' lives on platform, it could have a material adverse effect on our business, financial condition and results of operations. As we grow, our customer acquisition costs could outpace our build-up of recurring revenue, and we may be unable to reduce our total operating costs through economies of scale such that we are unable to achieve profitability. For example, some of our partnerships require significant upfront investment including, in the case of new markets, investments in infrastructure to meet readiness and operating requirements which have outpaced our revenue growth, which was the case with our Florida Medicaid partners. Under the ASC 606 revenue standard, certain set up costs we incur during the implementation phase may be deferred into the P&O phase, potentially along with associated revenues. If the economics of a partnership change such that we are unlikely to fully recover those costs, we may be required to write off a portion or all of those deferred costs and revenues and our operating results may suffer. In addition, we estimate the costs and timing for completing the transformation phase of relevant partner relationships. These estimates reflect our best



judgment. Any increased or unexpected costs or unanticipated delays, including delays caused by factors outside our control, could cause our operating results to suffer.

*If we do not continue to attract new partners and successfully capture new opportunities, we may not achieve our revenue projections, and our results of operations would be harmed.*

In order to grow our business, we must continually attract new partners and successfully capture new opportunities. Our ability to do so depends in large part on the success of our sales and marketing efforts. Potential partners may seek out other options. Therefore, we must demonstrate that our products and services provide a viable solution for potential partners. If we fail to provide high-quality solutions and convince individual partners of our value proposition, we may not be able to retain existing partners or attract new partners. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of the market for our products and services due in part to the rapidly evolving nature of the health care and technology industries and the substantial resources available to our existing and potential competitors. If the market for our products and services declines or grows more slowly than we expect, if we fail to successfully convert new growth opportunities or if the number of individual partners that use our

solutions declines or fails to increase as we expect, our revenue, results of operations, financial condition, business and prospects could be harmed.

*As we enter into an increasing number and variety of risk sharing arrangements with partners, our revenues and profitability could be limited and negatively impacted.*

We may choose to incorporate certain risk sharing arrangements as part of our contractual arrangements with our partners, and we expect to enter an increasing number and variety of risk sharing arrangements in the future. As an example, as part of our strategy to support certain partners, we entered into upside and downside risk-sharing arrangements. Through our specialty care management services, we take on members from payers through performance-based arrangements where we assume risks related to pricing of contracts for the provision of oncology and cardiology services. We may incur losses under these arrangements if we are unable to adjust our rates if faced with increased costs related to patient care or pharmaceutical products.

As the market evolves, we expect to engage in similar and new risk sharing strategies with our partners. As of December 31, 2020, Evolent had approximately \$4.7 million of restricted cash and restricted investments related to risk-sharing arrangements. These arrangements have included and may include provision of letters of credit, loans, reinsurance arrangements, equity investments and other extensions of capital, where we are and may be at risk of not recovering all or a portion of any such loan or other extension of capital. These and any other potential risk sharing arrangements could limit and negatively impact our revenue, results of operations, financial condition, business and prospects.

In addition, our failure to agree on satisfactory risk sharing solutions with potential partners could negatively impact our ability to attract new partners. We may also be required to make additional capital contributions as we invest and enter into new joint ventures and strategic alliances.

*If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted and our business would be harmed.*

Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Our estimates and forecasts relating to the size and expected growth of the markets for our services may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.

Our estimates of the market opportunities for our services are based on the assumption that the strategic approaches we offer will be attractive to potential partners. Potential partners may pursue different strategic options, or none at all. In addition, our assumptions could be impacted by changes to health care laws and regulations. If our assumptions prove inaccurate, our business, financial condition and results of operations could be adversely affected.

*If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.*

We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing partners and to our ability to attract new partners. The promotion of our brands may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our partners, or any adverse publicity or litigation involving or surrounding the Company or one of our joint venture partners, investors or strategic alliance partners could make

it substantially more difficult for us to attract new partners. Similarly, because our existing partners often act as references for us with prospective new partners, any existing partner that questions the quality of our work or that of our employees could impair our ability to secure additional new partners. Therefore, financial adversity of our partners' affiliated health plans may adversely affect our reputation. In addition, negative publicity resulting from any adverse government payer audit could injure our reputation. If we do not successfully maintain and enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with partners, which would harm our business, results of operations and financial condition.

*Consolidation in the health care industry could have a material adverse effect on our business, financial condition and results of operations.*

Many health care industry participants and payers are consolidating to create larger and more integrated health care delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the health care

industry in the future. As consolidation accelerates, the economies of scale of our partners' organizations may grow. If a partner experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as health care providers consolidate to create larger and more integrated health care delivery systems with greater market power, these providers may try to use their market power to negotiate fee reductions for our products and services. Finally, consolidation may also result in the acquisition or future development by our partners of products and services that compete with our products and services. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.

*We face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.*

The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, customer needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities.

We compete on the basis of several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement through the use of products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. Some of our competitors are more established, benefit from greater brand recognition, have larger client bases and have substantially greater financial, technical and marketing resources. Other competitors have proprietary technology that differentiates their product and service offerings from ours. Our competitors are constantly developing products and services that may become more efficient or appealing to our existing partners and potential partners. Additionally, some health care information technology providers have begun to incorporate enhanced analytical tools and functionality into their core product and service offerings used by health care providers. As a result of these competitive advantages, our competitors and potential competitors may be able to respond more quickly to market forces, undertake more extensive marketing campaigns for their brands, products and services and make more attractive offers to our existing partners and potential partners.

We also compete on the basis of price. We may be subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of health care industry participants, practices of managed care organizations, government action and financial stress experienced by our partners. If our pricing experiences significant downward pressure, our business will be less profitable and our results of operations will be adversely affected.

We cannot be certain that we will be able to retain our current partners or expand our partner base in this competitive environment. If we do not retain current partners or expand our partner base, or if we have to renegotiate existing contracts, our business, financial condition and results of operations will be harmed. Moreover, we expect that competition will continue to increase as a result of consolidation in both the health care information technology and health care industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could also adversely affect our ability to compete effectively and could harm our business, financial condition and results of operations.

*Our offerings could be subject to audits by CMS and other governmental payers and whistleblower claims under the False Claims Act.*

We support provider-sponsored health plans with Medicare Advantage, Medicaid and Exchange products, as well as health systems and physician groups participating in payer-delegated risk arrangements or in the CMS Next Generation ACO Model. We anticipate that CMS and other governmental payers will continue to review and audit the results of our services including risk adjustment offerings, with a focus on identifying possible false claims.

In addition, aspects of our review process and coding procedures could be subject to claims under the False Claims Act or Anti-Kickback Statute. Negative results of any such audit or claim could have a material adverse effect on our business, financial condition, results of operations or prospects and could damage our reputation.

*Exclusivity and right of first refusal clauses in some of our partner and founder contracts may prohibit us from partnering with certain other providers in the future, and as a result may limit our growth.*

Some of our partner and founder contracts include exclusivity and right of first refusal clauses. Any founder contracts with exclusivity, right of first refusal or other restrictive provisions may limit our ability to conduct business with certain potential partners, including competitors of our founders. For example, under the UPMC IP Agreement, if we were to conduct business with certain precluded providers, it would result in the loss of the license thereunder. Partner contracts with exclusivity or other restrictive provisions may limit our ability to partner with or provide services to other providers or purchase services from other vendors within certain time periods. These exclusivity or other restrictive provisions often apply to specific competitors of our health system partners or specific

geographic areas within a particular state or an entire state. Accordingly, these exclusivity clauses may prevent us from entering into relationships with potential partners and could cause our business, financial condition and results of operations to be harmed.

We have also entered into a reseller, services and non-competition agreement with an affiliate of UPMC, pursuant to which we are prohibited from providing products or services to certain third parties and in certain territories. These restrictions could cause our business, financial condition and results of operations to be harmed if we found it advantageous to provide products or services to such third parties or in such territories during the restricted period.

*We are subject to privacy and data protection laws governing the transmission, security and privacy of health information, which may impose restrictions on the manner in which we access personal data and subject us to penalties if we are unable to fully comply with such laws.*

As described below, we are required to comply with numerous federal and state laws and regulations governing the collection, use, disclosure, storage and transmission of individually identifiable health information that we may obtain or have access to in connection with the provision of our services. These laws and regulations, including their interpretation by governmental agencies, are subject to frequent change and could have a negative impact on our business.

- HIPAA expanded protection of the privacy and security of personal health information and required the adoption of standards for the exchange of electronic health information. Among the standards that the Department of Health and Human Services has adopted pursuant to HIPAA are standards for electronic transactions and code sets, unique identifiers for providers, employers, health plans and individuals, security, electronic signatures, privacy and enforcement. Privacy regulations under HIPAA also provide patients with rights related to understanding and controlling how their protected health information is used and disclosed. As a provider of services to entities subject to HIPAA, we are directly subject to certain provisions of the regulations as a “Business Associate.” We are also directly subject to the HIPAA privacy and security regulations as a “Covered Entity” with respect to True Health. If we are unable to properly protect the privacy and security of protected health information entrusted to us, we could be found to have breached our contracts with our customers and be subject to investigation by the U.S. Department of Health and Human Services Office for Civil Rights (“OCR”). In the event the OCR finds that we have failed to comply with applicable HIPAA privacy and security standards, we could face civil and criminal penalties that could have a material adverse effect on us. In addition, OCR performs compliance audits of Business Associates in order to proactively enforce the HIPAA privacy and security standards. OCR has become an increasingly active regulator and has signaled its intention to continue this trend. OCR has the discretion to impose penalties without being required to attempt to resolve violations through informal means; further, OCR may require companies to enter into resolution agreements and corrective action plans which impose ongoing compliance requirements. OCR enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources.
- The HITECH Act, enacted as part of the American Recovery and Reinvestment Act of 2009, also known as the “Stimulus Bill,” effective February 22, 2010, set forth health information security breach notification requirements and increased penalties for violation of HIPAA. The HITECH Act requires individual notification for all breaches, media notification of breaches for over 500 individuals and at least annual reporting of all breaches to the Department of Health and Human Services. Failure to comply with the HITECH Act could result in fines and penalties that could have a material adverse effect on us.
- Numerous other federal and state laws may apply that restrict the use and protect the privacy and security of individually identifiable information, as well as employee personal information. These include state medical privacy laws, state social security number protection laws and federal and state consumer protection laws. These various laws in many cases are not preempted by HIPAA and may be subject to varying interpretations by the courts and government agencies, creating

complex compliance issues for us and our partners and potentially exposing us to additional expense, adverse publicity and liability, any of which could adversely affect our business.

- Federal and state consumer protection laws are increasingly being applied by the FTC and states' attorneys general to regulate the collection, use, storage and disclosure of personal or individually identifiable information, through websites or otherwise, and to regulate the presentation of website content.

There is ongoing concern from privacy advocates, regulators and others regarding data protection and privacy issues, and the number of jurisdictions with data protection and privacy laws have been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identified, anonymous or pseudonymized health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. These discussions may lead to further restrictions on the use of such information. There can be no assurance that these initiatives or future initiatives will not adversely affect our ability to access and use data or to develop or market current or future services.

The security measures that we and our third-party vendors and subcontractors have in place to ensure compliance with privacy and data protection laws may not protect our facilities and systems from security breaches, acts of vandalism or theft, computer viruses,

misplaced or lost data, programming and human errors or other similar events. Under the HITECH Act, as a business associate we may also be liable for privacy and security breaches and failures of our subcontractors. Even though we provide for appropriate protections through our agreements with our subcontractors, we still have limited control over their actions and practices. A breach of privacy or security of individually identifiable health information by a subcontractor may result in an enforcement action, including criminal and civil liability, against us. Our failure to comply may result in criminal and civil liability because the potential for enforcement action against business associates is now greater. Enforcement actions against us could be costly and could interrupt regular operations, which may adversely affect our business. While we have not received any notices of violation of the applicable privacy and data protection laws and believe we are in compliance with such laws, there can be no assurance that we will not receive such notices in the future.

*Data loss or corruption due to failures or errors in our systems or service disruptions at our data centers may adversely affect our reputation and relationships with existing partners, which could have a negative impact on our business, financial condition and results of operations.*

Because of the large amount of data that we collect and manage, it is possible that hardware failures or errors in our systems could result in data loss or corruption or cause the information that we collect to be incomplete or contain inaccuracies that our partners regard as significant. Complex software such as ours may contain errors or failures that are not detected until after the software is introduced or updates and new versions are released. We continually introduce new software and updates and enhancements to our existing software. Despite testing by us, we may discover defects or errors in our software. In addition, we may encounter defects or errors in connection with the integration of software and technology we acquire. Any defects or errors could expose us to risk of liability to partners and the government and could cause delays in the introduction of new products and services, result in increased costs and diversion of development resources, require design modifications, decrease market acceptance or partner satisfaction with our products and services or cause harm to our reputation.

Furthermore, our partners might use our software together with products from other companies. As a result, when problems occur, it might be difficult to identify the source of the problem. Even when our software does not cause these problems, the existence of these errors might cause us to incur significant costs, divert the attention of our technical personnel from our product development efforts, impact our reputation and lead to significant partner relations problems.

*Our business is subject to online security risks, and if we are unable to safeguard the security and privacy of confidential data, we may face significant liabilities and our reputation and business will be harmed.*

Our services involve the collection, storage and analysis of confidential information, including intellectual property and personal information of employees, health providers and others, as well as protected health information of our partners' patients. Because of the extreme sensitivity of this information, the security features of our computer, network, and communications systems infrastructure are very important. In certain cases such information is provided to third parties, for example, to the service providers who provide hosting services for our technology platform, and we may be unable to control the use of such information or the security protections employed by such third parties. We may be required to expend significant capital and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures designed to help ensure data security and compliance with applicable laws and rules, our facilities and systems, and those of our third-party providers, may be vulnerable to cyber-attacks, security breaches, acts of vandalism or theft, computer viruses, misplaced or lost data, programming and/or human errors, power outages, hardware failures or other similar events. Furthermore, our increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic, has heightened these cybersecurity and privacy risks, including risks from cyber-attacks such as phishing, spam emails, hacking, social engineering, and malicious software. If an actual or perceived breach of our security occurs, or if we are unable to effectively resolve such breaches in a timely manner, the market perception of the effectiveness of our security measures could be harmed and we could lose sales and partners, which could have a material adverse effect on our business, operations, and financial results.



A cyber-attack that bypasses our, or our third-party providers', security systems successfully could require us to expend significant resources to remediate any damage, and prevent future occurrences, interrupt our operations, damage our reputation and our relationship with our partners, expose us or other third parties to a risk of loss or misuse of confidential information, reduce demand for our products and services or subject us to significant liability through litigation as well as regulatory action. While we maintain insurance covering certain security and privacy damages and claim expenses we may not carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not be available for renewal on acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage that could result from a security incident.

We may experience cybersecurity and other breach incidents that may remain undetected for an extended period. In addition, techniques used to obtain unauthorized access to information or to sabotage information technology systems change frequently. As a result, the costs of attempting to protect against cybersecurity risks and the costs of responding to cyber-attacks are significant. This

could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage.

New data security laws and regulations are being implemented rapidly and are evolving, and we may not be able to timely comply with such requirements, and such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could subject us to liability for non-compliance.

*If we are unable to obtain, maintain and enforce intellectual property protection for our technology and products or if the scope of our intellectual property protection is not sufficiently broad, others may be able to develop and commercialize technology and products substantially similar to ours, and our ability to successfully commercialize our technology and products may be adversely affected.*

Our business depends on proprietary technology and content, including software, databases, confidential information and know-how, the protection of which is crucial to the success of our business. We rely on a combination of trademark, trade-secret and copyright laws and confidentiality procedures and contractual provisions to protect our intellectual property rights in our proprietary technology and content. We may, over time, increase our investment in protecting our intellectual property through additional trademark, patent and other intellectual property filings that could be expensive and time-consuming. Effective trademark, trade-secret and copyright protection is expensive to develop and maintain, both in terms of initial and ongoing registration requirements and the costs of defending our rights. These measures, however, may not be sufficient to offer us meaningful protection. If we are unable to protect our intellectual property and other proprietary rights, our competitive position and our business could be harmed, as third parties may be able to commercialize and use technologies and software products that are substantially the same as ours without incurring the development and licensing costs that we have incurred. Any of our owned or licensed intellectual property rights could be challenged, invalidated, circumvented, infringed or misappropriated, our trade secrets and other confidential information could be disclosed in an unauthorized manner to third parties, or our intellectual property rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide us with competitive advantages, which could result in costly redesign efforts, discontinuance of certain offerings or other competitive harm.

Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors' products and services, and may in the future seek to enforce our rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent infringement or misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our ability to compete and reduce demand for our technology and products. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our products and services rely on technologies and software developed by or licensed from third parties, and we may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms or at all.

We may also be required to protect our proprietary technology and content in an increasing number of jurisdictions, a process that is expensive and may not be successful, or which we may not pursue in every location. In addition, effective intellectual property protection may not be available to us in every country, and the laws of some foreign countries may not be as protective of intellectual property rights as those in the United States. Additional uncertainty may result from changes to intellectual property legislation enacted in the United States and elsewhere, and from interpretations of intellectual property laws by applicable courts and agencies. Accordingly, despite our efforts, we may be unable to obtain and maintain the intellectual property rights necessary to provide us with a competitive advantage. Our failure to obtain, maintain and enforce our intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.

*If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.*

The registered or unregistered trademarks or trade names that we own or license may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to commercialize our technologies or products in certain relevant countries. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.

*Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business, financial condition and results of operations.*

Our commercial success depends on our ability to develop and commercialize our services and use our proprietary technology without infringing the intellectual property or proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. As the market for health care in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our products and technology of which we are not aware or that we must challenge to continue our operations as currently contemplated. Whether merited or not, we may face allegations that we, our partners, our licensees or parties indemnified by us have infringed or otherwise violated the patents, trademarks, copyrights or other intellectual property rights of third parties. Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties. Additionally, in recent years, individuals and groups have begun purchasing intellectual property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. We may also face allegations that our employees have misappropriated the intellectual property or proprietary rights of their former employers or other third parties. It may be necessary for us to initiate litigation to defend ourselves in order to determine the scope, enforceability and validity of third-party intellectual property or proprietary rights, or to establish our respective rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, such claims can be time-consuming, divert management's attention and financial resources and can be costly to evaluate and defend. Results of any such litigation are difficult to predict and may require us to stop commercializing or using our products or technology, obtain licenses, modify our services and technology while we develop non-infringing substitutes or incur substantial damages, settlement costs or face a temporary or permanent injunction prohibiting us from marketing or providing the affected products and services. If we require a third-party license, it may not be available on reasonable terms or at all, and we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services. We may also have to redesign our products or services so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our technology and products may not be available for commercialization or use. Even if we have an agreement to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot or do not obtain a third-party license to the infringed technology on reasonable terms or at all, or obtain similar technology from another source, our revenue and earnings could be adversely impacted.

From time to time, we may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. We are not currently subject to any claims from third parties asserting infringement of their intellectual property rights. Some third parties may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our Class A common stock. Moreover, any uncertainties resulting from the initiation and continuation of any legal proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations. Assertions by third parties that we violate their intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.

*Our use of "open source" software could adversely affect our ability to offer our services and subject us to possible litigation.*

We may use open source software in connection with our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the use of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to such software and/or make available any derivative

works of the open source code, which could include valuable proprietary code of the user, on unfavorable terms or at no cost. While we monitor the use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, in part because open source license terms are often ambiguous. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations and could help our competitors develop products and services that are similar to or better than ours.

*If we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary information, the value of our technology and products could be adversely affected.*

We may not be able to protect our trade secrets, know-how and other proprietary information adequately. Although we use reasonable efforts to protect this proprietary information and technology, our employees, consultants and other parties may unintentionally or

willfully disclose our information or technology to competitors. Enforcing a claim that a third-party illegally obtained and is using any of our proprietary information or technology is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets, know-how and other proprietary information. We rely, in part, on non-disclosure, confidentiality and invention assignment agreements with our employees, consultants and other parties to protect our trade secrets, know-how and other intellectual property and proprietary information. These agreements may not be self-executing, or they may be breached and we may not have adequate remedies for such breach. Moreover, third parties may independently develop similar or equivalent proprietary information or otherwise gain access to our trade secrets, know-how and other proprietary information.

*We depend on certain technologies that are licensed to us. We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from developing and/or commercializing our products.*

We are a party to a number of license agreements under which we are granted rights to intellectual property that is important to our business, and we expect that we may need to enter into additional license agreements in the future. We rely on these licenses to use various proprietary technologies that may be material to our business, including without limitation those technologies licensed under an intellectual property and development services license agreement between us and UPMC, or the UPMC IP Agreement, and a technology license agreement between us and UPMC, or the UPMC Technology Agreement. Under the UPMC IP Agreement, certain of UPMC's proprietary analytics models and know-how are licensed to us on a nonexclusive basis from UPMC; pursuant to the UPMC Technology Agreement, UPMC's proprietary technology platform, associated know-how and the Identifi<sup>®</sup> trademark are licensed to us on an irrevocable, non-exclusive basis from UPMC; in each case, subject to certain ongoing territorial, time and use restrictions. Our rights to use these technologies and know-how and employ the software claimed in the licensed technologies are subject to the continuation of and our compliance with the terms of those licenses. Our existing license agreements impose, and we expect that future license agreements will impose on us, various exclusivity obligations. If we fail to comply with our obligations under these agreements, the applicable licensor may have the right to terminate our license, in which case we may not be able to develop or commercialize the products or technologies covered by the license.

Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:

- the scope of rights granted under the license agreement and other interpretation-related issues;
- whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;
- our obligations with respect to the use of the licensed technology in relation to our services and technologies, and which activities satisfy those obligations;
- whether our activities are in compliance with the restrictions placed upon our rights to use the licensed technology by our licensors; and
- the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.

If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to obtain equivalent replacement licensing arrangements or to successfully develop and commercialize the affected products and technologies.

The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain and enforce these rights could have a material adverse effect on our business. In some cases, we do not have control over the prosecution, maintenance or enforcement of the intellectual property rights that we license, and may not have sufficient ability to consult and input into the prosecution and maintenance process with respect to such intellectual

property, and our licensors may fail to take the steps we feel are necessary or desirable in order to obtain, maintain and enforce the licensed intellectual property rights and, as a result, our ability to retain our competitive advantage with respect to our products and technologies may be materially affected.

*Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.*

We depend upon licenses from third parties for some of the technology and data used in our applications, and for some of the technology platforms upon which these applications are built and operate, including under the UPMC IP Agreement and the UPMC Technology Agreement. We expect that we may need to obtain additional licenses from third parties in the future in connection with the development of our products and services. In addition, we obtain a portion of the data that we use from government entities, public records and from our partners for specific partner engagements. We believe that we have all rights necessary to use the data that is incorporated into our products and services. However, we cannot assure you that our licenses for information will allow us to use that

information for all potential or contemplated applications and products. In addition, certain of our products depend on maintaining our data and analytics platform, which is populated with data disclosed to us by our partners with their consent. If these partners revoke their consent for us to maintain, use, de-identify and share this data, consistent with applicable law, our data assets could be degraded.

In the future, data providers could withdraw their data from us or restrict our usage for any reason, including if there is a competitive reason to do so, if legislation is passed restricting the use of the data or if judicial interpretations are issued restricting use of the data that we currently use in our products and services. In addition, data providers could fail to adhere to our quality control standards in the future, causing us to incur additional expense to appropriately utilize the data. If a substantial number of data providers were to withdraw or restrict their data, or if they fail to adhere to our quality control standards, and if we are unable to identify and contract with suitable alternative data suppliers and integrate these data sources into our service offerings, our ability to provide products and services to our partners would be materially adversely impacted, which could have a material adverse effect on our business, financial condition and results of operations.

We also integrate into our proprietary applications and use third-party software to maintain and enhance, among other things, content generation and delivery, and to support our technology infrastructure. Some of this software is proprietary and some is open source software. These technologies may not be available to us in the future on commercially reasonable terms or at all and could be difficult to replace once integrated into our own proprietary applications. Most of these licenses can be renewed only by mutual consent and may be terminated if we breach the terms of the license and fail to cure the breach within a specified period of time. Our inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and integrated, which would harm our business, financial condition and results of operations.

Most of our third-party licenses are non-exclusive and our competitors may obtain the right to use any of the technology covered by these licenses to compete directly with us. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own proprietary technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.

*We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with partners, adversely affecting our brand and our business.*

Our ability to deliver our products and services, particularly our cloud-based solutions, is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network connection with the necessary speed, data capacity and security for providing reliable Internet access and services and reliable telephone and facsimile services. As a result, our information systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in information technology, emerging cybersecurity risks and threats, evolving industry and regulatory standards and changing preferences of our partners.

Our services are designed to operate without interruption in accordance with our service level commitments. However, we have experienced limited interruptions in these systems in the past, including server failures that temporarily slow down the performance of our services, and we may experience more significant interruptions in the future. We rely on internal systems as well as third-party suppliers, including bandwidth and telecommunications equipment providers, to provide our services. We do not maintain redundant systems or facilities for some of these services. Interruptions in these systems, whether due to system failures, computer viruses, physical or electronic break-ins or other catastrophic events, could affect the security or availability of our services and prevent or inhibit the



ability of our partners to access our services. These systems may be at greater risk of interruption as a result of increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic.

In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could result in substantial costs to remedy those problems or negatively impact our relationship with our partners, our business, results of operations and financial condition. To operate without interruption, both we and our service providers must guard against:

- damage from fire, power loss and other natural disasters;
- telecommunications failures;
- software and hardware errors, failures and crashes;
- security breaches, computer viruses and similar disruptive problems; and
- other potential interruptions.

Any disruption in the network access, telecommunications or co-location services provided by third-party providers or any failure of or by third-party providers' systems or our own systems to handle current or higher volume of use could significantly harm our business. We exercise limited control over our third-party suppliers, which increases our vulnerability to problems with services they provide. Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with partners and adversely affect our business and could expose us to third-party liabilities. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue to be able to obtain adequate insurance coverage at an acceptable cost.

The reliability and performance of our Internet connection may be harmed by increased usage or by denial-of-service attacks. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services.

*We rely on third-party vendors to host and maintain our technology platform.*

We rely on third-party vendors to host and maintain our technology platform, including Identifi<sup>®</sup>. Our ability to offer our services and operate our business is therefore dependent on maintaining our relationships with third-party vendors and entering into new relationships to meet the changing needs of our business. Any deterioration in our relationships with such vendors or our failure to enter into agreements with vendors in the future could harm our business, results of operations and financial condition. Despite precautions taken at our vendors' facilities, the occurrence of a natural disaster, a decision to close the facilities without adequate notice or other unanticipated problems, including relating to the COVID-19 pandemic, could result in lengthy interruptions in our service. These service interruption events could cause our platform to be unavailable to our partners and impair our ability to deliver services and to manage our relationships with new and existing partners, which in turn could materially affect our results of operations.

If our vendors are unable or unwilling to provide the services necessary to support our business, or if our agreements with such vendors are terminated, our operations could be significantly disrupted. Certain vendor agreements may be unilaterally terminated by the licensor for convenience, and if such agreements are terminated, we may not be able to enter into similar relationships in the future on reasonable terms or at all. We may also incur substantial costs, delays and disruptions to our business in transitioning such services to ourselves or other third-party vendors. In addition, third-party vendors may not be able to provide the services required in order to meet the changing needs of our business.

*We have previously identified material weaknesses in our internal control over financial reporting. Although the material weaknesses were remediated, if we identify additional material weaknesses in the future, we and our auditor may conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements, any of which could adversely impact our investors' confidence and our stock price.*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company's internal control over financial reporting includes policies and procedures that provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis.

Management identified material weaknesses in its internal control over financial reporting as of December 31, 2019 related to the areas below.

Information and Communication - We did not maintain adequate user access role definitions within certain instances of one of our claims processing systems inherited in an acquisition that supported claims for True Health New Mexico that are included in claims expense and certain claims for specialty care businesses that are included in our cost of revenue (the "System") because of inadequate segregation of duties. This was a deficiency in the design of the control.

Control Activities - We did not maintain adequate controls over the set-up and modifications of claims data in the System. We lacked evidence of the operation of controls over claims data received from certain third-party service providers. These were deficiencies in the design and operation of the controls.

None of the control deficiencies resulted in any adjustments to our 2019 annual or interim consolidated financial statements, but as a result of these material weaknesses, our management concluded as of December 31, 2019 that our internal control over financial reporting was not effective, and also that our disclosure controls and procedures were not effective. In addition, our independent registered public accounting firm, which audits our annual financial statements, issued an adverse opinion on the effectiveness of internal control over financial reporting as of December 31, 2019. We concluded that these material weaknesses had been remediated as of December 31, 2020.

Our efforts to design and implement an effective control environment may not be sufficient to identify or prevent future material weaknesses or significant deficiencies from occurring. Any newly identified material weakness could result in a misstatement of our financial statements or disclosures that would result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected. A control system, no matter how well designed and operated, can provide only reasonable assurance that the control system's objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and all instances of fraud will be detected. In addition, if we identify future material weaknesses in our internal controls over financial reporting or if we are unable to comply with the demands that are placed upon us as a public company, including the requirements of Section 404 of the Sarbanes-Oxley Act, in a timely manner, we may be unable to accurately report our financial results, or report them within the timeframes required by the SEC. We also could become subject to investigations by the NYSE, the SEC or other regulatory authorities.

#### **Risks relating to our structure**

*We are required to pay certain of our pre-IPO investors for certain tax benefits we may claim in the future, and these amounts are expected to be material.*

Under an exchange agreement we entered into at the time of our IPO, we granted TPG, The Advisory Board and Ptolemy Capital (together, the "Investor Stockholders") an exchange right that allowed for receipt of newly-issued shares of the Company's Class A common stock in exchange (a "Class B Exchange") for an equal number of shares of the Company's Class B common stock (which were subsequently canceled) and an equal number of Evolent Health LLC's Class B common units. Class B common units received by the Company from relevant Investor Stockholders were simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC cancelled the Class B common units it received in the Class B Exchanges, resulting in an increase in the Company's economic interest in Evolent Health LLC.

As of December 31, 2019, all of the Class B common units held by the Investor Stockholders and certain other stockholders had been exchanged (together with an equal number of shares) for our Class A common stock. These exchanges resulted in increases in the tax basis of our share of the assets of Evolent Health LLC that otherwise would not have been available to the Company. In addition, we expect that certain NOLs will be available to us as a result of the transactions as described in "Part II - Item 8. Financial Statements and Supplementary Data - Note 14 - "Tax Receivables Agreement." These increases in tax basis and NOLs may reduce the amount of tax that we would otherwise be required to pay in the future, although the Internal Revenue Service ("IRS") may challenge all or a part of the tax basis increases and NOLs, and a court could sustain such a challenge.

We have entered into the TRA, related to the tax basis step-up of the assets of Evolent Health LLC and certain NOLs of the former members of Evolent Health LLC, with the Investor Stockholders and certain of our other investors (the "TRA Holders"). Pursuant to the TRA, we will pay the TRA Holders 85% of the amount of the cash savings, if any, in U.S. federal, state and local and non-U.S. income tax that we realize as a result of increases in tax basis resulting from exchanges of Class B common units for shares of our Class A common stock (calculated assuming that any post-IPO transfer of Class B common units (other than the exchanges) had not occurred) as well as certain other benefits attributable to payments under the TRA itself.

The TRA also requires us to pay 85% of the amount of the cash savings, if any, in U.S. federal, state and local and non-U.S. income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings and an affiliate of TPG attributable to periods prior to our IPO and the deduction of any imputed interest attributable to our payment obligations under the TRA.

The payments that we make under the TRA could be substantial. Assuming no material changes in relevant tax law and based on our current operating plan and other assumptions, including our estimate of the tax basis of our assets as of the date of the Offering Reorganization and the estimated tax basis step-ups resulting from each completed exchange, we estimate that the total amount that we would be required to pay under the TRA could be approximately \$101.7 million. This estimated amount includes approximately \$16.1 million of potential future payments under the TRA related to the future utilization of the pre-IPO NOLs described above and approximately \$85.6 million of potential future payments related to the tax basis step-up of the assets of Evolent Health LLC in connection with the exchanges that occurred in connection with our completed secondary offerings and private sales.

The actual amount we will be required to pay under the TRA may be materially greater than these hypothetical amounts, as potential future payments will vary as a consequence of our tax position, the relevant tax basis analysis, our ability to generate sufficient future taxable income in order to be able to benefit from the aforementioned tax attributes, the character and timing of our taxable income and the income tax rates applicable at the time we realize cash savings attributable to our recognition and utilization of the aforementioned tax attributes. Payments under the TRA are not conditioned on our existing investors' continued ownership of any of our equity.

*We will not be reimbursed for any payments made under the TRA in the event that any tax benefits are disallowed.*

If the IRS successfully challenges the tax basis increases resulting from the Class B Exchanges or the existence or amount of the pre-IPO NOLs at any point in the future after payments are made under the TRA, we will not be reimbursed for any payments made under the TRA (although future payments under the TRA, if any, would be netted against any unreimbursed payments to reflect the result of any such successful challenge by the IRS). As a result, in certain circumstances, we could be required to make payments under the TRA in excess of our cash tax savings.

*We may not be able to realize all or a portion of the tax benefits that resulted from the exchanges of Class B common units for our Class A common stock from the utilization of NOLs previously held by Evolent Health Holdings and an affiliate of TPG and from payments made under the TRA.*

Our ability to realize the tax benefits that we expect to be available as a result of the increases in tax basis created by the Class B Exchanges and by the payments made pursuant to the TRA, and our ability to utilize the pre-IPO NOLs of Evolent Health Holdings and an affiliate of TPG and the interest deductions imputed under the TRA all depend on a number of assumptions, including that we earn sufficient taxable income each year during the period over which such deductions are available and that there are no adverse changes in applicable law or regulations. If our actual taxable income is insufficient or there are adverse changes in applicable law or regulations, we may be unable to realize all or a portion of these expected benefits and our cash flows and stockholders' equity could be negatively affected. Please refer to the discussion in "Part II - Item 8. Financial Statements and Supplementary Data - Note 14 - Tax Receivables Agreement" for additional information.

*In certain cases, payments by us under the TRA may be accelerated or significantly exceed the tax benefits we realize in respect of the tax attributes subject to the TRA.*

The TRA provides that upon certain changes of control, or if, at any time, we elect an early termination of the TRA or are in material breach of our obligations under the TRA, we would be required to make an immediate payment equal to the present value of the anticipated future tax benefits to certain current or former shareholders. Such payment would be based on certain valuation assumptions and deemed events set forth in the TRA, including the assumption that we have sufficient taxable income to fully utilize such tax benefits. The benefits would be payable even though, in certain circumstances, no tax basis step-up deductions and no NOLs are actually used at the time of the accelerated payment under the TRA. Accordingly, payments under the TRA may be made years in advance of the actual realization, if any, of the anticipated future tax benefits and may be significantly greater than the benefits we realize in respect of the tax attributes subject to the TRA. In these situations, our obligations under the TRA could have a substantial negative impact on our liquidity. We may not be able to finance our obligations under the TRA and any indebtedness we incur may limit our subsidiaries' ability to make distributions to us to pay these obligations. In addition, our obligations under the TRA could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control that could be in the best interests of holders of our Class A common stock.

*The agreements between us and certain of our pre-IPO investors were made in the context of an affiliated relationship and may contain different terms than comparable agreements with unaffiliated third parties.*

The contractual agreements that we have with certain of our pre-IPO investors were negotiated in the context of an affiliated relationship in which representatives of such pre-IPO investors and their affiliates comprised a significant portion of our board of directors. As a result, the financial provisions, and the other terms of these agreements, such as covenants, contractual obligations on our part and on the part of such pre-IPO investors and termination and default provisions, may be less favorable to us than terms that we might have obtained in negotiations with unaffiliated third parties in similar circumstances, which could have a material adverse effect on our business, financial condition and results of operations.

### **Risks Relating to Our Convertible Notes**

*The conditional conversion feature of the 2025 Notes, if triggered, may adversely affect our financial condition and operating results.*

In the event the conditional conversion feature of the 2025 Notes is triggered, holders of such notes will be entitled to convert such notes at any time during specified periods at their option. If one or more holders elect to convert their 2025 Notes, unless we elect to

satisfy our conversion obligation by delivering solely shares of our Class A common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the 2025 Notes, as applicable, as a current rather than long-term liability, which would result in a material reduction of our net working capital.

*The accounting method for convertible debt securities that may be settled in cash, such as the 2024 Notes and the 2025 Notes, could have a material effect on our reported financial results.*

Under Accounting Standards Codification 470-20, Debt with Conversion and Other Options, (“ASC 470-20”), an entity must separately account for the liability and equity components of the convertible debt instruments (such as the 2024 Notes and the 2025 Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for the 2024 Notes and the 2025 Notes is that the equity component is required to be included in the additional paid-in capital section of stockholders’ equity on our consolidated balance sheet, and the value of the equity component would be treated as original issue discount for purposes of accounting for the debt component of the 2024 Notes and the 2025 Notes. As a result, we will be required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discounted carrying value of the 2024 Notes and the 2025 Notes to their face amount over the term of the 2024 Notes and the 2025 Notes, respectively. We may report lower net income in our financial results because ASC 470-20 will require interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest, which could adversely affect our reported or future financial results, the trading price of our Class A common stock and the trading prices of the 2024 Notes and the 2025 Notes.

In addition, under certain circumstances, convertible debt instruments (such as the 2024 Notes and the 2025 Notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the 2024 Notes and the 2025 Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the 2024 Notes and the 2025 Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued. We cannot be sure that the accounting standards in the future will continue to permit the use of the treasury stock method. For example, in August 2020, the Financial Accounting Standards Board published Accounting Standards Update (“ASU”) 2020-06, which simplifies the accounting for certain financial instruments, including convertible instruments. We have not yet completed our assessment of ASU 2020-06, however, if we are unable to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes, then our diluted earnings per share would be adversely affected.

### **Risks relating to ownership of our Class A common stock**

*We expect that our stock price will be volatile and may fluctuate or decline significantly.*

The trading price of our Class A common stock has been and may continue to be volatile and subject to wide price fluctuations in response to various factors, including:

- economic and political conditions or events;
- market conditions in the broader stock market in general, or in our industry in particular, including as a result of COVID-19 related impacts;
- actual or anticipated fluctuations in our quarterly financial reports and results of operations;
- our ability to satisfy our ongoing capital needs and unanticipated cash requirements;
- indebtedness incurred in the future;
- introduction of new products and services by us or our competitors;



- business developments of our partners;
- issuance of new or changed securities analysts' reports or recommendations;
- sales of large blocks of our stock;
- additions or departures of key personnel;
- regulatory developments; and
- litigation and governmental investigations.

These and other factors may cause the market price and demand for our Class A common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of Class A common stock, including any shares of Class A common stock they receive upon conversion of our convertible notes, and may otherwise negatively affect the liquidity of our Class A common stock. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. We are, and from time to time may become, subject to such litigation, and we

could incur substantial costs defending a lawsuit. Such a lawsuit could also divert the time and attention of our management from our business.

The trading market for our Class A common stock will also be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us downgrades our stock, or if our results of operations do not meet their expectations, our stock price could decline.

*We are subject to securities class action litigation and an adverse outcome in such litigation could have an adverse effect on our financial condition.*

On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Exchange Act, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020. The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer and Steven Wigginton, alleges that Evolent's executives made false or misleading statements regarding its business with Passport. A second amended complaint, which was substantially similar to the amended complaint, was filed on June 8, 2020. The Company filed a motion to dismiss in response on June 22, 2020 and the briefing was completed on July 17, 2020; the parties are now waiting for the court's decision. We and the individuals dispute these claims and intend to defend the matter vigorously. This litigation could result in substantial costs and a diversion of management's resources and attention, which could harm our business and the value of our common stock.

*The market price of our Class A common stock could decline due to the large number of shares of Class A common stock issuable upon conversion of our convertible notes, or by sales or issuances of substantial amounts of our Class A common stock.*

The market price of our Class A common stock could decline as a result of sales of a large number of the shares of our Class A common stock issuable upon the conversion of our convertible notes, or the perception that such sales could occur. These sales, or the possibility that these sales may occur, may also make it more difficult for us to raise additional capital by selling equity or equity-linked securities in the future, at a time and price that we deem appropriate. As of February 22, 2021, 86.1 million shares of our Class A common stock were outstanding. Up to a maximum of 13.3 million shares of our Class A common stock is reserved for issuance upon the conversion of our convertible notes. Similarly, sales or issuances of substantial amounts of our Class A common stock in the public market by us or by our stockholders into the public market could cause the market price of our Class A common stock to decrease significantly.

*Some provisions of Delaware law, our second amended and restated certificate of incorporation and our third amended and restated by-laws and certain of our contracts may deter third parties from acquiring us.*

Among other things, our second amended and restated certificate of incorporation and our third amended and restated by-laws:

- divide our board of directors into three staggered classes of directors that are each elected to three-year terms;
- prohibit stockholder action by written consent;
- authorize the issuance of "blank check" preferred stock that could be issued by our board of directors to increase the number of outstanding shares of capital stock, making a takeover more difficult and expensive;
- prohibit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;
- provide that special meetings of the stockholders may be called only by or at the direction of the board of directors, the chairman of our board or the chief executive officer;
- require advance notice to be given by stockholders for any stockholder proposals or director nominees;

- require the affirmative vote of holders of at least 75% of the voting power of our outstanding shares of stock to amend certain provisions of our second amended and restated certificate of incorporation and any provision of our third amended and restated by-laws; and
- require the affirmative vote of holders of at least 75% of the voting power of our outstanding shares of stock to remove directors and only for cause.

In addition, Section 203 of the DGCL may affect the ability of an “interested stockholder” to engage in certain business combinations, for a period of three years following the time that the stockholder becomes an “interested stockholder.” We have elected in our second amended and restated certificate of incorporation not to be subject to Section 203 of the DGCL. Nevertheless, our second amended and restated certificate of incorporation contains provisions that have the same effect as Section 203 of the DGCL, except that they provide that each of TPG, UPMC and The Advisory Board and their transferees will not be deemed to be “interested stockholders,” and accordingly are not subject to such restrictions.

These and other provisions could have the effect of discouraging, delaying or preventing a transaction involving a change in control of our company or could make it more difficult for stockholders to elect directors of their choosing or to cause us to take other corporate actions that they desire. Provisions in certain of our contracts may also deter third parties from acquiring us. In addition, certain partners would have the right to terminate if we are acquired by certain competitors.

*Our second amended and restated certificate of incorporation and stockholders' agreement contain provisions renouncing our interest and expectation to participate in certain corporate opportunities identified by or presented to certain of our pre-IPO investors.*

UPMC and its affiliates may engage in activities similar to ours or lines of business or have an interest in the same areas of corporate opportunities as we do. Our second amended and restated certificate of incorporation and stockholders' agreement provide that UPMC and its affiliates do not have any duty to refrain from (1) engaging, directly or indirectly, in the same or similar business activities or lines of business as us, including those business activities or lines of business deemed to be competing with us, or (2) doing business with any of our clients, customers or vendors. In the event that UPMC or any of its affiliates acquires knowledge of a potential business opportunity which may be a corporate opportunity for us, they have no duty to communicate or offer such corporate opportunity to us. Our second amended and restated certificate of incorporation and stockholders' agreement also provide that, to the fullest extent permitted by law, UPMC and its affiliates will not be liable to us for breach of any fiduciary duty or otherwise, by reason of directing such corporate opportunity to another person, or otherwise not communicating information regarding such corporate opportunity to us, and we have waived and renounced any claim that such business opportunity constituted a corporate opportunity that should have been presented to us. These potential conflicts of interest could have a material adverse effect on our business, financial condition, results of operations or prospects if attractive business opportunities are allocated by UPMC to itself or its affiliates instead of to us.

*Our second amended and restated certificate of incorporation designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.*

Our second amended and restated certificate of incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the DGCL, our second amended and restated certificate of incorporation or our third amended and restated by-laws, (d) any action to interpret, apply, enforce or determine the validity of our second amended and restated certificate of incorporation or third amended and restated by-laws or (e) any other action asserting a claim against us that is governed by the internal affairs doctrine. We refer to each of these proceedings as a covered proceeding. In addition, our second amended and restated certificate of incorporation provides that if any action the subject matter of which is a covered proceeding is filed in a court other than the specified Delaware courts without the approval of our board of directors, which we refer to as a foreign action, the claiming party will be deemed to have consented to (1) the personal jurisdiction of the specified Delaware courts in connection with any action brought in any such courts to enforce the exclusive forum provision described above and (2) having service of process made upon such claiming party in any such enforcement action by service upon such claiming party's counsel in the foreign action as agent for such claiming party. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these provisions. These provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our second amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.

*We do not anticipate paying any cash dividends in the foreseeable future.*

We currently intend to retain our future earnings, if any, for the foreseeable future to fund the development and growth of our business. We do not intend to pay any dividends to holders of our Class A common stock. As a result, capital appreciation in the price of our Class A common stock, if any, will be your only source of gain on an investment in our Class A common stock. See “Part II - Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities - Dividends” for a discussion of our dividend policy.

**Item 1B. Unresolved Staff Comments**

Not applicable.

**Item 2. Properties**

Our corporate headquarters and executive officers are located in Arlington, Virginia, where we occupy approximately 91,000 square feet of office space. We also lease offices throughout the United States and in Pune, India. We lease all of our facilities and we do not own any real property. As provided in “Part II – Item 8. Financial Statements and Supplementary Data - Note 11 - Leases,” the total rental expense on operating leases, net of sublease income, was \$21.2 million for the year ended December 31, 2020.

### **Item 3. Legal Proceedings**

For information regarding legal proceedings, see “Part II – Item 8. Financial Statements and Supplementary Data - Note 10 - Commitments and Contingencies - Litigation Matters.”

### **Item 4. Mine Safety Disclosures**

Not applicable.

## PART II

### Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

#### Market and Dividend Information

##### *Market Information*

Our Class A common stock is traded on the New York Stock Exchange under the symbol "EVH."

##### *Holdings*

As of February 22, 2021, there were 48 holders of record of our Class A common stock. The number of record holders does not include individuals or entities who beneficially own shares and whose shares are held of record by a broker, bank, or other nominee, but does include each such broker, bank, or other nominee as one record holder.


##### *Dividends*

We have not declared or paid any cash dividends on our common stock. We do not anticipate paying any cash dividends on our Class A common stock for the foreseeable future. The timing and amount of future cash dividends, if any, is periodically evaluated by our board of directors and would depend on, among other factors, our current and expected earnings, financial condition, projected cash flows and anticipated financing needs.

##### *Performance Graph*

The following graph compares the cumulative total stockholder return on our Class A common stock for the last 5 years ended December 31, 2020, to the cumulative total returns of the NASDAQ Health Care Index and the NYSE Composite Index over the same period. This graph assumes an investment of \$100 at the closing price of the markets on December 31, 2015, in our Class A common stock, the NASDAQ Health Care Index and the NYSE Composite Index, and assumes the reinvestment of dividends, if any.

The comparisons shown in the following graph are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our Class A common stock.





***Recent Sales of Unregistered Securities, Purchases of Equity Securities by the Issuer or Affiliated Purchases or Other Stockholder Matters***

Not applicable.

**Item 6. Selected Financial Data**

Omitted.

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to help the reader understand the Company's financial condition and results of operations. The MD&A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements presented in "Part II – Item 8. Financial Statements and Supplementary Data" as well as "Part I - Item 1A. Risk Factors."

**INTRODUCTION**

***Background and Recent Events***

Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

**Evolent Health's Response to COVID-19**

On March 11, 2020, the World Health Organization (the "WHO") declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. While response to the COVID-19 outbreak continues to rapidly evolve, it has led to aggressive actions to reduce the spread of the disease that have seriously disrupted activities in large segments of the economy. We are continuing to monitor the COVID-19 outbreak and its impact on our business.

Because of the nature of the services we provide, market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition or results of operations or our outlook. As of December 31, 2020 we had cash and cash equivalents of \$340.5 million and as of the date the financial statements were available to be issued we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. The COVID-19 crisis has also adversely impacted global access to capital and caused significant volatility in financial markets. Significant deterioration of the U.S. and global economies could have a significant adverse impact on our investment income, the value of our investments, or future liquidity needs. Although the impact of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.

Evolent's focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish high quality service to our partners. Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel and Chief Compliance Officer, that focuses on maintaining its workforce in

a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities. Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors, and we will continue to work with them regarding our collective obligations to Evolent's customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner.

***Summary of Impact of COVID-19***

In evaluating the impact of COVID-19 on our Services business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends. In evaluating our health plan businesses, we focused on possible changes in membership and medical utilization trends.

## Services Business

Our two most significant service offerings in terms of revenue are specialty care management and administrative health services. Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic.

The three key end-markets we serve are Medicaid, Medicare and Commercial.

Across 2020 we saw changes in membership and medical utilization in our end-markets as a result of the COVID-19 pandemic. The pandemic has resulted in a significant increase in unemployment in the United States. Historically, Medicaid enrollment has increased during periods of rising unemployment as individuals lose access to employer sponsored health care and turn to government sponsored health care. In addition, with respect to Medicaid, many states (including Florida, Kentucky and Illinois) put in place new rules during the pandemic eliminating the ability of Medicaid health plans to dis-enroll non-paying members, as well as waiving certain eligibility requirements, which together we expect will result in higher membership during the period of the pandemic. It is possible to see an opposite trends in the commercial market, where employees who are made redundant lose access to employer sponsored health care. We do not expect to see meaningful changes in membership in the Medicare market as a result of COVID-19. In aggregate, as more than 50% of the lives on our platform are currently in Medicaid and we generally earn revenue with respect to those lives based on a per member per month model, we expect to see a net benefit in our business from increased membership in that market in the near-term. We cannot predict the magnitude of this potential benefit, or how long it will last.

With respect to medical utilization, following the declaration of the pandemic by the WHO, many state-wide mandates deferred non-essential medical procedures to allow hospitals to focus on providing care to COVID-19 patients. Across all markets, our partners experienced declines in non-essential care throughout the year ended December 31, 2020, offset in part by increased costs for care of COVID-19 patients. We continue to monitor medical utilization trends closely as the pandemic progresses. Beginning late in the first quarter after declaration of the pandemic and continuing across the year, we have seen a modest benefit in our business from lower utilization trends. However, we cannot predict with any certainty the net impact of lower utilization on our business, as it is possible we will experience a surge in utilization if and when consumer behavior changes (for example if the novel coronavirus is controlled by a vaccine or other measures).

Our two largest customers in terms of revenue, EVH Passport/UHC and Cook County Health and Hospitals Systems, together accounted for approximately 37.1% and 28.2% of revenue for the year ended December 31, 2020 and 2019, respectively, and both participate in the Medicaid market. During the year ended December 31, 2020, we saw a modest increase in the membership at Cook County Health and Hospitals Systems; further increases in unemployment in Illinois could result in higher Medicaid enrollment in the future. In addition, during the year ended December 31, 2020 we saw modestly lower claims volume at both clients tied to State mandates curtailing non-essential care.

## Health Plans

Our True Health plan serves approximately 17,000 members in the small and large group market in New Mexico as well as 6,700 members in the individual and federal employee markets in New Mexico. At the end of December 2020, the membership in group plans was not meaningfully changed relative to the year ended December 31, 2019. Beginning at the end of the three months ended March 31, 2020, we observed a decline in medical utilization tied to a state-wide mandate prohibiting non-essential care in the period from March 13, 2020, resulting in slightly lower than expected claims expenses. In our two Medicaid equity method investees (Lighthouse Health Plan and Miami Children's Health Plan in Florida) and our wholly-owned Medicaid plan (EVH Passport), we saw modest increases in membership during the year ended December 31, 2020 however reduced medical utilization resulted in reduced claims expenses in the

same period. While we cannot estimate the magnitude of reduced medical utilization and its impact on our business, we expect this trend to continue until the COVID-19 pandemic moderates.

Overall, we are unable to determine or predict the nature, duration, or scope of the overall impact the COVID-19 pandemic will have on our business, results of operations, liquidity, or capital resources. We are actively monitoring the ongoing situation and may take further actions that change our operations if required by law or that we determine are in the best interests of our employees or partners.

### **Transactions**

The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.

## *Passport*

On December 30, 2019, UHC, Passport Health Solutions, LLC (“PHS I”), the Company and EVH Passport, closed a transaction whereby EVH Passport acquired substantially all of the assets and assumed substantially all of the liabilities of UHC, including the Passport Medicaid Contract. The purchase price paid by EVH Passport consisted of \$70.0 million in cash and a 30% equity interest in EVH Passport issued to the Sponsors; however, \$16.2 million of the foregoing cash purchase price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements.

On September 1, 2020, EVH Passport and Molina completed the Molina Closing and the Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, Molina deposited \$20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting. As a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company’s consolidated financials, EVH Passport redeemed the Sponsors’ equity interests in EVH Passport in accordance with the terms of EVH Passport’s Stockholders’ Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company. The Company expects a return of capital from EVH Passport, expected to be between \$130 million and \$170 million in total, which is subject to regulatory approval from the Kentucky Department of Insurance.

Refer to “Part II - Item 8. Financial Statements - Note 4” for additional discussion regarding the Passport transactions.

## *GlobalHealth*

As of March 31, 2020, the Oklahoma Insurance Division (“OID”) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately \$47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the three months ended March 31, 2020.

## *Convertible Debt Issuance, Extinguishment of Debt and Repayment of Notes*

In August 2020, the Company issued \$117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the “2024 Notes”) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued \$84.2 million aggregate principal amount of 2024 Notes in exchange for \$84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of \$2.5 million, and issued \$32.8 million aggregate principal amount of New Notes for cash at par. We incurred \$3.0 million of debt issuance costs in connection with the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.

The exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of \$4.8 million, including an aggregate cash payment to noteholders of \$2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations.

In August 2020, we also repurchased \$14.0 million of the 2021 Notes with \$13.9 million of cash and recorded an immaterial gain on extinguishment of debt. Refer to “Part II - Item 8. Financial Statements - Note 9” for additional discussion relating to the convertible debt issuance, extinguishment of debt and partial repayment of 2021 Notes.

*Agreement for the Sale of True Health New Mexico*

On January 11, 2021, Evolent LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into the SPA with Bright HealthCare, pursuant to which EH Holdings expects to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of \$22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the True Health Closing based in part on actual medical claims experience. Refer to “Part II - Item 8. Financial Statements - Note 26” for additional discussion regarding the True Health sale.

### *Repayment and Termination of Existing Credit Agreement*

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was \$98.6 million, which included \$9.7 million for the make-whole premium as well as \$0.2 million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for \$13.7 million. Refer to “Part II - Item 8. Financial Statements - Note 9” for additional discussion relating to the repayment of the Credit Agreement.

### **Repositioning Plan**

We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including the assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.

In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (“Repositioning Plan”). These actions included making organizational changes across our Services segment as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021.

The Company recorded approximately \$1.3 million of repositioning costs in selling, general and administrative expenses during the year ended December 31, 2020. The following tables provide a summary of our total costs associated with the Repositioning Plan, included in the line item within our consolidated statements of operations, for the year ended December 31, 2020, by major type of cost:

	<b>Incurred For the Year Ended December 31, 2020</b>	<b>Total Amount Expected to be Incurred in the Repositioning Plan</b>	<b>Cumulative Amount Incurred through December 31, 2020</b>
Severance and termination benefits	\$ —	\$ 2,500	\$ —
Office space consolidation	—	2,100	—
Professional services	1,275	4,200	1,275
Total	\$ 1,275	\$ 8,800	\$ 1,275

### ***Business Overview***

We are a market leader in the new era of value-based care, in which leading health systems and physician organizations, which we refer to as providers, as well as health plans, which we refer to as payers, are moving their business models from traditional FFS reimbursement to an increasingly integrated clinical and financial responsibility for populations. We refer to our provider and payer customers as partners. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology.

We were founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. We provide integrated, technology-enabled services to our national network of leading health systems, physician organizations and national and regional payers across Medicare, Medicaid and commercial markets.

During 2020, we managed our operations and allocate resources across two reportable segments, our Services segment and our True Health Segment. The Company's Services segment provides our customers two clinical solutions: (i) total cost of care services and (ii) specialty care management services, and one administrative solution: comprehensive health plan administration services. These services enable payers and providers to manage patient health in a more cost-effective manner. The Company's contracts are structured as a combination of monthly member service fees, percentage of plan premiums, shared medical savings arrangements and/or other performance-based arrangements including taking responsibility for all or substantially all of the cost of care. Our True Health



segment consists of a commercial health plan we operate in New Mexico that focuses on individual and family as well as small and large businesses.

The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company will bifurcate its Services segment into two reportable segments as follows:

- Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and
- Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands.

All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.

We have incurred operating losses since our inception, as we have invested heavily in resources to support our growth. We intend to continue to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. We also expect to continue to incur operating losses for the foreseeable future and if we are unable to achieve our revenue growth and cost management objectives, we may not be able to achieve profitability.

### ***Critical Accounting Policies and Estimates***

We have identified the accounting policies below as critical to the understanding of our results of operations and our financial condition. In applying these critical accounting policies in preparing our financial statements, management must use critical assumptions, estimates and judgments concerning future results or other developments, including the likelihood, timing or amount of one or more future events. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our assumptions, estimates and judgments based upon historical experience and various other information that we believe to be reasonable under the circumstances. For a detailed discussion of other significant accounting policies, see “Part II - Item 8. Financial Statements and Supplementary Data - Note 2.”

### ***Goodwill***

We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has four reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.

Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).

A description of our 2020 goodwill impairment test follows below.

The Company performed an interim goodwill impairment assessment in one of our three reporting units in the Services segment as of March 31, 2020 due to the decline in the Company's stock price during the first quarter of 2020 and lack of excess of fair value over the carrying value considering the \$199.8 million impairment charge taken in the fourth quarter of 2019. The Company concluded that the fair value of its reporting unit was more than its carrying value as of March 31, 2020. In addition, the Company performed an interim goodwill impairment assessment as of May 31, 2020 and concluded that the fair value of one of our three reporting units in the Services segment was less than its carrying value by \$215.1 million as of May 31, 2020. The decrease in fair value was due to our largest customer, EVH Passport, not obtaining a renewal of its Kentucky managed Medicaid contract, which was its sole business. The non-renewal of EVH Passport's contract caused a reduction in the Company's cash flow projections.

As a result of the impairment charges in the fourth quarter of 2019 and second quarter of 2020, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for the specific reporting

unit that incurred those impairment charges. This election does not preclude Management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required.

In performing our October 31, 2020 impairment test for one of the three reporting units in the Services segment, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (“income approach”). In determining the estimated fair value using the income approach, we projected future cash flows based on management’s estimates and long-term plans and applied a discount rate based on the Company’s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.

As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit’s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was \$214.3 million.

#### *Revenue Recognition*

#### **Services**

Our services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Revenue is recognized when control of the services is transferred to our customers. We use the following 5-Step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, *Revenue from Contracts with Customers* (“ASC 606”), to determine revenue recognition on our contracts with customers:

- Identify the contract(s) with a customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to performance obligations
- Recognize revenue when (or as) the entity satisfies a performance obligation

#### **Transformation Services Revenue**

Transformation services consist of strategic assessments, or Blueprint contracts, and implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.

#### **Platform and Operations Services Revenue**

Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily third-party administration (“TPA”) services. Revenue is recognized when control of the services is transferred to our customers.

We use the following 5-step model outlined in ASC 606 to determine revenue recognition for our services segment from our contracts with customers:

- Identify the contract(s) with a customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to performance obligations
- Recognize revenue when (or as) the entity satisfies a performance obligation

### Contracts with Multiple Performance Obligations

Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.

### Principal vs Agent

We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.

### True Health

Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derives revenue from reinsurance premiums assumed from NMHC under the terms of the Reinsurance Agreement. The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as short-term deferred revenue on our Consolidated Balance Sheets.

### *Income Taxes*

Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We estimate our actual current tax expense, including permanent charges and benefits, and temporary differences resulting from differing treatment of items, such as deferred revenue for tax and book accounting purposes. These temporary differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheets.

We assess the likelihood that our deferred tax assets will be recovered from future taxable income by considering both positive and negative evidence relating to their recoverability. If we believe that recovery of these deferred tax assets is not more likely than not, we establish a valuation allowance. To the extent that we increase a valuation allowance in a period, we include an expense in the consolidated statement of operations in the period in which such determination is made.

In assessing the need for a valuation allowance, we considered all available evidence, including recent operating results, projections of future taxable income, our ability to utilize loss and credit carryforwards, and the feasibility of tax planning strategies. A significant piece of objective positive evidence evaluated for jurisdictions in a net deferred tax asset position was cumulative pre-tax income over the three years ended December 31, 2020. In addition, we considered that loss and credit carryforwards have not expired unused and the majority of our loss and credit carryforwards will not expire prior to 2031.

As of December 31, 2020, we have determined that it is more likely than not that we will realize the benefit related to our deferred tax assets, except for a valuation allowance related to the realization of existing US deferred tax assets.

Deferred tax liabilities, net of deferred tax assets, as of December 31, 2020 were \$0.7 million, net of our valuation allowance of \$89.9 million.

We account for uncertainty in income taxes by recognizing a tax position only when it is more likely than not that the tax position, based on its technical merits, will be sustained upon ultimate settlement with the applicable tax authority. The tax benefit to be recognized is the largest amount of tax benefit that is greater than fifty percent likely of being realized upon ultimate settlement with the applicable tax authority that has full knowledge of all relevant information.

Our gross unrecognized benefits are \$0.7 million as of December 31, 2020. Our evaluation of uncertain tax positions is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit, and new audit activity. If actual settlements differ from these estimates, or we adjust these estimates in future periods, we may need to recognize additional tax benefits or charges that could materially impact our financial position and results of operations.

We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable on the Company's federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.

#### *Reserve for Claims and Performance-based Arrangements*

Reserves for performance-based arrangements and claims for our services and True Health segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.

#### **Adoption of New Accounting Standards**

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, customer advances and certain off-balance sheet credit exposures, by replacing the existing "incurred loss" framework with an expected credit loss recognition model. The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts. The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of \$3.0 million to January 1, 2020 retained earnings (accumulated deficit). In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based on specific identification. Under the new accounting standard, we utilize several factors to develop historical losses, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance. In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach. Refer to Note 6 for additional disclosures related to current expected credit losses.

## RESULTS OF OPERATIONS

Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

### Key Components of our Results of Operations

#### *Revenue*

Our services segment derives revenue from three sources: (i) transformation services, (ii) platform and operations services and (iii) premiums earned.

#### Transformation Services Revenue

Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.

#### Platform and Operations Services Revenue

Platform and Operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our clinical solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services; our administrative solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services. Contracts to provide these services may be developed on an integrated basis. For purposes of revenue disaggregation, we classify contracts including both clinical and administrative solutions into the category corresponding to the majority of services provided under those contracts.

Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.

#### Contracts with Multiple Performance Obligations

Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer



demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.

#### Premiums Earned

Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. True Health also derived revenue from reinsurance premiums assumed from NMHC under the terms of the reinsurance agreements, prior to their termination in the fourth quarter of 2019.

During the third quarter of 2019, the Company terminated the reinsurance agreement with NMHC effective in the fourth quarter of 2019, approximately one and a half months prior to its scheduled end.

In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.

#### *Cost of Revenue (exclusive of depreciation and amortization)*

Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements. Subsequent to the consolidation of EVH Passport on September 1, 2020, our cost of revenue includes the consolidated impact of the runout of EVH Passport's operations, consisting principally of updates to EVH Passport's claims reserve based on actual claims payments.

#### *Claims Expenses*

Our claims expenses consist of the direct medical expenses incurred by our health plan, including expenses incurred related to the reinsurance agreement. Claims expenses are recognized in the period in which services are provided and include amounts that have been paid by us through the reporting date, as well as estimated medical claims and benefits payable for costs that have been incurred but not paid by us as of the reporting date. Claims expenses include, among other items, fee-for-service claims, pharmacy benefits, various other related medical costs and expenses related to our reinsurance agreement. We use judgment to determine the appropriate assumptions for determining the required estimates.

#### *Selling, General and Administrative Expenses*

Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.

#### *Depreciation and amortization expense*

Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC's assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.

## **Evolent Health, Inc. Consolidated Results**

(in thousands, except percentages)	For the Year Ended		Change Over Prior		For the Year Ended		Change Over Prior	
	December 31,		Period		December 31,		Period	
	2020	2019	\$	%	2019	2018	\$	%
<b>Revenue</b>								
Services:								
Transformation services	\$ 11,990	\$ 15,203	\$ (3,213)	(21.1)%	\$ 15,203	\$ 32,916	\$ (17,713)	(53.8)%
Platform and operations services	893,066	659,438	233,628	35.4%	659,438	500,190	159,248	31.8%
Total Services	905,056	674,641	230,415	34.2%	674,641	533,106	141,535	26.5%
True Health:								
Premiums	117,377	171,742	(54,365)	(31.7)%	171,742	93,957	77,785	82.8%
Total revenue	1,022,433	846,383	176,050	20.8%	846,383	627,063	219,320	35.0%
<b>Expenses</b>								
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)	701,373	513,059	188,314	36.7%	513,059	327,825	185,234	56.5%
Claims expenses	87,951	135,774	(47,823)	(35.2)%	135,774	70,889	64,885	91.5%
Selling, general and administrative expenses	222,600	257,046	(34,446)	(13.4)%	257,046	235,418	21,628	9.2%
Depreciation and amortization expenses	61,475	60,913	562	0.9%	60,913	44,515	16,398	36.8%
Loss (gain) on disposal of assets and consolidation	698	(9,600)	10,298	107.3%	(9,600)	—	(9,600)	(100.0)%
Goodwill impairment	215,100	199,800	15,300	7.7%	199,800	—	199,800	100.0%
Change in fair value of contingent consideration and indemnification asset	3,860	(3,997)	7,857	196.6%	(3,997)	(4,104)	107	2.6%
Total operating expenses	1,293,057	1,152,995	140,062	12.1%	1,152,995	674,543	478,452	70.9%
Operating loss	\$ (270,624)	\$ (306,612)	\$ 35,988	11.7%	\$ (306,612)	\$ (47,480)	\$ (259,132)	(545.8)%
Transformation services revenue as a % of total revenue								
	1.2 %	1.8 %			1.8 %	5.2 %		
Platform and operations services revenue as a % of total revenue								
	87.3 %	77.9 %			77.9 %	79.8 %		
Premiums as a % of total revenue								
	11.5 %	20.3 %			20.3 %	15.0 %		
Cost of revenue as a % of services revenue								
	77.5 %	76.0 %			76.0 %	61.5 %		
Claims expenses as a % of premiums								
	74.9 %	79.1 %			79.1 %	75.4 %		
Selling, general and administrative expenses as a % of total revenue								
	21.8 %	30.4 %			30.4 %	37.5 %		

## Comparison of the Results for the Year Ended December 31, 2020 to 2019

### *Revenue*

Total revenue increased by \$176.1 million, or 20.8%, to \$1.0 billion for the year ended December 31, 2020, as compared to 2019.

Transformation services revenue decreased by \$3.2 million, or 21.1%, to \$12.0 million for year ended December 31, 2020, as compared to 2019, due primarily to the timing of implementation activities. Transformation services revenue accounted for 1.2% and 1.8% of our total revenue for the years ended December 31, 2020 and 2019, respectively.

Platform and operations services revenue increased by \$233.6 million, or 35.4%, to \$893.1 million for the year ended December 31, 2020, as compared to 2019 primarily as a result of membership growth with existing partners, cross-sell of new services to existing

partners and new partner additions. We expect our platform and operations growth rate in 2021 to be negatively impacted by the wind-down of EVH Passport's operations. Platform and operations services revenue accounted for 87.3% and 77.9% of our total revenue for years ended December 31, 2020 and 2019, respectively.

We had 3.6 million lives on full platform and approximately 6.2 million lives on our New Century Technology & Services Suite as of December 31, 2020. Lives on platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform, as well as members covered for oncology specialty care services and members covered for cardiology specialty care services. Members covered for more than one category are counted in each category. Management uses lives on platform as a supplemental performance measure because we believe that it provides insight into the unit economics of our services. We believe that this measure is also useful to investors because it allows further insight into the period over period operational performance. We had 37 and 39 operating partners as of December 31, 2020 and 2019, respectively.

Premiums decreased by \$54.4 million, or 31.7%, to \$117.4 million, for year ended December 31, 2020, as compared to 2019. The decrease is primarily attributable to the termination of the quota-share reinsurance agreement with NMHC signed in the fourth quarter of 2018. Under this reinsurance agreement, NMHC ceded 90% of its gross premiums to the Company and the Company indemnified NMHC for 90% of its claims liability. The agreement qualified for reinsurance accounting due to the deemed risk transfer, and therefore we recorded the gross premiums assumed on our consolidated statements of operations and comprehensive income (loss). Effective in the fourth quarter of 2019, the Company terminated the reinsurance agreement with NMHC and True Health revenues decreased as a result. Premiums accounted for 11.5% and 20.3% of our total revenue for years ended December 31, 2020 and 2019, respectively. Refer to "Part II - Item 8. Financial Statements - Note 10" in this Form 10-K for further discussion of the reinsurance agreement.

On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, agreed to sell True Health to Bright Health Management, Inc. Though we cannot predict the certainty or timing of closing, we expect the transaction to close in the first half of 2021, subject to satisfaction of customary closing conditions, including regulatory approvals. Following the closing of this transaction, we will not report any premiums revenues.

#### *Cost of Revenue*

Cost of revenue increased by \$188.3 million, or 36.7%, to \$701.4 million for the year ended December 31, 2020, as compared to the year ended December 31, 2019. Cost of revenue increased by approximately \$182.8 million period over period as a result of growth of our revenue generating services and additional payments related to performance-based arrangements, an increase of \$5.8 million in professional fees due to the nature and timing of our projects, offset, in part by a decrease of \$4.4 million in our technology services, TPA fees, personnel costs and other costs period over period. Cost of revenue for the year ended December 31, 2020 includes approximately \$(11.9) million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport's claims reserve. Approximately \$1.8 million and \$2.7 million of total personnel costs was attributable to stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively. Cost of revenue represented 77.5% and 76.0% of total services revenue for the years ended December 31, 2020 and 2019, respectively. Our cost of revenue increased as a percentage of our total services revenue due to a change in the mix of our service offerings towards lower gross margin services, principally New Century Health, during 2020; however, we expect our cost of revenue to decrease as a percentage of total services revenue over the longer-term subject to the composition of our growth.

#### *Claims Expenses*

Claims expenses attributable to our True Health segment were \$88.0 million for the year ended December 31, 2020, as compared to \$135.8 million in 2019. The decrease is primarily attributable to the quota-share reinsurance agreement with NMHC signed in the fourth quarter of 2018 that terminated in the fourth quarter of 2019 and savings from cancellation of non-essential services such as elective and non-emergency medical services as a result of COVID-19. Claims expenses represented 74.9% and 79.1% of premiums for the year

ended December 31, 2020, as compared to 2019, respectively. We expect future claims expenses to decrease as a percentage of premiums revenue due to the termination of the reinsurance agreement. Refer to “Part II - Item 8. Financial Statements - Note 10” in this Form 10-K for further discussion of the reinsurance agreement.

*Selling, General and Administrative Expenses*

Selling, general, and administrative expenses decreased by \$34.4 million, or 13.4%, to \$222.6 million for the year ended December 31, 2020, as compared to the year ended December 31, 2019. During the year ended December 31, 2020, personnel costs decreased by \$31.8 million period over period due to a reduction in employee headcount. Approximately \$12.8 million and \$12.9 million of total personnel costs were attributable to stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively. Ceded expenses under the reinsurance agreement were \$14.0 million for the year ended December 31, 2019. Technology costs increased by \$5.5 million period over period as a result of the growing customer base and service offerings. Legal and professional fees increased by \$6.1 million and other costs decreased by \$17.4 million for the year ended December 31, 2020, as compared to 2019,

respectively, due to the nature and timing of our projects. Transaction, transition and severance costs accounted for approximately \$9.0 million and \$17.4 million of total selling, general and administrative expenses for the years ended December 31, 2020 and 2019, respectively. Selling, general and administrative expenses represented 21.8% and 30.4% of total revenue for the year ended December 31, 2020, as compared to 2019, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to continue to decrease as a percentage of our total revenue over the long term due to cost saving initiatives introduced in the year ended December 31, 2020.

#### *Depreciation and Amortization Expenses*

Depreciation and amortization expenses increased \$0.6 million, or 0.9%, to \$61.5 million for the year ended December 31, 2020, as compared to 2019. The increase was due primarily to additional depreciation and amortization expenses related to assets acquired through business combinations and asset acquisitions during 2019 and the increase in amortization expense for internal-use software. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations (including possible future transactions).

#### *Goodwill Impairment*

During the year ended December 31, 2020, we recorded a non-cash impairment charge of \$215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the three reporting units in the Services segment was less than the carrying amount. During the year ended December 31, 2019, we recorded a non-cash impairment charge of \$199.8 million in the same reporting unit. Both of these charges related to the value of our investment in EVH Passport. See “Part II - Item 8. Financial Statements - Note 8” for further details of the impairment charge to goodwill.

#### *Gain (Loss) on Disposal of Assets and Consolidation*

During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the year ended December 31, 2020, the Company sold its interest in the subsidiary and recorded a \$6.4 million loss in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.

On September 1, 2020, EVH Passport and Molina consummated the Molina Closing, and the Passport Medicaid Contract was novated to Molina. As a result, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 and recorded a \$5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.

#### *Loss on extinguishment of debt, net*

In August 2020, as part of the issuance of the 2024 Notes, the Company issued \$84.2 million aggregate principal amount of the 2024 Notes in exchange for \$84.2 million aggregate principal of its 2021 Notes. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of \$4.8 million, including an aggregate cash payment to noteholders of \$2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations.

In August 2020, we also repurchased \$14.0 million of the 2021 Notes with \$13.9 million of cash and recorded an immaterial gain on extinguishment of debt.



*Change in Fair Value of Contingent Consideration and Indemnification Asset*

We recorded a (gain) loss on change in fair value of contingent consideration and indemnification asset of \$3.9 million and \$(4.0) million for the years December 31, 2020 as compared to 2019, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering in the warrant agreements compared to the liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018 and 2019. See “Part II - Item 8. Financial Statements - Note 18” in this Form 10-K for the information related to the fair value of our warrant agreements.

## Comparison of the Results for the Year Ended December 31, 2019 to 2018

### *Revenue*

Total revenue increased by \$219.3 million, or 35.0%, to \$846.4 million for the year ended December 31, 2019, as compared to 2018.

Transformation services revenue decreased by \$17.7 million, or 53.8%, to \$15.2 million for the year ended December 31, 2019, as compared to 2018, due primarily to the fact that our offering has become more product-oriented, thereby resulting in lower average transformation services revenue per newly added partner. As a result, we expect future transformation services revenue to continue to decrease as a percentage of total revenue. Transformation services revenue accounted for 1.8% and 5.2% of our total revenue for the years ended December 31, 2019 and 2018, respectively.

Platform and operations services revenue accounted for 77.9% and 79.8% of our total revenue for the years ended December 31, 2019 and 2018, respectively. Platform and operations services revenue increased by \$159.2 million, or 31.8%, to \$659.4 million for the year ended December 31, 2019, as compared to 2018, primarily as a result of additional revenue from our acquisition of New Century Health during the fourth quarter of 2018, new partner additions, cross-sell, an increase in our average PMPM fee and an aggregate enrollment growth of 35.5% in lives on platform. We ended the quarter with 39 operating partners as of December 31, 2019, as compared to 35 as of December 31, 2018.

Premiums increased by \$77.8 million, or 82.8%, to \$171.7 million, for the year ended December 31, 2019, as compared to the same period in 2018. The increase is primarily attributable to the quota-share reinsurance agreement with NMHC signed in the fourth quarter of 2018. Under this reinsurance agreement, NMHC ceded 90% of its gross premiums to the Company and the Company indemnified NMHC for 90% of its claims liability. The agreement qualified for reinsurance accounting due to the deemed risk transfer, and therefore we recorded the gross premiums assumed on our consolidated statements of operations and comprehensive income (loss). Refer to “Part II - Item 8. Financial Statements - Note 10” in this Form 10-K for further discussion of the reinsurance agreement. Premiums accounted for \$171.7 million and \$94.0 million, or 20.3% and 15.0% of our total revenue for the year ended December 31, 2019 and 2018, respectively. Effective in the fourth quarter of 2019, the Company terminated the reinsurance agreement with NMHC and we expect future True Health revenues to be diminished as a result.

### *Cost of Revenue*

Cost of revenue increased by \$185.2 million, or 56.5%, to \$513.1 million for the year ended December 31, 2019, as compared to 2018. Cost of revenue increased by approximately \$222.3 million period over period as a result of business combinations completed in the fourth quarter of 2018 and additional payments related to performance-based arrangements. The increase was partially offset by a decrease in our professional fees of \$9.0 million due to the nature and timing of our projects, and a decrease of \$28.0 million in our technology services, TPA fees, personnel costs and other costs period over period. Approximately \$2.7 million and \$1.5 million of total personnel costs was attributable to stock-based compensation expense for the years ended December 31, 2019 and 2018, respectively. Cost of revenue represented 76.0% and 61.5% of total services revenue for the years ended December 31, 2019 and 2018, respectively. Our cost of revenue increased as a percentage of our total services revenue as we integrated new businesses acquired during 2018; however, we expect our cost of revenue to decrease as a percentage of total services revenue going forward subject to the composition of our growth.

### *Claims Expenses*

Claims expenses attributable to our True Health segment, including \$72.6 million of expenses assumed from the Reinsurance Agreement, were \$135.8 million for the year ended December 31, 2019, as compared to \$70.9 million for the prior year. Claims expenses consist of claims paid during the period and the change in reserve for incurred but unreported claims. The increase is primarily attributable to the quota-share reinsurance agreement with NMHC signed in the fourth quarter of 2018. Claims expenses represented 79.1% of premiums for the year ended December 31, 2019. We expect future claims expenses to decrease as a percentage of premiums revenue due to the termination of the new reinsurance agreement. Refer to “Part II - Item 8. Financial Statements - Note 10” in this Form 10-K for further discussion of the reinsurance agreement.

#### *Selling, General and Administrative Expenses*

Selling, general, and administrative expenses increased by \$21.6 million, or 9.2%, to \$257.0 million for the year ended December 31, 2019, as compared to 2018. During the year ended December 31, 2019, we incurred additional selling, general and administrative expenses due partially to growth in our business resulting from business combinations completed in 2018. Technology costs, personnel costs and lease costs increased by \$2.6 million, \$8.0 million and \$3.6 million, respectively, period over period, as a result of the growing customer base and service offerings. Approximately \$12.9 million and \$16.1 million of total personnel costs were attributable to stock-based compensation expense for the years ended December 31, 2019 and 2018, respectively. Ceded expenses

under the reinsurance agreement were \$14.0 million and \$0.6 million for the years ended December 31, 2019 and 2018, respectively. Legal fees and other costs increased by \$0.5 million and \$0.8 million for the year ended December 31, 2019, as compared to 2018, respectively, while our professional fees decreased by \$7.6 million due to the nature and timing of our projects. One-time transaction, transition and severance costs accounted for approximately \$17.4 million and \$4.4 million of total selling, general and administrative expenses for the years ended December 31, 2019 and 2018, respectively. Selling, general and administrative expenses represented 30.4% and 37.5% of total revenue for the years ended December 31, 2019 and 2018, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to continue to decrease as a percentage of our total revenue over the long term.

#### *Depreciation and Amortization Expenses*

Depreciation and amortization expenses increased \$16.4 million, or 36.8%, to \$60.9 million for the year ended December 31, 2019, as compared to 2018. The increase was due primarily to additional depreciation and amortization expenses related to assets acquired through business combinations and asset acquisitions during late 2018 and the increase in amortization expense for internal-use software. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations (including possible future transactions).

#### *Gain on disposal of assets*

On May 24, 2019, the Company entered into a joint venture arrangement in respect of GlobalHealth. The Company determined that it has significant influence over the entity, but that it does not have control over the entity. Accordingly, the investment is accounted for under the equity method of accounting and the Company is allocated its proportional share of the entity's earnings and losses for each reporting period. During the year ended December 31, 2019, we recorded a non-cash gain on disposal of assets of \$9.6 million upon the consummation of the GlobalHealth transaction.

#### *Goodwill impairment*

During the fourth quarter of 2019, we recorded a non-cash impairment charge of \$199.8 million on our consolidated statements of operations as we determined that the implied fair value of goodwill was less than the carrying amount. See "Part II - Item 8. Financial Statements and Supplementary Data - Note 8" for further details of the impairment charge to goodwill.

#### *Change in fair value of contingent consideration and indemnification asset*

We recorded a gain on change in fair value of contingent consideration and indemnification asset of \$4.0 million and \$4.1 million for the years ended December 31, 2019 and 2018, respectively. This variance is the result of changes in the fair values of mark-to-market contingent liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018 and 2019. See "Part II - Item 8. Financial Statements and Supplementary Data - Note 18" in this Form 10-K for further details regarding the fair value of our mark-to-market contingent liabilities.

### **Discussion of Non-Operating Results**

#### *Interest Income*

Interest income consists of interest from investing cash in money market funds, interest from both our short-term and long-term investments, interest earned on the capital-only reinsurance agreement with NMHC and interest from the implementation loan and amounts contributed to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC. We recorded

interest income of \$3.2 million, \$4.0 million and \$3.4 million for years ended December 31, 2020, 2019 and 2018, respectively. Interest income decreased during 2020 as a result of lower interest income generated from the capital-only reinsurance agreement with NMHC which was terminated in the fourth quarter of 2019. Interest income increased during 2019 as a result of additional interest income generated from interest payments received on the Implementation Loan and the capital-only reinsurance agreement with NMHC.

### *Interest Expense*

Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes, 2025 Notes and Credit Agreement with Ares Capital Corporation.

The Company issued its 2021 Notes in December 2016. Holders of the 2021 Notes are entitled to cash interest payments at a rate equal to 2.00% per annum. In addition, we incurred \$4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes.

The Company issued its 2024 Notes in August 2020. As part of the issuance of the 2024 Notes, the Company consummated an exchange offer pursuant to which it issued \$84.2 million aggregate principal amount of the 2024 Notes in exchange for \$84.2 million aggregate principal of its 2021 Notes. Holders of the 2024 Notes are entitled to cash interest payments at a rate equal to 3.50% per annum. In addition, the 2024 Notes contain a cash conversion option, which resulted in a debt discount of \$38.1 million, allocated to equity. The amount allocated to equity, along with \$3.0 million of debt issuance costs in connection with the 2024 Notes, will be amortized to non-cash interest expense using the effective interest method over the contractual term of the 2024 Notes.

The Company issued its 2025 Notes in October 2018. Holders of the 2025 Notes are entitled to cash interest payments at a rate equal to 1.50% per annum. The 2025 Notes contain a cash conversion option, which resulted in a debt discount of \$71.8 million, allocated to equity. The amount allocated to equity, along with \$3.4 million of issuance costs, will be amortized to non-cash interest expense using the effective interest method over the contractual term of the 2025 Notes.

The Company entered into the Credit Agreement in December 2019 with Ares Credit Corporation in connection with the Company's acquisition of certain assets of UHC. Ares Capital Corporation was entitled to cash interest payments. The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. As of December 31, 2020, the Company had \$75.0 million outstanding under its Credit Agreement. On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation.

We recorded interest expense (including amortization of deferred financing costs) of approximately \$28.3 million, \$14.5 million and \$5.5 million for years ended December 31, 2020, 2019 and 2018, respectively. See "Part II - Item 8. Financial Statements - Note 9" in this Form 10-K for further details.

### *Impairment of Equity Method Investments*

As of March 31, 2020, the Oklahoma Insurance Division ("OID") informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately \$47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the three months ended March 31, 2020.

#### *Gain (Loss) from Equity Method Investees*

The Company has acquired economic interests in several entities that are accounted for under the equity method of accounting. The Company is allocated its proportional share of the investees' earnings and losses each reporting period. The Company's proportional share of the gains (losses) from these investments was approximately \$10.0 million, \$(9.5) million and \$(4.7) million for the years ended December 31, 2020, 2019 and 2018, respectively.

#### *Loss on Extinguishment of Debt*

In August 2020, as part of the issuance of the 2024 Notes, the Company issued \$84.2 million aggregate principal amount of the 2024 Notes in exchange for \$84.2 million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of \$2.5 million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of \$4.8 million, including an aggregate cash payment of \$2.5 million paid to exchanging noteholders. See "Part II - Item 8. Financial Statements - Note 9" in this Form 10-K for additional discussion of our exchange of 2021 Notes.

#### *Provision (Benefit) for Income Taxes*

The Company recorded \$(3.6) million, \$(21.5) million and less than \$0.1 million in income tax expense (benefit) for the years ended December 31, 2020, 2019 and 2018, respectively, which resulted in effective tax rates of 1.0%, 6.7% and (0.1)%, respectively. The difference between our effective tax rate and our statutory rate is primarily due to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act").

#### *Net Loss Attributable to Non-controlling Interests*

For the years ended December 31, 2019 and 2018, our results reflected net losses of \$3.6 million and \$1.5 million, respectively, attributable to non-controlling interests, which represented 1.2% and 3.2% of the operating losses. See "Part II - Item 8. Financial Statements - Note 17" in this Form 10-K for additional discussion of our non-controlling interests.

## REVIEW OF CONSOLIDATED FINANCIAL CONDITION

### Liquidity and Capital Resources

Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of \$270.6 million and \$306.6 million for the twelve months ended December 31, 2020 and 2019, respectively. Net cash and restricted cash from (used in) operating activities was \$(16.2) million and \$(42.6) million for the twelve months ended December 31, 2020 and 2019, respectively.

As of December 31, 2020, the Company had \$340.5 million of cash and cash equivalents and \$21.7 million in restricted cash and restricted investments.

We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months as of the date these financial statements were available to be issued. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies.

#### Cash Flows

The following summary of cash flows (in thousands) has been derived from our financial statements included in “Part II - Item 8. Financial Statements and Supplementary Data:”

	For the Year Ended December 31,		
	2020	2019	2018
Net cash and restricted cash used in operating activities	\$ (16,225)	\$ (42,645)	\$ (20,651)
Net cash and restricted cash from (used in) investing activities	261,072	(181,634)	(160,375)
Net cash and restricted cash from (used in) financing activities	(11,862)	(35,545)	274,024

#### Operating Activities

Cash flows used in operating activities of \$16.2 million in the year ended December 31, 2020 were due primarily to our net loss of \$334.2 million, partially offset by non-cash items, including an impairment of goodwill of \$215.1 million, an impairment of an equity method investment of \$47.1 million, depreciation and amortization expenses of \$61.5 million, stock-based compensation expense of \$14.6 million and a loss on the disposal of assets and consolidation of \$0.7 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and decreases in claims reserves contributed approximately \$94.5 million to our cash outflows. Those cash outflows were partially offset by an increase in accounts payable, accrued expenses and accrued compensation and employee benefits contributed of approximately \$23.5 million.

Cash flows used in operating activities of \$42.6 million in the year ended December 31, 2019 were due primarily to our net loss of \$305.6 million, partially offset by non-cash items, including goodwill impairment of \$199.8 million, depreciation and amortization expenses of \$60.9 million, stock-based compensation expense of \$15.6 million and a decrease in deferred tax liability of \$23.1 million. Our operating cash outflows were affected by the timing of our customer and vendor payments. An increase in contract cost assets combined with



accounts payable and accrued liabilities contributed approximately \$50.4 million to our cash outflows. Those cash outflows were partially offset by decreases in accounts receivable combined with increases in accrued compensation and employee benefits and claims reserves of approximately \$49.1 million.

Cash flows used in operating activities of \$20.7 million in the year ended December 31, 2018 were due primarily to our net loss of \$54.2 million, partially offset by non-cash items, including depreciation and amortization expenses of \$44.5 million and stock-based compensation expense of \$17.6 million. Our operating cash outflows were affected by the timing of our customer and vendor payments. A decrease in accrued compensation and employee benefits, combined with increases in accounts receivable, prepaid expenses and contract cost assets, contributed approximately \$65.0 million to our cash outflows. Those cash outflows were partially offset by increases in accounts payable, accrued liabilities, claims reserves and other long-term liabilities of approximately \$32.0 million.

## Investing Activities

Cash flows from investing activities of \$261.1 million in the year ended December 31, 2020 were primarily attributable to cash flows from the impact of the initial consolidation of EVH Passport of \$159.8 million, maturities and sales of investments primarily held by EVH Passport of \$143.4 million, offset, in part by investments in internal-use software and purchases of property and equipment of \$29.5 million, disposal of non-strategic assets of \$2.3 million and purchases of investments of \$11.2 million.

Cash flows used in investing activities of \$181.6 million in the year ended December 31, 2019 were primarily attributable to purchases of property and equipment of \$35.5 million, cash paid for asset acquisitions, business combinations and equity method investments of \$96.1 million, amounts advanced to satisfy regulatory capital requirements of \$46.4 million and purchases of investments of \$11.1 million, partially offset by a customer's repayment of advance to satisfy regulatory capital requirements of \$5.4 million.

Cash flows used in investing activities of \$160.4 million in the year ended December 31, 2018 primarily relate to cash paid for asset acquisitions or business combinations of \$130.2 million, investments in internal-use software and purchases of property and equipment of \$39.6 million, purchases of investments of \$10.0 million and investments in equity method investees of \$9.4 million. These amounts were partially offset by the \$20.0 million principal repayment of the implementation funding loan and net maturities of restricted investments of \$7.9 million.

## Financing Activities

Cash flows used in financing activities of \$11.9 million in the year ended December 31, 2020 were primarily related to a \$20.0 million redemption of the Sponsors equity in EVH Passport in accordance with the terms of EVH Passport's Stockholders' Agreement as part of the EVH Passport wind-down and repurchase of our 2021 Notes of \$16.6 million, \$1.9 million of taxes withheld and paid for vests of restricted stock units and a \$6.0 million decrease in working capital balances held on behalf of our partners for claims processing services offset, in part by \$30.1 million from proceeds of convertible debt. The change in working capital balances held on behalf of partners for claims processing are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.

Cash flows used in financing activities of \$35.5 million in the year ended December 31, 2019 were primarily related to a \$104.3 million increase in working capital balances held on behalf of our partners for claims processing as well as \$2.6 million of taxes withheld and paid for vests of restricted stock units, offset, in part by net proceeds of \$62.6 million from borrowings under the credit agreement.

Cash flows provided by financing activities of \$274.0 million in the year ended December 31, 2018 were primarily related to net proceeds of \$167.2 million from the issuance of convertible notes. In addition, there was a \$96.2 million increase in working capital balances held on behalf of our partners for claims processing. Stock option exercises during the year resulted in additional proceeds of \$11.9 million, which were partially offset by \$1.2 million of taxes withheld and paid for vests of restricted stock units.

## *Contractual Obligations*

Our estimated contractual obligations (in thousands) as of December 31, 2020, were as follows:

	<b>2021</b>	<b>2022-2023</b>	<b>2024-2025</b>	<b>2026+</b>	<b>Total</b>
Operating leases for facilities	\$ 12,244	\$ 19,260	\$ 16,998	\$ 47,760	\$ 96,262
Purchase obligations related to vendor contracts	9,444	4,235	—	—	13,679
Debt interest and termination payments	17,071	13,369	9,279	—	39,719
Debt principal repayment <sup>(1)</sup>	101,737	—	289,551	—	391,288
Warrant settlement <sup>(2)</sup>	13,730	—	—	—	13,730
<b>Total contractual obligations</b>	<b>\$ 154,226</b>	<b>\$ 36,864</b>	<b>\$ 315,828</b>	<b>\$ 47,760</b>	<b>\$ 554,678</b>

<sup>1.</sup> Debt principal repayments in 2021 includes voluntary prepayment of the Credit Agreement principal of \$75.0 million and the remaining \$26.7 million of 2021 Notes. Refer to “Part II - Item 8. Financial Statements - Note 26” for additional discussion relating to the repayment of the Credit Agreement and 2021 Notes.

<sup>2.</sup> Warrant settlement in 2021 includes voluntary settlement of the Ares warrant agreements. Refer to “Part II - Item 8. Financial Statements - Note 26” for additional discussion relating to the settlement of the warrant agreements.

During the year ended December 31, 2020, the only material change outside the ordinary course of business in the contractual obligations set forth above was the addition of the principal and interest payments related to the 2024 Notes and the exchange and repurchase of 2021 Notes. Refer to the discussion in “Part II - Item 8. Financial Statements - Note 9” for additional information on our long-term debt.

### *Restricted Cash and Restricted Investments*

Restricted cash and restricted investments of \$21.7 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of \$12.1 million, collateral for letters of credit required as security deposits for facility leases of \$3.5 million, amounts held with financial institutions for risk-sharing arrangements of \$4.7 million and other restricted balances of \$1.3 million as of December 31, 2020. See “Part II - Item 8. Financial Statements - Note 2” for further details of the Company’s restricted cash balances.

### *Uses of Capital*

Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.

## **OTHER MATTERS**

### *Off-balance Sheet Arrangements*

Through December 31, 2020, the Company had not entered into any off-balance sheet arrangements, other than the operating leases and notes receivable noted above, and did not have any holdings in variable interest entities, other than the unconsolidated variable interest entities discussed in “Part II - Item 8. Financial Statements - Note 16” within this Form 10-K.

### *Related Party Transactions*

In the ordinary course of business, we enter into transactions with related parties. Information regarding transactions and amounts with related parties is discussed in “Part II - Item 8. Financial Statements - Note 19” within this Form 10-K.

### *Other Factors Affecting Our Business*

In general, our business is subject to a changing social, economic, legal, legislative and regulatory environment. Although the eventual effect on us of the changing environment in which we operate remains uncertain, these factors and others could have a material effect on our results of operations, liquidity and capital resources. Factors that could cause actual results to differ materially from those set forth in this section are described in “Part I - Item 1A. Risk Factors” and “Forward-Looking Statements – Cautionary Language.”

## **Item 7A. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.

### *Interest Rate Risk*

As of December 31, 2020, the Company had cash and cash equivalents and restricted cash and restricted investments of \$362.2 million, which consisted of bank deposits with FDIC participating banks of \$355.2 million, bank deposits in international banks of \$0.5 million, cash equivalents deposited in a money-market fund of \$5.9 million, and \$0.6 million of restricted investments that are classified as held-to-maturity investments. In addition, we have unrestricted investments of \$14.8 million, which are classified as held-to-maturity investments.

Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.

As of December 31, 2020, we had \$316.3 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. As of December 31, 2020, we also had \$75.0 million of aggregate principal amount in a secured term loan, which was a floating rate instrument and subject to fluctuations in interest rates. The secured term loan was repaid in full on January 8, 2021. Refer to the discussion in “Part II - Item 8. Financial Statements - Note 9” for additional information on our long-term debt.

### *Foreign Currency Exchange Risk*

Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized foreign currency translation loss of \$44 thousand for the year ended December 31, 2020.

**Item 8. Financial Statements and Supplementary Data**

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**

	<b>Page</b>
<a href="#">Reports of Independent Registered Public Accounting Firms</a>	<a href="#">66</a>
<a href="#">Consolidated Balance Sheets</a>	<a href="#">71</a>
<a href="#">Consolidated Statements of Operations and Comprehensive Income (Loss)</a>	<a href="#">72</a>
<a href="#">Consolidated Statements of Changes in Shareholders' Equity (Deficit)</a>	<a href="#">73</a>
<a href="#">Consolidated Statements of Cash Flows</a>	<a href="#">75</a>
<a href="#">Notes to Consolidated Financial Statements</a>	<a href="#">77</a>

## REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of Evolent Health, Inc.

### Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Evolent Health, Inc. and subsidiaries (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive income (loss), changes in shareholders' equity (deficit), and cash flows, for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2021, expressed an unqualified opinion on the Company's internal control over financial reporting.

### Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

### Critical Audit Matters

The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

### *Goodwill — Reporting Unit Within the Services Segment — Refer to Note 8 to the financial statements*

#### *Critical Audit Matter Description*

The Company's evaluation of goodwill for impairment involves the comparison of the fair value of each of its reporting units to the respective carrying value for each of those reporting units at least annually. In addition to the annual impairment evaluation, the Company evaluates goodwill for impairment if an event occurs or circumstances change during the period that indicates that the fair value of a reporting unit may be below its carrying value. The Company performed an interim goodwill impairment assessment as of March 31, 2020 due to the decline in the Company's stock price during the first quarter of 2020 and lack of excess of fair value over the carrying value given the impairment charge taken in the fourth quarter of 2019. The Company concluded that the fair value of its reporting unit was more than its carrying value as of March 31, 2020. In addition, the Company performed an interim goodwill impairment assessment as of May 31, 2020 and concluded that the fair value of one of its reporting units in the Services segment was less than its carrying value by \$215.1 million as of May 31, 2020. The decrease in fair value was due to EVH Passport not obtaining a renewal of the Passport Medicaid Contract. The non-renewal of the Passport Medicaid Contract caused a reduction in the Company's cash flow projections and, therefore, an impairment was recognized during the second quarter of 2020. The Company also performed a goodwill impairment assessment on its annual measurement date and determined that no further impairment of goodwill was required. The Company used a discounted cash flow valuation approach ("income approach") to estimate the fair values as of March 31, 2020, May 31, 2020 and October 31, 2020, which required management to make significant estimates and assumptions related to discount



rates and forecasts of future revenues and expenses. Changes in these assumptions have a significant impact on either the fair value, the amount of any goodwill impairment charge, or both. The goodwill balance was \$354.7 million as of December 31, 2020, of which \$349.0 million was allocated to the Services segment.

Given the significant judgments made by management of the Company to estimate the fair values of one of its reporting units in the Services segment and the sensitivity of assumptions used to estimate the fair values, performing audit procedures to evaluate the reasonableness of management's estimates and assumptions related to the revenue growth rates, operating margins, the discount rates, and the implied control premium required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists.

#### *How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to management's assumptions for the interim and annual assessment periods related to revenue growth rates, operating margins, selection of the discount rate, and the implied control premium for one of the Company's reporting units in the Services segment included the following, among others:

- We tested the effectiveness of controls over management's goodwill impairment evaluations, including controls over management's assumptions related to revenue growth rates, operating margins, selection of the discount rate, and the implied control premium.
- We evaluated management's ability to accurately forecast future revenues and operating margins by comparing actual results to management's historical forecasts.
- We evaluated the reasonableness of management's revenue and operating margin forecasts by comparing the forecasts to:
  - Historical revenues and operating margins.
  - Internal communications to management and the Board of Directors.
  - Forecasted information included in the Company's press releases, analyst and industry reports for the Company and certain of its peer companies.
- We evaluated the impact of changes in management's forecasts each quarter and from the October 31, 2020 annual measurement date to December 31, 2020.
- With the assistance of our fair value specialists, we evaluated the reasonableness of the (i) valuation methodology, (ii) discount rate, and (iii) implied control premium by:
  - Testing the source information underlying the determination of the discount rate and the mathematical accuracy of the calculation.
  - Developing a range of independent estimates and comparing those to the discount rate selected by management and the implied control premium.
  - Evaluating the Company's reconciliation between fair value of the reporting units and the Company's market capitalization by considering factors such as implied control premiums in the health service industry and other industries, and market trends.

#### ***Reserve for Claims — Refer to Note 22 to the financial statements***

##### *Critical Audit Matter Description*

The Company records reserves for the ultimate cost of claims that have been incurred but not reported (IBNR), including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. The liability

is primarily calculated using completion factors developed by comparing the claim incurred date to the date claims were paid. Key assumptions include current payment experience, trend factors, and completion factors. Completion factors are impacted by several key items including changes in 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership, and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.

For more recent months, and for newer lines of business where there is insufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflect expected claim payment patterns and other relevant operational considerations or authorization analysis. For each reporting period, the Company compares key assumptions used to establish the reserves for claims to actual experience. When actual experience differs from these assumptions, reserves for claims are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting

future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. The reserve for claims as of December 31, 2020 was \$188.7 million.

We identified the IBNR reserve as a critical audit matter because the development of the IBNR reserve involves significant estimation by management. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our actuarial specialists.

#### *How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to the reserve for claims included the following, among others:

- We tested the effectiveness of controls related to the reserve for claims, including management's controls over the development and reporting of the IBNR reserve.
- We tested the underlying data that served as the basis for the actuarial analysis, including claims lag triangles and membership data, to test that the inputs to the actuarial estimate were complete and accurate.
- With the assistance of our actuarial specialists, we evaluated the reasonableness of the actuarial methods and assumptions used by management to estimate the IBNR reserve by:
  - Developing an independent estimate of the IBNR reserve and comparing our estimate to management's estimates.
  - Comparing management's September 30, 2020 assumptions of expected development and ultimate cost of claims to actuals incurred during the fourth quarter of 2020 to identify potential bias in the determination of the reserve for claims.

#### ***Investments In and Advances to Equity Method Investees — Passport — Refer to Notes 4 and 16 to the financial statements***

##### *Critical Audit Matter Description*

The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a variable interest entity (VIE) or a voting interest entity (VOE) and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both 1) the power to direct the activities that most significantly impact the economic performance of the VIE and 2) a variable interest that could potentially be significant to the VIE. To determine whether a variable interest that the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company uses the equity method to account for investments in companies if the investment provides the Company with the ability to exercise significant influence over operating and financial policies of the investee. The Company will reconsider whether an entity is a VIE upon the occurrence of certain types of events.

On December 30, 2019, the Company completed the acquisition of an approximately 70 percent ownership interest in EVH Passport which was determined to be a VIE and accounted for under the equity method. On September 1, 2020, the Company agreed to the sale of certain assets of EVH Passport and the novation of the Passport Medicaid Contract. As a result of the transaction, the Company concluded that a VIE reconsideration event occurred whereby EVH Passport was determined to be a VOE and that the Company had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport's net assets of as of September 1, 2020 in its consolidated financial statements.

We identified the Company's investment in EVH Passport as a critical audit matter given the complexity in the accounting literature related to consolidation; particularly, the judgment required to determine 1) whether a VIE reconsideration event had occurred, 2) whether EVH Passport was a VOE as of September 1, 2020 and 3) whether the Company had control over EVH Passport based on the

reconsideration event. Specifically, a high level of judgment and an increased level of effort was required, including the need to involve professionals in our firm with consolidation accounting expertise.

*How the Critical Audit Matter Was Addressed in the Audit*

- We tested the effectiveness of controls related to the VIE reconsideration event of EVH Passport.
- With the assistance of professionals in our firm with expertise in consolidation accounting, we evaluated the appropriateness of the Company's reconsideration of the EVH Passport investment as a VOE rather than a VIE and whether the Company had a controlling financial interest. In addition, we evaluated the consolidation model that was used.
- We evaluated the Company's analysis by performing procedures including, but not limited to:
  - Obtaining and reading the asset purchase agreement between the Company, EVH Passport, and Molina.
  - Engaging in conversations with management about the activities related to Passport during the wind down phase of EVH Passport based on EVH Passport not being awarded the Passport Medicaid Contract.

/s/ Deloitte & Touche LLP

McLean, Virginia

February 25, 2021

We have served as the Company's auditor since 2019.

## REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Evolent Health, Inc.

### *Opinion on the Financial Statements*

We have audited the consolidated statements of operations and comprehensive income (loss), of changes in shareholders' equity (deficit) and of cash flows of Evolent Health, Inc. and its subsidiaries (the "Company") for the year ended December 31, 2018, including the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operations and cash flows of the Company for the year ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America.

### *Changes in Accounting Principles*

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for revenue from contracts with customers in 2018.

### *Basis for Opinion*

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ PricewaterhouseCoopers LLP  
McLean, Virginia  
February 28, 2019

We served as the Company's or its predecessor's auditor from 2012 to 2019, which includes periods before the Company became subject to SEC reporting requirements.

**EVOLENT HEALTH, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
(in thousands, except share data)



	December 31,	
	2020	2019
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 340,490	\$ 101,008
Restricted cash and restricted investments	14,437	20,080
Accounts receivable, net <sup>(1)</sup>	125,986	75,667
Prepaid expenses and other current assets <sup>(1)</sup>	61,034	28,488
Investments, at amortized cost	3,858	1,807
Contract assets	329	1,751
Total current assets	546,134	228,801
Restricted cash and restricted investments	7,270	8,260
Investments, at amortized cost	10,919	16,751
Investments in and advances to equity method investees	6,498	122,618
Property and equipment, net	86,240	85,155
Right-of-use assets - operating	57,799	72,173
Customer advance for regulatory capital requirements, net of allowances <sup>(1)</sup>	—	40,000
Prepaid expenses and other noncurrent assets, net of allowances <sup>(1)</sup>	5,832	6,253
Contract assets	—	999
Contract cost assets	26,687	36,482
Intangible assets, net	268,072	308,459
Goodwill	354,734	572,064
Total assets	\$ 1,370,185	\$ 1,498,015
<b>LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</b>		
<b>Liabilities</b>		
Current liabilities:		
Accounts payable <sup>(1)</sup>	\$ 32,068	\$ 37,488
Accrued liabilities <sup>(1)</sup>	84,507	33,343
Short-term debt, net of discount	26,557	—
Operating lease liability - current	7,357	6,269
Accrued compensation and employee benefits	48,278	34,691
Deferred revenue	14,327	19,828
Reserve for claims and performance-based arrangements <sup>(1)</sup>	188,685	61,150
Total current liabilities	401,779	192,769
Long-term debt, net of discount	263,343	293,667
Other long-term liabilities	22,209	11,732
Operating lease liabilities - noncurrent	62,526	68,858
Deferred tax liabilities, net	728	1,942
Total liabilities	750,585	568,968
<b>Commitments and Contingencies (See Note 10)</b>		
<b>Shareholders' Equity (Deficit)</b>		
Class A common stock - \$0.01 par value; 750,000,000 shares authorized, 85,894,459 and 84,588,629 shares issued, respectively	859	846

<sup>(1)</sup> See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

See accompanying Notes to Consolidated Financial Statements

**EVOLENT HEALTH, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)**  
(in thousands, except per share data)

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Revenue</b>			
Transformation services <sup>(1)</sup>	\$ 11,990	\$ 15,203	\$ 32,916
Platform and operations services <sup>(1)</sup>	893,066	659,438	500,190
Premiums	117,377	171,742	93,957
Total revenue	<u>1,022,433</u>	<u>846,383</u>	<u>627,063</u>
<b>Expenses</b>			
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) <sup>(1)</sup>	701,373	513,059	327,825
Claims expenses	87,951	135,774	70,889
Selling, general and administrative expenses <sup>(1)</sup>	222,600	257,046	235,418
Depreciation and amortization expenses	61,475	60,913	44,515
(Gain) loss on disposal of assets and consolidation	698	(9,600)	—
Goodwill impairment	215,100	199,800	—
Change in fair value of contingent consideration and indemnification asset	3,860	(3,997)	(4,104)
Total operating expenses	<u>1,293,057</u>	<u>1,152,995</u>	<u>674,543</u>
Operating loss	(270,624)	(306,612)	(47,480)
Interest income	3,164	3,987	3,440
Interest expense	(28,337)	(14,534)	(5,484)
Impairment of equity method investments	(47,133)	—	—
Gain (loss) from equity method investees	10,039	(9,465)	(4,736)
Loss on extinguishment of debt, net	(4,789)	—	—
Other income (expense), net	(119)	(492)	109
Loss before income taxes and non-controlling interests	(337,799)	(327,116)	(54,151)
Provision (benefit) for income taxes	(3,553)	(21,536)	40
Net loss	(334,246)	(305,580)	(54,191)
Net loss attributable to non-controlling interests	—	(3,609)	(1,533)
Net loss attributable to common shareholders of Evolent Health, Inc.	<u>\$ (334,246)</u>	<u>\$ (301,971)</u>	<u>\$ (52,658)</u>
<b>Loss per common share</b>			
Basic and diluted	<u>\$ (3.94)</u>	<u>\$ (3.67)</u>	<u>\$ (0.68)</u>
<b>Weighted-average common shares outstanding</b>			
Basic and diluted	<u>84,928</u>	<u>82,364</u>	<u>77,338</u>
<b>Comprehensive loss</b>			
Net loss	\$ (334,246)	\$ (305,580)	\$ (54,191)
Other comprehensive loss, net of taxes, related to:			
Foreign currency translation adjustment	(44)	(52)	(182)
Total comprehensive loss	(334,290)	(305,632)	(54,373)
Total comprehensive loss attributable to non-controlling interests	—	(3,609)	(1,533)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.	<u>\$ (334,290)</u>	<u>\$ (302,023)</u>	<u>\$ (52,840)</u>

<sup>(1)</sup> See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

See accompanying Notes to Consolidated Financial Statements



**EVOLENT HEALTH, INC.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)**  
(in thousands)

	Class A Common Stock		Class B Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Treasury Stock	Total Shareholders' Equity		Total Equity (Deficit)
	Shares	Amount	Shares	Amount					Attributable to Evolent Health, Inc.	Non- controlling Interests	
<b>Balance as of</b>											
<b>December 31, 2017</b>	74,723	\$ 747	2,654	\$ 27	\$ 924,153	\$ —	\$ 85,952	\$ —	\$ 1,010,879	\$ 35,427	1,046,306
Cumulative-effect adjustment from adoption of ASC 606	—	—	—	—	—	—	16,715	—	16,715	594	17,309
Stock-based compensation expense	—	—	—	—	17,221	—	—	—	17,221	—	17,221
Exercise of stock options	1,720	16	—	—	11,913	—	—	—	11,929	—	11,929
Restricted stock units vested, net of shares withheld for taxes	212	2	—	—	(1,238)	—	—	—	(1,236)	—	(1,236)
Issuance of Class B common stock for business combination	—	—	3,120	31	40,355	—	—	—	40,386	42,787	83,173
Equity component of 2025 Notes, net of issuance costs	—	—	—	—	69,378	—	—	—	69,378	—	69,378
Exchange of Class B common stock	2,584	27	(2,584)	(27)	34,682	—	—	—	34,682	(34,682)	—
Tax impact of Class B common stock exchange	—	—	—	—	652	—	—	—	652	—	652
Shares released from Valence Health escrow	(67)	—	—	—	(1,003)	—	—	—	(1,003)	—	(1,003)
Foreign currency translation adjustment	—	—	—	—	—	(182)	—	—	(182)	—	(182)
Net loss	—	—	—	—	—	—	(52,658)	—	(52,658)	(1,533)	(54,191)
Reclassification of non-controlling interests	—	—	—	—	(2,939)	—	—	—	(2,939)	2,939	—
<b>Balance as of</b>											
<b>December 31, 2018</b>	79,172	702	2,100	21	1,002,174	(182)	50,000	—	1,142,824	45,532	1,189,256







**EVOLENT HEALTH, INC.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)**  
(in thousands)

	Class A		Class B		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Treasury Stock	Total Shareholders' Equity		Total Equity (Deficit)
	Common Stock		Common Stock						Attributable to Evolent Health, Inc.	Non- controlling Interests	
	Shares	Amount	Shares	Amount							
<b>Balance as of December 31, 2019</b>	84,589	846	—	—	1,173,708	(234)	(251,962)	—	922,358	6,689	929,047
Cumulative- effect adjustment from adoption of ASU 2016-03	—	—	—	—	—	—	(2,970)	—	(2,970)	—	(2,970)
Stock-based compensation expense	—	—	—	—	14,606	—	—	—	14,606	—	14,606
Exercise of stock options	416	4	—	—	2,573	—	—	—	2,577	—	2,577
Restricted stock units vested, net of shares withheld for taxes	462	5	—	—	(1,856)	—	—	—	(1,851)	—	(1,851)
Consolidation of equity method investment	—	—	—	—	—	—	—	(21,123)	(21,123)	—	(21,123)
Share retirement	(188)	(2)	—	—	(683)	—	—	—	(685)	—	(685)
Class A common stock issued for payment of earn- outs	616	6	—	—	4,179	—	—	—	4,185	—	4,185
Equity component of 2024 notes, net of issuance costs	—	—	—	—	36,793	—	—	—	36,793	—	36,793
Disposal of assets	—	—	—	—	—	—	—	—	—	(6,689)	(6,689)
Foreign currency translation adjustment	—	—	—	—	—	(44)	—	—	(44)	—	(44)
Net income (loss)	—	—	—	—	—	—	(334,246)	—	(334,246)	—	(334,246)
<b>Balance as of December 31, 2020</b>	85,895	\$ 859	—	\$ —	\$ 1,229,320	\$ (278)	\$ (589,178)	\$ (21,123)	\$ 619,600	\$ —	\$ 619,600



**EVOLENT HEALTH, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(in thousands)

**For the Year Ended December 31,**

	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Cash Flows Used In Operating Activities</b>			
Net loss	\$ (334,246)	\$ (305,580)	\$ (54,191)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:			
Change in fair value of contingent consideration and indemnification asset	3,860	(3,997)	(4,104)
Loss (gain) on disposal of assets and consolidation	698	(9,600)	—
(Gain) loss from equity method investees	(10,039)	9,465	4,736
Depreciation and amortization expenses	61,475	60,913	44,515
Goodwill impairment	215,100	199,800	—
Impairment of equity method investments	47,133	—	—
Stock-based compensation expense	14,606	15,618	17,609
Deferred tax (benefit) provision	(1,132)	(23,124)	44
Amortization of contract cost assets	21,195	5,723	2,703
Amortization of deferred financing costs	14,780	9,370	2,455
Loss on extinguishment of debt	4,789	—	—
Interest from customer advance for regulatory capital requirements	(1,869)	(1,300)	—
Other current operating cash inflows (outflows), net	2,744	(264)	448
Changes in assets and liabilities, net of acquisitions:			
Accounts receivable, net and contract assets	(47,017)	6,326	(24,503)
Prepaid expenses and other current and noncurrent assets	7,340	791	(14,746)
Contract cost assets	(11,400)	(23,057)	(11,179)
Accounts payable	3,547	(5,480)	7,598
Accrued liabilities	8,801	(21,852)	12,180
Accrued compensation and employee benefits	11,143	9,246	(14,571)
Deferred revenue	(8,943)	(756)	(1,819)
Reserve for claims and performance-based arrangements	(36,108)	33,555	8,964
Right-of-use operating assets	11,934	(20,811)	—
Operating lease liabilities	(2,782)	27,724	—
Other long-term liabilities	8,166	(5,355)	3,210
Net cash and restricted cash used in operating activities	<u>(16,225)</u>	<u>(42,645)</u>	<u>(20,651)</u>

**Cash Flows From (Used In) Investing Activities**

Cash paid for asset acquisitions or business combinations	(300)	(8,575)	(130,241)
Customer advance for regulatory capital requirements	—	(46,400)	—
Principal repayment of implementation funding loan and regulatory and capital requirements	1,000	5,400	20,000
Disposal of non-strategic assets	(2,287)	—	—
Amount received from escrow in asset acquisition	—	—	500
Investments in and advances to equity method investees	—	(87,480)	(9,360)
Impact to cash and cash equivalents and restricted cash from initial consolidation of Passport	159,755	—	—
Purchases of investments	(11,170)	(11,125)	(10,010)
Maturities and sales of investments	143,441	2,575	349

See accompanying Notes to Consolidated Financial Statements

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Amount received from escrow in asset acquisition	—	500	—
Proceeds from issuance of long-term debt, net of offering costs	30,062	62,648	167,178
Distributions to Sponsors	(20,000)	—	—
Repurchase of 2021 Notes and lender fees	(16,606)	—	—
Issuance of warrant liability	—	7,092	—
Proceeds from stock option exercises	2,577	1,092	11,929
Taxes withheld and paid for vesting of restricted stock units	(1,851)	(2,609)	(1,236)
Net cash and restricted cash from (used in) financing activities	(11,862)	(35,545)	274,024
Effect of exchange rate on cash and cash equivalents and restricted cash	65	30	(36)
Net increase (decrease) in cash and cash equivalents and restricted cash	233,050	(259,794)	92,962
Cash and cash equivalents and restricted cash as of beginning-of-period	128,531	388,325	295,363
Cash and cash equivalents and restricted cash as of end-of-period	<u>\$ 361,581</u>	<u>\$ 128,531</u>	<u>\$ 388,325</u>

See accompanying Notes to Consolidated Financial Statements

**EVOLENT HEALTH, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1. Organization**

Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations as well as health plans to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. The Company operates through two segments.

The Company's Services segment ("Services") includes clinical and administrative solutions designed to help our partners manage and administer patient health in a more cost-effective manner. We have two clinical solutions: (i) total cost of care management and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one type of solution, or multiple types of solutions, depending on specific needs. True Health is our second segment. True Health is a physician led health plan offering individual, small group, large group, ASO and Federal Employee Health Benefit health insurance products to New Mexico consumers.

Since its inception, the Company has incurred losses from operations. As of December 31, 2020, the Company had unrestricted cash and cash equivalents of \$340.5 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.

The Company's headquarters is located in Arlington, Virginia.

*Evolent Health LLC Governance*

Our operations are conducted through Evolent Health LLC and subsequent to the offering reorganization at the time of our initial public offering (the "Offering Reorganization"), the financial results of Evolent Health LLC were consolidated in the financial statements of Evolent Health, Inc. Evolent Health, Inc. is a holding company whose only business is to act as sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC's business and affairs and is responsible for the management of its business.

*Issuances of Common Units*

Evolent Health LLC may only issue Class A common units to us, as the sole managing member of Evolent Health LLC. Class B common units may be issued only to persons or entities we permit. Such issuances of Class B common units shall be made in exchange for cash or other consideration. Class B common units may not be transferred as Class B common units except to certain permitted transferees and in accordance with the restrictions on transfer set forth in the third amended and restated operating agreement of Evolent Health LLC. Any such transfer must be accompanied by the transfer of an equal number of shares of our Class B common stock. As of December 31, 2020 and 2019, there are no Class B common units outstanding.

**Note 2. Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles**

**Basis of Presentation**

The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries.



## Summary of Significant Accounting Policies

Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.

### *Accounting Estimates and Assumptions*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling

prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.

### *Principles of Consolidation*

The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

### *Operating Segments*

Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company operates through two segments: (1) Services, and (2) True Health. Our Services segment consists of two clinical solutions: (i) total cost of care services and (ii) specialty care management services, and one administrative solution: comprehensive health plan administration services. Our True Health segment consists of a commercial health plan we operate in New Mexico that historically focused on small and large businesses. In 2020, True Health diversified its services to offer coverage for individuals and families as well as the Federal Employee Health Benefits Program. Refer to Note 21 for a discussion of our operating results by segment and Note 26 for a discussion of a subsequent change in operating segments.

### *Cash and Cash Equivalents*

We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.

### *Restricted Cash and Restricted Investments*

Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:

	December 31,	
	2020	2019
Collateral for letters of credit for facility leases <sup>(1)</sup>	\$ 3,510	\$ 3,610
Collateral with financial institutions <sup>(2)</sup>	4,743	5,742
Claims processing services <sup>(3)</sup>	12,127	18,171
Other	1,327	817
<b>Total restricted cash and restricted investments</b>	<b>\$ 21,707</b>	<b>\$ 28,340</b>
Current restricted investments	\$ —	\$ 704
Current restricted cash	14,437	19,376
<b>Total current restricted cash and restricted investments</b>	<b>\$ 14,437</b>	<b>\$ 20,080</b>
Non-current restricted investments	\$ 616	\$ 113
Non-current restricted cash	6,654	8,147
<b>Total non-current restricted cash and restricted investments</b>	<b>\$ 7,270</b>	<b>\$ 8,260</b>

<sup>(1)</sup> Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments.

<sup>(2)</sup> Represents collateral held with financial institutions for risk-sharing and other arrangements. As of both December 31, 2020 and December 31, 2019, approximately \$4.7 million, of the collateral amounts were held in a FDIC participating bank account. As December 31, 2019, approximately \$1.0 million, of the collateral amount was held in a trust account and invested in money market funds related to risk-sharing arrangements. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 18 for discussion of fair value measurement and Note 10 for discussion of our risk-sharing arrangements.

<sup>(3)</sup> Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands).

	<b>As of December 31,</b>	
	<b>2020</b>	<b>2019</b>
Cash and cash equivalents	\$ 340,490	\$ 101,008
Restricted cash and restricted investments	21,707	28,340
Restricted investments included in restricted cash and restricted investments	(616)	(817)
Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows	<u>\$ 361,581</u>	<u>\$ 128,531</u>

#### *Accounts Receivable and Allowances*

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.

#### *Property and Equipment, Net*

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:

Computer hardware	3 years
Computer software	1 year
Furniture and equipment	3-7 years
Internal-use software development costs	5 years
Leasehold improvements	Shorter of useful life or remaining lease term

When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in gain (loss) on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).

We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.

#### *Software Development Costs*

The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage – when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during

subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.

#### *Research and Development Costs*

Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were \$15.1 million, \$19.8 million and \$18.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

### *Notes Receivable*

Notes receivable are carried at the face amount of each note plus accrued interest receivable, less received payments and net of allowances. The Company does not typically carry notes receivable in the course of its regular business, but contributed \$40.0 million in the form of an advance for regulatory capital requirements (the "Passport Note") for EVH Passport/UHC during the second quarter of 2019. Refer to Note 4 for a discussion of our Passport Note.

### *Business Combinations*

Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates.

The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss).

For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.

### *Equity Method Investments*

For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in and advances to equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).

### *Impairment of Equity Method Investments*

The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount,

management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 16 for additional discussion regarding impairments on equity method investments.

### *Goodwill*

We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has four reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.

Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit's fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2020 and 2019.

### *Intangible Assets, Net*

Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used.

The following summarizes the estimated useful lives by asset classification:

Corporate trade name	10 - 20 years
Customer relationships	10 - 25 years
Technology	5 years
Provider network contracts	4 - 5 years

Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset's carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.

### *Reserves for Claims and Performance-based Arrangements*

Reserves for performance-based arrangements and claims for our Services and True Health segments reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under a reinsurance agreement for 2019 as discussed further in Note 10. The reinsurance agreement was terminated in December 2019. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.



### *Long-term Debt*

Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 9 for further discussion regarding our convertible notes and credit agreement.

### *Leases*

As discussed in Note 3, we adopted Accounting Standards Update (“ASU”) 2016-02, *Leases*, effective January 1, 2019. The following reflects our updated policy for leases.

The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.

The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.

Refer to Note 11 for additional lease disclosures.

#### *Revenue Recognition*

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, in order to clarify the principles of recognizing revenue. The Company adopted the standard effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application.

Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.

We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, *Revenue from Contracts with Customers* (“ASC 606”), to determine revenue recognition for our Services segment from our contracts with customers:

- Identify the contract(s) with a customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to performance obligations
- Recognize revenue when (or as) the entity satisfies a performance obligation

Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derived revenue in 2019 from reinsurance premiums assumed from NMHC under the terms of the reinsurance agreement (as defined in Note 10). The portion of premiums that will be earned in the future or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as deferred revenue on our consolidated balance sheets.

*Cost of Revenue (Exclusive of Depreciation and Amortization)*

Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.

*Claims Expenses*

Our claims expenses consist of the direct medical expenses incurred by our True Health segment. Claims expenses are recognized in the period in which services are provided and include amounts that have been paid by us through the reporting date, as well as estimated medical claims and benefits payable for costs that have been incurred but not paid by us as of the reporting date. Claims expenses include, among other items, fee-for-service claims, pharmacy benefits, various other related medical costs and expenses

related to our reinsurance agreement. We use judgment to determine the appropriate assumptions for determining the required estimates.

### *Stock-based Compensation*

The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.

We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.

### *Income Taxes*

Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.

We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2020 and 2019, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.

We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company's federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.

### *Earnings (Loss) per Share*

Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.

For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.

*Fair Value Measurement*

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.

See Note 18 for further discussion regarding fair value measurement.

### *Foreign Currency*

The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2020, 2019, and 2018.

## **Note 3. Recently Issued Accounting Standards**

### **Adoption of New Accounting Standards**

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, *Leases*, in order to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases, including a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02. We adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. Further, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional right-of-use assets and lease liabilities of approximately \$51.4 million and \$47.4 million, respectively, on our consolidated balance sheet as of January 1, 2019. The standard had no impact on our results of operations.

In August 2018, the FASB issued ASU 2018-15, *Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Services Contract*. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted the requirements of ASU 2018-15 effective January 1, 2019. There was no material impact to our consolidated balance sheets or results of operations as of or for the year ended December 31, 2019.

In July 2019, the FASB issued ASU 2019-07, *Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update)*. ASU 2019-07 clarifies or improves the disclosure and presentation

requirements of a variety of codification topics by aligning them with the SEC's regulations, thereby eliminating redundancies and making the codification easier to apply. The disclosure and presentation amendments included in ASU 2019-07, which were effective upon issuance of the standard and were to be applied prospectively, did not have a material impact on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing "incurred loss" framework with an expected credit loss recognition model. The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts. The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified

retrospective approach and recorded a cumulative effect adjustment of \$3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of ASU 2016-13, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance. In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach. For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 6 for additional disclosures related to current expected credit losses.

In August 2018, the FASB issued ASU 2018-13, *Changes to the Disclosure Requirements for Fair Value Measurement*. ASU 2018-13 amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosures. This ASU is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. We adopted the requirements of this standard effective January 1, 2020 and determined it did not have a material impact on our consolidated financial statements and related disclosures.

#### **Note 4. Transactions**

##### *Passport*

On May 28, 2019, UHC, Passport Health Solutions, LLC (“PHS I”), the Company and EVH Passport entered into an Asset Purchase Agreement (the “Passport APA”), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC’s Kentucky Medicaid contract (the “Passport Medicaid Contract”), to EVH Passport for a purchase price of \$70.0 million in cash and the issuance of a 30% interest in EVH Passport (the “Passport Purchase Price”) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the “Sponsors”).

On June 18, 2019, the Company contributed \$40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the “Passport Note”). The Passport Note carried a fixed interest rate of 6.5% per annum. Additionally, on June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the “Indemnity Agreement”), with an insurance company (the “Surety”). The Surety issued a performance bond in the amount of \$25.0 million to secure UHC’s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond’s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020.

On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the “Passport Closing”). At the Passport Closing, \$16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC’s dual eligible special needs business (the “DNP Business”) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport. At the Passport Closing, EVH Passport assumed UHC’s obligations under the Passport Note and the Indemnity Agreement.



On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (“Molina”) entered into an Asset Purchase Agreement (the “Molina APA”), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the “Molina Closing”), and the Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, Molina deposited \$20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina’s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina.

Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting. As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company's consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors' equity interests in EVH Passport for \$20.0 million in cash in accordance with the terms of EVH Passport's Stockholders' Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.

As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of \$159.8 million, available for sale securities of \$88.6 million, receivables related to unsettled sales of securities of \$43.0 million and other assets of \$50.2 million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of \$164.8 million and accrued liabilities of \$50.0 million. Subsequent to winddown activities, any remaining cash will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance. In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the \$40.0 million Passport Note was repaid in full by EVH Passport including approximately \$3.6 million of accrued interest.

#### **Gain (Loss) on Disposal of Assets and Consolidation**

On September 1, 2020, as a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 and recorded a \$5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.

During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary and recorded a loss of \$6.4 million in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.

#### **Securities Offerings and Sales**

Under exchange agreements we entered into at the time of our IPO and as part of the New Century Health acquisition, we granted TPG, The Advisory Board Company ("The Advisory Board") and Ptolemy Capital, LLC (together, the "Investor Stockholders") and certain former owners of New Century Health (the "New Century Health Class B Members") an exchange right that allows receipt of newly issued shares of the Company's Class A common stock in exchange (a "Class B Exchange") for an equal number of shares of the Company's Class B common stock (which are subsequently canceled) and an equal number of Evolent Health LLC's Class B common units ("Class B units"). Under the terms of the exchange agreements, Class B units received by the Company from relevant Investor Stockholders and New Century Health Class B Members were simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC canceled the Class B units received in the Class B Exchange. On December 27, 2019, the cancellation of the remaining Class B units results in an increase in the Company's economic interest in Evolent Health LLC.

#### **Note 5. Revenue Recognition**

Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services.

*Transformation Services Revenue*

Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.

### *Platform and Operations Services Revenue*

Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our clinical solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services; our administrative solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services. Contracts to provide these services may be developed on an integrated basis. For purposes of revenue disaggregation, we classify contracts including both clinical and administrative solutions into the category corresponding to the majority of services provided under those contracts.

Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.

### *Contracts with Multiple Performance Obligations*

Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.

### *Principal vs. Agent*

We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.

### **Disaggregation of Revenue**

The following table represents Evolent's Services segment revenue disaggregated by type of services (in thousands), excluding revenues from our health plan operations, which include the True Health segment and EVH Passport, and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, *Financial Services-Insurance*.

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Services Revenue</b>			
Transformation services	\$ 11,990	\$ 15,203	\$ 32,916
Platform and operations services			
Clinical solutions	690,391	458,991	228,464
Administrative solutions	202,547	198,618	264,104



## Transaction Price Allocated to the Remaining Performance Obligations

For contracts with a term greater than one year, we have allocated approximately \$87.8 million of transaction price to performance obligations that are unsatisfied as of December 31, 2020. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 54% and 86% of these remaining performance obligations by December 31, 2021, and December 31, 2022, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.

## Contract Balances

Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within contract assets on our consolidated balance sheets. Our current accounts receivable are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.

Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets, and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.

The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):

	December 31, 2020	December 31, 2019
Short-term receivables <sup>(1)</sup>	\$ 122,167	\$ 71,707
Long-term receivables <sup>(1)</sup>	4,554	709
Short-term contract assets	329	1,751
Long-term contract assets	—	999
Short-term deferred revenue	14,327	19,828
Long-term deferred revenue	3,593	1,330

<sup>(1)</sup> Excludes pharmacy claims receivable and premiums receivable

Changes in contract assets and deferred revenue for the year ended December 31, 2020 are as follows (in thousands):

**Contract assets**

Balance as of beginning-of-period	\$	2,750
Reclassification to receivables, as the right to consideration becomes unconditional		(2,539)
Contract assets recognized, net of reclassification to receivables		118
Balance as of end-of-period	\$	329

**Deferred revenue**

Balance as of beginning-of-period	\$	21,158
Reclassification to revenue, as a result of performance obligations satisfied		(18,481)
Cash received in advance of satisfaction of performance obligations		15,243
Balance as of end-of-period	\$	17,920

The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in previous period was \$12.1 million and \$1.1 million during the years ended December 31, 2020, and 2019, respectively, due primarily to net gain share as well as changes in other estimates.

### **Contract Cost Assets**

Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2020 and 2019, the Company had \$3.3 million and \$4.7 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of \$1.9 million, \$1.0 million and \$0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.

In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2020 and 2019, the Company had \$23.4 million and \$31.8 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of \$13.0 million, \$4.7 million and \$2.4 million for the years ended December 31, 2020, 2019 and 2018, respectively.

These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.

### **Note 6. Credit Losses**

We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers' and other third parties' ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2020. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2020.

#### *Accounts Receivable from Revenue Transactions*

Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company's consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company's consolidated balance sheets.

We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals, and then applied to the composition of



the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.

Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets at December 31, 2020, 59% were current, 24% were past due less than 60 days, with 37% past due less than 120 days. At December 31, 2020, we reported \$173.7 million of accounts receivable, certain non-trade accounts receivable included in prepaids and other assets on the consolidated balance sheet and contract assets, net of allowances of \$7.1 million. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2020 (in thousands):

Balance as of December 31, 2019	\$ (41)
Passport acquisition	(2,582)
Cumulative transition adjustment	(2,815)
Provision for credit losses	(3,283)
Charge-offs	1,665
Balance as of December 31, 2020	<u>\$ (7,056)</u>

#### *Investments Held at Amortized Cost*

True Health invests in certain debt securities which are classified as held-to-maturity in Evolent's consolidated financial statements because True Health, as Evolent's wholly-owned subsidiary, has the intent and ability to hold the securities until their individual maturities. True Health invests in debt securities pursuant to an investment policy governing the nature and type of investments based on the Company's business strategy, risk tolerance, and investment objectives.

The amortized cost of our investments as of December 31, 2020 and 2019 and interest income for the years ended December 31, 2020 and 2019 were as follows (in thousands):

	Amortized Cost		Interest Income for the Year Ended December 31,	
	December 31, 2020	December 31, 2019	2020	2019
U.S. Treasury bills	\$ 8,909	\$ 10,784	\$ 239	\$ 249
Corporate bonds	1,707	1,705	524	49
Collateralized mortgage obligations	3,433	5,472	339	112
Corporate stock	130	—	—	—
Yankees	598	597	21	21
Total investments	<u>\$ 14,777</u>	<u>\$ 18,558</u>	<u>\$ 1,123</u>	<u>\$ 431</u>

The Company reviewed its held-to-maturity investments to determine which types of securities have zero risk of credit loss because payments are guaranteed by a third party. Based on this analysis, the Company determined that the expected credit losses on U.S. Treasury bills and mortgage backed securities from government sponsored enterprise ("GSE") is zero. The expected credit losses on non-GSE backed securities is considered immaterial.

As of December 31, 2020 and 2019, all of the Company's held-to-maturity investments were rated investment-grade or better and all payments of interest or principal are current.

#### **Note 7. Property and Equipment, Net**

The following summarizes our property and equipment (in thousands):

	December 31,	
	2020	2019
Computer hardware	\$ 18,866	\$ 11,604
Furniture and equipment	3,559	3,649
Internal-use software development costs	137,085	112,501
Leasehold improvements	15,586	12,415
Total property and equipment	175,096	140,169
Accumulated depreciation and amortization expenses	(88,856)	(55,014)
Total property and equipment, net	<u>\$ 86,240</u>	<u>\$ 85,155</u>

The Company capitalized \$24.6 million, \$30.9 million and \$33.1 million of internal-use software development costs for the years ended December 31, 2020, 2019 and 2018, respectively. The net book value of capitalized internal-use software development costs was \$75.3 million and \$74.9 million as of December 31, 2020 and 2019, respectively.

Depreciation expense related to property and equipment was \$28.3 million, \$23.3 million and \$17.3 million for the years ended December 31, 2020, 2019 and 2018, respectively, of which amortization expense related to capitalized internal-use software development costs was \$24.3 million, \$18.7 million and \$12.4 million, respectively.

## **Note 8. Goodwill and Intangible Assets, Net**

### *Goodwill*

Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

The Company has four reporting units, each with discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a goodwill impairment analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies.

Our annual goodwill impairment review occurs during the fourth quarter of each fiscal year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.

### *2019 Goodwill Impairment Test*

During the second half of 2019, the price of our Class A common stock declined significantly. The average closing price per share of our Class A common stock for the period from May 1 to October 31 decreased by \$6.59 per common share, or 43.5%, compared to the average closing price for the period from January 1 to April 30. At the time of our 2019 annual goodwill impairment test, it was not known if UHC/EVH Passport would be awarded a contract under the RFP, which was expected to begin on January 1, 2021. If it was not awarded a contract, it was expected that we would not receive any material revenue under our management services agreement from EVH Passport subsequent to December 31, 2020 and the value of our investment in EVH Passport and goodwill would be negatively impacted. The non-renewal of EVH Passport's Medicaid contract would reduce our medium-term cash flow projections for one of our reporting units, causing the decline in our stock price to possibly be further prolonged, indicating it was more likely than not that the fair value of the reporting units is less than the reporting unit's carrying amounts, triggering an interim quantitative assessment.

In performing our October 31, 2019 annual goodwill impairment test, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach ("income approach"). In determining the estimated fair value using the income approach, we projected future cash flows based on management's estimates and long-term plans and applied a discount rate based on the Company's weighted average cost of capital. This analysis required us to make judgments, including about revenues, expenses, fixed asset and working capital requirements, the timing of exchanges of our Class B common shares, capital market assumptions, cash flows, the probability of the Kentucky Medicaid RFP outcome and discount rates. The fair values determined by the income approach were weighted considering future resolution of the Kentucky Medicaid RFP result to determine the concluded fair value for each reporting unit.

As of October 31, 2019, we determined that one of our three reporting units in the Services segment had an estimated fair value less than its carrying value. As a result, we recorded a non-cash goodwill impairment charge of \$199.8 million in goodwill impairment on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2019. If other indications of impairment exist we may be required to recognize additional impairments in the future as a result of market conditions or other factors

related to our performance, including changes in our forecasted results, investment strategy, interest rates or assumptions used as part of the goodwill impairment analysis. Any further impairment charges that we may record in the future could be material to our results of operations. As of December 31 2019, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge for the year ended December 31, 2019 was \$431.7 million.

## *2020 Goodwill Impairment Test*

As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units' carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company's Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019.

During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of one of its three reporting units in the Services segment was less than the reporting unit's carrying amount triggering an interim quantitative assessment.

In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach ("income approach"). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management's estimates and long-term plans and applied a discount rate based on the Company's weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.

As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value. As a result, we recorded a non-cash goodwill impairment charge of \$215.1 million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020.

During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020.

During the Company's annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of \$199.8 million and \$215.1 million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in one of our three reporting units in the Services segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required.

In performing our October 31, 2020 impairment test for one of the three reporting units in the Services segment, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach ("income approach"). In determining the estimated fair value using the income approach, we projected future cash flows based on management's estimates and long-term plans and applied a discount rate based on the Company's weighted average cost of capital. This analysis required us to make judgments about revenues,

expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that one of our three reporting units in the Services segment had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.

As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit's carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was \$214.3 million.

The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):

	<u>Services</u>	<u>True Health</u>	<u>Consolidated</u>
Balance as of December 31, 2018	\$ 762,419	\$ 5,705	\$ 768,124
Goodwill acquired	3,416	—	3,416
Measurement period adjustments	351	—	351
Impairment	(199,800)	—	(199,800)
Foreign currency translation	(27)	—	(27)
Balance as of December 31, 2019 <sup>(1)</sup>	<u>566,359</u>	<u>5,705</u>	<u>572,064</u>
Goodwill disposal <sup>(2)</sup>	(2,200)	—	(2,200)
Impairment	(215,100)	—	(215,100)
Foreign currency translation	(30)	—	(30)
Balance as of December 31, 2020 <sup>(1)</sup>	<u>\$ 349,029</u>	<u>\$ 5,705</u>	<u>\$ 354,734</u>

<sup>(1)</sup> Net of cumulative inception to date impairment of \$575.5 million and \$360.4 million as of December 31, 2020 and 2019, respectively.

<sup>(2)</sup> Goodwill written-off upon disposal of a consolidated subsidiary.

#### *Intangible Assets, Net*

Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:

	<u>As of December 31, 2020</u>				<u>As of December 31, 2019</u>			
	<u>Weighted-Average Remaining Useful Life</u>	<u>Gross Carrying Amount</u>	<u>Accumulated Amortization</u>	<u>Net Carrying Value</u>	<u>Weighted-Average Remaining Useful Life</u>	<u>Gross Carrying Amount</u>	<u>Accumulated Amortization</u>	<u>Net Carrying Value</u>
Corporate trade name	13.2	\$ 23,300	\$ 6,271	\$ 17,029	14.2	\$ 23,300	\$ 4,891	\$ 18,409
Customer relationships	16.1	281,219	58,256	222,963	16.8	291,519	44,750	246,769
Technology	1.8	82,922	63,507	19,415	2.0	82,922	49,760	33,162
Below market lease, net	2.3	1,118	648	470	2.2	2,048	1,334	714
Provider network contracts	2.8	14,475	6,280	8,195	3.7	12,725	3,320	9,405
Total intangible assets, net		<u>\$ 403,034</u>	<u>\$ 134,962</u>	<u>\$ 268,072</u>		<u>\$ 412,514</u>	<u>\$ 104,055</u>	<u>\$ 308,459</u>

Amortization expense related to intangible assets for the years ended December 31, 2020, 2019 and 2018, was \$32.9 million, \$37.7 million, and \$27.2 million, respectively.



Future estimated amortization of intangible assets (in thousands) as of December 31, 2020, is as follows:

2021	\$	28,701
2022		24,819
2023		22,055
2024		16,171
2025		15,916
Thereafter		160,410
Total future amortization of intangible assets	\$	<u>268,072</u>

Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets' carrying value. We did not identify any circumstances during the year ended December 31, 2020, that would require an impairment test for our intangible assets.

## Note 9. Long-term Debt

### *2024 Notes*

In August 2020, the Company issued \$117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the "2024 Notes") in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued \$84.2 million aggregate principal amount of 2024 Notes in exchange for \$84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of \$2.5 million, and issued \$32.8 million aggregate principal amount of New Notes for cash at par. We incurred \$3.0 million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.

Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company's Class A common stock. We recorded interest expense of \$1.5 million for the year ended December 31, 2020.

The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per \$1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately \$18.23 per share of the Company's Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4 million shares of the Company's Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election.

The option to settle the 2024 Notes in cash or shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be \$78.9 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be \$38.1 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of \$1.7 million and \$1.3 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of \$38.1 million, \$1.7 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the year ended December 31, 2020, the Company recorded \$2.7 million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.

Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company's Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including,

the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

#### *Credit Agreement*

On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the “Borrower”), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the “Credit Agreement”), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of \$75.0 million (the “Initial Term Loan Facility”) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to \$50.0 million (the “DDTL Facility” and, together with the Initial Term Loan Facility, the “Senior Credit Facilities”), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December

30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company's domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions.

The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company's satisfaction of specified conditions, to finance the repayment or repurchase of the Company's 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the "Maturity Date"). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. The Company recorded \$8.0 million in interest expense related to our Credit Agreement for the year ended December 31, 2020.

Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.

The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred \$4.7 million of debt issuance costs in connection with this Credit Agreement, which will be included in long-term debt, net of discount on our consolidated balance sheets and will be amortized into interest expense over the life of the agreement. For the year ended December 31, 2020, the Company recorded \$2.2 million in interest expense related to the amortization of the debt discount and the issuance costs.

On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.

The Company was in compliance with all applicable covenants as of December 31, 2020.

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. Refer to Note 26 for additional information about the repayment of the Credit Agreement.

*Warrant Agreement*

In conjunction with the Company's entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to \$8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement. The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.

On January 8, 2021, the Company settled all amounts under the warrant agreements with Ares Capital Corporation. Refer to Note 26 for additional information about the settlement of the warrant agreements.

## 2025 Notes

In October 2018, the Company issued \$172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The 2025 Notes were issued at par for net proceeds of \$166.6 million. We incurred \$5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of \$150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018, and the Company completed the offering and sale of an additional \$22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018, pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes.

Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019, at a rate equal to 1.50% per annum. The Company recorded interest expense of \$2.6 million, \$2.6 million and \$0.5 million related to the 2025 Notes for the years ended December 31, 2020, 2019, and 2018, respectively. The 2025 Notes will mature on October 15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.

Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.

The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per \$1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately \$33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election.

The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be \$100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be \$71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of \$3.4 million and \$2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of \$71.8 million, \$3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the years ended December 31, 2020, 2019 and 2018, the Company recorded \$9.2 million, \$8.5 million and \$1.5 million, respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.

Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022, if the last reported sale price of the

Company's Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

#### *2021 Notes*

In December 2016, the Company issued \$125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the "2021 Notes") in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of \$120.4 million. We incurred \$4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of

the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016.

Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes will mature on December 1, 2021, unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase all or part of their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental repurchase date. Upon maturity the principal amount of the notes may be settled via shares of the Company's Class A common stock. We recorded interest expense of \$1.7 million \$2.5 million and \$2.5 million for each of the years ended December 31, 2020, 2019 and 2018, respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of \$0.6 million, \$0.9 million and \$0.9 million for each of the years ended December 31, 2020, 2019 and 2018, respectively.

The 2021 Notes are convertible into shares of the Company's Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per \$1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately \$24.03 per share of the Company's Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company's Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture). The conversion rate may be adjusted under certain circumstances.

The 2021 Notes are convertible, in multiples of \$1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each \$1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date.

In August 2020, as part of the issuance of the 2024 Notes, the Company issued \$84.2 million aggregate principal amount of the 2024 Notes in exchange for \$84.2 million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of \$2.5 million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of \$4.8 million, including an aggregate cash payment of \$2.5 million paid to exchanging noteholders.

In August 2020, we also repurchased \$14.0 million of the 2021 Notes with \$13.9 million of cash and recorded an immaterial gain on extinguishment of debt.

#### *Convertible Senior Notes Carrying Value*

The 2025 Notes, 2024 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December 31, 2020. However, the 2025 Notes, 2024 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes, 2024 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt (in thousands):



	December 31,	
	2020	2019
<b>2024 Notes</b>		
Carrying value	\$ 81,462	\$ —
Unamortized debt discount and issuance costs	35,589	—
Principal amount	\$ 117,051	\$ —
Remaining amortization period (years)	3.9	
Fair value	\$ 153,220	\$ —
<b>2025 Notes</b>		
Carrying value	\$ 116,349	\$ 107,169
Unamortized debt discount and issuance costs	56,151	65,331
Principal amount	\$ 172,500	\$ 172,500
Remaining amortization period (years)	4.8	5.8
Fair value	\$ 147,488	\$ 122,048
<b>2021 Notes</b>		
Carrying value	\$ 26,557	\$ 123,237
Unamortized issuance costs	180	1,763
Principal amount	\$ 26,737	\$ 125,000
Remaining amortization period (years)	0.9	1.9
Fair value	\$ 26,470	\$ 111,250

## Note 10. Commitments and Contingencies

### Commitments

#### *Commitments to Equity-Method Investees*

During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period. As a result of EVH Passport not being awarded a new Medicaid contract with CHFS, the Company acquired the Sponsors' 30% ownership interest in EVH Passport for \$20.0 million during the three months ended December 31, 2020. Refer to Note 4 for additional information about the Passport transaction.

#### *Letters of Credit*

During the second quarter of 2020, the Company established an irrevocable standby letter of credit with a bank for \$5.0 million for the benefit of a regulatory authority. The letter of credit expired during the fourth quarter of 2020.

During the third quarter of 2019, the Company established an irrevocable standby letter of credit with a bank for \$1.8 million for the benefit of a regulatory authority and, as such, held \$1.8 million in restricted cash and restricted investments as collateral as of

both December 31, 2020 and December 31, 2019, respectively. The original letter of credit expired on December 31, 2019 and was automatically extended without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date, unless the bank elects not to extend beyond the initial or any extended expiry date.

### *Indemnifications*

The Company's customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.

During the second quarter of 2019, the Company and UHC, a then current customer (collectively the "Indemnitors"), pursuant to a state requirement of all participating Medicaid Managed Care Organizations, entered into an indemnity agreement with a surety. The surety issued a performance bond in the amount of \$25.0 million to secure the customer's performance under a contract to provide

Medicaid managed care services for the benefit of a beneficiary. Pursuant to the indemnity agreement, the Indemnitors are jointly and severally liable to the surety in the maximum amount of the bond, plus certain costs of the surety, in the event of losses arising under the bond. The bond's effective date is July 1, 2019, and original expiry date was June 30, 2020. During the three months June 30, 2020, the expiry date was extended to December 31, 2020 and the bond was released in October 2020. To date, the Company has not incurred any material costs as a result of the Indemnity Agreement and has not accrued any liabilities related to it in the accompanying consolidated financial statements.

#### *Pre-IPO Investor Registration Rights Agreement*

We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.

We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the year ended December 31, 2020, 2019 and 2018, respectively.

#### *Guarantees*

In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance ("KY DOI") regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations.

As part of our strategy to support certain of our partners in the Next Generation Accountable Care Program, we entered into upside and downside risk-sharing arrangements. Our downside risk-sharing arrangements are limited to our fees and are executed through our wholly-owned captive insurance company. To satisfy the capital requirements of our captive insurance entity as well as state insurance regulators, the Company entered into letters of credit of \$4.7 million and \$5.7 million as of December 31, 2020 and December 31, 2019, respectively, to secure potential losses related to insurance services. These amounts are in excess of our actuarial assessment of loss.

During 2020, the Company entered into a guarantee agreement with the KY DOI whereby it agreed to provide support on behalf of EVH Passport to maintain a minimum risk-based-capital of 150%. The maximum exposure is limited to amounts funded to return EVH Passport to a risk-based-capital of 150%, however as of December 31, 2020, no amounts have been funded under this guarantee.

#### *Reinsurance Agreements*

At the Passport Closing, \$16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH

Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.

At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina's Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina.

During the fourth quarter of 2017, the Company entered into a \$10.0 million capital-only reinsurance agreement with NMHC which expired on December 31, 2018. The purpose of the capital-only reinsurance was to provide balance sheet support to NMHC. There was no uncertainty to the outcome of the agreement as there was no transfer of underwriting risk to Evolent or True Health, and neither Evolent nor True Health was at risk for any cash payments on behalf of NMHC. As a result, this agreement did not qualify for reinsurance accounting.

During the fourth quarter of 2018, the Company terminated its prior reinsurance agreement with NMHC and entered into a 15-month quota-share reinsurance agreement with NMHC. Under the terms of the new reinsurance agreement, NMHC ceded 90% of its gross premiums to the Company and the Company indemnified NMHC for 90% of its claims liability. The maximum amount of exposure to the Company was capped at 105% of premiums ceded to the Company by NMHC. The new reinsurance agreement qualified for reinsurance accounting due to the deemed risk transfer and, as such, the Company recorded the full amount of the gross reinsurance premiums and claims assumed by the Company within premiums and claims expenses, respectively, and recorded claims-related administrative expenses within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) from the legal effective date of the Reinsurance Agreement. Amounts owed to NMHC under the reinsurance agreement are recorded within reserves for claims and performance-based arrangements on our consolidated balance sheets. Amounts owed by NMHC under the reinsurance agreement are recorded within accounts receivable, net on our consolidated balance sheets.

During the third quarter of 2019, the Company terminated the new reinsurance agreement with NMHC effective in the fourth quarter of 2019, approximately one and a half months prior to its scheduled end.

The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Reinsurance premiums assumed	\$ 19,130	\$ 83,325	\$ 3,242
Reinsurance premiums ceded	(3,275)	—	—
Claims assumed	14,812	72,594	3,934
Claims ceded	(422)	—	—
Claims-related administrative expenses	—	14,024	551
Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement	1,465	(3,293)	(1,243)
Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period	—	1,243	—
Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement	(502)	—	—
Reinsurance payments paid (received)	(3,039)	4,536	—
Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period	<u>\$ 4,002</u>	<u>\$ —</u>	<u>\$ 1,243</u>

#### *UPMC Reseller Agreement*

The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain

conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company's obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company's customers.

## **Contingencies**

### *Tax Receivables Agreement*

In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the "TRA") with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs.

Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company's historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.

### *Litigation Matters*

We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.

On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020. The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer, and Steven Wigginton, alleges that the Company's executives made false or misleading statements regarding its business with Passport. A second amended complaint, which was substantially similar to the amended complaint, was filed on June 8, 2020. The Company filed a motion to dismiss in response on June 22, 2020 and the briefing was completed on July 17, 2020; the parties are now waiting for the court's decision. Under the Private Securities Litigation Reform Act, PSLRA, all discovery in the case is stayed until the motion to dismiss is decided upon by the court. Based on the Company's investigation so far, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain, and at this early stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.

The Company is not aware of any other legal proceedings or claims as of December 31, 2020, that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company's financial position or result of operations.

### **Credit and Concentration Risk**

The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December 31, 2020, approximately 98.2% of our \$361.6 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks, approximately 1.6% were held in money market funds and 0.2% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.

The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partner included in our Services segment who represented at least 10.0% of our consolidated trade accounts receivable for the periods presented:

	<b>As of December 31,</b>	
	<b>2020</b>	<b>2019</b>
Cook County Health and Hospitals System	61.5 %	48.4 %

In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.





The following table summarizes those customers of our Services segment who represented at least 10.0% of our consolidated revenue for the periods presented:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Cook County Health and Hospitals Systems	20.3 %	*	*
Passport <sup>(1)</sup>	16.8 %	18.7 %	17.5 %
New Mexico Health Connections	*	10.9 %	*

<sup>1</sup>. Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 8.8% of our consolidated revenues for the year ended December 31, 2020.

\* Represents less than 10.0% of the respective balance

We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.

#### **Note 11. Leases**

The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases.

The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company's primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois.

In connection with various lease agreements, the Company is required to maintain \$3.5 million in letters of credit. As of December 31, 2020 and December 31, 2019, the Company held \$3.5 million and \$3.6 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.

The following table summarizes our primary office leases as of December 31, 2020 (in thousands, other than term):

<b>Location</b>	<b>Lease Termination Term (in years)</b>	<b>Future Minimum Lease Commitments</b>	<b>Letter of Credit Amount Required</b>
Arlington, VA	11.1	\$ 38,675	\$ 1,579
Riverside, IL	10.3	44,605	232
Pune, India	2.7	2,318	—
Brea, CA	1.4	1,555	—

The following table summarizes the components of our lease expense (in thousands):

	<b>For the Year Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
Operating lease cost	\$ 15,848	\$ 13,903
Amortization of right-of-use assets	299	598
Interest expense	3	26
Variable lease cost	5,097	4,177
<b>Total lease cost</b>	<b>\$ 21,247</b>	<b>\$ 18,704</b>

As discussed in Note 3, the Company adopted ASU 2016-02 effective January 1, 2019, which resulted in accounting for leases under ASC 842. Prior to the adoption, we accounted for leases under ASC 840. In accordance with ASC 840, rent expense, net of sublease income, on operating leases for the year ended December 31, 2018 was \$14.2 million. The Company does not have any material capital leases.

Maturity of lease liabilities (in thousands) as of December 31, 2020, is as follows:

	<b>Operating lease expense<sup>(1)</sup></b>
2021	11,558
2022	9,562
2023	9,012
2024	8,733
2025	8,265
Thereafter	47,759
<b>Total lease payments</b>	<b>94,889</b>
Less:	
Interest	25,006
<b>Present value of lease liabilities</b>	<b>\$ 69,883</b>

<sup>(1)</sup> We have additional operating lease agreements for office space that have not yet commenced as of December 31, 2020. The minimum lease payments for those leases are \$0.7 million commencing in both 2021 and 2022.

Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:

	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
Weighted average discount rate	6.44 %	6.25 %
Weighted average remaining lease term	9.4	9.9

## Note 12. Earnings (Loss) Per Common Share

The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):

	For the Year Ended December 31,		
	2020	2019	2018
Net loss	\$ (334,246)	\$ (305,580)	\$ (54,191)
Less:			
Net loss attributable to non-controlling interests	—	(3,609)	(1,533)
Net loss available for common shareholders - basic and diluted <sup>(1)</sup>	<u>\$ (334,246)</u>	<u>\$ (301,971)</u>	<u>\$ (52,658)</u>
Weighted-average common shares outstanding - basic and diluted <sup>(1)</sup>	<u>84,928</u>	<u>82,364</u>	<u>77,338</u>
<b>Loss per common share</b>			
Basic and diluted	\$ (3.94)	\$ (3.67)	\$ (0.68)

<sup>(1)</sup> Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share.

Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:

	For the Year Ended December 31,		
	2020	2019	2018
Exchangeable Class B common stock	—	1,399	1,831
Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")	797	813	1,027
Stock options	1,141	1,324	2,517
Convertible senior notes	11,206	10,361	6,176
Total	<u>13,144</u>	<u>13,897</u>	<u>11,551</u>

## Note 13. Stock-based Compensation

### 2011 and 2015 Equity Incentive Plans

The Company issues awards, including stock options, performance-based stock options, restricted stock LSUs and RSUs, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the "2011 Plan") and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the "2015 Plan"). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1 million of the Company's common stock. As of December 31, 2020 and 2019, 4.8 million stock options and 3.8 million shares of restricted stock have been issued, net of forfeitures, under the 2011 Plan.

On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company's Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018, to increase the number of shares authorized to 10.5 million. Upon confirmation of the amended 2015 Plan, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan will continue to govern awards previously granted under the 2011 Plan. As of December 31, 2020 and 2019, 2.8 million and 2.8 million stock options and 4.7 million and 4.4 million RSUs have been issued, net of forfeitures, under the 2015 Plan.

We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees.

### Stock-based Compensation Expense

Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Award Type</b>			
Stock options	\$ 2,927	\$ 4,237	\$ 9,008
Performance-based stock options	75	448	447
RSUs	7,763	8,877	7,766
Performance-based RSUs	—	(388)	388
LSUs	3,841	2,444	—
Total compensation expense by award type	<u>\$ 14,606</u>	<u>\$ 15,618</u>	<u>\$ 17,609</u>
<b>Line Item</b>			
Cost of revenue	\$ 1,811	\$ 2,673	\$ 1,475
Selling, general and administrative expenses	12,795	12,945	16,134
Total compensation expense by financial statement line item	<u>\$ 14,606</u>	<u>\$ 15,618</u>	<u>\$ 17,609</u>

No stock-based compensation was capitalized as software development costs for the years ended December 31, 2020, 2019 and 2018.

Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:

	<b>As of December 31, 2020</b>	
	<b>Unrecognized Compensation Expense</b>	<b>Weighted Average Period</b>
Stock options	\$ 1,971	1.55
RSUs	11,914	1.89
LSUs	6,694	1.77
Total	<u>\$ 20,579</u>	

### Stock Options

Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures.

The option price assumptions used for our stock option awards were as follows:

	<b>For the Year Ended December 31,</b>	
	<b>2019</b>	<b>2018</b>
Weighted-average fair value per option granted	\$ 6.52	\$ 6.30
<b>Assumptions:</b>		
Expected term (in years)	6.25	6.25
Expected volatility	51.6 %	38.9 %
Risk-free interest rate	1.9% - 2.7%	2.6% - 2.9%
Dividend yield	— %	— %

The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company's awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting

date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options.

Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2019	4,828	\$ 9.44	6.01	\$ (1,880)
Granted	—	—		
Exercised	(416)	4.75		
Forfeited	(342)	14.80		
Outstanding as of December 31, 2020	<u>4,070</u>	<u>\$ 9.32</u>	5.25	\$ 12,578
Vested and expected to vest after December 31, 2020	3,951	\$ 9.17	4.95	\$ 27,095
Exercisable at December 31, 2020	3,475	\$ 8.48	4.63	\$ 26,228

The total fair value of options vested during the years ended December 31, 2020, 2019 and 2018, was \$3.6 million, \$5.9 million and \$11.3 million, respectively. The total intrinsic value of options exercised during 2020, 2019 and 2018 was \$2.2 million, \$0.6 million and \$25.1 million, respectively. We issue new shares to satisfy option exercises.

#### *Performance-based stock option awards*

In March 2016, the Company granted approximately 0.3 million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders' interests. Each of the grants is subject to market-based vesting, as follows:

- one-third of the shares subject to the option award will vest in the event that the average closing price of the Company's Class A common stock on the NYSE is at least \$13.35 per share for a consecutive ninety days period;
- one-third of the shares subject to the option award will vest in the event that the average closing price of the Company's Class A common stock on the NYSE is at least \$16.43 per share for a consecutive ninety days period; and
- one-third of the shares subject to the option award will vest in the event that the average closing price of the Company's Class A common stock on the NYSE is at least \$19.51 per share for a consecutive ninety days period.

In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:

- 50% of the shares subject to the option award vested on March 1, 2019, and
- 50% of the shares subject to the option award vested on March 1, 2020.



We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of \$6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.

Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:

	Options	Weighted Average Exercise Price	Weighted Average Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2019	268	\$ 10.27	6.17	\$ (326)
Outstanding as of December 31, 2020	268	10.27	6.17	(326)
Vested and expected to vest after December 31, 2020	268	\$ 10.27	6.17	\$ (326)

#### *Restricted Stock Units*

Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a one-year vesting period in conjunction with the New Century Health transaction. Information with respect to our RSUs is presented below (in thousands, except for weighted-average grant-date fair value):

	Total RSUs	Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2019	1,493	\$ 12.23
Granted	1,202	8.88
Forfeited	(304)	11.38
Vested	(654)	11.11
Outstanding as of December 31, 2020	<u>1,737</u>	<u>\$ 10.13</u>

During the years ended December 31, 2020, 2019 and 2018, we granted RSUs with a weighted-average grant date fair value of \$8.88, \$10.66 and \$16.12, respectively, which represents the weighted-average closing price of our common stock on the grant date.

The total fair value of RSUs vested during the years ended December 31, 2020, 2019 and 2018 was \$6.1 million, \$7.3 million and \$4.8 million, respectively.

#### *Leveraged Stock Unit Awards*

During 2020 and 2019, the Company granted 0.5 million and 0.7 million shares, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders' interests. Each of the grants is subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:

- If the stock price has increased by 33.3%, 75% of the shares will vest
- If the stock price has increased by 50%, 100% of the shares will vest

- If the stock price has increased by 100%, 150% of the shares will vest
- If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount)

The price assumptions used for our leveraged stock unit awards were as follows:

	<b>For the Year Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
Weighted-average fair value per leveraged stock unit granted	\$ 8.90	\$ 6.52
<b>Assumptions:</b>		
Expected term	10 years	10 years
Expected volatility	62.1 %	51.7 %
Risk-free interest rate	0.85%	2.54%
Dividend yield	— %	— %

The fair value of leveraged stock units are determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company's awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.

Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:

	<b>Leveraged Stock Units</b>	<b>Weighted Average Grant Date Fair Value</b>	<b>Weighted Average Remaining Contractual Term</b>	<b>Aggregate Intrinsic Value</b>
Outstanding as of December 31, 2020	1,170	\$ 11.10	8.65	\$ 5,771
Vested and expected to vest after December 31, 2020	1,170	\$ 11.10	8.65	\$ 5,771

#### *Performance-based RSUs*

During 2018, in conjunction with the New Century Health transaction, we issued performance-based RSU awards to certain employees of New Century Health that became Evolent Health employees following the transaction. The awards were to vest based on the passage of time (18-month vesting period) and the achievement of certain operating results by New Century Health in 2019. Upon completion of the vesting period, the award recipients would have received a variable number of Evolent Health Class A common shares based on the predetermined monetary value of the award. Accordingly, these performance-based RSUs are recorded as liability awards. As one of the vesting criteria was continued employment at Evolent Health, these performance-based RSUs were considered compensation expense for the Company as opposed to contingent consideration related to the acquisition of New Century Health.

The maximum monetary value of the original performance-based award, provided New Century Health meets or exceeds the defined operating results targets, was capped at \$8.6 million. The fair value of the performance-based RSUs was estimated based on the real options approach, a form of the income approach, which estimated the probability of New Century Health achieving certain operating results during 2019. The most significant unobservable inputs used in the valuation of the performance-based RSUs was the risk-neutral probability of New Century Health achieving the defined operating results target or meeting the operating results target cap. A significant increase in either of those metrics, in isolation, would result in a significantly higher fair value of the performance-based RSUs. In determining the fair value of the performance-based RSUs, we determined the risk-neutral probability of New Century Health achieving operating results target was approximately 39% and we determined the risk-neutral probability of New Century Health meeting the operating results target cap was approximately 24%.

In August 2019, in connection with the settlement of the earn-out payable to the former employees of New Century Health, the Company canceled outstanding restricted stock units held by the former employees of New Century Health and issued new restricted stock units with modified performance conditions. No other changes to the original grant terms were made. In accordance with ASC Topic 718, *Share Based Payments*, canceled equity award accompanied by the concurrent grant of a replacement award shall be accounted

for as a modification of the terms of the canceled award. The modification was treated as a Type 1 modification, as the awards were expected to vest under the original terms. Incremental compensation cost of \$4.7 million was measured as the excess of the fair value of the modified award over the fair value of the original award immediately before the terms were modified and will be recorded over the remaining requisite service period. As of December 31, 2020 and 2019, the required performance conditions for the performance-based RSUs were not met and no shares will be issued in conjunction with these awards.

**Note 14. Income Taxes**

An income tax expense (benefit) of \$(3.6) million, \$(21.5) million and less than \$0.1 million was recognized for the years ended December 31, 2020, 2019 and 2018, respectively.

Our loss before provision for income taxes was as follows (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Domestic	\$ (339,632)	\$ (328,161)	\$ (54,681)
Foreign	1,833	1,045	530
Income (loss) before income taxes and non-controlling interests	<u>\$ (337,799)</u>	<u>\$ (327,116)</u>	<u>\$ (54,151)</u>

Components of income tax expense (benefit) (in thousands) consist of the following:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Current</b>			
Federal	\$ (3,338)	\$ 1,175	\$ 458
State and local	200	14	9
Foreign	721	399	251
Total current tax expense (benefit)	<u>(2,417)</u>	<u>1,588</u>	<u>718</u>
<b>Deferred</b>			
Federal	(38,312)	(27,334)	(14,820)
State and local	(9,546)	(5,046)	(2,252)
Foreign	(303)	6	(49)
Total deferred tax expense (benefit)	<u>(48,161)</u>	<u>(32,374)</u>	<u>(17,121)</u>
Change in valuation allowance	47,025	9,250	16,443
Total tax expense (benefit)	<u>\$ (3,553)</u>	<u>\$ (21,536)</u>	<u>\$ 40</u>

As of December 31, 2020 and 2019, the Company has \$3.9 million income taxes receivable and \$0.6 million income taxes payable, respectively, which is recorded in accrued liabilities on the consolidated balance sheets.

A reconciliation of the U.S. statutory tax rate to our effective tax rate and our statutory rate is presented below:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
U.S. statutory tax rate	21.0 %	21.0 %	21.0 %
U.S. state income taxes, net of U.S. federal tax benefit	2.9 %	4.4 %	3.6 %
Foreign earnings at other than U.S. rates	— %	(0.1)%	(0.2)%
Change in valuation allowance	(13.9)%	(2.8)%	(30.4)%
Benefit of net operating loss carryback provision	1.1 %	— %	— %
Non-deductible goodwill impairment	(11.2)%	(15.8)%	— %
Non-controlling interest	— %	(0.3)%	(0.7)%
Excess tax benefits on stock-based compensation	(0.3)%	(0.2)%	3.9 %
Federal and state research tax credits	— %	— %	4.5 %
Change in uncertain tax positions	— %	0.1 %	(1.1)%
Effect of investment in MHG	— %	(1.4)%	— %
Change in state rate	1.3 %	— %	— %
Change in indefinite reinvestment assertion for domestic subsidiaries	1.0 %	2.6 %	— %
Other, net	(0.9)%	(0.8)%	(0.7)%
Effective rate	<u>1.0 %</u>	<u>6.7 %</u>	<u>(0.1)%</u>

Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates in effect when the temporary differences are expected to be recovered or settled.

Significant components of the Company's deferred tax assets and liabilities (in thousands) were as follows:

	<b>As of December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>Deferred Tax Assets</b>		
Start-up and organizational costs	\$ 117	\$ 149
Goodwill	23,534	19,142
Operating lease liabilities	15,963	18,055
Accrued expenses	7,488	9,534
Stock based compensation	8,530	8,899
Net operating loss carryforwards	123,604	112,316
Federal and state research tax credits	1,828	1,828
Fixed assets	131	—
Interest deduction limitation	2,452	2,490
Outside basis differences	197	—
Other	8,640	1,451
Subtotal	192,484	173,864
Valuation allowance	(89,902)	(50,815)
Total deferred tax assets	102,582	123,049
<b>Deferred Tax Liabilities</b>		
Internally developed software costs	12,973	14,603
Intangible assets	48,857	58,655
Outside basis differences	—	5,865
Right-of-use assets - Operating	13,122	16,180
Contract fulfillment costs	6,375	9,510
Convertible debt	20,411	15,732
Fixed assets	—	796
Other	1,572	3,650
Total deferred tax liabilities	103,310	124,991
Net deferred tax assets (liabilities)	\$ (728)	\$ (1,942)

Changes in our valuation allowance (in thousands) were as follows:



	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Balance at beginning-of-year	\$ 50,815	\$ 37,037	\$ 53,201
Charged to costs and expenses	47,025	9,250	16,443
Charged to other accounts <sup>(1)</sup>	(7,938)	4,528	(32,607)
Balance at end-of-year	<u>\$ 89,902</u>	<u>\$ 50,815</u>	<u>\$ 37,037</u>

<sup>(1)</sup> Amounts charged to other accounts includes a decrease of \$7.9 million, an increase of \$4.5 million and a decrease of \$32.6 million charged to additional paid-in-capital for the years ended December 31, 2020, 2019 and 2018, respectively.

For the year ended December 31, 2020, the effective tax rate was 1% and the corresponding tax benefit recorded was \$3.6 million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allows net operating losses (“NOLs”) incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to carrying back New Century Health’s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, apart from the aforementioned NOL carryback, did not have a significant impact on the Company.

For the year ended December 31, 2019, the effective tax rate was 6.7%, and the corresponding tax benefit recorded was \$21.5 million. Our effective tax rate in 2019 was impacted by the tax expense for the impairment of non-deductible goodwill, change in valuation allowance for current year losses, and offset in part by the tax effects resulting from the Company’s acquisition of all remaining Class B units of Evolent Health LLC, resulting in it becoming a disregarded entity for U.S. federal and state income purposes on December 26, 2019. The change in Evolent Health LLC’s tax status resulted in a tax benefit from the reversal of the Company’s deferred tax liability related to its investment in certain U.S. corporate subsidiaries through Evolent Health LLC, offset by an increase in valuation

allowance. In addition, the Company intends to file a consolidated tax return beginning January 1, 2020, which resulted in a tax benefit offsetting the change in valuation allowance to the extent the deferred tax liabilities of our U.S. corporate subsidiaries can be used as a source of future taxable income to support the Company's deferred tax assets. Our valuation allowance assessment is made without considering deferred tax liabilities of \$1.9 million established with respect to certain indefinite-lived components that cannot be utilized against indefinite-lived deferred tax assets or components that are expected to reverse outside of the net operating loss carryover period, as these are not considered a source of future taxable income for realizing our deferred tax assets.

For the year ended December 31, 2018, the effective tax rate was (0.1)%, due to the impact of the valuation allowance recorded against the Company's net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period as part of the outside basis difference in our partnership interest in Evolent Health LLC.

As of December 31, 2020, the Company had \$203.1 million of federal and \$253.4 million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2022, respectively, and \$288.5 million federal and \$153.0 million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as realization of such tax benefit is not more likely than not, based on our evaluation, we have established a valuation allowance. Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could impose an annual limit on the Company's ability to utilize NOLs and could cause U.S. federal income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect.

As of December 31, 2020, the Company had \$2.4 million and \$0.3 million of research and development credits for federal and state income tax purposes, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established valuation allowance against those credits.

Changes in our unrecognized tax benefits (in thousands) were as follows:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Balance at beginning-of-year	\$ 753	\$ 934	\$ 762
Gross increases - tax positions in prior period	—	—	934
Gross decreases - tax positions in prior period	—	—	(762)
Lapse of statute of limitations	(75)	(181)	—
Balance at end-of-year	<u>\$ 678</u>	<u>\$ 753</u>	<u>\$ 934</u>

We are subject to taxation in various jurisdictions in the U.S. and India. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December 31, 2020, are \$0.7 million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company's valuation allowance. The Company has not recognized interest and penalties related to uncertain tax positions due to the current NOL position. The Company had recognized \$0.8 million of uncertain tax positions as of December 31, 2019, and \$0.9 million as of December 31, 2018. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.

#### *Tax Receivables Agreement*

Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC's tangible and intangible assets. These increases in tax basis increased our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.

In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local and foreign income tax (as applicable) we realize as a result of any deductions attributable to future increases in tax basis following the Class B Exchanges (calculated assuming that any post-offering transfer of Class B common units had not occurred) or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. We are accounting for these payments as contingent liabilities and will recognize them in our Consolidated Statements of Operations and Comprehensive Income (Loss) when their realization is probable. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local and foreign income tax that we realize as a result of the

utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately \$79.3 million, as well as deductions attributable to imputed interest on any payments made under the agreement.

We will benefit from the remaining 15% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated. See Note 10 for additional discussion of the implications of the TRA.

#### **Note 15. Employee Benefit Plans**

We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made \$6.4 million, \$2.6 million and \$8.6 million in contributions to the 401(k) plan for the years ended December 31, 2020, 2019 and 2018, respectively.

#### **Note 16. Investments in and Advances to Equity Method Investees**

The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.

As of December 31, 2020 and December 31, 2019, the Company's economic interests in its equity method investments ranged between 4% and 38%, and 4% and 70%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, and 25% and 57%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities' earnings and losses for each reporting period. The Company's proportional share of the (gain) losses from these investments was approximately \$(10.0) million, \$9.5 million and \$4.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.

The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were \$192.8 million, \$41.5 million and \$10.7 million for the years ended December 31, 2020, 2019 and 2018 respectively.

#### *Passport*

At the Passport Closing, we paid approximately \$70.0 million in cash and issued a 30% equity interest in the EVH Passport to the Sponsors. As a result of the Molina Closing, the Company no longer accounts for its investment in EVH Passport under the equity method of accounting. Refer to Note 4 for additional information about the investment in EVH Passport.

#### **Unconsolidated VIEs**

#### *Global*

On May 24, 2019, we completed the acquisition of approximately a 45% ownership interest in MHG, the sole owner of Momentum Health Acquisition, Inc. (“MHA”), which is the sole owner of GlobalHealth Holdings, LLC (“GHH”), which is the sole owner of GlobalHealth, Inc., a health maintenance organization based in the State of Oklahoma that offers, among other things, Medicare Advantage products in the State of Oklahoma. At closing, we contributed approximately \$15.0 million in cash and 1,577,841 shares of our Class A common stock to MHG, together with certain of our other assets. Upon the contribution, the Company recorded a \$9.6 million non-cash gain in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations. We also recognized a short-term contingent consideration liability fair valued at \$5.9 million at the time of the transaction. At the closing of the transaction, our economic interest in GlobalHealth was approximately 45% and our voting interest was approximately 29%.

As of March 31, 2020, the Oklahoma Insurance Division (“OID”) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be

placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately \$47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the three months ended March 31, 2020.

The following table represents the carrying value of the associated assets and liabilities and the associated maximum loss exposure for the unconsolidated VIEs as of the date indicated (in thousands):

	<b>December 31, 2019</b>	
	<b>EVH Passport</b>	<b>Momentum Health Group, LLC</b>
<b>Assets:</b>		
Current assets	\$ 271,894	\$ 50,729
Non current assets	577	39,259
Total assets	<u>\$ 272,471</u>	<u>\$ 89,988</u>
<b>Liabilities:</b>		
Current liabilities	181,206	55,442
Non current liabilities	40	44,650
Total liabilities	<u>\$ 181,246</u>	<u>\$ 100,092</u>
Investment carrying value	\$ 70,000	\$ 46,456
Loan and interest receivable	41,387	—
Guarantee	25,000	—
Maximum exposure	<u>\$ 136,387</u>	<u>\$ 46,456</u>

#### Summarized Financial Information of Equity Method Investees

The following table represents the aggregated summarized financial information as of and for the dates indicated (in thousands):

	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
Current assets	\$ 69,218	\$ 356,085
Non-current assets	3,859	43,744
Current liabilities	54,885	267,300
Non-current liabilities	20,693	57,599
Non-controlling interests	2,671	70,535

	For the Year Ended December 31,		
	2020	2019	2018
Revenue	\$ 1,766,641	\$ 387,960	\$ 3,591
Operating income (loss)	8,112	(60,572)	(13,085)
Net income (loss)	6,606	(73,685)	(13,066)
Net income (loss) attributable to entity	5,632	(23,348)	(4,099)

**Note 17. Non-controlling Interests**

Immediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company's ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company's ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders' equity attributable to Evolent Health, Inc.

2020

On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a \$25.7 million non-controlling interest for the Sponsors' 30% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders' agreement with the Sponsors, the Company was required to acquire the Sponsors' 30% ownership interest for \$20.0 million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors' 30% equity interest and reclassified the non-controlling interests into shareholders' equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a \$5.7 million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.

2019

During 2019, all remaining holders of Class B units executed Class B Exchanges. These Class B Exchanges resulted in the issuance of 3.1 million shares of the Company's Class A common stock. As a result of these Class B Exchanges and Evolent Health LLC's cancellation of the related Class B units, the Company's economic interest in Evolent Health LLC increased to 100% immediately following the final Class B Exchange during the quarter, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders' equity attributable to Evolent Health, Inc. The Company paid \$1.3 million on behalf of certain holders of Class B units to satisfy income tax obligations related to certain exchanges.

In May 2019, the Company issued 1.6 million Class A common shares as part of the consideration for the GlobalHealth transaction. For each share of Class A common stock issued by Evolent Health, Inc., the Company received a corresponding Class A common unit from Evolent Health LLC. As a result of the Class A common units (and corresponding Class A common shares) issued as part of the GlobalHealth transaction, the Company's economic interest in Evolent Health LLC increased from 99.1% to 99.2%, immediately following the transaction.

2018

During the year ended December 31, 2018, the Company completed the March 2018 Private Sale. The shares sold in the March 2018 Private Sale consisted of 1.2 million existing shares of the Company's Class A common stock owned and held by The Advisory Board and 1.8 million newly-issued shares of the Company's Class A common stock received by The Advisory Board pursuant to a Class B Exchange.

As a result of this Class B Exchange and Evolent Health LLC's cancellation of the Class B common units during the March 2018 Private Sale, the Company's economic interest in Evolent Health LLC increased from 96.6% to 98.9% immediately following the March 2018 Private Sale and, accordingly, we reclassified a portion of our non-controlling interests into shareholders' equity attributable to Evolent Health, Inc.

Also, during the year ended December 31, 2018, the Company issued 3.1 million shares of Evolent Health LLC's Class B common units and an equal number of the Company's Class B common shares as part of the consideration for the New Century Health transaction. The Class B common units, together with a corresponding number of shares of the Company's Class B common stock, can be exchanged for an equivalent number of shares of the Company's Class A common stock. As a result of the Class B common units (and corresponding Class B common shares) issued as part of the New Century Health transaction, the Company's economic interest in Evolent Health LLC decreased from 99.0% to 95.3%, immediately following the acquisition.

In addition, the Company completed the November 2018 Private Sales during 2018. The shares sold in the November 2018 Private Sales consisted of 0.1 million existing shares of the Company's Class A common stock owned by TPG and 0.7 million newly-issued shares



of the Company's Class A common stock received by TPG pursuant to Class B Exchanges. As a result of these Class B Exchanges and Evolent Health LLC's cancellation of the Class B common units during the November 2018 Private Sales, the Company's economic interest in Evolent Health LLC increased from 95.3% to 96.1% immediately following the November 2018 Private Sales.

Changes in non-controlling interests (in thousands) for the periods presented were as follows:

	<b>For the Year Ended</b>	
	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
Non-controlling interests balance as of beginning of period	\$ 6,689	\$ 45,532
Decrease in non-controlling interests as a result of Class B Exchanges	—	(42,377)
Issuance of non-controlling interest	25,749	6,500
Net loss attributable to non-controlling interests	—	(3,609)
Disposal of assets	(6,689)	—
Redemption of Sponsor's equity	(25,749)	—
Reclassification of non-controlling interests	—	643
Non-controlling interests balance as of end of period	<u>\$ —</u>	<u>\$ 6,689</u>

#### **Note 18. Fair Value Measurement**

GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:

- Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;
- Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and
- Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured.

#### **Recurring Fair Value Measurements**

In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company's assets and liabilities measured at fair value on a recurring basis (in thousands):

	December 31, 2020			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 5,877	\$ —	\$ —	\$ 5,877
Total fair value of assets measured on a recurring basis	\$ 5,877	\$ —	\$ —	\$ 5,877
<b>Liabilities</b>				
Warrants <sup>(3)</sup>	\$ —	\$ —	\$ 13,730	\$ 13,730
Total fair value of liabilities measured on a recurring basis	\$ —	\$ —	\$ 13,730	\$ 13,730

	December 31, 2019			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 3,698	\$ —	\$ —	\$ 3,698
Restricted cash and restricted investments <sup>(1)</sup>	1,004	—	—	1,004
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 4,702</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 4,702</b>
<b>Liabilities</b>				
Contingent consideration <sup>(2)</sup>	\$ —	\$ —	\$ 9,883	\$ 9,883
Warrants <sup>(3)</sup>	—	—	7,092	7,092
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 16,975</b>	<b>\$ 16,975</b>

<sup>(1)</sup> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December 31, 2020 and December 31, 2019, as presented in the tables above.

<sup>(2)</sup> Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4.

<sup>(3)</sup> Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9.

The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels for the years ended December 31, 2020 and 2019, respectively.

In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.

In conjunction with the Credit Agreement discussed in Note 9, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would result in a significantly higher fair value of the contingent consideration.

The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands):

	For the Year Ended December 31,	
	2020	2019
Balance as of beginning of period	\$ 16,975	\$ 8,800
Additions	—	12,992
Settlements	(3,500)	(800)
Realized and unrealized gains (losses), net	255	(4,017)
<b>Balance as of end of period</b>	<b>\$ 13,730</b>	<b>\$ 16,975</b>

The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:

<b>December 31, 2020</b>				
	<b>Fair Value</b>	<b>Valuation Technique</b>	<b>Significant Unobservable Inputs</b>	<b>Assumption or Input Ranges</b>
Warrants	\$ 13,730	Black-Scholes	Stock price volatility	62.2 %
			Annual risk free rate	0.2 %

**December 31, 2019**

	<b>Fair Value</b>	<b>Valuation Technique</b>	<b>Significant Unobservable Inputs</b>	<b>Assumption or Input Ranges</b>
Passport contingent consideration	\$ 3,700	Real options approach	Risk-adjusted recurring revenue CAGR	93.9 % <sup>(1)</sup>
			Discount rate/time value	4.8% - 5.3%
GlobalHealth contingent consideration	\$ 5,200	Monte Carlo simulation	Stock price volatility	80.0 % <sup>(2)</sup>
Other contingent considerations	\$ 983	Management estimate	Adjusted EBITDA	\$ 19,235
Warrants	\$ 7,092	Black-Scholes	Stock price volatility	55.0 %
			Annual risk free rate	1.7 %

<sup>(1)</sup> The risk-adjusted recurring revenue CAGR is calculated over the five-year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of \$1.0 million, resulting in a higher growth rate.

<sup>(2)</sup> Equity volatility based on Evolent's daily stock price returns for a look-back period corresponding to the time until the second test date. The large one-day stock price drop on November 27, 2019, was excluded from the volatility calculation.

### **Nonrecurring Fair Value Measurements**

In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value.

### **Other Fair Value Disclosures**

The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.

See Note 9 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.

### **Note 19. Related Parties**

The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.

As discussed in Note 16, the Company had economic interests in several entities that were previously accounted for under the equity method of accounting, including EVH Passport. The Company has allocated its proportional share of the investees' earnings and losses

each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings.

The Company also works closely with UPMC, one of its founding investors. The Company's relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest.

The following table presents assets and liabilities attributable to our related parties (in thousands):

	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>Assets</b>		
Accounts receivable, net	\$ 9,474	\$ 8,781
Prepaid expenses and other current assets	51	1,592
Customer advance for regulatory capital requirements, net of allowances	—	40,000
Prepaid expenses and other noncurrent assets, net of allowances	4,554	2,709
<b>Liabilities</b>		
Accounts payable	\$ 2,509	\$ 6,429
Accrued liabilities	1,520	2,583
Reserve for claims and performance-based arrangements	435	4,264

The following table presents revenues and expenses attributable to our related parties (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Revenue</b>			
Transformation services	\$ 5,416	\$ 4,009	\$ 10,540
Platform and operations services	226,339	60,325	37,490
<b>Expenses</b>			
Cost of revenue (exclusive of depreciation and amortization expenses)	2,863	28,954	9,451
Selling, general and administrative expenses	113	991	917



## Note 20 - Repositioning and Other Changes

We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.

In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (“Repositioning Plan”). These actions included making organizational changes across our Services segment as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021.

The Company recorded approximately \$1.3 million of repositioning costs in selling, general and administrative expenses during the year ended December 31, 2020 in connection with the Repositioning Plan. The following tables provide a summary of our total costs associated with the Repositioning Plan for the year ended December 31, 2020, by major type of cost:

	<b>Incurred For the Year Ended December 31, 2020</b>	<b>Total Amount Expected to be Incurred in the Repositioning Plan</b>	<b>Cumulative Amount Incurred through December 31, 2020</b>
Severance and termination benefits	\$ —	\$ 2,500	\$ —
Office space consolidation	—	2,100	—
Professional services	1,275	4,200	1,275
Total	\$ 1,275	\$ 8,800	\$ 1,275

## Note 21. Segment Reporting

We define our reportable segments based on the way the CODM, currently the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:

- Services, which consists of two clinical solutions: (i) total cost of care management, and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services; and
- True Health, which consists of a commercial health plan we operate in New Mexico that focuses on individual and family as well as small and large group businesses as well as the Federal Employee Health Benefits Program.

In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.

The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources.

Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies.

Adjusted EBITDA is defined as EBITDA (net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses), adjusted to exclude equity method investment impairment, loss on extinguishment of debt, gain (loss) from equity method investees, gain (loss) on disposal of assets and consolidation, goodwill impairment, changes in fair value of contingent consideration and indemnification asset, other income (expense), net, net loss attributable to non-controlling interests, ASC 606 transition adjustments, purchase accounting adjustments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets and acquisition-related costs.

Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance.

The following tables present our segment information (in thousands):



	<u>Services</u>	<u>True Health</u>	<u>Intersegment Eliminations</u>	<u>Consolidated</u>
<b>Revenue</b>				
<b>For the Year Ended December 31, 2020</b>				
Services:				
Transformation services	\$ 11,990	\$ —	\$ —	\$ 11,990
Platform and operations services	913,005	—	(19,939)	893,066
Services revenue	924,995	—	(19,939)	905,056
True Health:				
Premiums	—	117,579	(202)	117,377
Total revenue	<u>\$ 924,995</u>	<u>\$ 117,579</u>	<u>\$ (20,141)</u>	<u>\$ 1,022,433</u>

**For the Year Ended December 31, 2019**

Services:				
Transformation services	\$ 15,203	\$ —	\$ —	\$ 15,203
Platform and operations services	671,919	—	(12,481)	659,438
Services revenue	687,122	—	(12,481)	674,641
True Health:				
Premiums	—	172,722	(980)	171,742
Total revenue	<u>\$ 687,122</u>	<u>\$ 172,722</u>	<u>\$ (13,461)</u>	<u>\$ 846,383</u>

**For the Year Ended December 31, 2018**

Services:				
Transformation services	\$ 32,916	\$ —	\$ —	\$ 32,916
Platform and operations services	514,515	—	(14,325)	500,190
Services revenue	547,431	—	(14,325)	533,106
True Health:				
Premiums	—	94,763	(806)	93,957
Total revenue	<u>\$ 547,431</u>	<u>\$ 94,763</u>	<u>\$ (15,131)</u>	<u>\$ 627,063</u>

	<u>Services</u>	<u>True Health</u>	<u>Segments Total</u>
<b>For the Year Ended December 31, 2020</b>			
Adjusted EBITDA	<u>\$ 48,573</u>	<u>\$ (7,137)</u>	<u>\$ 41,436</u>
<b>For the Year Ended December 31, 2019</b>			
Adjusted EBITDA	<u>\$ (14,667)</u>	<u>\$ 3,699</u>	<u>\$ (10,968)</u>
<b>For the Year Ended December 31, 2018</b>			
Adjusted EBITDA	<u>\$ 21,310</u>	<u>\$ 1,915</u>	<u>\$ 23,225</u>



The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Net loss attributable to common shareholders of Evolent Health, Inc.</b>	\$ (334,246)	\$ (301,971)	\$ (52,658)
Less:			
Interest income	3,164	3,987	3,440
Interest expense	(28,337)	(14,534)	(5,484)
(Provision) benefit for income taxes	3,553	21,536	(40)
Depreciation and amortization expenses	(61,475)	(60,913)	(44,515)
Equity method investment impairment	(47,133)	—	—
Loss on extinguishment of debt, net	(4,789)	—	—
Gain (loss) from equity method investees	10,039	(9,465)	(4,736)
Gain (loss) on disposal of assets and consolidation	(698)	9,600	—
Goodwill impairment	(215,100)	(199,800)	—
Change in fair value of contingent consideration and indemnification asset	(3,860)	3,997	4,104
Other income (expense), net	(119)	(492)	109
Net loss attributable to non-controlling interests	—	3,609	1,533
ASC 606 transition adjustments	—	—	(4,498)
Purchase accounting adjustments	—	(1,915)	(861)
Repositioning costs	(1,275)	—	—
Stock-based compensation expense	(14,606)	(15,618)	(17,609)
Severance costs	(8,986)	(17,350)	(2,205)
Amortization of contract cost assets	(3,944)	(2,876)	(2,456)
Acquisition costs	(2,116)	(10,769)	(2,665)
<b>Adjusted EBITDA</b>	<b>\$ 41,436</b>	<b>\$ (10,968)</b>	<b>\$ 23,225</b>

Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.

## **Note 22. Reserve for Claims and Performance-Based Arrangements**

The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. The Company also maintained reserves for claims incurred but not paid related to its capitation arrangement and for its health plan, True Health, in New Mexico.

Reserves for claims and performance-based arrangements for our Services and True Health segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care

professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 10.

The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability, for reserves related to its total cost of care and specialty care management services and True Health, is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products.

The Company's policy for reserves related to its total cost of care and specialty care management services and True Health is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of

completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.

For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment.

For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.

Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2020 and 2019, was as follows (in thousands):

	For the Year Ended December 31,					
	2020			2019		
	Services <sup>(1)(2)</sup>	True Health <sup>(2)</sup>	Total	Services <sup>(1)</sup>	True Health <sup>(2)</sup>	Total
Beginning balance	\$ 54,510	\$ 6,640	\$ 61,150	\$ 17,715	\$ 9,880	\$ 27,595
Incurring costs related to current year	420,597	89,008	509,605	\$ 267,064	\$ 136,303	\$ 403,367
Incurring costs related to prior year	2,878	799	3,677	(334)	(529)	(863)
Paid costs related to current year	464,571	79,640	544,211	220,050	61,621	281,671
Paid costs related to prior year	9,598	6,949	16,547	8,165	8,092	16,257
Change during the year	(50,694)	3,218	(47,476)	38,515	66,061	104,576
Impact of consolidation on reserves for claims and performance-based arrangements	164,297	—	164,297	—	—	—
Other adjustments <sup>(3)</sup>	10,714	—	10,714	(1,720)	(69,301)	(71,021)
Ending balance	\$ 178,827	\$ 9,858	\$ 188,685	\$ 54,510	\$ 6,640	\$ 61,150

<sup>(1)</sup> Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. EVH Passport operations are not included in 2019 activity.

<sup>(2)</sup> There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. The number of claims processed for the Services and True Health segments for years ended December 31, 2020 and 2019 were 2,279,228 and 317,187, respectively.



<sup>(3)</sup> Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to EVH Passport and our True Health segment represent premiums received less administrative expenses related to the reinsurance agreements. Refer to Note 10 for additional information about the reinsurance agreements.

### **Note 23. Investments**

Our investments held by wholly-owned subsidiaries other than EVH Passport are classified as held-to-maturity as we have both the intent and ability to hold the investments until their individual maturities. Investments held by EVH Passport are classified as available-for-sale upon their consolidation. The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of December 31, 2020 and 2019 (in thousands) were as follows:

	December 31, 2020				December 31, 2019			
	Amortized Cost	Gross Unrealized		Fair Value	Amortized Cost	Gross Unrealized		Fair Value
		Gains	Losses			Gains	Losses	
U.S. Treasury bills	\$ 8,909	\$ 384	\$ —	\$ 9,293	\$ 10,784	\$ 270	\$ —	\$ 11,054
Corporate bonds	1,707	132	—	1,839	1,705	70	—	1,775
Collateralized mortgage obligations	3,433	149	—	3,582	5,472	56	(5)	5,523
Corporate stock	130	—	—	130	—	—	—	—
Yankees	598	49	—	647	597	30	—	627
Total investments	\$ 14,777	\$ 714	\$ —	\$ 15,491	\$ 18,558	\$ 426	\$ (5)	\$ 18,979

The amortized cost and fair value of our investments by contractual maturities as of December 31, 2020 and 2019 (in thousands) were as follows:

	December 31, 2020		December 31, 2019	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in one year or less	\$ 3,858	\$ 3,915	\$ 1,807	\$ 1,810
Due after one year through five years	10,919	11,576	16,121	16,542
Due after five years through ten years	—	—	630	627
Total investments	\$ 14,777	\$ 15,491	\$ 18,558	\$ 18,979

When a held-to-maturity investment is in an unrealized loss position, we assess whether or not we expect to recover the entire cost basis of the security, based on our best estimate of the present value of cash flows expected to be collected from the debt security. Factors considered in our analysis include the reasons for the unrealized loss position, the severity and duration of the unrealized loss position, credit worthiness and forecasted performance of the investee. In cases where the estimated present value of future cash flows is less than our cost basis, we recognize an other than temporary impairment and write the investment down to its fair value. The new cost basis would not be changed for subsequent recoveries in fair value.

There were no securities held in an unrealized loss position for more than twelve months as of December 31, 2020 or 2019.

#### Note 24. Quarterly Results of Operations (unaudited)

The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:

**For the Three Months Ended**

	<b>December 31</b>	<b>September 30</b>	<b>June 30</b>	<b>March 31</b>
<b>2020</b>				
Total revenue	\$ 271,923	\$ 264,593	\$ 238,632	\$ 247,285
Total operating expenses	276,659	277,512	466,101	272,785
Net loss	(13,803)	(38,170)	(203,521)	(78,752)
Net loss attributable to non-controlling interests	822	(822)	—	—
Net loss attributable to common shareholders of Evolent Health, Inc.	(14,625)	(37,348)	(203,521)	(78,752)
<i>Loss per common share</i>				
Basic and Diluted	\$(0.17)	\$(0.44)	\$(2.38)	\$(0.93)
<b>2019</b>				
Total revenue	\$ 236,525	\$ 220,143	\$ 191,959	\$ 197,756
Total operating expenses <sup>(1)</sup>	451,120	240,281	217,192	244,402
Net loss	(199,293)	(25,738)	(31,900)	(48,649)
Net loss attributable to non-controlling interests	(1,197)	(217)	(285)	(1,910)
Net loss attributable to common shareholders	(198,096)	(25,521)	(31,615)	(46,739)

	<b>For the Three Months Ended</b>			
	<b>December 31</b>	<b>September 30</b>	<b>June 30</b>	<b>March 31</b>

<i>Loss per common share</i>				
Basic and Diluted	\$(2.36)	\$(0.30)	\$(0.38)	\$(0.59)

<sup>(1)</sup> The Company recorded goodwill impairment of \$199.8 million during the three months ended December 31, 2019.

## Note 25. Supplemental Cash Flow Information

The following represents supplemental cash flow information (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Supplemental Disclosure of Non-cash Investing and Financing Activities</b>			
Class A and Class B common stock issued in connection with business combinations	\$ —	\$ 23,556	\$ 83,173
Change in goodwill from measurement period adjustments/business combinations	2,200	(351)	(117)
Acquisition consideration payable	4,185	800	—
Settlement of escrow related to asset acquisition	—	—	2,519
Settlement of indemnification asset	—	—	1,004
Accrued property and equipment purchases	11	(527)	368
Accrued deferred financing costs	—	—	607
Consideration for asset acquisitions or business combinations	—	16,000	500
<i>Effects of Leases</i>			
Operating cash flows from operating leases	13,708	12,330	—
Leased assets obtained in exchange for operating lease liabilities	(2,170)	30,463	—
<i>Effects of Class B Exchanges</i>			
Decrease in non-controlling interests as a result of Class B Exchanges	—	42,377	34,682
Decrease in deferred tax liability as a result of securities offerings and exchanges	—	(22)	652
<b>Supplemental Disclosures</b>			
Cash paid for interest	13,352	5,037	2,500
Cash paid for taxes, net	9,679	1,484	343

## Note 26. Subsequent Events

### *Agreement for the Sale of True Health New Mexico*

On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the “True Health SPA”) with Bright Health Management, Inc. (“Bright HealthCare”), pursuant to which EH Holdings expects to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of \$22.0 million plus excess

risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the closing of the transactions (the “True Health Closing”) based in part on actual medical claims experience.

In the True Health SPA, EH Holdings, True Health and Bright HealthCare have made customary representations and warranties and have agreed to customary covenants, indemnification and termination rights relating to the transactions contemplated by the True Health SPA. Among other things, True Health will be subject to certain business conduct restrictions with respect to its operations prior to the True Health Closing. Evolent Health LLC has guaranteed the obligations of EH Holdings under the True Health SPA.

The True Health Closing is conditioned on customary conditions, including, among others, (i) the accuracy of the representations and warranties of the parties at True Health Closing (generally, subject to a material adverse effect standard), (ii) material compliance with the covenants and the agreements made by the parties in the True Health SPA, (iii) approval of the Transactions by the New Mexico Office of Superintendent of Insurance, (iv) the absence of any legal restraints prohibiting the Transactions and (v) the entry into a transition services agreement. The True Health Closing is expected to occur on or after the end of the first half of 2021.

As of December 31, 2020, the Company determined that True Health did not meet the held for sale criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are not classified as held for sale and are included in continuing operations in the consolidated financial statements.

#### *Change in Reportable Segments*

The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Notably, the chief executive officer will remain the CODM and will no longer manage the operations for purposes of allocating resources and assessing performance through the Services and True Health segments. Effective during the first quarter of 2021, the Company will bifurcate its Services segment into two reportable segments as follows:

- Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and
- Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands.

The CODM continues to use revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. The impact of the organizational changes on the Company's operating segments, reportable segments and reporting units will be reflected in the Company's financial statements as of and for the three months ending March 31, 2021. Prior year segment information will be reclassified to conform to the reporting structure change.

#### *Repayment and Termination of Existing Credit Agreement*

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was \$98.6 million, which included \$9.7 million for the make-whole premium as well as \$0.2 million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for \$13.7 million.

## **Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

### **Item 9A. Controls and Procedures**

#### *Evaluation of Disclosure Controls and Procedures*

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of December 31, 2020 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.

#### *Management's Annual Report on Internal Control Over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.

As permitted by the SEC rules, management's assessment and conclusion on the effectiveness of our internal control over financial reporting as of December 31, 2020 excludes an assessment of the internal control over financial reporting of EVH Passport, consolidated on September 1, 2020.

Under the supervision of and with the participation of our management, we assessed the effectiveness of our internal control over financial reporting as of December 31, 2020, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework.

As disclosed in Part II-Item 9A-Controls and Procedures in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, during fiscal 2019 we identified material weaknesses in internal control related to inadequate user access role definitions within certain instances of one of our claims processing systems due to inadequate segregation of duties, inadequate controls over the set-up and modifications of claims data, and lack of evidence of the operation of controls over claims data received from certain third-party service providers. None of the control deficiencies resulted in any adjustments to our 2019 annual or interim 2020 consolidated financial statements.

During fiscal year 2020, management implemented our previously disclosed remediation plan as described in the Remediation of Material Weakness in Internal Controls over Financial Reporting section, below. We have completed execution of our remediation plan and successfully remediated the material weaknesses in internal control over financial reporting as of December 31, 2020.

#### *Remediation of Material Weaknesses in Internal Controls over Financial Reporting*

During the year ended December 31, 2020, management designed and implemented enhanced procedures to remediate the deficiencies in our internal control over financial reporting that resulted in the material weaknesses. These remediation efforts included the following:

- System enhancements, implementation of role-based access, and updated policies and control procedures related to user access role definitions and segregation of duties within certain instances of one of our claims processing systems;
- Expanded controls and/or applied other appropriate procedures to address the design and operation of internal controls related to the set-up and modification of claims data; and
- Enhanced monitoring processes and internal controls related to claims data received from certain third-party service providers.

During the fourth quarter of 2020, we completed our testing of the operating effectiveness of the implemented controls and found them to be effective. As a result we have concluded the material weaknesses have been remediated as of December 31, 2020.



### *Changes in Internal Control over Financial Reporting*

Except for the changes in connection with our implementation of the remediation plan discussed above, there were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

### *Inherent Limitations of Internal Controls*

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of Evolent Health, Inc.

### Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of Evolent Health, Inc. and subsidiaries (the “Company”) as of December 31, 2020, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2020, of the Company and our report dated February 25, 2021, expressed an unqualified opinion on those financial statements.

As described in *Management’s Annual Report on Internal Control Over Financial Reporting*, management excluded from its assessment the internal control over financial reporting at EVH Passport, which was a voting interest entity consolidated on September 1, 2020, and whose financial statements constitute 13% and 14% of total assets and total liabilities, respectively, and 3% of net loss of the consolidated financial statement amounts as of and for the year ended December 31, 2020. Accordingly, our audit did not include the internal control over financial reporting at EVH Passport.

### Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying *Management’s Annual Report on Internal Control Over Financial Reporting*. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

### Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention

or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

McLean, Virginia  
February 25, 2021

**Item 9B. Other Information**

None.

## PART III

### **Item 10. Directors, Executive Officers and Corporate Governance**

The information called for by this Item 10 pertaining to Directors is incorporated herein by reference to Evolent Health, Inc.'s definitive proxy statement for the Annual Meeting of Shareholders to be held on June 10, 2021, to be filed by Evolent Health, Inc. with the SEC pursuant to Regulation 14A within 120 days after the year ended December 31, 2020 (the "2021 Proxy Statement").

The information called for by this Item 10 pertaining to Executive Officers appears in "Part I - Item 1. Business - Information about our Executive Officers" in this Annual Report on Form 10-K and our 2021 Proxy Statement.

We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our investor relations website ([ir.evolenthealth.com](http://ir.evolenthealth.com)) under "Corporate Governance." We intend to satisfy the SEC's disclosure requirements regarding amendments to, or waivers of, the code of ethics by posting such information on our website.

### **Item 11. Executive Compensation**

Information required by this Item 11 is incorporated herein by reference to our 2021 Proxy Statement.

### **Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

Information required by this Item 12 is incorporated herein by reference to our 2021 Proxy Statement.

### **Item 13. Certain Relationships and Related Transactions, and Director Independence**

Information required by this Item 13 is incorporated herein by reference to our 2021 Proxy Statement.

### **Item 14. Principal Accounting Fees and Services**

Information required by this Item 14 is incorporated herein by reference to our 2021 Proxy Statement.

## PART IV

### Item 15. Exhibits

(a) The following documents are filed as part of this report:

(1) The following financial statements of the registrant and report of independent registered public accounting firm are included of Item 8 hereof:

[Report of Independent Registered Public Accounting Firm](#)

[Consent of Previous Registered Public Accounting Firm](#)

[Consolidated Balance Sheets](#)

[Consolidated Statements of Operations and Comprehensive Income \(Loss\)](#)

[Consolidated Statements of Changes in Shareholders' Equity \(Deficit\)](#)

[Consolidated Statements of Cash Flows](#)

[Notes to Consolidated Financial Statements](#)

(2) All financial statement schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission either have been included in the Financial Statements, are not required under the related instructions, or are not applicable and therefore have been omitted.

(3) The Exhibits listed in the Exhibit Index below are filed with or incorporated by reference into this report.

**EVOLENT HEALTH, INC.**

**Exhibit Index**

- [2.1\\*](#) [Agreement and Plan of Merger, dated July 12, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as the Securityholders' Representative, filed as Exhibit 2.1 to the Company's Report on Form 8-K filed with the SEC on July 14, 2016, and incorporated herein by reference](#)
- [2.2\\*](#) [First Amendment to Agreement and Plan of Merger, dated October 3, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as securityholders' representative, filed as Exhibit 2.2 to the Company's Report on Form 8-K filed with the SEC on October 3, 2016, and incorporated herein by reference](#)
- [2.3\\*](#) [Agreement and Plan of Merger, dated September 7, 2018, by and among Evolent Health, Inc., Evolent Health LLC, Element Merger Sub, Inc., NCIS Holdings, Inc. and New Century Investment, LLC, in the capacity set forth therein, filed as Exhibit 2.1 to the Company's Report on Form 8-K filed with the SEC on September 12, 2018, and incorporated herein by reference](#)
- [2.4\\*](#) [Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company's Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference](#)
- [2.5\\*](#) [First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company's Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference](#)
- [3.1](#) [Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., filed as Exhibit 3.1 to the Company's Report on Form 8-K filed with the SEC on June 15, 2016, and incorporated herein by reference](#)
- [3.2](#) [Third Amended and Restated By-laws of Evolent Health, Inc., filed as Exhibit 3.1 to the Company's Report on Form 8-K filed with the SEC on December 14, 2020, and incorporated herein by reference](#)
- [4.1](#) [Form of Class A common stock certificate, filed as Exhibit 4.1 to Amendment No. 1 to the Company's Registration Statement on Form S-1 filed with the SEC on May 18, 2015, and incorporated herein by reference](#)
- [4.2](#) [Registration Rights Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC, The Advisory Board Company and Ptolemy Capital, LLC, filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference](#)
- [4.3](#) [Indenture dated as of December 5, 2016, between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on December 5, 2016, and incorporated herein by reference](#)
- [4.4](#) [Form of 2.00% Convertible Senior Notes due 2021, filed as Exhibit A to the Indenture \(Item 4.3 above\), which was filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on December 5, 2016, and incorporated herein by reference](#)





- [4.5](#) [Indenture dated as of October 22, 2018, between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on October 23, 2018, and incorporated herein by reference](#)
- [4.6](#) [Form of 1.50% Convertible Senior Notes due 2025, filed as Exhibit A to the Indenture \(Item 4.5 above\), which was filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on October 23, 2018, and incorporated herein by reference](#)
- [4.7](#) [Registration Rights Agreement, dated May 24, 2019, by and between Evolent Health, Inc. and Momentum Health Group, LLC, filed as exhibit 4.1 to the Company's Report on Form 8-K filed with the SEC on May 28, 2019, and incorporated herein by reference.](#)
- [4.8](#) [Description of Registrant's Securities, filed as exhibit 4.8 to the Company's Report on Form 10-K filed with the SEC on March 2, 2020, and incorporated herein by reference.](#)
- [4.9\\*](#) [Indenture, dated as of August 19, 2020, by and between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company's Current Report on Form 8-K with the SEC on August 25, 2020, and incorporated herein by reference](#)
- [4.10\\*](#) [Form of 3.50% Convertible Senior Note due 2024 \(included as Exhibit A to Exhibit 4.1\), filed as Exhibit 4.2 to the Company's Current Report on Form 8-K with the SEC on August 25, 2020, and incorporated herein by reference](#)
- [10.1](#) [Third Amended and Restated Operating Agreement of Evolent Health LLC, dated as of June 4, 2015, filed as Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference](#)
- [10.2](#) [Income Tax Receivables Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health LLC and certain stockholders of Evolent Health, Inc., filed as Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference](#)
- [10.3](#) [Exchange Agreement, dated June 4, 2015, by and among Evolent Health, Inc., Evolent Health LLC, TPG Eagle Holdings, L.P., The Advisory Board Company and Ptolemy Capital, LLC, filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference](#)
- [10.4\\*](#) [Exchange Agreement, dated October 1, 2018, by and among Evolent Health, Inc., Evolent Health LLC and certain holders of Class B common units in Evolent Health LLC, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on October 2, 2018, and incorporated herein by reference](#)
- [10.5](#) [Amended and Restated Master Investors' Rights Agreement among Evolent Health Holdings, Inc., Evolent Health LLC and the Investors named therein, dated as of January 6, 2014, filed as Exhibit 10.6 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.6](#) [Stockholders Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC and The Advisory Board Company, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference](#)
- [10.7](#) [VPHealth, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.8 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.8+](#) [Amendment No. 1 to the Evolent Health, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.9 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.9+](#) [Evolent Health, Inc. 2015 Omnibus Equity Incentive Plan, filed as Exhibit 10.9 to Amendment No. 1 to the Company's Registration Statement on Form S-1 filed with the SEC on May 18, 2015, and incorporated herein by reference](#)
- [10.10+](#) [Amendment to the Evolent Health, Inc. 2015 Omnibus Equity Incentive Plan, filed as Appendix B to the Company's Definitive Proxy Statement on Schedule 14A filed with the SEC on April 27, 2018, and incorporated herein by reference](#)
- [10.11+](#) [Form of Executive Officer Option Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.5 to the Company's Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference](#)
- [10.12+](#) [Form of Executive Officer Restricted Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive](#)





- [10.16†](#) [Amended and Restated HealthPlaNet Technology License Agreement between UPMC and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.17†](#) [Amended and Restated Intellectual Property License and Development Services Agreement between UPMC and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.13 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.18](#) [Amended and Restated Intellectual Property License and Data Access Agreement by and between The Advisory Board Company and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.15 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.19](#) [Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of July 31, 2012, filed as Exhibit 10.18 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.20](#) [First Amendment to Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of March 1, 2013, filed as Exhibit 10.19 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.21](#) [Second Amendment to Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of April 1, 2014, filed as Exhibit 10.20 to the Company's Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference](#)
- [10.22](#) [Form of Director Indemnification Agreement, filed as Exhibit 10.20 to Amendment No. 2 to the Company's Registration Statement on Form S-1 filed with the SEC on May 26, 2015, and incorporated herein by reference](#)
- [10.23+](#) [Form of Executive Officer Performance-Based Option Award Agreement Under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on May 16, 2016, and incorporated herein by reference](#)
- [10.24+](#) [Form of Non-Employee Director Restricted Stock Unit Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2017, and incorporated herein by reference](#)
- [10.25+](#) [Form of Leveraged Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.26 to the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2019, and incorporated herein by reference](#)
- [10.26\\*](#) [Asset Purchase Agreement, dated July 16, 2020, by and among Passport Health Plan, Inc., Evolent Health LLC, and Molina Healthcare, Inc., filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q with the SEC on August 7, 2020, and incorporated herein by reference](#)
- [10.27](#) [Cooperation Agreement, dated December 21, 2020, by and among Evolent Health, Inc., Engaged Capital Flagship Master Fund, LP, Engaged Capital Co-Invest XI, LP, Engaged Capital Special Situation Fund, LP, Engaged Capital Flagship Fund, LP, Engaged Capital Flagship Fund, Ltd., Engaged Capital LLC, Engaged Capital Holdings, LLC and Glenn W. Welling, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on December 22, 2020, and incorporated by reference herein](#)
- [10.28+](#) [Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Frank Williams, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein](#)
- [10.29+](#) [Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Seth Blackley, filed as Exhibit 10.2 to the Company's Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein](#)
- [10.30+](#) [Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. John Johnson, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein](#)



<a href="#"><u>31.2</u></a>	<a href="#"><u>Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</u></a>
<a href="#"><u>32.1</u></a>	<a href="#"><u>Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>
<a href="#"><u>32.2</u></a>	<a href="#"><u>Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u></a>
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
104	The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL

† The Company's request for confidential treatment with respect to certain portions of this exhibit has been accepted.

+ Constitutes a management contract or other compensatory plan or arrangement.

\* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K.

**Item 16. Form 10-K Summary**

Not Applicable.





<b>Signature</b>	<b>Title</b>	<b>Date</b>
<u>/s/ Seth Blackley</u> <b>Seth Blackley</b>	Chief Executive Officer and Director (Principal Executive Officer)	February 25, 2021
<u>/s/ John Johnson</u> <b>John Johnson</b>	Chief Financial Officer (Principal Financial Officer)	February 25, 2021
<u>/s/ Aammaad Shams</u> <b>Aammaad Shams</b>	Corporate Controller (Principal Accounting Officer)	February 25, 2021
<u>/s/ Frank Williams</u> <b>Frank Williams</b>	Executive Chair, Director	February 25, 2021
<u>/s/ Michael D'Amato</u> <b>Michael D'Amato</b>	Director	February 25, 2021
<u>/s/ Craig Barbarosh</u> <b>Craig Barbarosh</b>	Director	February 25, 2021
<u>/s/ M. Bridget Duffy</u> <b>M. Bridget Duffy, MD</b>	Director	February 25, 2021
<u>/s/ David Farner</u> <b>David Farner</b>	Director	February 25, 2021
<u>/s/ Peter Grua</u> <b>Peter Grua</b>	Director	February 25, 2021
<u>/s/ Diane Holder</u> <b>Diane Holder</b>	Director	February 25, 2021
<u>/s/ Kim Keck</u> <b>Kim Keck</b>	Director	February 25, 2021
<u>/s/ Cheryl Scott</u> <b>Cheryl Scott</b>	Director	February 25, 2021

**SEVERANCE AND  
CHANGE-IN-CONTROL AGREEMENT**

THIS SEVERANCE AND CHANGE-IN-CONTROL AGREEMENT (this “Agreement”), dated as of January 27, 2021 (the “Effective Date”), is made by and between Evolent Health, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and Steve Tutewohl (“Executive”).

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of a termination of employment or the occurrence of a Change in Control (as defined below) of the Company;

WHEREAS, the Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive’s employment and to motivate Executive to maximize the value of the Company for the benefit of its stockholders; and

WHEREAS, the Board further believes that it is imperative to provide Executive with certain severance benefits upon termination of Executive’s employment and with certain additional benefits upon a termination of employment in connection with a Change in Control of the Company to provide Executive with enhanced financial security and incentive to remain with the Company.

NOW, THEREFORE, in consideration of the promises, agreements and conditions contained in this Agreement, the Company and Executive agree as follows:

**SECTION I  
DEFINITIONS**

For the purposes of this Agreement the following definitions shall apply:

1.1 “Accrued Obligations” means (a) any unpaid Base Salary through the Date of Termination, payable within 30 days following the Date of Termination, or on such earlier date as may be required by applicable law; (b) any Annual Bonus for a prior year earned but unpaid, payable at the time such bonuses would have been paid if Executive was still employed with the Company; (c) reimbursement for any unreimbursed business expenses incurred through the Date of Termination, payable in accordance with the Company’s policy; and (d) all vested benefits under the Company’s retirement, health and welfare and equity-based employee benefit plans to which Executive is entitled, payable in accordance with the terms of such plan or program.

1.2 “Affiliate” means any entity controlled by, controlling, or under common control with, the Company.

1.3 “Annual Bonus” means Executive’s annual bonus under the Company’s or an Affiliate’s annual executive bonus program, as in effect from time to time, under which Executive is covered.

1.4 “Annual Salary” means Executive’s annual base salary, exclusive of any bonus pay, commissions or other additional compensation, in effect on the Date of Termination.

1.5 “Cause” means:

(a) Executive's failure to perform any of Executive's material duties to the Company, including, without limitation, a breach of the Company's code of ethics, conflict of interest or employment policies;

(b) Executive's misappropriation of a material business opportunity of the Company, including securing or attempting to secure any personal profit in connection with any transaction entered into on behalf of the Company;

---

- (c) Executive's misappropriation (or attempted misappropriation) of any Company funds or property;
- (d) Executive's conviction of, indictment for (or its procedural equivalent), or entering of a guilty plea or plea of no contest with respect to (or its procedural equivalent), a felony or any other crime involving dishonesty or theft of property;
- (e) Executive's commission of one or more acts of sexual harassment in violation of applicable federal, state or local laws;
- (f) Executive's use of illegal drugs, abuse of controlled substances, or abuse or excessive use of alcohol, which (in the case of alcohol use) interferes with or affects Executive's responsibilities to the Company or which reflects negatively upon the integrity or reputation of the Company; or
- (g) Executive's breach of the terms of this Agreement, any other employment agreement, any confidentiality agreement, non-competition agreement or non-solicitation agreement or any other material agreement between Executive and the Company, after giving effect to the notification provisions, if any, and the mechanisms to remedy or cure such breach as described in any such agreement.

The Company shall determine whether conduct constituting "Cause" has occurred for purposes of this Agreement. For purposes of this definition, (i) "Company" includes any Subsidiary or Affiliate and (ii) "Cause" is not limited to events that have occurred before a termination of Executive's employment or services with the Company, nor is it necessary that the Company's finding of "Cause" occur prior to termination of such employment or services with the Company.

1.6 "Change in Control" means:

(a) During any period of twenty-four (24) consecutive calendar months, individuals who were directors of the Company on the first day of such period (the "Incumbent Directors") cease for any reason to constitute a majority of the Board; provided, however, that any individual becoming a director subsequent to the first day of such period, whose election, or nomination for election by the Company's stockholders, was made pursuant to the Stockholders Agreement by and among the Company, the Advisory Board, TPG Growth II BDH, L.P., TPG Eagle Holdings L.P. and UPMC, dated as of June 4, 2015 or was approved by a vote of at least a majority of the Incumbent Directors shall be considered as though such individual were an Incumbent Director, but excluding, for purposes of this proviso, any such individual whose initial assumption of office occurs as a result of an actual or threatened proxy contest with respect to election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a "person" (as used in Section 13(d) of the Securities Exchange Act of 1934, as amended) (a "Person"), in each case other than the Board;

(b) The consummation of (i) a merger, consolidation, statutory share exchange or similar form of corporate transaction involving (A) the Company or (B) any of its Subsidiaries, but in the case of this clause (B) only if Company Voting Securities (as defined below) are issued or issuable (each of the events referred to in this clause (i) being hereinafter referred to as a "Reorganization") or (ii) the sale or other disposition of all or substantially all the assets of the Company to an entity that is not an Affiliate (a "Sale"), in each case, if such Reorganization or Sale requires the approval of the Company's stockholders under the law of the Company's jurisdiction of organization (whether such approval is required for such Reorganization or Sale or for the issuance of securities of the Company in such Reorganization or Sale), unless, immediately following such Reorganization or Sale, (1) all or substantially all the Persons who were the "beneficial owners" (as used in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (or a successor rule thereto)) of the securities eligible to vote for the election of the Board ("Company Voting Securities") outstanding immediately prior

to the consummation of such Reorganization or Sale continue to beneficially own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the corporation or other entity resulting from such Reorganization or Sale (including a corporation or other entity that, as a result of such transaction, owns the

---

Company or all or substantially all the Company's assets either directly or through one or more subsidiaries) (the "Continuing Company") in substantially the same proportions as their ownership, immediately prior to the consummation of such Reorganization or Sale, of the outstanding Company Voting Securities (excluding, for such purposes, any outstanding voting securities of the Continuing Company that such beneficial owners hold immediately following the consummation of the Reorganization or Sale as a result of their ownership prior to such consummation of voting securities of any corporation or other entity involved in or forming part of such Reorganization or Sale other than the Company), (2) no Person (excluding any employee benefit plan (or related trust) sponsored or maintained by the Continuing Company or any entity controlled by the Continuing Company) beneficially owns, directly or indirectly, fifty percent (50%) or more of the combined voting power of the then outstanding voting securities of the Continuing Company and (3) at least fifty percent (50%) of the members of the board of directors of the Continuing Company were Incumbent Directors at the time of the execution of the definitive agreement providing for such Reorganization or Sale or, in the absence of such an agreement, at the time at which approval of the Board was obtained for such Reorganization or Sale;

(c) The stockholders of the Company approve a plan of complete liquidation or dissolution of the Company unless such liquidation or dissolution is part of a transaction or series of transactions described in paragraph (b) above that does not otherwise constitute a Change of Control; or

(d) Any Person, corporation or other entity or "group" (as used in Section 13(d) of the Securities Exchange Act of 1934, as amended) (other than (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or an Affiliate or (iii) any entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of the voting power of the Company Voting Securities) becomes the beneficial owner, directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company Voting Securities; provided, however, that for purposes of this subparagraph (d), the following acquisitions shall not constitute a Change of Control: (A) any acquisition directly from the Company, (B) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or an Affiliate, (C) any acquisition by an underwriter temporarily holding such Company Voting Securities pursuant to an offering of such securities or any acquisition by a pledgee of Company Voting Securities holding such securities as collateral or temporarily holding such securities upon foreclosure of the underlying obligation or (D) any acquisition pursuant to a Reorganization or Sale that does not constitute a Change of Control for purposes of subparagraph (b) above.

Notwithstanding anything to the contrary, to the extent that nonqualified deferred compensation as defined in and subject to Section 409A is payable under this Agreement upon a Change in Control, an event shall not be considered to be a Change in Control with respect to such nonqualified deferred compensation unless such event is also a "change in ownership," a "change in effective control" or a "change in the ownership of a substantial portion of the assets" of the Company within the meaning of Section 409A.

1.7 "Change in Control Protection Period" means the period commencing thirty (30) days prior to a Change in Control and ending twenty-four (24) months after a Change in Control.

1.8 "COBRA" means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended from time to time.

1.9 "Code" means the Internal Revenue Code of 1986, as amended from time to time, and the regulations issued thereunder.

1.10 "Date of Termination" means the effective date of Executive's termination of employment and service with the Company and its Affiliates.

1.11 “Good Reason” means the occurrence, without Executive’s written consent, of any of the events or circumstances set forth below:

---

- (a) a material reduction in Executive's annual Base Salary or Target Bonus, as the same may be increased from time to time;
- (b) the assignment of duties to Executive inconsistent in any material respect with Executive's position, authority or responsibilities with the Company, or any other action or omission by the Company which results in a material diminution of such position, authority or responsibilities;
- (c) a relocation of Executive's principal work location by more than fifty (50) miles from such location as of immediately prior to the Date of Termination;
- (d) a material diminution of the authority, duties or responsibilities of the supervisor to whom Executive reports; or
- (e) any material breach of this Agreement by the Company.

Good Reason shall not exist unless Executive gives the Company notice of the event giving rise to Good Reason within sixty (60) days of the date Executive has knowledge of such event. Such notice shall specifically delineate such claimed breach and shall inform the Company that it is required to cure such breach (if curable) within ninety (90) days (the "Cure Period") after such notice is given in accordance with Section VII. If such breach is not so cured (or is not curable), Executive may resign for Good Reason within three (3) months following the end of the Cure Period. If such breach is cured within the Cure Period or if such breach is not cured but Executive does not resign for Good Reason within three (3) months following the end of the Cure Period, Good Reason shall not exist hereunder.

1.12 "Section 409A" means Section 409A of the Code and any regulations or other formal guidance promulgated thereunder.

1.13 "Subsidiary" means any entity in which the Company, directly or indirectly, possesses fifty percent (50%) or more of the total combined voting power of all classes of its stock.

1.14 "Target Bonus" means Executive's target Annual Bonus under the Company's or Affiliate's annual bonus program, as in effect from time to time, under which Executive is covered.

## SECTION II SEVERANCE PAYMENTS AND BENEFITS

2.1 Change in Control Protection Period. If, during a Change in Control Protection Period, the Company terminates Executive's employment without Cause or Executive terminates employment for Good Reason, then the Company shall pay or provide the following amounts and benefits to Executive, in addition to the Accrued Obligations:

(a) Severance Payment. Executive will be paid an amount equal to one and one-half (1.5) times the sum of Executive's Annual Salary and Target Bonus in effect immediately prior to the Date of Termination. Such severance shall be paid in a lump sum within sixty (60) days following the Date of Termination.

(b) Bonus for Year of Termination.



(i) If the Date of Termination occurs during the first six (6) months of the year, Executive will be paid a pro-rata portion of the Target Bonus in effect on the Date of Termination, determined by multiplying the amount of the Target Bonus by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).

---

(ii) If the Date of Termination occurs during the last six (6) months of the year, Executive will be paid a pro-rata portion of the Annual Bonus based on actual performance for such year, determined by multiplying the amount of the Annual Bonus that would be due for the full year by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).

(iii) Such pro-rated Target Bonus or Annual Bonus shall be paid in a lump sum at the same time the Annual Bonus would have been paid if Executive continued to be employed by the Company, but in any event in the calendar year following the year during which the Date of Termination occurs.

(c) COBRA Payments. If Executive timely elects coverage under COBRA under any group health plan of the Company or an Affiliate, the Company will pay Executive a taxable monthly amount that, after applicable federal, state and local tax withholdings, is equal to the portion of the cost of coverage that is subsidized by the Company for active employees as in effect from time to time until the earlier of: (i) eighteen (18) months following the Date of Termination and (ii) the expiration of the Executive's COBRA coverage. The first monthly payment shall be paid to Executive within sixty (60) days following the Date of Termination and, thereafter, each subsequent monthly payment shall be paid on the first payroll date in each month following the Date of Termination.

(d) Equity Awards. Notwithstanding anything to the contrary in any equity plan of the Company or its Affiliates or Executive's award agreement thereunder, any and all outstanding equity awards granted to Executive under any equity plan of the Company or its Affiliates will be treated as follows: (i) all time-based vesting conditions applicable to such awards will be treated as satisfied in full and shall lapse on the Date of Termination, and (ii) any performance-based vesting conditions applicable to such awards shall be deemed to have been satisfied at the greater of target and actual performance through the Date of Termination. Such awards will be settled in accordance with, and otherwise be subject to, the terms of the equity plan of the Company or its Affiliates or Executive's award agreement thereunder; provided, however, that any vested restricted stock units shall be settled upon Executive within sixty (60) days following the Date of Termination.

2.2 Outside of Change in Control Protection Period. If the Company terminates Executive's employment without Cause, or Executive terminates employment for Good Reason, in either case other than during a Change in Control Protection Period, then the Company shall pay or provide the following amounts and benefits to Executive, in addition to the Accrued Obligations:

(a) Severance. Executive will be paid an amount equal to one (1) times the sum of Executive's Annual Salary in effect immediately prior to the Date of Termination, payable for a period of twelve (12) months following the Date of Termination in accordance with the Company's normal payroll practices and commencing within sixty (60) days following the Date of Termination; provided, however, that any payments that would otherwise be payable during the period following the Date of Termination until the payment commencement date shall be accumulated without interest and paid on such commencement date.

(b) Bonus for Year of Termination.

(i) If the Date of Termination occurs during the first six (6) months of the year, Executive will be paid a pro-rata portion of the Target Bonus in effect on the Date of Termination, determined by multiplying the amount of the Target Bonus by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).

(ii) If the Date of Termination occurs during the last six (6) months of the year, Executive will be paid a pro-rata portion of the Annual Bonus based on actual performance for such year, determined by multiplying the amount of the Annual

Bonus that would be due for the full year by a fraction, the numerator of which is the number of days from January 1 of the year during which the Date of Termination occurs to the Date of Termination and the denominator of which is three hundred and sixty-five (365).

---

(iii) Such pro-rated Target Bonus or Annual Bonus shall be paid in a lump sum at the same time the Annual Bonus would have been paid had Executive continued to be employed by the Company, but in any event in the calendar year following the year during which the Date of Termination occurs.

(c) COBRA Payments. If Executive timely elects coverage under COBRA under any group health plan of the Company or an Affiliate, the Company will pay Executive a taxable monthly amount that, after applicable federal, state and local tax withholdings, is equal to that portion of the cost of coverage that is subsidized by the Company for active employees as in effect from time to time until the earlier of: (i) twelve (12) months following the Date of Termination and (ii) the expiration of the Executive's COBRA coverage. The first monthly payment shall be paid to Executive within sixty (60) days following the Date of Termination and thereafter each subsequent monthly payment shall be paid on the first payroll date in each month following the Date of Termination.

(d) Equity Awards. Notwithstanding anything to the contrary in any equity plan of the Company or its Affiliates or Executive's award agreement thereunder, any and all outstanding equity awards granted to Executive under any equity plan of the Company or its Affiliates shall be treated as follows: (i) for purposes of any time-based vesting conditions applicable to such awards, Executive shall be deemed to have completed an additional twelve (12) months of employment following the Date of Termination, and (ii) satisfaction of any performance-based vesting conditions applicable to such awards shall be determined at the end of the applicable performance period based on actual performance through the end of the performance period, and pro-rated based on (A) the number of days Executive was employed by the Company during the vesting measurement period through the Date of Termination plus twelve (12) months (but not to exceed the performance period) over (B) the number of days in the performance period. Such awards will be settled in accordance with, and otherwise be subject to, the terms of the equity plan of the Company or its Affiliates or Executive's award agreement thereunder.

2.3 Termination for Any Other Reason. If Executive's employment and service with the Company and its Affiliates is terminated for any reason other than by the Company without Cause or by Executive for Good Reason, including due to Executive's retirement, death or disability, no amounts or benefits will be payable or provided under this Agreement, except the Accrued Amounts.

2.4 Release. Notwithstanding anything contained in this Agreement to the contrary, the Company shall not be obligated to provide any payments or benefits to Executive under Section 2.1 or Section 2.2 hereof other than the Accrued Obligations unless Executive executes and delivers to the Company a general release of claims in favor of the Company and its Affiliates and their respective employees, officers and directors in such form as is reasonably requested by the Company, and such release becomes irrevocable by its terms, no later than sixty (60) days after the Date of Termination.

2.5 No Duplication. In no event shall payments and benefits provided in accordance with this Agreement be made in respect of more than one of Section 2.1 or 2.2.

2.6 Offset. Notwithstanding the provisions of this Section II, the Company's obligation to make the severance payments and benefits described herein shall be reduced by any amounts owed by Executive to the Company and its Affiliates; provided, however, that offsets of amounts owed by Executive that are nonqualified deferred compensation (within the meaning of Section 409A) shall only be made in accordance with Section 409A.

2.7 Equity Award Vesting. Notwithstanding anything to the contrary in any equity plan of the Company or its Affiliates or in any award agreement thereunder, any requirement of an equity award held by Executive that Executive remain an employee of the Company or an Affiliate or a member of the Board through an applicable vesting date shall be deemed satisfied if Executive remains an employee of, or provides services as a consultant to, the Company or an Affiliate, or continues as a member of the Board, through such vesting date.



### SECTION III TAX INFORMATION

3.1 Tax Withholding. The Company shall deduct from payments to be paid to Executive or any beneficiary all federal, state and local withholding and other taxes and charges required to be deducted under applicable law.

3.2 Section 409A.

(a) The intent of the parties is that payments and benefits under this Agreement shall comply with or be exempt from Section 409A and this Agreement shall be interpreted in accordance with such intentions. Notwithstanding the foregoing, neither the Company, its Affiliates nor their respective directors, officers, employees or advisers shall be held liable for any taxes, interest, penalties or other monetary amounts owed by Executive (or any other individual claiming a benefit through Executive) as a result of this Agreement.

(b) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and references to the “Date of Termination,” a “termination,” “termination of employment” or like terms shall mean “separation from service,” within the meaning of Section 409A, from the Company.

(c) Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company. In the event the payment period under this Agreement commences in one calendar year and ends in a second calendar year, the payments shall not be paid (or installments commenced) until the second calendar year. For purposes of Section 409A, Executive’s right to receive installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.

(d) If Executive is deemed on the Date of Termination to be a “specified employee” within the meaning of that term under Section 409A(a)(2)(B), then with regard to any payment or benefit subject to Section 409A that is payable on account of a “separation from service,” such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six (6)-month period measured from the date of such “separation from service” of Executive, and (ii) the date of Executive’s death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this section (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid to Executive in a lump sum without interest, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.

### SECTION IV RESTRICTIVE COVENANTS

4.1 Confidential Information.

(a) Executive acknowledges that the Company and its Affiliates continually develop Confidential Information (as defined below), that Executive may develop Confidential Information for the Company or its Affiliates and that Executive may learn of Confidential Information during the course of Executive’s employment. Executive will comply with the policies and procedures of the Company and its Affiliates for protecting Confidential Information and shall not disclose to any person or use, other than as required by

applicable law or for the proper performance of Executive's duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained by Executive incident to Executive's employment or other association with the Company or any of its Affiliates. Executive understands that this restriction shall continue to apply after Executive's employment terminates, regardless of the reason for such termination. The confidentiality obligation under this Section 4.1 shall not apply to information which is generally known or readily available to the public at the time of

---

disclosure or becomes generally known through no wrongful act on the part of Executive or any other person having an obligation of confidentiality to the Company or any of its Affiliates or is required to be disclosed in order to enforce this Agreement.

(b) All documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the Company or its Affiliates and any copies, in whole or in part, thereof (the “Documents”), whether or not prepared by Executive, shall be the sole and exclusive property of the Company and its Affiliates. Executive shall safeguard all Documents and shall surrender to the Company at the time Executive’s employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in Executive’s possession or control.

(c) “Confidential Information” means any and all information of the Company and its Affiliates that is not generally known by those with whom the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete or do business and any and all information, publicly known in whole or in part or not, which, if disclosed by the Company or any of its Affiliates would assist in competition against them. Confidential Information includes without limitation such information relating to (i) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates, (ii) the products and services of the Company and its Affiliates, (iii) the costs, sources of supply, financial performance and strategic plans of the Company and its Affiliates, (iv) the identity and special needs of the customers of the Company and its Affiliates and (v) the people and organizations with whom the Company and its Affiliates have business relationships and the nature and substance of those relationships. Confidential Information also includes any information that the Company or any of its Affiliates has received, or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not be disclosed.

#### 4.2 Non-Competition and Non-Solicitation.

(a) Executive agrees and acknowledges that the business (the “Business”) of the Company is any business activity engaged in, or actively contemplated by the Company (or any Subsidiary) to be engaged in, by the Company (or any Subsidiary) and with which Executive or was involved on or prior to the Date of Termination.

(b) Executive agrees that, except as the Company expressly agrees in writing, during the Restricted Period (defined below), Executive shall not within the Territory (defined below), directly or indirectly, as an owner, partner, affiliate, stockholder, joint venturer, director, employee, consultant, contractor, principal, trustee or licensor, or in any other similar capacity whatsoever of or for any person or entity (other than for the Company):

(i) engage in, own, manage, operate, sell, finance, control, advise or participate in the ownership, management, operation, sales, finance or control of, be employed or employed by, or be connected in any manner with, any business that competes with (i) the Business or (ii) if Executive has provided services directly to any health maintenance organization, health insurance company or similar health insurance plan, owned or operated by a customer of the Company, during the Restricted Period, such customer (each, a “Competitor”). Notwithstanding this Section 4.2(b)(i), Executive may accept employment with a Competitor whose business is diversified, provided that (A) such employment is with a portion of the Competitor’s business that does not provide products or services that are the same as, are similar to, or compete with the Company’s products or services (“Competing Products or Services”) and (B) prior to Executive’s acceptance of such employment with Competitor, the Company receives separate written assurances satisfactory to the Company from such Competitor and from Executive that Executive will not provide any Competing Products or Services;



(ii) approach, solicit, divert, interfere with, or take away, the business or patronage of any of the actual or prospective members, customers, or clients of the Company, with whom Executive had material Business-related contact and/or about which Executive had access to and/or knowledge of Confidential Information, for a purpose that is competitive with the Business; or

---

(iii) solicit (whether as an employee, consultant, agent, independent contractor, or otherwise) any person who is, or who at any time during the six (6)-month period prior to the Date of Termination had been, employed or engaged by the Company, or induce or take any action which is intended to induce any such person to terminate his or her employment or relationship, or otherwise cease his or her relationship, with the Company, or interfere in any manner with the contractual or employment relationship between the Company and any employee of or any other person engaged by the Company.

“Restricted Period” shall mean the period of time beginning on the Effective Date and ending on the date that is (i) eighteen (18) months following the Date of Termination where Section 2.1 applies because the termination occurs during a Change in Control Protection Period or (ii) twelve (12) months following the Date of Termination where Section 2.2 applies because the termination occurs other than during a Change in Control Protection Period.

“Territory” shall mean the United States of America (including the following states: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming, as well as the District of Columbia) and any other country or territory with respect to which Executive has been materially engaged in Business-related activities on behalf of the Company and/or about which Executive has had access to and/or knowledge of Confidential Information.

4.3 Notwithstanding anything to the contrary in Section 4.2(b) of this Agreement, Executive is permitted to own, individually, as a passive investor (with no director designation rights, voting rights or veto rights or other special governance or voting rights), up to a one percent (1%) interest in any publicly traded entity that is a Competitor.

4.4 Executive shall disclose in writing all of Executive’s relationships as a director, employee, consultant, contractor, principal, trustee, licensor, agent, or otherwise, with a Competitor or any other business entity, to the Company until the end of the Restricted Period. Executive shall not disparage the Company or any of its officers, directors, or employees; provided, however, that this Section 4.4 shall not prohibit or constrain truthful testimony by Executive compelled by any valid legal process or valid legal dispute resolution process. Notwithstanding anything herein to the contrary, nothing in this Section IV shall prevent either party hereto from enforcing such party’s rights or remedies hereunder or that such party may otherwise be entitled to enforce or assert under any other agreement or applicable law, or shall limit such rights or remedies in any way.

4.5 During the Restricted Period, Executive shall notify in writing any prospective new employer or entity otherwise seeking to engage Executive that the provisions of this Section IV exist prior to accepting employment or such other engagement.

4.6 The terms of this Section IV are reasonable and necessary in light of Executive’s position with the Company and responsibility and knowledge of the operations of the Company and its Subsidiaries and are not more restrictive than necessary to protect the legitimate interests of the parties hereto. In addition, any breach of the covenants contained in this Section IV would cause irreparable harm to the Company, its Subsidiaries and Affiliates and there would be no adequate remedy at law or in damages to compensate the Company, its Subsidiaries and Affiliates for any such breach. In the event of a breach or threatened breach by Executive of any of the provisions of this Agreement, Executive hereby consents and agrees that money damages would not afford an adequate remedy and that the Company shall be entitled to seek a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual damages, and without the necessity of posting any bond or other security, where permissible under applicable law. Any equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages, or other available relief. Notwithstanding the foregoing, this Agreement is not intended to, and shall

be interpreted in a manner that does not, limit or restrict Executive from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Securities Exchange Act of 1934).

---

4.7 Survival of Restrictive Covenants. Upon termination of Executive's employment for any reason whatsoever, the obligations of Executive pursuant to this Section IV shall survive and remain in effect for the periods described herein.

4.8 No Waiver of Legal Remedies. The restrictions in this Agreement are in addition to and not in lieu of any other obligation of Executive to protect confidential information and trade secrets and any rights and remedies which the Company may have at law or in equity. Nothing in this Agreement is intended to or should be interpreted as diminishing any rights and remedies the Company has. Enforcement of rights and remedies pursuant to this Agreement by the Company and/or any other entity shall not be construed as a waiver of any other rights or remedies at law or equity.

4.9 Protected Rights. Notwithstanding any other provision of this Agreement, nothing contained in this Agreement limits Executive's ability to file a charge or complaint with the Securities and Exchange Commission or any other federal, state or local government agency or commission (collectively, "Government Agencies"), or prevents Executive from providing truthful testimony in response to a lawfully-issued subpoena or court order. Further, this Agreement does not limit Executive's ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing non-privileged documents or other information, without notice to the Company.

4.10 Defend Trade Secrets Act. Executive is hereby notified that under the Defend Trade Secrets Act: (a) no individual will be held criminally or civilly liable under federal or state trade secret law for disclosure of a trade secret (as defined in the Economic Espionage Act) that is: (i) made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and made solely for the purpose of reporting or investigating a suspected violation of law, or (ii) made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (b) an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.

## **SECTION V DISPUTES**

### 5.1 Dispute Resolution.

(a) Jurisdiction and Venue. Executive and the Company irrevocably submit to the exclusive jurisdiction of (i) the United States District Court for the District of Delaware and (ii) the courts of the State of Delaware for the purposes of any suit, action or other proceeding arising out of this Agreement. Executive and the Company agree to commence any such action, suit or proceeding either in the United States District Court for the District of Delaware or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the courts of the State of Delaware with jurisdiction over New Castle County. Executive and the Company further agree that service of any process, summons, notice or document by U.S. registered mail to the other party's address set forth below shall be effective service of process for any action, suit or proceeding in Delaware with respect to any matters to which Executive has submitted to jurisdiction in this Section 5.1. Executive and the Company irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or in (A) the United States District Court for the District of Delaware or (B) the courts of the State of Delaware, and hereby and thereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

(b) Waiver of Jury Trial. Executive and the Company hereby waive, to the fullest extent permitted by applicable law, any right either of Executive may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement.

---

(c) Confidentiality. Executive hereby agrees to keep confidential the existence of, and any information concerning, a dispute described in this Section 5.1, except that Executive may disclose information concerning such dispute to the court that is considering such dispute or to Executive's legal counsel (provided that such counsel agrees not to disclose any such information other than as necessary to the prosecution or defense of the dispute).

## **SECTION VI SUCCESSORS**

6.1 In addition to any obligations imposed by law upon any successor to the Company, the Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. The provisions of this Section VI shall continue to apply to each subsequent employer of Executive bound by this Agreement in the event of any merger, consolidation or transfer of all or substantially all of the business or assets of that subsequent employer. This Agreement shall inure to the benefit of the Company, such successors and any assigns. The term "the Company" as used herein shall include such successors, and any assigns.

6.2 This Agreement shall inure to the benefit of and be enforceable by Executive's personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.

## **SECTION VII NOTICES**

7.1 For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be in writing (including email, provided, that such email states that it is a notice delivered pursuant to this Section 7.1) and shall be given at the address or email address set forth below (or to such other address or email address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address or email address shall be effective only upon actual receipt). All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a business day in the place of receipt. Otherwise, any such notice, request or communication shall be deemed to have been received on the next succeeding business day in the place of receipt.

To the Company:

Evolent Health, Inc.  
800 N. Glebe Road, Suite 500  
Arlington, VA 22203  
Attention: General Counsel  
Email: JWeinberg@evolenthealth.com

To Executive: At Executive's most recent mailing address in the records of the Company, or at Executive's employee email address (during employment).

## **SECTION VIII MISCELLANEOUS**

8.1 Any compensation paid or payable to Executive pursuant to this Agreement which is subject to recovery under any law, government regulation, order or stock exchange listing requirement, or under any policy of the Company adopted from time to time, will be subject to such deductions and clawback (recovery) as may be required to be made pursuant to such law, government regulation, order, stock exchange listing requirement or policy of the Company. Executive specifically authorizes the Company to withhold from future salary or wages any amounts that may become due under this provision.

---

8.2 This Agreement embodies the entire agreement of the Company and Executive relating to separation or severance pay and, except as specifically provided herein, no provisions of any employee manual, personnel policies, corporate directives or other agreement or document shall be deemed to modify the terms of this Agreement. Except as otherwise provided in Section 5.1, no amendment or modification of this Agreement shall be valid or binding upon Executive or the Company unless made in writing and signed by the Company and Executive. This Agreement supersedes all prior understandings and agreements addressing severance or separation pay to which Executive and the Company or an Affiliate are or were parties, including any previous change in control agreement, severance plan, offer letter provisions, or other employment agreements.

8.3 No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.

8.4 No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.

8.5 This Agreement shall not modify the “at will” nature of Executive’s employment, nor shall it confer upon Executive any right to continue employment or service with the Company or its affiliates, nor shall this Agreement interfere in any way with the right of the Company or its affiliates to terminate Executive’s employment or service at any time.

8.6 The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. If a judicial determination is made that any provision of this Agreement constitutes an unreasonable or otherwise unenforceable restriction against Executive, such provision shall be rendered void only to the extent that such judicial determination finds the provision to be unreasonable or otherwise unenforceable with respect to Executive. In this regard, Executive hereby agrees that any judicial authority construing this Agreement shall be empowered to reform any portion of this Agreement, including without limitation the scope of the Business, the Territory, and the Restricted Period, in order to make the covenants herein binding and enforceable with respect to Executive, and to apply the provisions of this Agreement and to enforce against Executive the remaining portion of such provisions as the judicial authority determines to be reasonable and enforceable. All of the covenants contained in this Agreement shall be construed as an agreement independent of any other provisions in this Agreement, and the existence of any claim or cause of action Executive may have against the Company and/or its affiliates (other than in connection with a material breach of this Agreement by the Company) shall not constitute a defense to the enforcement by the Company and/or its affiliates of such covenants.

8.7 The Agreement shall be construed, administered and governed in all respects under and by the applicable laws of the State of Delaware.

8.8 This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by “.pdf” format or scanned pages shall be effective as delivery of a manually executed counterpart to this Agreement.

*[Remainder of page left intentionally blank.]*





IN WITNESS WHEREOF, the parties have signed this Agreement to be effective as of the Effective Date.

**EVOLENT HEALTH, INC.**

By: /s/ Jonathan Weinberg

Name: Jonathan Weinberg

Title: General Counsel

**EXECUTIVE**

/s/ Steve Tutewohl

Steve Tutewohl

## List of Subsidiaries

<b>Legal Name</b>	<b>Jurisdiction of Organization</b>
Evolut Health LLC	Delaware
NCIS Holdings, Inc.	Delaware
NCH Management Systems, Inc.	California
Evolut Assurance Solutions, LLC	Vermont
EH Holding Company, Inc.	Delaware
True Health New Mexico, Inc.	New Mexico
Justify Holdings, Inc.	Kentucky
Juntos Health Plan Inc.	Texas
Evolut Health International Private Ltd.	India
Evolut Care Partners Holding Company, Inc.	Delaware
Evolut Care Partners of Texas, Inc.	Texas
The Accountable Care Organization Ltd.	Michigan
Evolut Care Partners of North Carolina, Inc.	North Carolina

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement Nos. 333-212709 and 333-219755 on Form S-3 and Registration Statement Nos. 333-204785 and 333-225714 on Form S-8 of our reports dated February 25, 2021, relating to the financial statements of Evolent Health, Inc. and subsidiaries (the “Company”) and the effectiveness of the Company’s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.

/s/ Deloitte & Touche LLP

McLean, Virginia  
February 25, 2021

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-212709, No. 333-219755) and Form S-8 (No. 333-204785, No. 333-225714) of Evolent Health, Inc. of our report dated February 28, 2019 relating to the financial statements which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

McLean, Virginia  
February 25, 2021

**Certification Pursuant to Section 302 of the  
Sarbanes-Oxley Act of 2002**

I, Seth Blackley, certify that:

1. I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 25, 2021

/s/ Seth Blackley

---

Name: Seth Blackley

Title: Chief Executive Officer

**Certification Pursuant to Section 302 of the  
Sarbanes-Oxley Act of 2002**

I, John Johnson, certify that:

1. I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Dated: February 25, 2021

/s/ John Johnson

---

Name: John Johnson

Title: Chief Financial Officer

**Certification Pursuant to 18 U.S.C. Section 1350,  
As Adopted Pursuant to Section 906  
Of the Sarbanes-Oxley Act of 2002**

I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1. The Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 25, 2021    /s/ Seth Blackley

Name: Seth Blackley

Title: Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

**Certification Pursuant to 18 U.S.C. Section 1350,  
As Adopted Pursuant to Section 906  
Of the Sarbanes-Oxley Act of 2002**

I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1. The Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 25, 2021    /s/ John Johnson  
Name: John Johnson  
Title: Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Cover Page - USD (\$)
\$ in Millions

12 Months Ended

Dec. 31, 2020

Feb. 22, 2021
Jun. 30, 2020

Cover [Abstract]

Table with 2 columns: Field Name and Value. Fields include Document Type, Document Annual Report, Document Period End Date, Current Fiscal Year End Date, Document Transition Report, Entity File Number, Entity Registrant Name, Entity Incorporation, State or Country Code, Entity Tax Identification Number, Entity Address, Address Line One, Entity Address, Address Line Two, Entity Address, City or Town, Entity Address, State or Province, Entity Address, Postal Zip Code, City Area Code, Local Phone Number, Title of 12(b) Security, Trading Symbol, Security Exchange Name, Entity Well-known Seasoned Issuer, Entity Voluntary Filers, Entity Current Reporting Status, Entity Interactive Data Current, Entity Filer Category, Entity Small Business, Entity Emerging Growth Company, ICFR Auditor Attestation Flag, Entity Shell Company, Entity Public Float.

\$ 540.0

<a href="#">Entity Common Stock, Shares Outstanding (in shares)</a>		86,091,822
<a href="#">Entity Central Index Key</a>	0001628908	
<a href="#">Amendment Flag</a>	false	
<a href="#">Document Fiscal Year Focus</a>	2020	
<a href="#">Document Fiscal Period Focus</a>	FY	
<a href="#">Documents Incorporated by Reference</a>	Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for June 10, 2021, have been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2020.	

**CONSOLIDATED  
BALANCE SHEETS - USD**  
(**\$**)  
**\$ in Thousands**

**Dec. 31, Dec. 31,**  
**2020 2019**

**Current assets:**

<u>Cash and cash equivalents</u>	\$ 340,490	\$ 101,008
<u>Restricted cash and restricted investments</u>	14,437	20,080
<u>Accounts receivable, net</u>	[1] 125,986	75,667
<u>Prepaid expenses and other current assets</u>	[1] 61,034	28,488
<u>Investments, at amortized cost</u>	3,858	1,807
<u>Contract assets</u>	329	1,751
<u>Total current assets</u>	546,134	228,801
<u>Restricted cash and restricted investments</u>	7,270	8,260
<u>Investments, at amortized cost</u>	10,919	16,751
<u>Investments in and advances to equity method investees</u>	6,498	122,618
<u>Property and equipment, net</u>	86,240	85,155
<u>Right-of-use assets - operating</u>	57,799	72,173
<u>Customer advance for regulatory capital requirements, net of allowances</u>	[1] 0	40,000
<u>Prepaid expenses and other noncurrent assets, net of allowances</u>	[1] 5,832	6,253
<u>Contract assets</u>	0	999
<u>Contract cost assets</u>	26,687	36,482
<u>Intangible assets, net</u>	268,072	308,459
<u>Goodwill</u>	354,734	572,064
<u>Total assets</u>	1,370,185	1,498,015

**Current liabilities:**

<u>Accounts payable</u>	[1] 32,068	37,488
<u>Accrued liabilities</u>	[1] 84,507	33,343
<u>Short-term debt, net of discount</u>	26,557	0
<u>Operating lease liability - current</u>	7,357	6,269
<u>Accrued compensation and employee benefits</u>	48,278	34,691
<u>Deferred revenue</u>	14,327	19,828
<u>Reserve for claims and performance-based arrangements</u>	[1] 188,685	61,150
<u>Total current liabilities</u>	401,779	192,769
<u>Long-term debt, net of discount</u>	263,343	293,667
<u>Other long-term liabilities</u>	22,209	11,732
<u>Operating lease liabilities - noncurrent</u>	62,526	68,858
<u>Deferred tax liabilities, net</u>	728	1,942
<u>Total liabilities</u>	750,585	568,968
<u>Commitments and Contingencies (See Note 10)</u>		
<b><u>Shareholders' Equity (Deficit)</u></b>		
<u>Additional paid-in-capital</u>	1,229,320	1,173,708
<u>Accumulated other comprehensive income (loss)</u>	(278)	(234)

<u>Retained earnings (accumulated deficit)</u>	(589,178)	(251,962)
<u>Treasury stock, at cost; 1,537,582 and 0 shares issued, respectively</u>	(21,123)	0
<u>Total shareholders' equity attributable to Evolent Health, Inc.</u>	619,600	922,358
<u>Non-controlling interests</u>	0	6,689
<u>Total shareholders' equity (deficit)</u>	619,600	929,047
<u>Total liabilities and shareholders' equity (deficit)</u>	1,370,185	1,498,015
<u>Class A Common Stock</u>		
<b><u>Shareholders' Equity (Deficit)</u></b>		
<u>Class A common stock - \$0.01 par value; 750,000,000 shares authorized; 85,894,450 and 84,588,629 shares issued, respectively</u>	\$ 859	\$ 846

[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

**CONSOLIDATED  
BALANCE SHEETS  
(Parenthetical) - \$ / shares**

**Dec. 31, 2020 Dec. 31, 2019**

**Statement of Financial Position [Abstract]**

<u>Common stock, par value (in dollars per share)</u>	\$ 0.01	\$ 0.01
<u>Common stock, shares authorized (in shares)</u>	750,000,000	750,000,000
<u>Common stock, shares issued (in shares)</u>	85,894,450	84,588,629
<u>Treasury stock, at cost (in shares)</u>	1,537,582	0



**CONSOLIDATED  
STATEMENTS OF  
OPERATIONS AND  
COMPREHENSIVE  
INCOME (LOSS) - USD (\$)  
shares in Thousands**

**12 Months Ended**

	<b>Dec. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>
<b>Revenue</b>			
<u>Total revenue</u>	\$ 1,022,433,000	\$ 846,383,000	\$ 627,063,000
<b>Expenses</b>			
<u>Cost of revenue (exclusive of depreciation and amortization expenses)</u>	701,373,000	[1] 513,059,000	[1] 327,825,000
<u>Claims expenses</u>	87,951,000	135,774,000	70,889,000
<u>Selling, general and administrative expenses</u>	222,600,000	[1] 257,046,000	[1] 235,418,000
<u>Depreciation and amortization expenses</u>	61,475,000	60,913,000	44,515,000
<u>(Gain) loss on disposal of assets and consolidation</u>	698,000	(9,600,000)	0
<u>Goodwill impairment</u>	215,100,000	199,800,000	0
<u>Change in fair value of contingent consideration and indemnification asset</u>	3,860,000	(3,997,000)	(4,104,000)
<u>Total operating expenses</u>	1,293,057,000	1,152,995,000	674,543,000
<u>Operating loss</u>	(270,624,000)	(306,612,000)	(47,480,000)
<u>Interest income</u>	3,164,000	3,987,000	3,440,000
<u>Interest expense</u>	(28,337,000)	(14,534,000)	(5,484,000)
<u>Impairment of equity method investments</u>	(47,133,000)	0	0
<u>Gain (loss) from equity method investees</u>	10,039,000	(9,465,000)	(4,736,000)
<u>Loss on extinguishment of debt, net</u>	(4,789,000)	0	0
<u>Other income (expense), net</u>	(119,000)	(492,000)	109,000
<u>Loss before income taxes and non-controlling interests</u>	(337,799,000)	(327,116,000)	(54,151,000)
<u>Provision (benefit) for income taxes</u>	(3,553,000)	(21,536,000)	40,000
<u>Net loss</u>	(334,246,000)	(305,580,000)	(54,191,000)
<u>Net loss attributable to non-controlling interests</u>	0	(3,609,000)	(1,533,000)
<u>Net loss attributable to common shareholders of Evolent Health, Inc.</u>	\$ (334,246,000)	\$ (301,971,000)	\$ (52,658,000)
<b>Loss per common share</b>			
<u>Basic and diluted (in dollars per share)</u>	\$ (3.94)	\$ (3.67)	\$ (0.68)
<b>Weighted-average common shares outstanding</b>			
<u>Basic and diluted (in shares)</u>	84,928	82,364	77,338
<b>Comprehensive loss</b>			
<u>Net loss</u>	\$ (334,246,000)	\$ (305,580,000)	\$ (54,191,000)
<b>Other comprehensive loss, net of taxes, related to:</b>			
<u>Foreign currency translation adjustment</u>	(44,000)	(52,000)	(182,000)
<u>Total comprehensive loss</u>	(334,290,000)	(305,632,000)	(54,373,000)

<u>Total comprehensive loss attributable to non-controlling interests</u>	0	(3,609,000)	(1,533,000)
<u>Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</u>	(334,290,000)	(302,023,000)	(52,840,000)
<u>Transformation services</u>			
<b><u>Revenue</u></b>			
<u>Total revenue</u>	[1] 11,990,000	15,203,000	32,916,000
<u>Platform and operations services</u>			
<b><u>Revenue</u></b>			
<u>Total revenue</u>	[1] 893,066,000	659,438,000	500,190,000
<u>Premiums</u>			
<b><u>Revenue</u></b>			
<u>Total revenue</u>	\$ 117,377,000	\$ 171,742,000	\$ 93,957,000

[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

**CONSOLIDATED  
STATEMENTS OF  
CHANGES IN  
SHAREHOLDERS'  
EQUITY (DEFICIT) - USD  
(\$)  
shares in Thousands, \$ in  
Thousands**

	Total	Cumulative Effect, Period of Adoption, Adjustment	Parent	Parent Cumulative Effect, Period of Adoption, Adjustment	Common Stock Class A Common Stock	Common Stock Class B Common Stock	Additional Paid-In Capital	Accumulated Other Income (Loss)	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock	Non- controlling Interests	Non- controlling Interests Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2017					74,723	2,654							
Beginning balance at Dec. 31, 2017	\$ 1,046,306	\$ 17,309	\$ 1,010,879	\$ 16,715	\$ 747	\$ 27	\$ 924,153	\$ 0	\$ 85,952	\$ 16,715		\$ 35,427	\$ 594
<b>Increase (Decrease) in Stockholders' Equity [Roll Forward]</b>													
Stock-based compensation expense	17,221		17,221				17,221						
Exercise of stock options (in shares)					1,720								
Exercise of stock options	11,929		11,929		\$ 16		11,913						
Restricted stock units vested, net of shares withheld for taxes (in shares)					212								
Restricted stock units vested, net of shares withheld for taxes	(1,236)		(1,236)		\$ 2		(1,238)						
Shares released from Valence Health escrow (in shares)					(67)								
Shares released from Valence Health escrow	(1,003)		\$ (1,003)				(1,003)						
Issuance of common stock for business combinations (in shares)			40,386			3,120							
Issuance of common stock for business combinations	83,173					\$ 31	40,355					42,787	
Equity component of notes, net of issuance costs	69,378		\$ 69,378				69,378						
Exchange of Class B common stock (in shares)					2,584	(2,584)							
Exchange of Class B common stock		34,682			\$ 27	\$ (27)	34,682					(34,682)	
Tax impact of Class B common stock exchange	652		652				652						
Foreign currency translation adjustment	(182)		(182)					(182)					
Net income (loss)	(54,191)		(52,658)						(52,658)				(1,533)
Reclassification of non-controlling interests			(2,939)				(2,939)						2,939
Ending balance (in shares) at Dec. 31, 2018					79,172	3,190							
Ending balance at Dec. 31, 2018	\$ 1,189,356		1,143,824		\$ 792	\$ 31	1,093,174	(182)	50,009				45,532
<b>Increase (Decrease) in Stockholders' Equity [Roll Forward]</b>													
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member												
Stock-based compensation expense	\$ 16,006		16,006				16,006						
Exercise of stock options (in shares)					138								
Exercise of stock options	1,092		1,092		\$ 1		1,091						
Restricted stock units vested, net of shares withheld for taxes (in shares)					363								
Restricted stock units vested, net of shares withheld for taxes	(2,609)		(2,609)		\$ 4		(2,613)						
Share retirement (in shares)					(5)								
Share retirement							\$ (44)						
Class A common stock issued for payment of earn-outs (in shares)					43								
Class A common stock issued for payment of earn-outs	800		800		\$ 0		800						
Issuance of non-controlling interest	6,500											6,500	
Shares issued for equity-method investments and asset acquisitions (in shares)					1,732								
Shares issued for equity-method investments and asset acquisitions	23,556		23,556		\$ 18		23,538						
Issuance of common stock for business combinations (in shares)					3,100								
Exchange of Class B common stock (in shares)					3,146	(3,146)							
Exchange of Class B common stock		42,377			\$ 31	\$ (31)	42,377					(42,377)	
Tax impact of Class B common stock exchange	(22)		(22)				(22)						
Foreign currency translation adjustment	(52)		(52)					(52)					

<a href="#">Net income (loss)</a>	(305,580)		(301,971)				(301,971)		(3,609)			
<a href="#">Reclassification of non-controlling interests</a>			(643)			(643)			643			
<a href="#">Ending balance (in shares) at Dec. 31, 2019</a>				84,589	0							
<a href="#">Ending balance at Dec. 31, 2019</a>	\$ 929,047	\$ (2,970)	922,358	\$ (2,970)	\$ 846	\$ 0	1,173,708	(234)	(251,962)	\$ (2,970)	\$ 0	6,689
<b>Increase (Decrease) in Stockholders' Equity [Roll Forward]</b>												
<a href="#">Accounting Standards Update [Extensible List]</a>	us-gaap:AccountingStandardsUpdate201613Member											
<a href="#">Stock-based compensation expense</a>	\$ 14,606		14,606				14,606					
<a href="#">Exercise of stock options (in shares)</a>	416				416							
<a href="#">Exercise of stock options</a>	\$ 2,577		2,577		\$ 4		2,573					
<a href="#">Restricted stock units vested, net of shares withheld for taxes (in shares)</a>					462							
<a href="#">Restricted stock units vested, net of shares withheld for taxes</a>	(1,851)		(1,851)		\$ 5		(1,856)					
<a href="#">Share retirement (in shares)</a>					(188)							
<a href="#">Share retirement</a>	(685)		(685)		\$ (2)		(683)					
<a href="#">Consolidation of equity method investment</a>	(21,123)		(21,123)								(21,123)	
<a href="#">Class A common stock issued for payment of earn-outs (in shares)</a>					616							
<a href="#">Class A common stock issued for payment of earn-outs</a>	4,185		4,185		\$ 6		4,179					
<a href="#">Disposal of assets</a>	(6,689)											(6,689)
<a href="#">Equity component of notes, net of issuance costs</a>	36,793		36,793				36,793					
<a href="#">Foreign currency translation adjustment</a>	(44)		(44)				(44)					
<a href="#">Net income (loss)</a>	(334,246)		(334,246)						(334,246)			
<a href="#">Reclassification of non-controlling interests</a>												0
<a href="#">Ending balance (in shares) at Dec. 31, 2020</a>				85,895	0							
<a href="#">Ending balance at Dec. 31, 2020</a>	\$ 619,600	\$ 619,600		\$ 859	\$ 0	\$ 1,229,320	\$ (278)	\$ (589,178)		\$ (21,123)	\$ 0	

**CONSOLIDATED  
STATEMENTS OF CASH  
FLOWS - USD (\$)**

**12 Months Ended**

**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**Cash Flows Used In Operating Activities**

	\$	\$	\$
<u>Net loss</u>	(334,246,000)	(305,580,000)	(54,191,000)
<b><u>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</u></b>			
<u>Change in fair value of contingent consideration and indemnification asset</u>	3,860,000	(3,997,000)	(4,104,000)
<u>(Gain) loss on disposal of assets and consolidation</u>	698,000	(9,600,000)	0
<u>(Gain) loss from equity method investees</u>	(10,039,000)	9,465,000	4,736,000
<u>Depreciation and amortization expenses</u>	61,475,000	60,913,000	44,515,000
<u>Goodwill impairment</u>	215,100,000	199,800,000	0
<u>Impairment of equity method investments</u>	47,133,000	0	0
<u>Stock-based compensation expense</u>	14,606,000	15,618,000	17,609,000
<u>Deferred tax (benefit) provision</u>	(1,132,000)	(23,124,000)	44,000
<u>Amortization of contract cost assets</u>	21,195,000	5,723,000	2,703,000
<u>Amortization of deferred financing costs</u>	14,780,000	9,370,000	2,455,000
<u>Loss on extinguishment of debt</u>	4,789,000	0	0
<u>Interest from customer advance for regulatory capital requirements</u>	(1,869,000)	(1,300,000)	0
<u>Other current operating cash inflows (outflows), net</u>	2,744,000	(264,000)	448,000
<b><u>Changes in assets and liabilities, net of acquisitions:</u></b>			
<u>Accounts receivable, net and contract assets</u>	(47,017,000)	6,326,000	(24,503,000)
<u>Prepaid expenses and other current and noncurrent assets</u>	7,340,000	791,000	(14,746,000)
<u>Contract cost assets</u>	(11,400,000)	(23,057,000)	(11,179,000)
<u>Accounts payable</u>	3,547,000	(5,480,000)	7,598,000
<u>Accrued liabilities</u>	8,801,000	(21,852,000)	12,180,000
<u>Accrued compensation and employee benefits</u>	11,143,000	9,246,000	(14,571,000)
<u>Deferred revenue</u>	(8,943,000)	(756,000)	(1,819,000)
<u>Reserve for claims and performance-based arrangements</u>	(36,108,000)	33,555,000	8,964,000
<u>Right-of-use operating assets</u>	11,934,000	(20,811,000)	
<u>Operating lease liabilities</u>	(2,782,000)	27,724,000	
<u>Other long-term liabilities</u>	8,166,000	(5,355,000)	3,210,000
<u>Net cash and restricted cash used in operating activities</u>	(16,225,000)	(42,645,000)	(20,651,000)
<b><u>Cash Flows From (Used In) Investing Activities</u></b>			
<u>Cash paid for asset acquisitions or business combinations</u>	(300,000)	(8,575,000)	(130,241,000)
<u>Customer advance for regulatory capital requirements</u>	0	(46,400,000)	0
<u>Principal repayment of implementation funding loan and regulatory and capital requirements</u>	1,000,000	5,400,000	20,000,000
<u>Disposal of non-strategic assets</u>	(2,287,000)	0	0
<u>Amount received from escrow in asset acquisition</u>	0	0	500,000
<u>Investments in and advances to equity method investees</u>	0	(87,480,000)	(9,360,000)

<u>Impact to cash and cash equivalents and restricted cash from initial consolidation of Passport</u>	159,755,000	0	0
<u>Purchases of investments</u>	(11,170,000)	(11,125,000)	(10,010,000)
<u>Maturities and sales of investments</u>	143,441,000	2,575,000	349,000
<u>Investments in internal-use software and purchases of property and equipment</u>	(29,473,000)	(35,534,000)	(39,550,000)
<u>Purchase and maturities of restricted investments</u>	106,000	(495,000)	7,937,000
<u>Net cash and restricted cash from (used in) investing activities</u>	261,072,000	(181,634,000)	(160,375,000)
<b><u>Cash Flows From (Used In) Financing Activities</u></b>			
<u>Changes in working capital balances related to claims processing on behalf of partners</u>	(6,044,000)	(104,268,000)	96,153,000
<u>Amount received from escrow in asset acquisition</u>	0	500,000	0
<u>Proceeds from issuance of long-term debt, net of offering costs</u>	30,062,000	62,648,000	167,178,000
<u>Distributions to Sponsors</u>	(20,000,000)	0	0
<u>Repurchase of 2021 Notes and lender fees</u>	(16,606,000)	0	0
<u>Issuance of warrant liability</u>	0	7,092,000	0
<u>Proceeds from stock option exercises</u>	2,577,000	1,092,000	11,929,000
<u>Taxes withheld and paid for vesting of restricted stock units</u>	(1,851,000)	(2,609,000)	(1,236,000)
<u>Net cash and restricted cash from (used in) financing activities</u>	(11,862,000)	(35,545,000)	274,024,000
<u>Effect of exchange rate on cash and cash equivalents and restricted cash</u>	65,000	30,000	(36,000)
<u>Net increase (decrease) in cash and cash equivalents and restricted cash</u>	233,050,000	(259,794,000)	92,962,000
<u>Cash and cash equivalents and restricted cash as of beginning-of-period</u>	128,531,000	388,325,000	295,363,000
<u>Cash and cash equivalents and restricted cash as of end-of-period</u>	\$	\$	\$
	361,581,000	128,531,000	388,325,000

## Organization

**12 Months Ended  
Dec. 31, 2020**

### Organization, Consolidation and Presentation of Financial Statements

#### [Abstract]

#### Organization

#### Organization

Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations as well as health plans to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. The Company operates through two segments.

The Company's Services segment ("Services") includes clinical and administrative solutions designed to help our partners manage and administer patient health in a more cost-effective manner. We have two clinical solutions: (i) total cost of care management and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one type of solution, or multiple types of solutions, depending on specific needs. True Health is our second segment. True Health is a physician led health plan offering individual, small group, large group, ASO and Federal Employee Health Benefit health insurance products to New Mexico consumers.

Since its inception, the Company has incurred losses from operations. As of December 31, 2020, the Company had unrestricted cash and cash equivalents of \$340.5 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.

The Company's headquarters is located in Arlington, Virginia.

#### *Evolent Health LLC Governance*

Our operations are conducted through Evolent Health LLC and subsequent to the offering reorganization at the time of our initial public offering (the "Offering Reorganization"), the financial results of Evolent Health LLC were consolidated in the financial statements of Evolent Health, Inc. Evolent Health, Inc. is a holding company whose only business is to act as sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC's business and affairs and is responsible for the management of its business.

#### *Issuances of Common Units*

Evolent Health LLC may only issue Class A common units to us, as the sole managing member of Evolent Health LLC. Class B common units may be issued only to persons or entities we permit. Such issuances of Class B common units shall be made in exchange for cash or other consideration. Class B common units may not be transferred as Class B common units except to certain permitted transferees and in accordance with the restrictions on transfer set forth in the third amended and restated operating agreement of Evolent Health LLC. Any such transfer must be accompanied by

the transfer of an equal number of shares of our Class B common stock. As of December 31, 2020 and 2019, there are no Class B common units outstanding.



**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle**

**12 Months Ended**

**Dec. 31, 2020**

[Accounting Policies](#)

[\[Abstract\]](#)

[Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle](#)

**Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles**  
**Basis of Presentation**

The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the Company and its subsidiaries.

**Summary of Significant Accounting Policies**

Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.

*Accounting Estimates and Assumptions*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets, liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, we use estimates for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, useful lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, taxable stock transactions and useful lives of intangible assets.

*Principles of Consolidation*

The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

*Operating Segments*

Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available and is regularly evaluated, on a regular basis, by the chief operating decision maker ("CODM") to decide how to allocate resources and assess performance. The Company has two segments: (1) Services, and (2) True Health. Our Services segment consists of two clinical solutions: (i) total cost of care services and (ii) comprehensive health plan administration services, and one administrative solution: comprehensive health plan administration services. Our True Health segment consists of a commercial health plan in New Mexico that historically focused on small and large businesses. In 2020, True Health diversified its services to offer coverage for individuals through the Federal Employee Health Benefits Program. Refer to Note 21 for a discussion of our operating results by segment and Note 26 for a discussion of our operating segments.

*Cash and Cash Equivalents*

We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all cash and cash equivalents as deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at cost, which approximates cost.

*Restricted Cash and Restricted Investments*

Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:

	December 31,	
	2020	2019
Collateral for letters of credit for facility leases <sup>(1)</sup>	\$ 3,510	\$ 3,610
Collateral with financial institutions <sup>(2)</sup>	4,743	5,742
Claims processing services <sup>(3)</sup>	12,127	18,171
Other	1,327	817
<b>Total restricted cash and restricted investments</b>	<b>\$ 21,707</b>	<b>\$ 28,340</b>
Current restricted investments	\$ —	\$ 704
Current restricted cash	14,437	19,376
<b>Total current restricted cash and restricted investments</b>	<b>\$ 14,437</b>	<b>\$ 20,080</b>
Non-current restricted investments	\$ 616	\$ 113
Non-current restricted cash	6,654	8,147
<b>Total non-current restricted cash and restricted investments</b>	<b>\$ 7,270</b>	<b>\$ 8,260</b>

<sup>(1)</sup> Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments.

<sup>(2)</sup> Represents collateral held with financial institutions for risk-sharing and other arrangements. As of both December 31, 2020 and December 31, 2019, approximately \$4.7 million held in a FDIC participating bank account. As December 31, 2019, approximately \$1.0 million, of the collateral amount was held in a trust account and invested in money market arrangements. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 18 for discussion of fair value for discussion of our risk-sharing arrangements.

<sup>(3)</sup> Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period until the claims are processed.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that reconcile to the amounts shown in the consolidated statements of cash flows (in thousands).

	As of December 31,	
	2020	2019
Cash and cash equivalents	\$ 340,490	\$ 101,008
Restricted cash and restricted investments	21,707	28,340
Restricted investments included in restricted cash and restricted investments	(616)	(817)
<b>Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</b>	<b>\$ 361,581</b>	<b>\$ 128,531</b>

#### *Accounts Receivable and Allowances*

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make provisions for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the aging of receivables, credit balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.

#### *Property and Equipment, Net*

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is calculated using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives:

Computer hardware	
Computer software	
Furniture and equipment	
Internal-use software development costs	
Leasehold improvements	Shorter of useful life or remaining lease term

When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is reported in the disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).

We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount exceeds the fair value less costs to sell.

asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of the asset group exceeds its fair value.

#### *Software Development Costs*

The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation, employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the development stage – when the research stage is complete and management has committed to a project to develop software that will be used for internal purposes. Costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their useful life and begin once the project is substantially complete and the software is ready for its intended purpose.

#### *Research and Development Costs*

Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on technologies that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are included within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were \$15.5 million, \$18.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

#### *Notes Receivable*

Notes receivable are carried at the face amount of each note plus accrued interest receivable, less received payments and net of allowances. The Company does not carry notes receivable in the course of its regular business, but contributed \$40.0 million in the form of an advance for regulatory capital requirements for EVH Passport/UHC during the second quarter of 2019. Refer to Note 4 for a discussion of our Passport Note.

#### *Business Combinations*

Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair value at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. Actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term operating expenses, cost of capital, and appropriate discount rates.

The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recognized as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about the fair value of the assets acquired and liabilities assumed that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may adjust the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss).

For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the carrying amount to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized in earnings as an expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.

#### *Equity Method Investments*

For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for its investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of the investee's net income or loss in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its equity method investments accounted for under the equity method. These investments are included in investments in and advances to equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).

#### *Impairment of Equity Method Investments*

The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other-than-temporary. Other-than-temporary impairment of equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may determine if there is other-than-temporary impairment of equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. These factors include the duration and extent of the impairment and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current expectations. Refer to Note 16 for additional discussion regarding impairments on equity method investments.

### *Goodwill*

We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable intangible assets as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other factors. We perform impairment tests of goodwill at a reporting unit level. The Company has four reporting units and our annual goodwill impairment tests are performed in the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would reduce the fair value of a reporting unit below its carrying amount.

Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to believe it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further testing is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the fair value. The charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 8 for additional information regarding goodwill impairment tests conducted during 2020 and 2019.

### *Intangible Assets, Net*

Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used.

The following summarizes the estimated useful lives by asset classification:

Corporate trade name	10 - 20 years
Customer relationships	10 - 25 years
Technology	5 years
Provider network contracts	4 - 5 years

Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset's carrying value. Impairment is determined by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group of assets are sufficient to recover the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.

### *Reserves for Claims and Performance-based Arrangements*

Reserves for performance-based arrangements and claims for our Services and True Health segments reflect estimates of payments under performance-based contracts and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other expenses for medical care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under reinsurance agreements for 2019 as discussed further in Note 10. The reinsurance agreement was terminated in December 2019. The Company uses actuarial principles and assumptions consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse conditions. The margin is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. Such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations. Changes in estimates are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.

### *Long-term Debt*

Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Interest is paid due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 9 for further information regarding convertible notes and credit agreement.

### *Leases*

As discussed in Note 3, we adopted Accounting Standards Update ("ASU") 2016-02, *Leases*, effective January 1, 2019. The following reflects our adoption of ASU 2016-02. The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of a contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines

are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statement of comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement of the lease term in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single lease component for all classes of underlying assets.

The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is reported in the consolidated statement of comprehensive income (loss) over the terms of the respective leases.

Refer to Note 11 for additional lease disclosures.

#### *Revenue Recognition*

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, in order to clarify the principles of recognizing revenue. The standard is effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application.

Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services include implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients. Platform and operations services generally include multi-year arrangements with customers to provide various population health services, operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers. Revenue is recognized when control of the services is transferred to our customers.

We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, *Revenue from Contracts with Customers*, to determine revenue recognition for our Services segment from our contracts with customers:

- Identify the contract(s) with a customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to performance obligations
- Recognize revenue when (or as) the entity satisfies a performance obligation

Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derives revenue from reinsurance premiums assumed from NMHC under the terms of the reinsurance agreement (as defined in Note 10). The portion of premiums that are earned but not received or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as liabilities on our consolidated balance sheets.

#### *Cost of Revenue (Exclusive of Depreciation and Amortization)*

Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of salaries and benefits (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. Our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenses and other arrangements.

#### *Claims Expenses*

Our claims expenses consist of the direct medical expenses incurred by our True Health segment. Claims expenses are recognized in the period in which the claims are incurred and include amounts that have been paid by us through the reporting date, as well as estimated medical claims and benefits payable for costs that have not yet been paid by us as of the reporting date. Claims expenses include, among other items, fee-for-service claims, pharmacy benefits, various other related medical expenses and amounts related to our reinsurance agreement. We use judgment to determine the appropriate assumptions for determining the required estimates.

#### *Stock-based Compensation*

The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employees of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.

We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using the Black-Scholes valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel costs for the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.

### *Income Taxes*

Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance should be recorded, and so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and amount of tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and the strategies we would employ to avoid a tax benefit from expiring unused.

We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions that are not reflected in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We also recognize and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2020 and 2019, the amount of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.

We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and was subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. Following the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity owned from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company's federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporations that are subject to U.S. and foreign taxes with respect to their own operations during 2019.

### *Earnings (Loss) per Share*

Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.

For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of all potentially dilutive common shares, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards. For periods of net loss, the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent potentially dilutive shares would be anti-dilutive.

### *Fair Value Measurement*

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market as of the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted stock awards, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.

See Note 18 for further discussion regarding fair value measurement.

### *Foreign Currency*

The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. For the years ended December 31, 2020 and 2018, translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2020 and 2018.

[Accounting Policies](#)

[\[Abstract\]](#)

[Recently Issued Accounting  
Standards](#)

Recently Issued Accounting Standards  
**Adoption of New Accounting Standards**

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, *Leases*, in order to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases, including a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in ASC 606. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) transition method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective on the same date as the requirements of ASU 2016-02. We adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. Further, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of additional right-of-use assets and lease liabilities of approximately \$51.4 million and \$47.4 million, respectively, on our consolidated balance sheet as of January 1, 2019. The standard had no impact on our results of operations.

In August 2018, the FASB issued ASU 2018-15, *Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Services Contract*. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted the requirements of ASU 2018-15 effective January 1, 2019. There was no material impact to our consolidated balance sheets or results of operations as of or for the year ended December 31, 2019.

In July 2019, the FASB issued ASU 2019-07, *Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update)*. ASU 2019-07 clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. The disclosure and presentation amendments included in ASU 2019-07, which were effective upon issuance of the standard and were to be applied prospectively, did not have a material impact on our consolidated financial statements and related disclosures.



In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing “incurred loss” framework with an expected credit loss recognition model. The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts. The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of \$3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of ASU 2016-13, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance. In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach. For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 6 for additional disclosures related to current expected credit losses.

In August 2018, the FASB issued ASU 2018-13, *Changes to the Disclosure Requirements for Fair Value Measurement*. ASU 2018-13 amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosures. This ASU is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. We adopted the requirements of this standard effective January 1, 2020 and determined it did not have a material impact on our consolidated financial statements and related disclosures.



## Transactions

12 Months Ended  
Dec. 31, 2020

### [Business Combinations](#)

#### [\[Abstract\]](#)

#### [Transactions](#)

#### Transactions

##### *Passport*

On May 28, 2019, UHC, Passport Health Solutions, LLC (“PHS I”), the Company and EVH Passport entered into an Asset Purchase Agreement which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC’s Kentucky Medicaid contract (the “Passport Medicaid Contract”) to EVH Passport for a purchase price of \$70.0 million in cash and the issuance of a 30% interest in EVH Passport (the “Passport Purchase Price”) to The University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville Primary Care Association (collectively, the “Sponsors”).

On June 18, 2019, the Company contributed \$40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement (the “Passport Note”). The Passport Note carried a fixed interest rate of 6.5% per annum. Additionally, on June 6, 2019, the Company and UHC entered into an “Indemnity Agreement”, with an insurance company (the “Surety”). The Surety issued a performance bond in the amount of \$25.0 million to UHC under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond’s original expiry date was June 30, 2020 and during the term of the bond, the bond, was extended to December 31, 2020. The bond was released in October 2020.

On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the “Passport Closing”). \$16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain assets and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the assumption of the financial risks by EVH Passport of UHC’s dual eligible special needs business (the “DNP Business”) until such time as EVH Passport becomes a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred to EVH Passport. At the Passport Closing, EVH Passport assumed UHC’s obligations under the Passport Note and the Indemnity Agreement.

On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (“Molina”) entered into an Asset Purchase Agreement (the “Molina Closing”) which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the “Molina Closing”). The Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, EVH Passport received \$20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina’s Kentucky Medicaid Contract becomes a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method. As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a wholly owned subsidiary of the Company. Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the Molina Closing met the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company’s consolidated financial statements, on July 16, 2020, EVH Passport redeemed the Sponsors’ equity interests in EVH Passport for \$20.0 million in cash in accordance with the terms of the Passport APA, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.

As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of \$88.6 million, receivables related to unsettled sales of securities of \$43.0 million and other assets of \$50.2 million and liabilities comprised of reserve for claims and performance-based arrangements of \$164.8 million and accrued liabilities of \$50.0 million. Subsequent to the consolidation, the remaining cash will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance. In addition, the Passport Note was repaid upon consolidation, and as of December 31, 2020, the outstanding principal balance of the \$40.0 million Passport Note was repaid in full by the Company, plus approximately \$3.6 million of accrued interest.

#### **Gain (Loss) on Disposal of Assets and Consolidation**

On September 1, 2020, as a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a wholly owned subsidiary of the Company and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements and recorded a \$5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.

During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary for a net amount of \$6.4 million in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have a continuing involvement with the entity after the consummation of this transaction.

## Securities Offerings and Sales

Under exchange agreements we entered into at the time of our IPO and as part of the New Century Health acquisition, we granted TPG, The Advisory Board”) and Ptolemy Capital, LLC (together, the “Investor Stockholders”) and certain former owners of New Century Health (the “New Members”) an exchange right that allows receipt of newly issued shares of the Company’s Class A common stock in exchange (a “Class B Exchange”) of shares of the Company’s Class B common stock (which are subsequently canceled) and an equal number of Evolent Health LLC’s Class B common stock. Under the terms of the exchange agreements, Class B units received by the Company from relevant Investor Stockholders and New Century Health were simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC canceled the Class B units. On December 27, 2019, the cancellation of the remaining Class B units results in an increase in the Company’s economic interest in Evolent Health LLC.

### Repositioning and Other Changes

We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to invest in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a major portion of our business, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we engaged a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in future periods.

In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these goals (the “Repositioning Plan”). These actions included making organizational changes across our Services segment as well as other profitability initiatives expected to result in the re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to be completed in the first quarter of 2021.

The Company recorded approximately \$1.3 million of repositioning costs in selling, general and administrative expenses during the year ended December 31, 2020, in connection with the Repositioning Plan. The following tables provide a summary of our total costs associated with the Repositioning Plan for the year ended December 31, 2020, by major type of cost:

	<b>Incurred For the Year Ended December 31, 2020</b>	<b>Total Amount Expected to be Incurred in the Repositioning Plan</b>	<b>Cumulative through</b>
Severance and termination benefits	\$ —	\$ 2,500	\$ —
Office space consolidation	—	2,100	—
Professional services	1,275	4,200	—
Total	<u>\$ 1,275</u>	<u>\$ 8,800</u>	<u>\$ —</u>

## Revenue Recognition

12 Months Ended  
Dec. 31, 2020

### [Revenue from Contract with Customer \[Abstract\]](#) [Revenue Recognition](#)

#### Revenue Recognition

Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services.

##### *Transformation Services Revenue*

Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.

##### *Platform and Operations Services Revenue*

Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. Our clinical solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services; our administrative solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services. Contracts to provide these services may be developed on an integrated basis. For purposes of revenue disaggregation, we classify contracts including both clinical and administrative solutions into the category corresponding to the majority of services provided under those contracts.

Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.

##### *Contracts with Multiple Performance Obligations*

Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.

##### *Principal vs. Agent*

We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.

#### **Disaggregation of Revenue**

The following table represents Evolent's Services segment revenue disaggregated by type of services (in thousands), excluding revenues from our health plan operations, which include the True Health segment and EVH Passport, and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, *Financial Services-Insurance*.

	For the Year Ended December 31,		
	2020	2019	2018
<b>Services Revenue</b>			
Transformation services	\$ 11,990	\$ 15,203	\$ 32,916
Platform and operations services			
Clinical solutions	690,391	458,991	228,464
Administrative solutions	202,547	198,618	264,104

#### **Transaction Price Allocated to the Remaining Performance Obligations**

For contracts with a term greater than one year, we have allocated approximately \$87.8 million of transaction price to performance obligations that are unsatisfied as of December 31, 2020. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 54% and 86% of these remaining performance obligations by December 31, 2021, and December 31, 2022, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.

### Contract Balances

Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within contract assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.

Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets, and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.

The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):

	December 31, 2020	December 31, 2019
Short-term receivables <sup>(1)</sup>	\$ 122,167	\$ 71,707
Long-term receivables <sup>(1)</sup>	4,554	709
Short-term contract assets	329	1,751
Long-term contract assets	—	999
Short-term deferred revenue	14,327	19,828
Long-term deferred revenue	3,593	1,330

<sup>(1)</sup> Excludes pharmacy claims receivable and premiums receivable

Changes in contract assets and deferred revenue for the year ended December 31, 2020 are as follows (in thousands):

<b>Contract assets</b>		
Balance as of beginning-of-period	\$	2,750
Reclassification to receivables, as the right to consideration becomes unconditional		(2,539)
Contract assets recognized, net of reclassification to receivables		118
Balance as of end-of-period	\$	329
<b>Deferred revenue</b>		
Balance as of beginning-of-period	\$	21,158
Reclassification to revenue, as a result of performance obligations satisfied		(18,481)
Cash received in advance of satisfaction of performance obligations		15,243
Balance as of end-of-period	\$	17,920

The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in previous period was \$12.1 million and \$1.1 million during the years ended December 31, 2020, and 2019, respectively, due primarily to net gain share as well as changes in other estimates.

### Contract Cost Assets

Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2020 and 2019, the Company had \$3.3 million and \$4.7 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of \$1.9 million, \$1.0 million and \$0.3 million for the years ended December 31, 2020, 2019 and 2018, respectively.

In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December 31, 2020 and 2019, the Company had \$23.4 million and \$31.8 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of \$13.0 million, \$4.7 million and \$2.4 million for the years ended December 31, 2020, 2019 and 2018, respectively.

These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.

## Credit Losses

[Credit Loss \[Abstract\]](#)  
[Credit Losses](#)

12 Months Ended  
 Dec. 31, 2020

### Credit Losses

We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts of the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions of the COVID-19 pandemic on our customers' and other third parties' ability to pay. We did not observe notable increases in delinquencies during 2020. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, and our forecasted economic conditions during the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2020.

#### Accounts Receivable from Revenue Transactions

Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivable are included within accounts receivable, net on the Company's consolidated balance sheets, while non-current accounts receivables are classified within non-current assets on the Company's consolidated balance sheets.

We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. We perform account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. We will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due buckets based on the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then compared to current conditions and reasonable and supportable forecasts.

Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets at December 31, 2020, 59% were less than 60 days, with 37% past due less than 120 days. At December 31, 2020, we reported \$173.7 million of accounts receivable, certain non-trade accounts receivable included in prepaids and other assets on the consolidated balance sheet and contract assets, net of allowances of \$7.1 million. The following table summarizes the allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2020.

Balance as of December 31, 2019

Passport acquisition

Cumulative transition adjustment

Provision for credit losses

Charge-offs

Balance as of December 31, 2020

#### Investments Held at Amortized Cost

True Health invests in certain debt securities which are classified as held-to-maturity in Evolent's consolidated financial statements because True Health, a wholly owned subsidiary, has the intent and ability to hold the securities until their individual maturities. True Health invests in debt securities pursuant to its investment policy governing the nature and type of investments based on the Company's business strategy, risk tolerance, and investment objectives.

The amortized cost of our investments as of December 31, 2020 and 2019 and interest income for the years ended December 31, 2020 and 2019 were as follows:

	Amortized Cost		Interest Income
	December 31, 2020	December 31, 2019	
U.S. Treasury bills	\$ 8,909	\$ 10,784	\$
Corporate bonds	1,707	1,705	
Collateralized mortgage obligations	3,433	5,472	
Corporate stock	130	—	
Yankees	598	597	
Total investments	\$ 14,777	\$ 18,558	\$

The Company reviewed its held-to-maturity investments to determine which types of securities have zero risk of credit loss because payments are guaranteed. Based on this analysis, the Company determined that the expected credit losses on U.S. Treasury bills and mortgage backed securities from government sponsored enterprises ("GSE") is zero. The expected credit losses on non-GSE backed securities is considered immaterial.

As of December 31, 2020 and 2019, all of the Company's held-to-maturity investments were rated investment-grade or better and all payments current.

**Property and Equipment,  
Net**

**12 Months Ended  
Dec. 31, 2020**

[Property, Plant and  
Equipment \[Abstract\]](#)

[Property and Equipment, Net](#)

Property and Equipment, Net

The following summarizes our property and equipment (in thousands):

	December 31,	
	2020	2019
Computer hardware	\$ 18,866	\$ 11,604
Furniture and equipment	3,559	3,649
Internal-use software development costs	137,085	112,501
Leasehold improvements	15,586	12,415
Total property and equipment	175,096	140,169
Accumulated depreciation and amortization expenses	(88,856)	(55,014)
Total property and equipment, net	\$ 86,240	\$ 85,155

The Company capitalized \$24.6 million, \$30.9 million and \$33.1 million of internal-use software development costs for the years ended December 31, 2020, 2019 and 2018, respectively. The net book value of capitalized internal-use software development costs was \$75.3 million and \$74.9 million as of December 31, 2020 and 2019, respectively.

Depreciation expense related to property and equipment was \$28.3 million, \$23.3 million and \$17.3 million for the years ended December 31, 2020, 2019 and 2018, respectively, of which amortization expense related to capitalized internal-use software development costs was \$24.3 million, \$18.7 million and \$12.4 million, respectively.



**Goodwill and Intangible  
Assets, Net**

**12 Months Ended  
Dec. 31, 2020**

[Goodwill and Intangible  
Assets Disclosure \[Abstract\]](#)

[Goodwill and Intangible  
Assets, Net](#)

Goodwill and Intangible Assets, Net

*Goodwill*

Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

The Company has four reporting units, each with discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a goodwill impairment analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies.

Our annual goodwill impairment review occurs during the fourth quarter of each fiscal year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.

*2019 Goodwill Impairment Test*

During the second half of 2019, the price of our Class A common stock declined significantly. The average closing price per share of our Class A common stock for the period from May 1 to October 31 decreased by \$6.59 per common share, or 43.5%, compared to the average closing price for the period from January 1 to April 30. At the time of our 2019 annual goodwill impairment test, it was not known if UHC/EVH Passport would be awarded a contract under the RFP, which was expected to begin on January 1, 2021. If it was not awarded a contract, it was expected that we would not receive any material revenue under our management services agreement from EVH Passport subsequent to December 31, 2020 and the value of our investment in EVH Passport and goodwill would be negatively impacted. The non-renewal of EVH Passport's Medicaid contract would reduce our medium-term cash flow projections for one of our reporting units, causing the decline in our stock price to possibly be further prolonged, indicating it was more likely than not that the fair value of the reporting units is less than the reporting unit's carrying amounts, triggering an interim quantitative assessment.

In performing our October 31, 2019 annual goodwill impairment test, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach ("income approach"). In determining the estimated fair value using the income approach, we projected future cash flows based on management's estimates and long-term plans and applied a discount rate based on the Company's weighted average cost of capital. This analysis required us to make judgments, including about revenues, expenses, fixed asset and working capital requirements, the timing of exchanges of our Class B common shares, capital market assumptions, cash flows, the probability of the Kentucky Medicaid RFP outcome and discount rates. The fair values determined by the income approach were weighted considering future resolution of the Kentucky Medicaid RFP result to determine the concluded fair value for each reporting unit.

As of October 31, 2019, we determined that one of our three reporting units in the Services segment had an estimated fair value less than its carrying value. As a result, we recorded a non-cash goodwill impairment charge of \$199.8 million in goodwill impairment on our consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2019. If other indications of impairment exist we may be required to recognize additional impairments in the future as a result of market conditions or other factors related to our performance, including changes in our forecasted results, investment strategy, interest rates or assumptions used as part of the goodwill impairment analysis. Any further impairment charges that we may record in the future could be material to our results of operations. As of December 31 2019, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge for the year ended December 31, 2019 was \$431.7 million.

*2020 Goodwill Impairment Test*

As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units' carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company's Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019.

During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of one of its three reporting units in the Services segment was less than the reporting unit's carrying amount triggering an interim quantitative assessment.

In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach ("income approach"). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management's estimates and long-term plans and applied a discount rate based on the Company's weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.

As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value. As a result, we recorded a non-cash goodwill impairment charge of \$215.1 million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020.

During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020.

During the Company's annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of \$199.8 million and \$215.1 million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in one of our three reporting units in the Services segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required.

In performing our October 31, 2020 impairment test for one of the three reporting units in the Services segment, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach ("income approach"). In determining the estimated fair value using the income approach, we projected future cash flows based on management's estimates and long-term plans and applied a discount rate based on the Company's weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that one of our three reporting units in the Services segment had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.

As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit's carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was \$214.3 million.

The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):

	Services	True Health	Consolidated
Balance as of December 31, 2018	\$ 762,419	\$ 5,705	\$ 768,124
Goodwill acquired	3,416	—	3,416
Measurement period adjustments	351	—	351
Impairment	(199,800)	—	(199,800)
Foreign currency translation	(27)	—	(27)
Balance as of December 31, 2019 <sup>(1)</sup>	566,359	5,705	572,064
Goodwill disposal <sup>(2)</sup>	(2,200)	—	(2,200)
Impairment	(215,100)	—	(215,100)
Foreign currency translation	(30)	—	(30)
Balance as of December 31, 2020 <sup>(1)</sup>	\$ 349,029	\$ 5,705	\$ 354,734

<sup>(1)</sup> Net of cumulative inception to date impairment of \$575.5 million and \$360.4 million as of December 31, 2020 and 2019, respectively.

<sup>(2)</sup> Goodwill written-off upon disposal of a consolidated subsidiary.

### Intangible Assets, Net

Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:

	As of December 31, 2020				As of December 31, 2019			
	Weighted-Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Value	Weighted-Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Value
Corporate trade name	13.2	\$ 23,300	\$ 6,271	\$ 17,029	14.2	\$ 23,300	\$ 4,891	\$ 18,409
Customer relationships	16.1	281,219	58,256	222,963	16.8	291,519	44,750	246,769
Technology	1.8	82,922	63,507	19,415	2.0	82,922	49,760	33,162
Below market lease, net	2.3	1,118	648	470	2.2	2,048	1,334	714
Provider network contracts	2.8	14,475	6,280	8,195	3.7	12,725	3,320	9,405
Total intangible assets, net		<u>\$ 403,034</u>	<u>\$ 134,962</u>	<u>\$ 268,072</u>		<u>\$ 412,514</u>	<u>\$ 104,055</u>	<u>\$ 308,459</u>

Amortization expense related to intangible assets for the years ended December 31, 2020, 2019 and 2018, was \$32.9 million, \$37.7 million, and \$27.2 million, respectively.

Future estimated amortization of intangible assets (in thousands) as of December 31, 2020, is as follows:

2021	\$ 28,701
2022	24,819
2023	22,055
2024	16,171
2025	15,916
Thereafter	160,410
Total future amortization of intangible assets	<u>\$ 268,072</u>

Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets' carrying value. We did not identify any circumstances during the year ended December 31, 2020, that would require an impairment test for our intangible assets.

## Long-term Debt

12 Months Ended  
Dec. 31, 2020

[Debt Disclosure \[Abstract\]](#)

[Long-term Debt](#)

### Long-term Debt

#### *2024 Notes*

In August 2020, the Company issued \$117.1 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the "2024 Notes") in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued \$84.2 million aggregate principal amount of 2024 Notes in exchange for \$84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of \$2.5 million, and issued \$32.8 million aggregate principal amount of New Notes for cash at par. We incurred \$3.0 million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.

Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company's Class A common stock. We recorded interest expense of \$1.5 million for the year ended December 31, 2020.

The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per \$1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately \$18.23 per share of the Company's Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4 million shares of the Company's Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election.

The option to settle the 2024 Notes in cash or shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be \$78.9 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be \$38.1 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of \$1.7 million and \$1.3 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of \$38.1 million, \$1.7 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the year ended December 31, 2020, the Company recorded \$2.7 million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.

Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company's Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

#### *Credit Agreement*

On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the "Borrower"), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the "Credit Agreement"), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of \$75.0 million (the "Initial Term Loan Facility") and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to \$50.0 million (the "DDTL Facility" and, together with the Initial Term Loan Facility, the "Senior Credit Facilities"), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December

30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company's domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions.

The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company's satisfaction of specified conditions, to finance the repayment or repurchase of the Company's 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the "Maturity Date"). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. The Company recorded \$8.0 million in interest expense related to our Credit Agreement for the year ended December 31, 2020.

Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.

The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred \$4.7 million of debt issuance costs in connection with this Credit Agreement, which will be included in long-term debt, net of discount on our consolidated balance sheets and will be amortized into interest expense over the life of the agreement. For the year ended December 31, 2020, the Company recorded \$2.2 million in interest expense related to the amortization of the debt discount and the issuance costs.

On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.

The Company was in compliance with all applicable covenants as of December 31, 2020.

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. Refer to Note 26 for additional information about the repayment of the Credit Agreement.

#### *Warrant Agreement*

In conjunction with the Company's entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to \$8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement. The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.

On January 8, 2021, the Company settled all amounts under the warrant agreements with Ares Capital Corporation. Refer to Note 26 for additional information about the settlement of the warrant agreements.

#### *2025 Notes*

In October 2018, the Company issued \$172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the “2025 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The 2025 Notes were issued at par for net proceeds of \$166.6 million. We incurred \$5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of \$150.0 million aggregate principal amount of the 2025 Notes occurred on October 22, 2018, and the Company completed the offering and sale of an additional \$22.5 million aggregate principal amount of the 2025 Notes on October 24, 2018, pursuant to the initial purchasers’ exercise in full of their option to purchase additional notes.

Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on April 15 and October 15 of each year, beginning on April 15, 2019, at a rate equal to 1.50% per annum. The Company recorded interest expense of \$2.6 million, \$2.6 million and \$0.5 million related to the 2025 Notes for the years ended December 31, 2020, 2019, and 2018, respectively. The 2025 Notes will mature on October 15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.

Prior to the close of business on the business day immediately preceding April 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October 22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April 15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.

The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per \$1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately \$33.43 per share of the Company’s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company’s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election.

The option to settle the 2025 Notes in cash or shares of the Company’s Class A common stock, or a combination of cash and shares of the Company’s Class A common stock, at the Company’s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be \$100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be \$71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of \$3.4 million and \$2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of \$71.8 million, \$3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. For the years ended December 31, 2020, 2019 and 2018, the Company recorded \$9.2 million, \$8.5 million and \$1.5 million, respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.

Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October 20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October 20, 2022, if the last reported sale price of the Company’s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

#### *2021 Notes*

In December 2016, the Company issued \$125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the “2021 Notes”) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of \$120.4 million. We incurred \$4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December 5, 2016.

Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June 1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes will mature on December 1, 2021, unless

earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase all or part of their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental repurchase date. Upon maturity the principal amount of the notes may be settled via shares of the Company's Class A common stock. We recorded interest expense of \$1.7 million \$2.5 million and \$2.5 million for each of the years ended December 31, 2020, 2019 and 2018, respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of \$0.6 million, \$0.9 million and \$0.9 million for each of the years ended December 31, 2020, 2019 and 2018, respectively.

The 2021 Notes are convertible into shares of the Company's Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per \$1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately \$24.03 per share of the Company's Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company's Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture). The conversion rate may be adjusted under certain circumstances.

The 2021 Notes are convertible, in multiples of \$1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each \$1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date.

In August 2020, as part of the issuance of the 2024 Notes, the Company issued \$84.2 million aggregate principal amount of the 2024 Notes in exchange for \$84.2 million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of \$2.5 million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of \$4.8 million, including an aggregate cash payment of \$2.5 million paid to exchanging noteholders.

In August 2020, we also repurchased \$14.0 million of the 2021 Notes with \$13.9 million of cash and recorded an immaterial gain on extinguishment of debt.

#### *Convertible Senior Notes Carrying Value*

The 2025 Notes, 2024 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December 31, 2020. However, the 2025 Notes, 2024 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes, 2024 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt (in thousands):



	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>2024 Notes</b>		
Carrying value	\$ 81,462	\$ —
Unamortized debt discount and issuance costs	35,589	—
Principal amount	<u>\$ 117,051</u>	<u>\$ —</u>
Remaining amortization period (years)	3.9	
Fair value	<u>\$ 153,220</u>	<u>\$ —</u>
<b>2025 Notes</b>		
Carrying value	\$ 116,349	\$ 107,169
Unamortized debt discount and issuance costs	56,151	65,331
Principal amount	<u>\$ 172,500</u>	<u>\$ 172,500</u>
Remaining amortization period (years)	4.8	5.8
Fair value	<u>\$ 147,488</u>	<u>\$ 122,048</u>
<b>2021 Notes</b>		
Carrying value	\$ 26,557	\$ 123,237
Unamortized issuance costs	180	1,763
Principal amount	<u>\$ 26,737</u>	<u>\$ 125,000</u>
Remaining amortization period (years)	0.9	1.9
Fair value	<u>\$ 26,470</u>	<u>\$ 111,250</u>



## Commitments and Contingencies

12 Months Ended  
Dec. 31, 2020

### [Commitments and Contingencies Disclosure](#)

#### [\[Abstract\]](#)

#### [Commitments and Contingencies](#)

#### Commitments and Contingencies

##### Commitments

##### *Commitments to Equity-Method Investees*

During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period. As a result of EVH Passport not being awarded a new Medicaid contract with CHFS, the Company acquired the Sponsors' 30% ownership interest in EVH Passport for \$20.0 million during the three months ended December 31, 2020. Refer to Note 4 for additional information about the Passport transaction.

##### *Letters of Credit*

During the second quarter of 2020, the Company established an irrevocable standby letter of credit with a bank for \$5.0 million for the benefit of a regulatory authority. The letter of credit expired during the fourth quarter of 2020.

During the third quarter of 2019, the Company established an irrevocable standby letter of credit with a bank for \$1.8 million for the benefit of a regulatory authority and, as such, held \$1.8 million in restricted cash and restricted investments as collateral as of both December 31, 2020 and December 31, 2019, respectively. The original letter of credit expired on December 31, 2019 and was automatically extended without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date, unless the bank elects not to extend beyond the initial or any extended expiry date.

##### *Indemnifications*

The Company's customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.

During the second quarter of 2019, the Company and UHC, a then current customer (collectively the "Indemnitors"), pursuant to a state requirement of all participating Medicaid Managed Care Organizations, entered into an indemnity agreement with a surety. The surety issued a performance bond in the amount of \$25.0 million to secure the customer's performance under a contract to provide Medicaid managed care services for the benefit of a beneficiary. Pursuant to the indemnity agreement, the Indemnitors are jointly and severally liable to the surety in the maximum amount of the bond, plus certain costs of the surety, in the event of losses arising under the bond. The bond's effective date is July 1, 2019, and original expiry date was June 30, 2020. During the three months June 30, 2020, the expiry date was extended to December 31, 2020 and the bond was released in October 2020. To date, the Company has not incurred any material costs as a result of the Indemnity Agreement and has not accrued any liabilities related to it in the accompanying consolidated financial statements.

##### *Pre-IPO Investor Registration Rights Agreement*

We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.

We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the year ended December 31, 2020, 2019 and 2018, respectively.

### *Guarantees*

In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (“KY DOI”) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations.

As part of our strategy to support certain of our partners in the Next Generation Accountable Care Program, we entered into upside and downside risk-sharing arrangements. Our downside risk-sharing arrangements are limited to our fees and are executed through our wholly-owned captive insurance company. To satisfy the capital requirements of our captive insurance entity as well as state insurance regulators, the Company entered into letters of credit of \$4.7 million and \$5.7 million as of December 31, 2020 and December 31, 2019, respectively, to secure potential losses related to insurance services. These amounts are in excess of our actuarial assessment of loss.

During 2020, the Company entered into a guarantee agreement with the KY DOI whereby it agreed to provide support on behalf of EVH Passport to maintain a minimum risk-based-capital of 150%. The maximum exposure is limited to amounts funded to return EVH Passport to a risk-based-capital of 150%, however as of December 31, 2020, no amounts have been funded under this guarantee.

### *Reinsurance Agreements*

At the Passport Closing, \$16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.

At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina’s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina.

During the fourth quarter of 2017, the Company entered into a \$10.0 million capital-only reinsurance agreement with NMHC which expired on December 31, 2018. The purpose of the capital-only reinsurance was to provide balance sheet support to NMHC. There was no uncertainty to the outcome of the agreement as there was no transfer of underwriting risk to Evolent or True Health, and neither Evolent nor True Health was at risk for any cash payments on behalf of NMHC. As a result, this agreement did not qualify for reinsurance accounting.

During the fourth quarter of 2018, the Company terminated its prior reinsurance agreement with NMHC and entered into a 15-month quota-share reinsurance agreement with NMHC. Under the terms of the new reinsurance agreement, NMHC ceded 90% of its gross premiums to the Company and the Company indemnified NMHC for 90% of its claims liability. The maximum amount of exposure to the Company was capped at 105% of premiums ceded to the Company by NMHC. The new reinsurance agreement qualified for reinsurance accounting due to the deemed risk transfer and, as such, the Company recorded the full amount of the gross reinsurance premiums and claims assumed by the Company within premiums and claims expenses, respectively, and recorded claims-related administrative expenses within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) from the legal effective date of the Reinsurance Agreement. Amounts owed to NMHC under the reinsurance agreement are recorded within reserves for claims and performance-based arrangements on our consolidated balance sheets. Amounts owed by NMHC under the reinsurance agreement are recorded within accounts receivable, net on our consolidated balance sheets.

During the third quarter of 2019, the Company terminated the new reinsurance agreement with NMHC effective in the fourth quarter of 2019, approximately one and a half months prior to its scheduled end.

The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Reinsurance premiums assumed	\$ 19,130	\$ 83,325	\$ 3,242
Reinsurance premiums ceded	(3,275)	—	—
Claims assumed	14,812	72,594	3,934
Claims ceded	(422)	—	—
Claims-related administrative expenses	—	14,024	551
Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement	1,465	(3,293)	(1,243)
Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period	—	1,243	—
Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement	(502)	—	—
Reinsurance payments paid (received)	(3,039)	4,536	—
Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period	<u>\$ 4,002</u>	<u>\$ —</u>	<u>\$ 1,243</u>

#### *UPMC Reseller Agreement*

The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the “UPMC Reseller Agreement”). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company’s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company’s customers.

#### **Contingencies**

##### *Tax Receivables Agreement*

In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the “TRA”) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs.

Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company’s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.

##### *Litigation Matters*

We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.

On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020. The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer, and Steven Wigginton, alleges that the Company’s executives made false or misleading statements regarding its business with Passport. A second amended complaint, which was substantially similar to the amended complaint, was filed on June 8, 2020. The Company filed a motion to dismiss in response on June 22, 2020 and the briefing was completed on July 17, 2020; the parties are now waiting for the court’s decision. Under the Private Securities Litigation Reform Act, PSLRA, all discovery in the case is stayed until the motion to dismiss is decided upon by the court. Based on the Company’s investigation so far, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain, and at this early stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.

The Company is not aware of any other legal proceedings or claims as of December 31, 2020, that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company's financial position or result of operations.

#### Credit and Concentration Risk

The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December 31, 2020, approximately 98.2% of our \$361.6 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks, approximately 1.6% were held in money market funds and 0.2% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.

The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partner included in our Services segment who represented at least 10.0% of our consolidated trade accounts receivable for the periods presented:

	As of December 31,	
	2020	2019
Cook County Health and Hospitals System	61.5 %	48.4 %

In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.

The following table summarizes those customers of our Services segment who represented at least 10.0% of our consolidated revenue for the periods presented:

	For the Year Ended December 31,		
	2020	2019	2018
Cook County Health and Hospitals Systems	20.3 %	*	*
Passport <sup>(1)</sup>	16.8 %	18.7 %	17.5 %
New Mexico Health Connections	*	10.9 %	*

<sup>1</sup> Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 8.8% of our consolidated revenues for the year ended December 31, 2020.

\* Represents less than 10.0% of the respective balance

We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.

## Leases

[Leases \[Abstract\]](#)  
[Leases](#)

12 Months Ended  
 Dec. 31, 2020

### Leases

The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of each lease, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether the lease term is reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are included on our consolidated balance sheets.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement of the lease to determine the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. The net expense attributable to subleases is offset against rent expense over the terms of the respective leases.

The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under these agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include incentives, allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized over the terms of the leases. The Company's primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2010. A certain office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office space in Illinois.

In connection with various lease agreements, the Company is required to maintain \$3.5 million in letters of credit. As of December 31, 2020 and 2019, the Company held \$3.5 million and \$3.6 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit.

The following table summarizes our primary office leases as of December 31, 2020 (in thousands, other than term):

Location	Lease Termination Term (in years)	Future Minimum Lease Commitments	Letter of Credit Amount Required
Arlington, VA	11.1	\$ 38,675	\$ 1,579
Riverside, IL	10.3	44,605	232
Pune, India	2.7	2,318	—
Brea, CA	1.4	1,555	—

The following table summarizes the components of our lease expense (in thousands):

	For the Year Ended December 31, 2020
Operating lease cost	\$ 15,848
Amortization of right-of-use assets	299
Interest expense	3
Variable lease cost	5,097
Total lease cost	\$ 21,247

As discussed in Note 3, the Company adopted ASU 2016-02 effective January 1, 2019, which resulted in accounting for leases under ASC 842. The Company also accounted for leases under ASC 840. In accordance with ASC 840, rent expense, net of sublease income, on operating leases for the year ended December 31, 2020 was \$14.2 million. The Company does not have any material capital leases.

Maturity of lease liabilities (in thousands) as of December 31, 2020, is as follows:

2021
2022
2023
2024
2025
Thereafter
Total lease payments
Less:
Interest
Present value of lease liabilities

<sup>(1)</sup> We have additional operating lease agreements for office space that have not yet commenced as of December 31, 2020. The minimum lease payments for those leases are \$0.7 million in 2022.

Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:

Weighted average discount rate
Weighted average remaining lease term

**Earnings (Loss) Per  
Common Share**

**12 Months Ended  
Dec. 31, 2020**

[Earnings Per Share](#)

[\[Abstract\]](#)

[Earnings \(Loss\) Per Common  
Share](#)

**Earnings (Loss) Per Common Share**

The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Net loss	\$ (334,246)	\$ (305,580)	\$ (54,191)
Less:			
Net loss attributable to non-controlling interests	—	(3,609)	(1,533)
Net loss available for common shareholders - basic and diluted <sup>(1)</sup>	<u>\$ (334,246)</u>	<u>\$ (301,971)</u>	<u>\$ (52,658)</u>
Weighted-average common shares outstanding - basic and diluted <sup>(1)</sup>	<u>84,928</u>	<u>82,364</u>	<u>77,338</u>
<b>Loss per common share</b>			
Basic and diluted	\$ (3.94)	\$ (3.67)	\$ (0.68)

<sup>(1)</sup> Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share.

Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Exchangeable Class B common stock	—	1,399	1,831
Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")	797	813	1,027
Stock options	1,141	1,324	2,517
Convertible senior notes	11,206	10,361	6,176
Total	<u>13,144</u>	<u>13,897</u>	<u>11,551</u>

## Stock-based Compensation

12 Months Ended  
Dec. 31, 2020

[Share-based Payment Arrangement \[Abstract\]](#)  
[Stock-based Compensation](#)

### Stock-based Compensation 2011 and 2015 Equity Incentive Plans

The Company issues awards, including stock options, performance-based stock options, restricted stock LSUs and RSUs, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the “2011 Plan”) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the “2015 Plan”). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1 million of the Company’s common stock. As of December 31, 2020 and 2019, 4.8 million stock options and 3.8 million shares of restricted stock have been issued, net of forfeitures, under the 2011 Plan.

On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company’s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018, to increase the number of shares authorized to 10.5 million. Upon confirmation of the amended 2015 Plan, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan will continue to govern awards previously granted under the 2011 Plan. As of December 31, 2020 and 2019, 2.8 million and 2.8 million stock options and 4.7 million and 4.4 million RSUs have been issued, net of forfeitures, under the 2015 Plan.

We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees.

#### Stock-based Compensation Expense

Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):

Award Type	For the Year Ended December 31,		
	2020	2019	2018
Stock options	\$ 2,927	\$ 4,237	\$ 9,008
Performance-based stock options	75	448	447
RSUs	7,763	8,877	7,766
Performance-based RSUs	—	(388)	388
LSUs	3,841	2,444	—
Total compensation expense by award type	<u>\$ 14,606</u>	<u>\$ 15,618</u>	<u>\$ 17,609</u>
Line Item			
Cost of revenue	\$ 1,811	\$ 2,673	\$ 1,475
Selling, general and administrative expenses	12,795	12,945	16,134
Total compensation expense by financial statement line item	<u>\$ 14,606</u>	<u>\$ 15,618</u>	<u>\$ 17,609</u>

No stock-based compensation was capitalized as software development costs for the years ended December 31, 2020, 2019 and 2018.

Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:

	As of December 31, 2020	
	Unrecognized Compensation Expense	Weighted Average Period
Stock options	\$ 1,971	1.55
RSUs	11,914	1.89
LSUs	6,694	1.77
Total	<u>\$ 20,579</u>	



### Stock Options

Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures.

The option price assumptions used for our stock option awards were as follows:

	For the Year Ended December 31,	
	2019	2018
Weighted-average fair value per option granted	\$ 6.52	\$ 6.30
<b>Assumptions:</b>		
Expected term (in years)	6.25	6.25
Expected volatility	51.6 %	38.9 %
Risk-free interest rate	1.9% - 2.7%	2.6% - 2.9%
Dividend yield	— %	— %

The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company's awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options.

Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2019	4,828	\$ 9.44	6.01	\$ (1,880)
Granted	—	—		
Exercised	(416)	4.75		
Forfeited	(342)	14.80		
Outstanding as of December 31, 2020	4,070	\$ 9.32	5.25	\$ 12,578
Vested and expected to vest after December 31, 2020	3,951	\$ 9.17	4.95	\$ 27,095
Exercisable at December 31, 2020	3,475	\$ 8.48	4.63	\$ 26,228

The total fair value of options vested during the years ended December 31, 2020, 2019 and 2018, was \$3.6 million, \$5.9 million and \$11.3 million, respectively. The total intrinsic value of options exercised during 2020, 2019 and 2018 was \$2.2 million, \$0.6 million and \$25.1 million, respectively. We issue new shares to satisfy option exercises.

### Performance-based stock option awards

In March 2016, the Company granted approximately 0.3 million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders' interests. Each of the grants is subject to market-based vesting, as follows:

- one-third of the shares subject to the option award will vest in the event that the average closing price of the Company's Class A common stock on the NYSE is at least \$13.35 per share for a consecutive ninety days period;
- one-third of the shares subject to the option award will vest in the event that the average closing price of the Company's Class A common stock on the NYSE is at least \$16.43 per share for a consecutive ninety days period; and

- one-third of the shares subject to the option award will vest in the event that the average closing price of the Company's Class A common stock on the NYSE is at least \$19.51 per share for a consecutive ninety days period.

In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:

- 50% of the shares subject to the option award vested on March 1, 2019, and
- 50% of the shares subject to the option award vested on March 1, 2020.

We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of \$6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.

Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2019	268	\$ 10.27	6.17	\$ (326)
Outstanding as of December 31, 2020	268	10.27	6.17	(326)
Vested and expected to vest after December 31, 2020	268	\$ 10.27	6.17	\$ (326)

#### *Restricted Stock Units*

Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a one-year vesting period in conjunction with the New Century Health transaction. Information with respect to our RSUs is presented below (in thousands, except for weighted-average grant-date fair value):

	Total RSUs	Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2019	1,493	\$ 12.23
Granted	1,202	8.88
Forfeited	(304)	11.38
Vested	(654)	11.11
Outstanding as of December 31, 2020	1,737	\$ 10.13

During the years ended December 31, 2020, 2019 and 2018, we granted RSUs with a weighted-average grant date fair value of \$8.88, \$10.66 and \$16.12, respectively, which represents the weighted-average closing price of our common stock on the grant date.

The total fair value of RSUs vested during the years ended December 31, 2020, 2019 and 2018 was \$6.1 million, \$7.3 million and \$4.8 million, respectively.

#### *Leveraged Stock Unit Awards*

During 2020 and 2019, the Company granted 0.5 million and 0.7 million shares, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders' interests. Each of the grants is subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:

- If the stock price has increased by 33.3%, 75% of the shares will vest
- If the stock price has increased by 50%, 100% of the shares will vest
- If the stock price has increased by 100%, 150% of the shares will vest

- If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount)

The price assumptions used for our leveraged stock unit awards were as follows:

	<b>For the Year Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
Weighted-average fair value per leveraged stock unit granted	\$ 8.90	\$ 6.52
<b>Assumptions:</b>		
Expected term	10 years	10 years
Expected volatility	62.1 %	51.7 %
Risk-free interest rate	0.85%	2.54%
Dividend yield	— %	— %

The fair value of leveraged stock units are determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company's awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.

Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:

	<b>Leveraged Stock Units</b>	<b>Weighted Average Grant Date Fair Value</b>	<b>Weighted Average Remaining Contractual Term</b>	<b>Aggregate Intrinsic Value</b>
Outstanding as of December 31, 2020	1,170	\$ 11.10	8.65	\$ 5,771
Vested and expected to vest after December 31, 2020	1,170	\$ 11.10	8.65	\$ 5,771

#### *Performance-based RSUs*

During 2018, in conjunction with the New Century Health transaction, we issued performance-based RSU awards to certain employees of New Century Health that became Evolent Health employees following the transaction. The awards were to vest based on the passage of time (18-month vesting period) and the achievement of certain operating results by New Century Health in 2019. Upon completion of the vesting period, the award recipients would have received a variable number of Evolent Health Class A common shares based on the predetermined monetary value of the award. Accordingly, these performance-based RSUs are recorded as liability awards. As one of the vesting criteria was continued employment at Evolent Health, these performance-based RSUs were considered compensation expense for the Company as opposed to contingent consideration related to the acquisition of New Century Health.

The maximum monetary value of the original performance-based award, provided New Century Health meets or exceeds the defined operating results targets, was capped at \$8.6 million. The fair value of the performance-based RSUs was estimated based on the real options approach, a form of the income approach, which estimated the probability of New Century Health achieving certain operating results during 2019. The most significant unobservable inputs used in the valuation of the performance-based RSUs was the risk-neutral probability of New Century Health achieving the defined operating results target or meeting the operating results target cap. A significant increase in either of those metrics, in isolation, would result in a significantly higher fair value of the performance-based RSUs. In determining the fair value of the performance-based RSUs, we determined the risk-neutral probability of New Century Health achieving operating results target was approximately 39% and we determined the risk-neutral probability of New Century Health meeting the operating results target cap was approximately 24%.

In August 2019, in connection with the settlement of the earn-out payable to the former employees of New Century Health, the Company canceled outstanding restricted stock units held by the former employees of New Century Health and issued new restricted stock units with modified performance conditions. No other changes to the original grant terms were made. In accordance with ASC Topic 718, *Share Based Payments*, canceled equity award accompanied by the concurrent grant of a replacement award shall be accounted for as a modification of the terms of the canceled award. The modification was treated as a Type 1 modification, as the awards were expected to vest under the original terms. Incremental compensation cost of \$4.7 million was measured as the excess of the fair value of the modified award over the fair value of the original award immediately before the terms were modified and will be recorded over the remaining requisite service period.

As of December 31, 2020 and 2019, the required performance conditions for the performance-based RSUs were not met and no shares will be issued in conjunction with these awards.

## Income Taxes

12 Months Ended  
Dec. 31, 2020

### [Income Tax Disclosure](#)

#### [\[Abstract\]](#)

#### [Income Taxes](#)

#### Income Taxes

An income tax expense (benefit) of \$(3.6) million, \$(21.5) million and less than \$0.1 million was recognized for the years ended December 31, 2020, 2019 and 2018, respectively.

Our loss before provision for income taxes was as follows (in thousands):

	For the Year Ended December 31,		
	2020	2019	2018
Domestic	\$ (339,632)	\$ (328,161)	\$ (54,681)
Foreign	1,833	1,045	530
Income (loss) before income taxes and non-controlling interests	<u>\$ (337,799)</u>	<u>\$ (327,116)</u>	<u>\$ (54,151)</u>

Components of income tax expense (benefit) (in thousands) consist of the following:

	For the Year Ended December 31,		
	2020	2019	2018
<b>Current</b>			
Federal	\$ (3,338)	\$ 1,175	\$ 458
State and local	200	14	9
Foreign	721	399	251
Total current tax expense (benefit)	<u>(2,417)</u>	<u>1,588</u>	<u>718</u>
<b>Deferred</b>			
Federal	(38,312)	(27,334)	(14,820)
State and local	(9,546)	(5,046)	(2,252)
Foreign	(303)	6	(49)
Total deferred tax expense (benefit)	<u>(48,161)</u>	<u>(32,374)</u>	<u>(17,121)</u>
Change in valuation allowance	47,025	9,250	16,443
Total tax expense (benefit)	<u>\$ (3,553)</u>	<u>\$ (21,536)</u>	<u>\$ 40</u>

As of December 31, 2020 and 2019, the Company has \$3.9 million income taxes receivable and \$0.6 million income taxes payable, respectively, which is recorded in accrued liabilities on the consolidated balance sheets.

A reconciliation of the U.S. statutory tax rate to our effective tax rate and our statutory rate is presented below:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
U.S. statutory tax rate	21.0 %	21.0 %	21.0 %
U.S. state income taxes, net of U.S. federal tax benefit	2.9 %	4.4 %	3.6 %
Foreign earnings at other than U.S. rates	— %	(0.1)%	(0.2)%
Change in valuation allowance	(13.9)%	(2.8)%	(30.4)%
Benefit of net operating loss carryback provision	1.1 %	— %	— %
Non-deductible goodwill impairment	(11.2)%	(15.8)%	— %
Non-controlling interest	— %	(0.3)%	(0.7)%
Excess tax benefits on stock-based compensation	(0.3)%	(0.2)%	3.9 %
Federal and state research tax credits	— %	— %	4.5 %
Change in uncertain tax positions	— %	0.1 %	(1.1)%
Effect of investment in MHG	— %	(1.4)%	— %
Change in state rate	1.3 %	— %	— %
Change in indefinite reinvestment assertion for domestic subsidiaries	1.0 %	2.6 %	— %
Other, net	(0.9)%	(0.8)%	(0.7)%
Effective rate	<u>1.0 %</u>	<u>6.7 %</u>	<u>(0.1)%</u>

Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates in effect when the temporary differences are expected to be recovered or settled.

Significant components of the Company's deferred tax assets and liabilities (in thousands) were as follows:

	<b>As of December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>Deferred Tax Assets</b>		
Start-up and organizational costs	\$ 117	\$ 149
Goodwill	23,534	19,142
Operating lease liabilities	15,963	18,055
Accrued expenses	7,488	9,534
Stock based compensation	8,530	8,899
Net operating loss carryforwards	123,604	112,316
Federal and state research tax credits	1,828	1,828
Fixed assets	131	—
Interest deduction limitation	2,452	2,490
Outside basis differences	197	—
Other	8,640	1,451
Subtotal	<u>192,484</u>	<u>173,864</u>
Valuation allowance	(89,902)	(50,815)
Total deferred tax assets	<u>102,582</u>	<u>123,049</u>
<b>Deferred Tax Liabilities</b>		
Internally developed software costs	12,973	14,603
Intangible assets	48,857	58,655
Outside basis differences	—	5,865
Right-of-use assets - Operating	13,122	16,180
Contract fulfillment costs	6,375	9,510
Convertible debt	20,411	15,732
Fixed assets	—	796
Other	1,572	3,650
Total deferred tax liabilities	<u>103,310</u>	<u>124,991</u>
Net deferred tax assets (liabilities)	<u>\$ (728)</u>	<u>\$ (1,942)</u>

Changes in our valuation allowance (in thousands) were as follows:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Balance at beginning-of-year	\$ 50,815	\$ 37,037	\$ 53,201
Charged to costs and expenses	47,025	9,250	16,443
Charged to other accounts <sup>(1)</sup>	(7,938)	4,528	(32,607)
Balance at end-of-year	<u>\$ 89,902</u>	<u>\$ 50,815</u>	<u>\$ 37,037</u>

<sup>(1)</sup> Amounts charged to other accounts includes a decrease of \$7.9 million, an increase of \$4.5 million and a decrease of \$32.6 million charged to additional paid-in-capital for the years ended December 31, 2020, 2019 and 2018, respectively.

For the year ended December 31, 2020, the effective tax rate was 1% and the corresponding tax benefit recorded was \$3.6 million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allows net operating losses ("NOLs") incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to carrying back New Century Health's 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, apart from the aforementioned NOL carryback, did not have a significant impact on the Company.

For the year ended December 31, 2019, the effective tax rate was 6.7%, and the corresponding tax benefit recorded was \$21.5 million. Our effective tax rate in 2019 was impacted by the tax expense for the impairment of non-deductible goodwill, change in valuation allowance for current year losses, and offset in part by the tax effects resulting from the Company's acquisition of all remaining Class B units of Evolent Health LLC, resulting in it becoming a disregarded entity for U.S. federal and state income purposes on December 26, 2019. The change in Evolent Health LLC's tax status resulted in a tax benefit from the reversal of the Company's deferred tax liability related to its investment in certain U.S. corporate subsidiaries through Evolent Health LLC, offset by an increase in valuation allowance. In addition, the Company intends to file a consolidated tax return beginning January 1, 2020, which resulted in a tax benefit offsetting the change in valuation allowance to the extent the deferred tax liabilities of our U.S. corporate subsidiaries can be used as a source of future taxable income to support the Company's deferred tax assets. Our valuation allowance assessment is made without considering deferred tax liabilities of \$1.9 million established with respect to certain indefinite-lived components that cannot be utilized against indefinite-lived deferred tax assets or components that are expected to reverse outside of the net operating loss carryover period, as these are not considered a source of future taxable income for realizing our deferred tax assets.

For the year ended December 31, 2018, the effective tax rate was (0.1)%, due to the impact of the valuation allowance recorded against the Company's net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period as part of the outside basis difference in our partnership interest in Evolent Health LLC.

As of December 31, 2020, the Company had \$203.1 million of federal and \$253.4 million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2022, respectively, and \$288.5 million federal and \$153.0 million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as realization of such tax benefit is not more likely than not, based on our evaluation, we have established a valuation allowance. Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could impose an annual limit on the Company's ability to utilize NOLs and could cause U.S. federal income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect.

As of December 31, 2020, the Company had \$2.4 million and \$0.3 million of research and development credits for federal and state income tax purposes, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established valuation allowance against those credits.

Changes in our unrecognized tax benefits (in thousands) were as follows:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Balance at beginning-of-year	\$ 753	\$ 934	\$ 762
Gross increases - tax positions in prior period	—	—	934
Gross decreases - tax positions in prior period	—	—	(762)
Lapse of statute of limitations	(75)	(181)	—
Balance at end-of-year	<u>\$ 678</u>	<u>\$ 753</u>	<u>\$ 934</u>

We are subject to taxation in various jurisdictions in the U.S. and India. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December 31, 2020, are \$0.7 million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company's valuation allowance. The Company has not recognized interest and penalties related to uncertain tax positions due to the current NOL position. The Company had recognized \$0.8 million of uncertain tax positions as of December 31, 2019, and \$0.9 million as of December 31, 2018. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.

#### *Tax Receivables Agreement*

Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC's tangible and intangible assets. These increases in tax basis increased our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.

In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local and foreign income tax (as applicable) we realize as a result of any deductions attributable to future increases in tax basis following the Class B Exchanges (calculated assuming that any post-offering transfer of Class B common units had not occurred) or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. We are accounting for these payments as contingent liabilities and will recognize them in our Consolidated Statements of Operations and Comprehensive Income (Loss) when their realization is probable. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately \$79.3 million, as well as deductions attributable to imputed interest on any payments made under the agreement.

We will benefit from the remaining 15% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated. See Note 10 for additional discussion of the implications of the TRA.



## Employee Benefit Plans

**12 Months Ended  
Dec. 31, 2020**

### Retirement Benefits

#### [Abstract]

#### Employee Benefit Plans

Employee Benefit Plans We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made \$6.4 million, \$2.6 million and \$8.6 million in contributions to the 401(k) plan for the years ended December 31, 2020, 2019 and 2018, respectively.

**Investments In and  
Advances to Equity Method  
Investees**

**Equity Method Investments  
and Joint Ventures**

**[Abstract]**

**Investments In and Advances  
to Equity Method Investees**

**12 Months Ended**

**Dec. 31, 2020**

**Investments in and Advances to Equity Method Investees**

The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is a legal entity or arrangement that is a beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) the obligation to absorb losses that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company's ownership interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct the activities that most significantly impact the economic performance of the VIE. Therefore, the Company did not consolidate the VIEs.

As of December 31, 2020 and December 31, 2019, the Company's economic interests in its equity method investments ranged between 4% and 10%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, and 25% and 57%, respectively. The Company does not have a significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities' earnings and losses for each reporting period. The Company's proportionate share of earnings and losses from these investments was approximately \$(10.0) million, \$9.5 million and \$4.7 million for the years ended December 31, 2020, 2019 and 2018 respectively.

The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services as elements of their service offerings. Revenue related to these services agreements were \$192.8 million, \$41.5 million and \$10.7 million for the years ended December 31, 2020, 2019 and 2018 respectively.

*Passport*

At the Passport Closing, we paid approximately \$70.0 million in cash and issued a 30% equity interest in the EVH Passport to the Sponsors. As a result of the Passport Closing, the Company no longer accounts for its investment in EVH Passport under the equity method of accounting. Refer to Note 4 for additional information regarding the investment in EVH Passport.

**Unconsolidated VIEs**

*Global*

On May 24, 2019, we completed the acquisition of approximately a 45% ownership interest in MHG, the sole owner of Momentum Health Acquisition, which is the sole owner of GlobalHealth Holdings, LLC ("GHH"), which is the sole owner of GlobalHealth, Inc., a health maintenance organization based in Oklahoma that offers, among other things, Medicare Advantage products in the State of Oklahoma. At closing, we contributed approximately \$15.0 million in cash and 10 million shares of our Class A common stock to MHG, together with certain of our other assets. Upon the contribution, the Company recorded a \$9.6 million non-cash impairment charge on the disposal of assets and consolidation on the consolidated statements of operations. We also recognized a short-term contingent consideration liability of approximately \$10.0 million at the time of the transaction. At the closing of the transaction, our economic interest in GlobalHealth was approximately 45% and our voting interest was approximately 29%.

As of March 31, 2020, the Oklahoma Insurance Division ("OID") informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital to more than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investment company. The Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately \$10.0 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the three months ended March 31, 2020.

The following table represents the carrying value of the associated assets and liabilities and the associated maximum loss exposure for the unconsolidated VIEs indicated (in thousands):

	D E V H P a s s e t s
<b>Assets:</b>	
Current assets	\$ 271
Non current assets	
Total assets	<u>\$ 272</u>
<b>Liabilities:</b>	
Current liabilities	181
Non current liabilities	
Total liabilities	<u>\$ 181</u>
Investment carrying value	\$ 70
Loan and interest receivable	41
Guarantee	25
Maximum exposure	<u>\$ 136</u>

#### Summarized Financial Information of Equity Method Investees

The following table represents the aggregated summarized financial information as of and for the dates indicated (in thousands):

	Dec 31 2020	
Current assets	\$	69,3
Non-current assets		3,5
Current liabilities		54,4
Non-current liabilities		20,6
Non-controlling interests		2,5

	For the Year Ended	
	2020	2019
Revenue	\$ 1,766,641	\$ 387
Operating income (loss)	8,112	(60)
Net income (loss)	6,606	(73)
Net income (loss) attributable to entity	5,632	(23)

## Non-controlling Interests

12 Months Ended  
Dec. 31, 2020

### [Noncontrolling Interest](#)

#### [\[Abstract\]](#)

### [Non-controlling Interests](#)

Non-controlling Interests Immediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company's ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company's ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders' equity attributable to Evolent Health, Inc.

2020

On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a \$25.7 million non-controlling interest for the Sponsors' 30% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders' agreement with the Sponsors, the Company was required to acquire the Sponsors' 30% ownership interest for \$20.0 million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors' 30% equity interest and reclassified the non-controlling interests into shareholders' equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a \$5.7 million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.

2019

During 2019, all remaining holders of Class B units executed Class B Exchanges. These Class B Exchanges resulted in the issuance of 3.1 million shares of the Company's Class A common stock. As a result of these Class B Exchanges and Evolent Health LLC's cancellation of the related Class B units, the Company's economic interest in Evolent Health LLC increased to 100% immediately following the final Class B Exchange during the quarter, and, accordingly, we reclassified a portion of our non-controlling interests into shareholders' equity attributable to Evolent Health, Inc. The Company paid \$1.3 million on behalf of certain holders of Class B units to satisfy income tax obligations related to certain exchanges.

In May 2019, the Company issued 1.6 million Class A common shares as part of the consideration for the GlobalHealth transaction. For each share of Class A common stock issued by Evolent Health, Inc., the Company received a corresponding Class A common unit from Evolent Health LLC. As a result of the Class A common units (and corresponding Class A common shares) issued as part of the GlobalHealth transaction, the Company's economic interest in Evolent Health LLC increased from 99.1% to 99.2%, immediately following the transaction.

2018

During the year ended December 31, 2018, the Company completed the March 2018 Private Sale. The shares sold in the March 2018 Private Sale consisted of 1.2 million existing shares of the Company's Class A common stock owned and held by The Advisory Board and 1.8 million newly-issued shares of the Company's Class A common stock received by The Advisory Board pursuant to a Class B Exchange.

As a result of this Class B Exchange and Evolent Health LLC's cancellation of the Class B common units during the March 2018 Private Sale, the Company's economic interest in Evolent Health LLC increased from 96.6% to 98.9% immediately following the March 2018 Private Sale and, accordingly, we reclassified a portion of our non-controlling interests into shareholders' equity attributable to Evolent Health, Inc.

Also, during the year ended December 31, 2018, the Company issued 3.1 million shares of Evolent Health LLC's Class B common units and an equal number of the Company's Class B common shares as part of the consideration for the New Century Health transaction. The Class B common units, together with a corresponding number of shares of the Company's Class B common stock, can be exchanged for an equivalent number of shares of the Company's Class A common stock. As a result of the Class B common units (and corresponding Class B common shares) issued as part of the New Century Health transaction, the Company's economic interest in Evolent Health LLC decreased from 99.0% to 95.3%, immediately following the acquisition.

In addition, the Company completed the November 2018 Private Sales during 2018. The shares sold in the November 2018 Private Sales consisted of 0.1 million existing shares of the Company's Class A common stock owned by TPG and 0.7 million newly-issued shares of the Company's Class A common stock received by TPG pursuant to Class B Exchanges. As a result of these Class B Exchanges and Evolent Health LLC's cancellation of the Class B common units during the November 2018 Private Sales, the Company's economic interest in Evolent Health LLC increased from 95.3% to 96.1% immediately following the November 2018 Private Sales.

Changes in non-controlling interests (in thousands) for the periods presented were as follows:

	<b>For the Year Ended</b>	
	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
Non-controlling interests balance as of beginning of period	\$ 6,689	\$ 45,532
Decrease in non-controlling interests as a result of Class B Exchanges	—	(42,377)
Issuance of non-controlling interest	25,749	6,500
Net loss attributable to non-controlling interests	—	(3,609)
Disposal of assets	(6,689)	—
Redemption of Sponsor's equity	(25,749)	—
Reclassification of non-controlling interests	—	643
Non-controlling interests balance as of end of period	<u>\$ —</u>	<u>\$ 6,689</u>

## Fair Value Measurement

12 Months Ended  
Dec. 31, 2020

### [Fair Value Disclosures](#)

#### [\[Abstract\]](#)

#### [Fair Value Measurement](#)

#### Fair Value Measurement

GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:

- Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;
- Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and
- Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured.

#### Recurring Fair Value Measurements

In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company's assets and liabilities measured at fair value on a recurring basis (in thousands):

	December 31, 2020			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 5,877	\$ —	\$ —	\$ 5,877
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 5,877</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 5,877</b>
<b>Liabilities</b>				
Warrants <sup>(3)</sup>	\$ —	\$ —	\$ 13,730	\$ 13,730
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 13,730</b>	<b>\$ 13,730</b>
	December 31, 2019			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 3,698	\$ —	\$ —	\$ 3,698
Restricted cash and restricted investments <sup>(1)</sup>	1,004	—	—	1,004
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 4,702</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 4,702</b>
<b>Liabilities</b>				
Contingent consideration <sup>(2)</sup>	\$ —	\$ —	\$ 9,883	\$ 9,883
Warrants <sup>(3)</sup>	—	—	7,092	7,092
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 16,975</b>	<b>\$ 16,975</b>

<sup>(1)</sup> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December 31, 2020 and December 31, 2019, as presented in the tables above.

<sup>(2)</sup> Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4.

<sup>(3)</sup> Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9.

The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels for the years ended December 31, 2020 and 2019, respectively.

In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.

In conjunction with the Credit Agreement discussed in Note 9, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would result in a significantly higher fair value of the contingent consideration.

The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands):

	<b>For the Year Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
Balance as of beginning of period	\$ 16,975	\$ 8,800
Additions	—	12,992
Settlements	(3,500)	(800)
Realized and unrealized gains (losses), net	255	(4,017)
Balance as of end of period	<u>\$ 13,730</u>	<u>\$ 16,975</u>

The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:

	<b>December 31, 2020</b>			
	<b>Fair Value</b>	<b>Valuation Technique</b>	<b>Significant Unobservable Inputs</b>	<b>Assumption or Input Ranges</b>
Warrants	\$ 13,730	Black-Scholes	Stock price volatility	62.2 %
			Annual risk free rate	0.2 %
	<b>December 31, 2019</b>			
	<b>Fair Value</b>	<b>Valuation Technique</b>	<b>Significant Unobservable Inputs</b>	<b>Assumption or Input Ranges</b>
Passport contingent consideration	\$ 3,700	Real options approach	Risk-adjusted recurring revenue CAGR	93.9 % <sup>(1)</sup>
			Discount rate/time value	4.8% - 5.3%
GlobalHealth contingent consideration	\$ 5,200	Monte Carlo simulation	Stock price volatility	80.0 % <sup>(2)</sup>
Other contingent considerations	\$ 983	Management estimate	Adjusted EBITDA	\$ 19,235
Warrants	\$ 7,092	Black-Scholes	Stock price volatility	55.0 %
			Annual risk free rate	1.7 %

<sup>(1)</sup> The risk-adjusted recurring revenue CAGR is calculated over the five-year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of \$1.0 million, resulting in a higher growth rate.

<sup>(2)</sup> Equity volatility based on Evolent's daily stock price returns for a look-back period corresponding to the time until the second test date. The large one-day stock price drop on November 27, 2019, was excluded from the volatility calculation.

#### **Nonrecurring Fair Value Measurements**

In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair

value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value.

**Other Fair Value Disclosures**

The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.

See Note 9 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.



## Related Parties

12 Months Ended  
Dec. 31, 2020

### [Related Party Transactions](#)

#### [\[Abstract\]](#)

#### [Related Parties](#)

#### Related Parties

The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.

As discussed in Note 16, the Company had economic interests in several entities that were previously accounted for under the equity method. The Company has allocated its proportional share of the investees' earnings and losses each reporting period. In addition, Evolve entered into agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their business.

The Company also works closely with UPMC, one of its founding investors. The Company's relationship with UPMC is a subcontractor relationship to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which we have an equity interest.

The following table presents assets and liabilities attributable to our related parties (in thousands):

	2020	2019
<b>Assets</b>		
Accounts receivable, net	\$ 9	9
Prepaid expenses and other current assets		
Customer advance for regulatory capital requirements, net of allowances		
Prepaid expenses and other noncurrent assets, net of allowances		4
<b>Liabilities</b>		
Accounts payable	\$ 2	2
Accrued liabilities		1
Reserve for claims and performance-based arrangements		

The following table presents revenues and expenses attributable to our related parties (in thousands):

	For the Year Ended December 31,		
	2020	2019	2018
<b>Revenue</b>			
Transformation services	\$ 5,416	\$ 4,009	\$ 10,540
Platform and operations services	226,339	60,325	37,490
<b>Expenses</b>			
Cost of revenue (exclusive of depreciation and amortization expenses)	2,863	28,954	9,451
Selling, general and administrative expenses	113	991	917

**Transactions**

*Passport*

On May 28, 2019, UHC, Passport Health Solutions, LLC (“PHS I”), the Company and EVH Passport entered into an Asset Purchase Agreement which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC’s Kentucky Medicaid contract (the “Passport Medicaid Contract”) to EVH Passport for a purchase price of \$70.0 million in cash and the issuance of a 30% interest in EVH Passport (the “Passport Purchase Price”) to The University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Kentucky Primary Care Association (collectively, the “Sponsors”).

On June 18, 2019, the Company contributed \$40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement (the “Passport Note”). The Passport Note carried a fixed interest rate of 6.5% per annum. Additionally, on June 6, 2019, the Company and UHC entered into an “Indemnity Agreement”, with an insurance company (the “Surety”). The Surety issued a performance bond in the amount of \$25.0 million to UHC under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond’s original expiry date was June 30, 2020 and during the term of the bond, the bond, was extended to December 31, 2020. The bond was released in October 2020.

On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the “Passport Closing”). \$16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain assets and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the assumption of the financial risks by EVH Passport of UHC’s dual eligible special needs business (the “DNP Business”) until such time as EVH Passport becomes a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred to EVH Passport. At the Passport Closing, EVH Passport assumed UHC’s obligations under the Passport Note and the Indemnity Agreement.

On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (“Molina”) entered into an Asset Purchase Agreement (the “Molina Closing”) contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport’s Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the “Molina Closing”). The Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, EVH Passport received \$20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina’s Kentucky Medicaid Contract becomes a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method. As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a wholly owned subsidiary of the Company. Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the Molina Closing met the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company’s consolidated financial statements, on July 16, 2020, EVH Passport redeemed the Sponsors’ equity interests in EVH Passport for \$20.0 million in cash in accordance with the terms of the Passport APA, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.

As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of \$88.6 million, receivables related to unsettled sales of securities of \$43.0 million and other assets of \$50.2 million and liabilities comprised of reserve for claims and performance-based arrangements of \$164.8 million and accrued liabilities of \$50.0 million. Subsequent to the consolidation, the remaining cash will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance. In addition, the Passport Note was repaid upon consolidation, and as of December 31, 2020, the outstanding principal balance of the \$40.0 million Passport Note was repaid in full by the Company, plus approximately \$3.6 million of accrued interest.

**Gain (Loss) on Disposal of Assets and Consolidation**

On September 1, 2020, as a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a wholly owned subsidiary of the Company and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements and recorded a \$5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.

During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary for a net amount of \$6.4 million in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have a continuing involvement with the entity after the consummation of this transaction.

## Securities Offerings and Sales

Under exchange agreements we entered into at the time of our IPO and as part of the New Century Health acquisition, we granted TPG, The Advisory Board”) and Ptolemy Capital, LLC (together, the “Investor Stockholders”) and certain former owners of New Century Health (the “New Members”) an exchange right that allows receipt of newly issued shares of the Company’s Class A common stock in exchange (a “Class B Exchange”) of shares of the Company’s Class B common stock (which are subsequently canceled) and an equal number of Evolent Health LLC’s Class B common stock. Under the terms of the exchange agreements, Class B units received by the Company from relevant Investor Stockholders and New Century Health were simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC canceled the Class B units. On December 27, 2019, the cancellation of the remaining Class B units results in an increase in the Company’s economic interest in Evolent Health LLC.

**Repositioning and Other Changes**  
We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to invest in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a major portion of our business, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we engaged a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in future periods.

In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these goals (the “Repositioning Plan”). These actions included making organizational changes across our Services segment as well as other profitability initiatives expected to result in the re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to be completed in the first quarter of 2021.

The Company recorded approximately \$1.3 million of repositioning costs in selling, general and administrative expenses during the year ended December 31, 2020, in connection with the Repositioning Plan. The following tables provide a summary of our total costs associated with the Repositioning Plan for the year ended December 31, 2020, by major type of cost:

	<b>Incurred For the Year Ended December 31, 2020</b>	<b>Total Amount Expected to be Incurred in the Repositioning Plan</b>	<b>Cumulative through</b>
Severance and termination benefits	\$ —	\$ 2,500	\$ —
Office space consolidation	—	2,100	—
Professional services	1,275	4,200	—
Total	<u>\$ 1,275</u>	<u>\$ 8,800</u>	<u>\$ —</u>

## Segment Reporting

12 Months Ended  
Dec. 31, 2020

[Segment Reporting](#)

[\[Abstract\]](#)

[Segment Reporting](#)

### Segment Reporting

We define our reportable segments based on the way the CODM, currently the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:

- Services, which consists of two clinical solutions: (i) total cost of care management, and (ii) specialty care management services, and one administrative solution: comprehensive health plan administrative services; and
- True Health, which consists of a commercial health plan we operate in New Mexico that focuses on individual and family as well as small and large group businesses as well as the Federal Employee Health Benefits Program.

In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.

The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources.

Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies.

Adjusted EBITDA is defined as EBITDA (net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses), adjusted to exclude equity method investment impairment, loss on extinguishment of debt, gain (loss) from equity method investees, gain (loss) on disposal of assets and consolidation, goodwill impairment, changes in fair value of contingent consideration and indemnification asset, other income (expense), net, net loss attributable to non-controlling interests, ASC 606 transition adjustments, purchase accounting adjustments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets and acquisition-related costs.

Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance.

The following tables present our segment information (in thousands):

	Services	True Health	Intersegment Eliminations	Consolidated
<b>Revenue</b>				
<b>For the Year Ended December 31, 2020</b>				
Services:				
Transformation services	\$ 11,990	\$ —	\$ —	\$ 11,990
Platform and operations services	913,005	—	(19,939)	893,066
Services revenue	924,995	—	(19,939)	905,056
True Health:				
Premiums	—	117,579	(202)	117,377
Total revenue	\$ 924,995	\$ 117,579	\$ (20,141)	\$ 1,022,433

**For the Year Ended December 31, 2019**

Services:				
Transformation services	\$ 15,203	\$ —	\$ —	\$ 15,203
Platform and operations services	671,919	—	(12,481)	659,438
Services revenue	687,122	—	(12,481)	674,641
True Health:				
Premiums	—	172,722	(980)	171,742
Total revenue	\$ 687,122	\$ 172,722	\$ (13,461)	\$ 846,383

**For the Year Ended December 31, 2018**

Services:				
Transformation services	\$ 32,916	\$ —	\$ —	\$ 32,916
Platform and operations services	514,515	—	(14,325)	500,190
Services revenue	547,431	—	(14,325)	533,106
True Health:				
Premiums	—	94,763	(806)	93,957
Total revenue	\$ 547,431	\$ 94,763	\$ (15,131)	\$ 627,063

	Services	True Health	Segments Total
<b>For the Year Ended December 31, 2020</b>			
Adjusted EBITDA	\$ 48,573	\$ (7,137)	\$ 41,436
<b>For the Year Ended December 31, 2019</b>			
Adjusted EBITDA	\$ (14,667)	\$ 3,699	\$ (10,968)
<b>For the Year Ended December 31, 2018</b>			
Adjusted EBITDA	\$ 21,310	\$ 1,915	\$ 23,225

The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Net loss attributable to common shareholders of Evolent Health, Inc.</b>	\$ (334,246)	\$ (301,971)	\$ (52,658)
Less:			
Interest income	3,164	3,987	3,440
Interest expense	(28,337)	(14,534)	(5,484)
(Provision) benefit for income taxes	3,553	21,536	(40)
Depreciation and amortization expenses	(61,475)	(60,913)	(44,515)
Equity method investment impairment	(47,133)	—	—
Loss on extinguishment of debt, net	(4,789)	—	—
Gain (loss) from equity method investees	10,039	(9,465)	(4,736)
Gain (loss) on disposal of assets and consolidation	(698)	9,600	—
Goodwill impairment	(215,100)	(199,800)	—
Change in fair value of contingent consideration and indemnification asset	(3,860)	3,997	4,104
Other income (expense), net	(119)	(492)	109
Net loss attributable to non-controlling interests	—	3,609	1,533
ASC 606 transition adjustments	—	—	(4,498)
Purchase accounting adjustments	—	(1,915)	(861)
Repositioning costs	(1,275)	—	—
Stock-based compensation expense	(14,606)	(15,618)	(17,609)
Severance costs	(8,986)	(17,350)	(2,205)
Amortization of contract cost assets	(3,944)	(2,876)	(2,456)
Acquisition costs	(2,116)	(10,769)	(2,665)
<b>Adjusted EBITDA</b>	<b>\$ 41,436</b>	<b>\$ (10,968)</b>	<b>\$ 23,225</b>

Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.

**Reserves for Claims and  
Performance-Based  
Arrangements**

**12 Months Ended**

**Dec. 31, 2020**

[Insurance \[Abstract\]  
Reserves for Claims and  
Performance-Based  
Arrangements](#)

**Reserve for Claims and Performance-Based Arrangements**

The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. The Company also maintained reserves for claims incurred but not paid related to its capitation arrangement and for its health plan, True Health, in New Mexico.

Reserves for claims and performance-based arrangements for our Services and True Health segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 10.

The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability, for reserves related to its total cost of care and specialty care management services and True Health, is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership and 4) the mix of products.

The Company's policy for reserves related to its total cost of care and specialty care management services and True Health is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.

For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment.

For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.

Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2020 and 2019, was as follows (in thousands):

	For the Year Ended December 31,					
	2020			2019		
	Services <sup>(1)(2)</sup>	True Health <sup>(2)</sup>	Total	Services <sup>(1)</sup>	True Health <sup>(2)</sup>	Total
Beginning balance	\$ 54,510	\$ 6,640	\$ 61,150	\$ 17,715	\$ 9,880	\$ 27,595
Incurring costs related to current year	420,597	89,008	509,605	\$ 267,064	\$ 136,303	\$ 403,367
Incurring costs related to prior year	2,878	799	3,677	(334)	(529)	(863)
Paid costs related to current year	464,571	79,640	544,211	220,050	61,621	281,671
Paid costs related to prior year	9,598	6,949	16,547	8,165	8,092	16,257
Change during the year	(50,694)	3,218	(47,476)	38,515	66,061	104,576
Impact of consolidation on reserves for claims and performance-based arrangements	164,297	—	164,297	—	—	—
Other adjustments <sup>(3)</sup>	10,714	—	10,714	(1,720)	(69,301)	(71,021)
Ending balance	\$ 178,827	\$ 9,858	\$ 188,685	\$ 54,510	\$ 6,640	\$ 61,150

<sup>(1)</sup> Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. EVH Passport operations are not included in 2019 activity.

<sup>(2)</sup> There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. The number of claims processed for the Services and True Health segments for years ended December 31, 2020 and 2019 were 2,279,228 and 317,187, respectively.

<sup>(3)</sup> Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to EVH Passport and our True Health segment represent premiums received less administrative expenses related to the reinsurance agreements. Refer to Note 10 for additional information about the reinsurance agreements.



## Investments

### 12 Months Ended Dec. 31, 2020

[Investments \[Abstract\]](#)  
[Investments](#)

Investments Our investments held by wholly-owned subsidiaries other than EVH Passport are classified as held-to-maturity as we have both the intent and ability to hold the investments until their individual maturities. Investments held by EVH Passport are classified as available-for-sale upon their consolidation. The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of December 31, 2020 and 2019 (in thousands) were as follows:

	December 31, 2020				December 31, 2019			
	Amortized Cost	Gross Unrealized		Fair Value	Amortized Cost	Gross Unrealized		Fair Value
		Gains	Losses			Gains	Losses	
U.S. Treasury bills	\$ 8,909	\$ 384	\$ —	\$ 9,293	\$ 10,784	\$ 270	\$ —	\$ 11,054
Corporate bonds	1,707	132	—	1,839	1,705	70	—	1,775
Collateralized mortgage obligations	3,433	149	—	3,582	5,472	56	(5)	5,523
Corporate stock	130	—	—	130	—	—	—	—
Yankees	598	49	—	647	597	30	—	627
Total investments	\$ 14,777	\$ 714	\$ —	\$ 15,491	\$ 18,558	\$ 426	\$ (5)	\$ 18,979

The amortized cost and fair value of our investments by contractual maturities as of December 31, 2020 and 2019 (in thousands) were as follows:

	December 31, 2020		December 31, 2019	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in one year or less	\$ 3,858	\$ 3,915	\$ 1,807	\$ 1,810
Due after one year through five years	10,919	11,576	16,121	16,542
Due after five years through ten years	—	—	630	627
Total investments	\$ 14,777	\$ 15,491	\$ 18,558	\$ 18,979

When a held-to-maturity investment is in an unrealized loss position, we assess whether or not we expect to recover the entire cost basis of the security, based on our best estimate of the present value of cash flows expected to be collected from the debt security. Factors considered in our analysis include the reasons for the unrealized loss position, the severity and duration of the unrealized loss position, credit worthiness and forecasted performance of the investee. In cases where the estimated present value of future cash flows is less than our cost basis, we recognize an other than temporary impairment and write the investment down to its fair value. The new cost basis would not be changed for subsequent recoveries in fair value.

There were no securities held in an unrealized loss position for more than twelve months as of December 31, 2020 or 2019.

Quarterly Results of  
Operations (unaudited)

[Quarterly Financial Data  
\[Abstract\]](#)

[Quarterly Results of  
Operations \(unaudited\)](#)

12 Months Ended  
Dec. 31, 2020

Quarterly Results of Operations (unaudited)

The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:

	For the Three Months Ended		
	December 31	September 30	June 30
<b>2020</b>			
Total revenue	\$ 271,923	\$ 264,593	\$ 264,593
Total operating expenses	276,659	277,512	277,512
Net loss	(13,803)	(38,170)	(38,170)
Net loss attributable to non-controlling interests	822	(822)	(822)
Net loss attributable to common shareholders of Evolent Health, Inc.	(14,625)	(37,348)	(37,348)
<i>Loss per common share</i>			
Basic and Diluted	\$(0.17)	\$(0.44)	\$(0.44)
<b>2019</b>			
Total revenue	\$ 236,525	\$ 220,143	\$ 220,143
Total operating expenses <sup>(1)</sup>	451,120	240,281	240,281
Net loss	(199,293)	(25,738)	(25,738)
Net loss attributable to non-controlling interests	(1,197)	(217)	(217)
Net loss attributable to common shareholders	(198,096)	(25,521)	(25,521)
<i>Loss per common share</i>			
Basic and Diluted	\$(2.36)	\$(0.30)	\$(0.30)

<sup>(1)</sup> The Company recorded goodwill impairment of \$199.8 million during the three months ended December 31, 2019.

**Supplemental Cash Flow  
Information**

**12 Months Ended  
Dec. 31, 2020**

[Supplemental Cash Flow  
Elements \[Abstract\]](#)  
[Supplemental Cash Flow  
Information](#)

**Supplemental Cash Flow Information**

The following represents supplemental cash flow information (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Supplemental Disclosure of Non-cash Investing and Financing Activities</b>			
Class A and Class B common stock issued in connection with business combinations	\$ —	\$ 23,556	\$ 83,173
Change in goodwill from measurement period adjustments/business combinations	2,200	(351)	(117)
Acquisition consideration payable	4,185	800	—
Settlement of escrow related to asset acquisition	—	—	2,519
Settlement of indemnification asset	—	—	1,004
Accrued property and equipment purchases	11	(527)	368
Accrued deferred financing costs	—	—	607
Consideration for asset acquisitions or business combinations	—	16,000	500
<i>Effects of Leases</i>			
Operating cash flows from operating leases	13,708	12,330	—
Leased assets obtained in exchange for operating lease liabilities	(2,170)	30,463	—
<i>Effects of Class B Exchanges</i>			
Decrease in non-controlling interests as a result of Class B Exchanges	—	42,377	34,682
Decrease in deferred tax liability as a result of securities offerings and exchanges	—	(22)	652
<b>Supplemental Disclosures</b>			
Cash paid for interest	13,352	5,037	2,500
Cash paid for taxes, net	9,679	1,484	343

## Subsequent Events

**12 Months Ended  
Dec. 31, 2020**

[Subsequent Events](#)

[\[Abstract\]](#)

[Subsequent Events](#)

### Subsequent Events

#### *Agreement for the Sale of True Health New Mexico*

On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the “True Health SPA”) with Bright Health Management, Inc. (“Bright HealthCare”), pursuant to which EH Holdings expects to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of \$22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the closing of the transactions (the “True Health Closing”) based in part on actual medical claims experience.

In the True Health SPA, EH Holdings, True Health and Bright HealthCare have made customary representations and warranties and have agreed to customary covenants, indemnification and termination rights relating to the transactions contemplated by the True Health SPA. Among other things, True Health will be subject to certain business conduct restrictions with respect to its operations prior to the True Health Closing. Evolent Health LLC has guaranteed the obligations of EH Holdings under the True Health SPA.

The True Health Closing is conditioned on customary conditions, including, among others, (i) the accuracy of the representations and warranties of the parties at True Health Closing (generally, subject to a material adverse effect standard), (ii) material compliance with the covenants and the agreements made by the parties in the True Health SPA, (iii) approval of the Transactions by the New Mexico Office of Superintendent of Insurance, (iv) the absence of any legal restraints prohibiting the Transactions and (v) the entry into a transition services agreement. The True Health Closing is expected to occur on or after the end of the first half of 2021.

As of December 31, 2020, the Company determined that True Health did not meet the held for sale criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are not classified as held for sale and are included in continuing operations in the consolidated financial statements.

#### *Change in Reportable Segments*

The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Notably, the chief executive officer will remain the CODM and will no longer manage the operations for purposes of allocating resources and assessing performance through the Services and True Health segments. Effective during the first quarter of 2021, the Company will bifurcate its Services segment into two reportable segments as follows:

- Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and

- Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands.

The CODM continues to use revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. The impact of the organizational changes on the Company's operating segments, reportable segments and reporting units will be reflected in the Company's financial statements as of and for the three months ending March 31, 2021. Prior year segment information will be reclassified to conform to the reporting structure change.

#### *Repayment and Termination of Existing Credit Agreement*

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was \$98.6 million, which included \$9.7 million for the make-whole premium as well as \$0.2 million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for \$13.7 million.

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle (Policies)**

**12 Months Ended**

**Dec. 31, 2020**

[Accounting Policies](#)

[\[Abstract\]](#)

[Basis of Presentation](#)

**Basis of Presentation**

The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the Company and its subsidiaries.

*Accounting Estimates and Assumptions*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets, liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance obligations, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred tax assets, valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.

*Principles of Consolidation*

The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

*Operating Segments*

Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available and is regularly evaluated, on a regular basis, by the chief operating decision maker (“CODM”) to decide how to allocate resources and assess performance. The Company has two segments: (1) Services, and (2) True Health. Our Services segment consists of two clinical solutions: (i) total cost of care services and (ii) administrative services, and one administrative solution: comprehensive health plan administration services. Our True Health segment consists of a commercial health plan in New Mexico that historically focused on small and large businesses. In 2020, True Health diversified its services to offer coverage for individuals in the Federal Employee Health Benefits Program. Refer to Note 21 for a discussion of our operating results by segment and Note 26 for a discussion of our operating segments.

*Cash and Cash Equivalents*

We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all cash and cash equivalents as deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at cost, which approximates cost.

*Accounts Receivable and Allowances*

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make an allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the aging of accounts receivable, credit balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.

*Property and Equipment, Net*

Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are recorded using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives of property and equipment:

Computer hardware	
Computer software	
Furniture and equipment	
Internal-use software development costs	
Leasehold improvements	Shorter of useful life or remaining lease term

When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recognized at the disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).

We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of an asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of the asset group exceeds its fair value.

#### [Software Development Costs](#) *Software Development Costs*

The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation, employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the development stage – when the research stage is complete and management has committed to a project to develop software that will be used for internal purposes. Costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are recorded on the consolidated balance sheets, net of property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over the estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.

#### [Research and Development Costs](#) *Research and Development Costs*

Research and development costs consist primarily of personnel and related expenses (including stock-based compensation, employee taxes and benefits) for employees engaged in research and development activities as well as other costs. Such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology development, clinical program development, data analytics and network development capabilities. Research and development costs are recorded on our consolidated statements of operations and comprehensive income (loss).

#### [Notes Receivable](#) *Notes Receivable*

Notes receivable are carried at the face amount of each note plus accrued interest receivable, less received payments and net of allowances. The Company carries notes receivable in the course of its regular business, but contributed \$40.0 million in the form of an advance for regulatory capital requirements for EVH Passport/UHC during the second quarter of 2019. Refer to Note 4 for a discussion of our Passport Note.

#### [Business Combinations](#) *Business Combinations*

Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their fair value at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. Actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term operating expenses, cost of capital, and appropriate discount rates.

The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recognized as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss).

For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized in expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.

#### [Equity Method Investments and Impairment of Equity Method Investments](#) *Equity Method Investments*

For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company invests in the entity under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of the investee's net income or loss in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of equity method investments accounted for under the equity method. These investments are included in investments in and advances to equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).

#### *Impairment of Equity Method Investments*

The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other-than-temporary. Other-than-temporary impairment of equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may evaluate equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the carrying amount is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The determination of whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current results. Refer to Note 16 for additional discussion regarding impairments on equity method investments.

#### [Goodwill](#) *Goodwill*

We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable intangible assets as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other factors. We perform impairment tests of goodwill at a reporting unit level. The Company has four reporting units and our annual goodwill impairment test results are as follows:

the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe reduce the fair value of a reporting unit below its carrying amount.

Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would indicate to the Company that it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company concludes that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill impairment test is performed. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income. See Note 8 for additional discussion regarding the goodwill impairment tests conducted during 2020 and 2019.

## [Intangible Assets, Net](#)

### *Intangible Assets, Net*

Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives of amortization that reflects the pattern in which the economic benefits of the intangible assets are used.

The following summarizes the estimated useful lives by asset classification:

Corporate trade name	10 - 20 years
Customer relationships	10 - 25 years
Technology	5 years
Provider network contracts	4 - 5 years

Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset's carrying value. Impairment is determined by recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group of assets at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess carrying amount of the long-lived asset or group over its fair value. See Note 8 for additional discussion regarding our intangible assets.

## [Reserves for Claims and Performance-based Arrangements](#)

### *Reserves for Claims and Performance-based Arrangements*

Reserves for performance-based arrangements and claims for our Services and True Health segments reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed to NMHC under performance-based arrangements for 2019 as discussed further in Note 10. The reinsurance agreement was terminated in December 2019. The Company uses actuarial principles consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse conditions consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. Such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.

## [Long-term Debt](#)

### *Long-term Debt*

Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on our balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Interest is paid due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 9 for further discussion of our convertible notes and credit agreement.

## [Leases](#)

### *Leases*

As discussed in Note 3, we adopted Accounting Standards Update ("ASU") 2016-02, *Leases*, effective January 1, 2019. The following reflects our lease activity. The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of each lease, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether the lease term is reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement of the lease to determine the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single lease component for all classes of underlying assets.



The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is reported over the terms of the respective leases.

Refer to Note 11 for additional lease disclosures.

## [Revenue Recognition and Cost of Revenue \(Exclusive of Depreciation and Amortization\)](#)

*Revenue Recognition*  
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, in order to clarify the principles of recognizing revenue. The standard is effective January 1, 2018, using the modified retrospective method for only contracts that were not completed at the date of initial application.

Our Services segment derives revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services include implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients or of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population management, operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers. Revenue is recognized when control of the services is transferred to our customers.

We use the following 5-step model, outlined in Accounting Standards Codification (“ASC”) Topic 606, *Revenue from Contracts with Customers*, to determine revenue recognition for our Services segment from our contracts with customers:

- Identify the contract(s) with a customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to performance obligations
- Recognize revenue when (or as) the entity satisfies a performance obligation

Our True Health segment derives revenue from premiums that are earned over the terms of the related insurance policies. True Health also derives revenue from reinsurance premiums assumed from NMHC under the terms of the reinsurance agreement (as defined in Note 10). The portion of premiums that are earned but not received or are received prior to the effectiveness of the policy are deferred and reported as premiums received in advance. These amounts are generally classified as liabilities on our consolidated balance sheets.

### *Cost of Revenue (Exclusive of Depreciation and Amortization)*

Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of salaries and benefits (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. The cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenses and other arrangements.

## [Claims Expenses](#)

### *Claims Expenses*

Our claims expenses consist of the direct medical expenses incurred by our True Health segment. Claims expenses are recognized in the period in which the claims are incurred and include amounts that have been paid by us through the reporting date, as well as estimated medical claims and benefits payable for costs that have not yet been paid by us as of the reporting date. Claims expenses include, among other items, fee-for-service claims, pharmacy benefits, various other related medical expenses and amounts related to our reinsurance agreement. We use judgment to determine the appropriate assumptions for determining the required reserves.

## [Stock-based Compensation](#)

### *Stock-based Compensation*

The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employees of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.

We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using the Black-Scholes valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel costs for the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.

## [Income Taxes](#)

### *Income Taxes*

Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is needed, and so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and amount of tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and the strategies we would employ to avoid a tax benefit from expiring unused.

We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2020 and 2019, the effect of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.

We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and was subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. Following the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity owned by us. From its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company's federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporations and is subject to U.S. and foreign taxes with respect to their own operations during 2019.

## Earnings (Loss) Per Share

### *Earnings (Loss) per Share*

Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.

For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of all potentially dilutive common shares, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent potentially dilutive shares would be anti-dilutive.

## Fair Value Measurement

### **Fair Value Measurement**

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.

See Note 18 for further discussion regarding fair value measurement.

GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of inputs used in measuring fair value. These tiers include:

- Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;
- Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and
- Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the instrument.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the hierarchy that is most significant to the fair value measurement is the level used for disclosure. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured.

### **Nonrecurring Fair Value Measurements**

In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets such as goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity investments. If, on a nonrecurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying amounts may not be recoverable, these items are not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying amounts may not be recoverable. In those situations, the assets are considered impaired and written down to current fair value.

### **Other Fair Value Disclosures**

The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, and other assets, and liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.

See Note 9 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.

## Foreign Currency

### *Foreign Currency*

The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian rupee. The Company translates the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. For the years ended December 31, 2020 and 2018, translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2020 and 2018.

## Adoption of New Accounting Standards

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, *Leases*, in order to establish the principles of economically neutral information about the assets and liabilities that arise from leases. This update introduces a new standard on accounting for leases that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with the new lessee model. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, *Leases*, which is intended to make targeted improvements to ASU 2016-02. The amendments in ASU 2018-11 provide entities with an additional (and optional) method to adopt the new leases standard using an effective date method rather than the earliest comparative period. The requirements of ASU 2018-11 are effective as of the date as the requirements of ASU 2016-02. We adopted ASU 2016-02 as of January 1, 2019, using the modified retrospective approach. Further practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease liabilities. Adoption of the new standard resulted in the recording of additional right-of-use assets and lease liabilities of approximately \$51.4 million and \$4.4 million on our consolidated balance sheet as of January 1, 2019. The standard had no impact on our results of operations.

In August 2018, the FASB issued ASU 2018-15, *Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation of a Cloud Computing Arrangement That Is a Services Contract*. The amendments in this ASU align the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software that is not a service contract for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption of the amendments in this update should be applied either retrospectively or prospectively to all implementation costs incurred after the date of the requirements of ASU 2018-15 effective January 1, 2019. There was no material impact to our consolidated balance sheets or results of operations as of December 31, 2019.

In July 2019, the FASB issued ASU 2019-07, *Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule on the Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Amendments*. ASU 2019-07 clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the requirements of the SEC’s disclosure update and simplification project. The amendments included in ASU 2019-07, which were issued in conjunction with the issuance of the standard and were to be applied prospectively, did not have a material impact on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*. ASU 2016-13 issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, and certain off-balance sheet credit exposures, by replacing the existing “incurred loss” framework with an expected credit loss recognition model. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020, using the modified retrospective approach and recorded a cumulative effect adjustment of \$3.0 million to January 1, 2020 retained earnings (accumulated deficit). Retained earnings beginning January 1, 2020 reflect the adoption of ASU 2016-13, while prior period amounts were not adjusted and continue to be reported in accordance with our previous accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop an allowance, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and forecasts in measurement of the allowance. In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance using a cash flow approach. For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 6 for additional disclosures related to credit losses.

In August 2018, the FASB issued ASU 2018-13, *Changes to the Disclosure Requirements for Fair Value Measurement*. ASU 2018-13 amends and clarifies disclosure requirements related to fair value measurement disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We adopted the requirements of this standard effective January 1, 2020 and determined it did not have a material impact on our consolidated financial statements and related disclosures.

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle (Tables)**

**12 Months Ended**

**Dec. 31, 2020**

[Accounting Policies](#)

[\[Abstract\]](#)

[Schedule of restricted cash and cash equivalents](#) Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:

	December 31,	
	2020	2019
Collateral for letters of credit for facility leases <sup>(1)</sup>	\$ 3,510	\$ 3,610
Collateral with financial institutions <sup>(2)</sup>	4,743	5,742
Claims processing services <sup>(3)</sup>	12,127	18,171
Other	1,327	817
<b>Total restricted cash and restricted investments</b>	<b>\$ 21,707</b>	<b>\$ 28,340</b>
Current restricted investments	\$ —	\$ 704
Current restricted cash	14,437	19,376
<b>Total current restricted cash and restricted investments</b>	<b>\$ 14,437</b>	<b>\$ 20,080</b>
Non-current restricted investments	\$ 616	\$ 113
Non-current restricted cash	6,654	8,147
<b>Total non-current restricted cash and restricted investments</b>	<b>\$ 7,270</b>	<b>\$ 8,260</b>

<sup>(1)</sup> Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 11 for further discussion of our lease commitments.

<sup>(2)</sup> Represents collateral held with financial institutions for risk-sharing and other arrangements. As of both December 31, 2020 and December 31, 2019, approximately \$4.7 million held in a FDIC participating bank account. As December 31, 2019, approximately \$1.0 million, of the collateral amount was held in a trust account and invested in money market arrangements. The amounts invested in money market funds are considered restricted cash and are carried at fair value, which approximates cost. See Note 18 for discussion of fair value for discussion of our risk-sharing arrangements.

<sup>(3)</sup> Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period as the claims are processed.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that reconcile to the amounts shown in the consolidated statements of cash flows (in thousands).

	As of December 31,	
	2020	2019
Cash and cash equivalents	\$ 340,490	\$ 101,008
Restricted cash and restricted investments	21,707	28,340
Restricted investments included in restricted cash and restricted investments	(616)	(817)
<b>Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</b>	<b>\$ 361,581</b>	<b>\$ 128,531</b>

[Summary of property and equipment](#)

The following summarizes the estimated useful lives by asset classification:

Computer hardware	
Computer software	
Furniture and equipment	
Internal-use software development costs	
Leasehold improvements	Shorter of useful life or remaining lease term

The following summarizes our property and equipment (in thousands):

	December 31,	
	2020	2019
Computer hardware	\$ 18,866	\$ 11,604
Furniture and equipment	3,559	3,649
Internal-use software development costs	137,085	112,501
Leasehold improvements	15,586	12,415
Total property and equipment	175,096	140,169
Accumulated depreciation and amortization expenses	(88,856)	(55,014)
Total property and equipment, net	\$ 86,240	\$ 85,155

[Schedule of intangible assets](#)

The following summarizes the estimated useful lives by asset classification:

Corporate trade name	10 - 20 years
Customer relationships	10 - 25 years
Technology	5 years
Provider network contracts	4 - 5 years

Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:

	As of December 31, 2020				As of December 31, 2019			
	Weighted-Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Value	Weighted-Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Value
Corporate trade name	13.2	\$ 23,300	\$ 6,271	\$ 17,029	14.2	\$ 23,300	\$ 4,891	\$ 18,409
Customer relationships	16.1	281,219	58,256	222,963	16.8	291,519	44,750	246,769
Technology	1.8	82,922	63,507	19,415	2.0	82,922	49,760	33,162
Below market lease, net	2.3	1,118	648	470	2.2	2,048	1,334	714
Provider network contracts	2.8	14,475	6,280	8,195	3.7	12,725	3,320	9,405
Total intangible assets, net		\$ 403,034	\$ 134,962	\$ 268,072		\$ 412,514	\$ 104,055	\$ 308,459

**Revenue Recognition  
(Tables)**

**12 Months Ended  
Dec. 31, 2020**

**[Revenue from Contract with  
Customer \[Abstract\]](#)**

**[Disaggregation of revenue](#)**

The following table represents Evolent's Services segment revenue disaggregated by type of services (in thousands), excluding revenues from our health plan operations, which include the True Health segment and EVH Passport, and from our downside risk sharing arrangements through our insurance subsidiary, which are accounted for under ASC 944, *Financial Services-Insurance*.

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Services Revenue</b>			
Transformation services	\$ 11,990	\$ 15,203	\$ 32,916
<b>Platform and operations services</b>			
Clinical solutions	690,391	458,991	228,464
Administrative solutions	202,547	198,618	264,104

**[Contract with customer, asset  
and liability](#)**

The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):

	<b>December 31, 2020</b>	<b>December 31, 2019</b>
Short-term receivables <sup>(1)</sup>	\$ 122,167	\$ 71,707
Long-term receivables <sup>(1)</sup>	4,554	709
Short-term contract assets	329	1,751
Long-term contract assets	—	999
Short-term deferred revenue	14,327	19,828
Long-term deferred revenue	3,593	1,330

<sup>(1)</sup> Excludes pharmacy claims receivable and premiums receivable

Changes in contract assets and deferred revenue for the year ended December 31, 2020 are as follows (in thousands):

<b>Contract assets</b>		
Balance as of beginning-of-period	\$	2,750
Reclassification to receivables, as the right to consideration becomes unconditional		(2,539)
Contract assets recognized, net of reclassification to receivables		118
Balance as of end-of-period	<u>\$</u>	<u>329</u>
<b>Deferred revenue</b>		
Balance as of beginning-of-period	\$	21,158
Reclassification to revenue, as a result of performance obligations satisfied		(18,481)
Cash received in advance of satisfaction of performance obligations		15,243
Balance as of end-of-period	<u>\$</u>	<u>17,920</u>

Credit Losses (Tables)

12 Months Ended  
Dec. 31, 2020

[Credit Loss \[Abstract\]](#)  
[Accounts receivable,  
allowance for credit loss](#)

The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade and contract assets for the year ended December 31, 2020 (in thousands):

Balance as of December 31, 2019

Passport acquisition

Cumulative transition adjustment

Provision for credit losses

Charge-offs

Balance as of December 31, 2020

[Held-to-maturity securities,  
amortized cost and interest  
income](#)

The amortized cost of our investments as of December 31, 2020 and 2019 and interest income for the years ended December 31, 2020 and 2019 were

	Amortized Cost		Interest
	December 31, 2020	December 31, 2019	
U.S. Treasury bills	\$ 8,909	\$ 10,784	\$
Corporate bonds	1,707	1,705	
Collateralized mortgage obligations	3,433	5,472	
Corporate stock	130	—	
Yankees	598	597	
Total investments	\$ 14,777	\$ 18,558	\$

**Property and Equipment,  
Net (Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Property, Plant and  
Equipment \[Abstract\]](#)  
[Summary of property and  
equipment](#)

The following summarizes the estimated useful lives by asset classification:

Computer hardware	
Computer software	
Furniture and equipment	
Internal-use software development costs	
Leasehold improvements	Shorter of useful life or remaining

The following summarizes our property and equipment (in thousands):

	<b>December 31,</b>	
	<b>2020</b>	<b>2019</b>
Computer hardware	\$ 18,866	\$ 11,604
Furniture and equipment	3,559	3,649
Internal-use software development costs	137,085	112,501
Leasehold improvements	15,586	12,415
Total property and equipment	175,096	140,169
Accumulated depreciation and amortization expenses	(88,856)	(55,014)
Total property and equipment, net	<u>\$ 86,240</u>	<u>\$ 85,155</u>



**Goodwill and Intangible  
Assets, Net (Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Goodwill and Intangible  
Assets Disclosure \[Abstract\]  
Schedule of goodwill](#)

The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):

	Services	True Health	Consolidated
Balance as of December 31, 2018	\$ 762,419	\$ 5,705	\$ 768,124
Goodwill acquired	3,416	—	3,416
Measurement period adjustments	351	—	351
Impairment	(199,800)	—	(199,800)
Foreign currency translation	(27)	—	(27)
Balance as of December 31, 2019 <sup>(1)</sup>	566,359	5,705	572,064
Goodwill disposal <sup>(2)</sup>	(2,200)	—	(2,200)
Impairment	(215,100)	—	(215,100)
Foreign currency translation	(30)	—	(30)
Balance as of December 31, 2020 <sup>(1)</sup>	\$ 349,029	\$ 5,705	\$ 354,734

<sup>(1)</sup> Net of cumulative inception to date impairment of \$575.5 million and \$360.4 million as of December 31, 2020 and 2019, respectively.

<sup>(2)</sup> Goodwill written-off upon disposal of a consolidated subsidiary.

[Schedule of intangible assets  
details](#)

The following summarizes the estimated useful lives by asset classification:

Corporate trade name	10 - 20 years
Customer relationships	10 - 25 years
Technology	5 years
Provider network contracts	4 - 5 years

Details of our intangible assets (in thousands, except weighted-average useful lives) are presented below:

	As of December 31, 2020				As of December 31, 2019			
	Weighted-Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Value	Weighted-Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Value
Corporate trade name	13.2	\$ 23,300	\$ 6,271	\$ 17,029	14.2	\$ 23,300	\$ 4,891	\$ 18,409
Customer relationships	16.1	281,219	58,256	222,963	16.8	291,519	44,750	246,769
Technology	1.8	82,922	63,507	19,415	2.0	82,922	49,760	33,162
Below market lease, net	2.3	1,118	648	470	2.2	2,048	1,334	714
Provider network contracts	2.8	14,475	6,280	8,195	3.7	12,725	3,320	9,405
Total intangible assets, net		\$ 403,034	\$ 134,962	\$ 268,072		\$ 412,514	\$ 104,055	\$ 308,459

[Schedule of future estimated  
amortization of intangible  
assets](#)

Future estimated amortization of intangible assets (in thousands) as of December 31, 2020, is as follows:

2021	\$ 28,701
2022	24,819
2023	22,055
2024	16,171
2025	15,916
Thereafter	160,410
Total future amortization of intangible assets	\$ 268,072

Long-term Debt (Tables)

12 Months Ended  
Dec. 31, 2020

[Debt Disclosure \[Abstract\]](#)  
[Schedule of convertible debt](#)

The following table summarizes the carrying value of the long-term convertible debt (in thousands):

	December 31,	
	2020	2019
<b>2024 Notes</b>		
Carrying value	\$ 81,462	\$ —
Unamortized debt discount and issuance costs	35,589	—
Principal amount	<u>\$ 117,051</u>	<u>\$ —</u>
Remaining amortization period (years)	3.9	
Fair value	<u>\$ 153,220</u>	<u>\$ —</u>
<b>2025 Notes</b>		
Carrying value	\$ 116,349	\$ 107,169
Unamortized debt discount and issuance costs	56,151	65,331
Principal amount	<u>\$ 172,500</u>	<u>\$ 172,500</u>
Remaining amortization period (years)	4.8	5.8
Fair value	<u>\$ 147,488</u>	<u>\$ 122,048</u>
<b>2021 Notes</b>		
Carrying value	\$ 26,557	\$ 123,237
Unamortized issuance costs	180	1,763
Principal amount	<u>\$ 26,737</u>	<u>\$ 125,000</u>
Remaining amortization period (years)	0.9	1.9
Fair value	<u>\$ 26,470</u>	<u>\$ 111,250</u>

**Commitments and  
Contingencies (Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Commitments and  
Contingencies Disclosure  
\[Abstract\]](#)  
[Summary of premiums and  
claims assumed](#)

The following summarizes premiums and claims assumed under the Reinsurance Agreements (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Reinsurance premiums assumed	\$ 19,130	\$ 83,325	\$ 3,242
Reinsurance premiums ceded	(3,275)	—	—
Claims assumed	14,812	72,594	3,934
Claims ceded	(422)	—	—
Claims-related administrative expenses	—	14,024	551
Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement	1,465	(3,293)	(1,243)
Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period	—	1,243	—
Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement	(502)	—	—
Reinsurance payments paid (received)	(3,039)	4,536	—
Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period	<u>\$ 4,002</u>	<u>\$ —</u>	<u>\$ 1,243</u>

[Summary of major customers](#)

The following table summarizes the partner included in our Services segment who represented at least 10.0% of our consolidated trade accounts receivable for the periods presented:

	<b>As of December 31,</b>	
	<b>2020</b>	<b>2019</b>
Cook County Health and Hospitals System	61.5 %	48.4 %

The following table summarizes those customers of our Services segment who represented at least 10.0% of our consolidated revenue for the periods presented:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Cook County Health and Hospitals Systems	20.3 %	*	*
Passport <sup>(1)</sup>	16.8 %	18.7 %	17.5 %
New Mexico Health Connections	*	10.9 %	*

<sup>1</sup> Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 8.8% of our consolidated revenues for the year ended December 31, 2020.

\* Represents less than 10.0% of the respective balance

Leases (Tables)

12 Months Ended  
Dec. 31, 2020

[Leases \[Abstract\]](#)

[Schedule of maturity of lease liabilities](#)

The following table summarizes our primary office leases as of December 31, 2020 (in thousands, other than term):

Location	Lease Termination Term (in years)	Future Minimum Lease Commitments	Letter of Credit Amount Required
Arlington, VA	11.1	\$ 38,675	\$ 1,579
Riverside, IL	10.3	44,605	232
Pune, India	2.7	2,318	—
Brea, CA	1.4	1,555	—

Maturity of lease liabilities (in thousands) as of December 31, 2020, is as follows:

2021	
2022	
2023	
2024	
2025	
Thereafter	
Total lease payments	
Less:	
Interest	

Present value of lease liabilities

<sup>(1)</sup> We have additional operating lease agreements for office space that have not yet commenced as of December 31, 2020. The minimum lease payments for those leases are \$0.7 million in 2022.

[Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms](#)

The following table summarizes the components of our lease expense (in thousands):

	For the Year Ended
	2020
Operating lease cost	\$ 15,848
Amortization of right-of-use assets	299
Interest expense	3
Variable lease cost	5,097
Total lease cost	\$ 21,247

Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:

Weighted average discount rate	20
Weighted average remaining lease term	

**Earnings (Loss) Per  
Common Share (Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Earnings Per Share  
\[Abstract\]](#)

[Computation of basic and  
diluted earnings per share](#)

The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Net loss	\$ (334,246)	\$ (305,580)	\$ (54,191)
Less:			
Net loss attributable to non-controlling interests	—	(3,609)	(1,533)
Net loss available for common shareholders - basic and diluted <sup>(1)</sup>	<u>\$ (334,246)</u>	<u>\$ (301,971)</u>	<u>\$ (52,658)</u>
Weighted-average common shares outstanding - basic and diluted <sup>(1)</sup>	<u>84,928</u>	<u>82,364</u>	<u>77,338</u>
<b>Loss per common share</b>			
Basic and diluted	\$ (3.94)	\$ (3.67)	\$ (0.68)

(1) Each Class B common unit of Evolent Health LLC can be exchanged (together with a corresponding number of shares of our Class B common stock) for one share of our Class A common stock. Therefore, shares of our Class B common stock are not considered dilutive shares for the purposes of calculating our diluted earnings (loss) per common share as related adjustment to net income (loss) available for common shareholders would equally offset the additional shares, resulting in the same earnings (loss) per common share.

Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Exchangeable Class B common stock	—	1,399	1,831
Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")	797	813	1,027
Stock options	1,141	1,324	2,517
Convertible senior notes	11,206	10,361	6,176
Total	<u>13,144</u>	<u>13,897</u>	<u>11,551</u>

[Schedule of antidilutive  
securities excluded from  
computation of earnings per  
share](#)

**Stock-based Compensation  
(Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Share-based Payment Arrangement \[Abstract\]](#)  
[Stock-based compensation expense](#)

Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):

	For the Year Ended December 31,		
	2020	2019	2018
<b>Award Type</b>			
Stock options	\$ 2,927	\$ 4,237	\$ 9,008
Performance-based stock options	75	448	447
RSUs	7,763	8,877	7,766
Performance-based RSUs	—	(388)	388
LSUs	3,841	2,444	—
Total compensation expense by award type	<u>\$ 14,606</u>	<u>\$ 15,618</u>	<u>\$ 17,609</u>
<b>Line Item</b>			
Cost of revenue	\$ 1,811	\$ 2,673	\$ 1,475
Selling, general and administrative expenses	12,795	12,945	16,134
Total compensation expense by financial statement line item	<u>\$ 14,606</u>	<u>\$ 15,618</u>	<u>\$ 17,609</u>

[Schedule of unrecognized compensation expense](#)

Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:

	As of December 31, 2020	
	Unrecognized Compensation Expense	Weighted Average Period
Stock options	\$ 1,971	1.55
RSUs	11,914	1.89
LSUs	6,694	1.77
Total	<u>\$ 20,579</u>	

[Option price assumptions](#)

The option price assumptions used for our stock option awards were as follows:

	For the Year Ended December 31,	
	2019	2018
Weighted-average fair value per option granted	\$ 6.52	\$ 6.30
<b>Assumptions:</b>		
Expected term (in years)	6.25	6.25
Expected volatility	51.6 %	38.9 %
Risk-free interest rate	1.9% - 2.7%	2.6% - 2.9%
Dividend yield	— %	— %

The price assumptions used for our leveraged stock unit awards were as follows:

	For the Year Ended December 31,	
	2020	2019
Weighted-average fair value per leveraged stock unit granted	\$ 8.90	\$ 6.52
<b>Assumptions:</b>		
Expected term	10 years	10 years
Expected volatility	62.1 %	51.7 %
Risk-free interest rate	0.85%	2.54%
Dividend yield	— %	— %

[Stock option information](#)

Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2019	4,828	\$ 9.44	6.01	\$ (1,880)
Granted	—	—		
Exercised	(416)	4.75		
Forfeited	(342)	14.80		
Outstanding as of December 31, 2020	4,070	\$ 9.32	5.25	\$ 12,578
Vested and expected to vest after December 31, 2020	3,951	\$ 9.17	4.95	\$ 27,095
Exercisable at December 31, 2020	3,475	\$ 8.48	4.63	\$ 26,228

[Performance-based stock option awards activity](#)

Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2019	268	\$ 10.27	6.17	\$ (326)
Outstanding as of December 31, 2020	268	10.27	6.17	(326)
Vested and expected to vest after December 31, 2020	268	\$ 10.27	6.17	\$ (326)

[Restricted stock units information](#)

Information with respect to our RSUs is presented below (in thousands, except for weighted-average grant-date fair value):

	Total RSUs	Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2019	1,493	\$ 12.23
Granted	1,202	8.88
Forfeited	(304)	11.38
Vested	(654)	11.11
Outstanding as of December 31, 2020	1,737	\$ 10.13

[Leveraged stock units activity](#)

Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:

	Leveraged Stock Units	Weighted Average Grant Date Fair Value	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2020	1,170	\$ 11.10	8.65	\$ 5,771
Vested and expected to vest after December 31, 2020	1,170	\$ 11.10	8.65	\$ 5,771

## Income Taxes (Tables)

12 Months Ended  
Dec. 31, 2020

### [Income Tax Disclosure \[Abstract\]](#)

#### [Schedule of loss before provision for income taxes](#)

Our loss before provision for income taxes was as follows (in thousands):

	For the Year Ended December 31,		
	2020	2019	2018
Domestic	\$ (339,632)	\$ (328,161)	\$ (54,681)
Foreign	1,833	1,045	530
Income (loss) before income taxes and non-controlling interests	<u>\$ (337,799)</u>	<u>\$ (327,116)</u>	<u>\$ (54,151)</u>

#### [Components of income tax expense \(benefit\)](#)

Components of income tax expense (benefit) (in thousands) consist of the following:

	For the Year Ended December 31,		
	2020	2019	2018
<b>Current</b>			
Federal	\$ (3,338)	\$ 1,175	\$ 458
State and local	200	14	9
Foreign	721	399	251
Total current tax expense (benefit)	<u>(2,417)</u>	<u>1,588</u>	<u>718</u>
<b>Deferred</b>			
Federal	(38,312)	(27,334)	(14,820)
State and local	(9,546)	(5,046)	(2,252)
Foreign	(303)	6	(49)
Total deferred tax expense (benefit)	<u>(48,161)</u>	<u>(32,374)</u>	<u>(17,121)</u>
Change in valuation allowance	47,025	9,250	16,443
Total tax expense (benefit)	<u>\$ (3,553)</u>	<u>\$ (21,536)</u>	<u>\$ 40</u>

#### [Schedule of reconciliation of the U.S. statutory tax rate to our effective tax rate](#)

A reconciliation of the U.S. statutory tax rate to our effective tax rate and our statutory rate is presented below:

	For the Year Ended December 31,		
	2020	2019	2018
U.S. statutory tax rate	21.0 %	21.0 %	21.0 %
U.S. state income taxes, net of U.S. federal tax benefit	2.9 %	4.4 %	3.6 %
Foreign earnings at other than U.S. rates	— %	(0.1)%	(0.2)%
Change in valuation allowance	(13.9)%	(2.8)%	(30.4)%
Benefit of net operating loss carryback provision	1.1 %	— %	— %
Non-deductible goodwill impairment	(11.2)%	(15.8)%	— %
Non-controlling interest	— %	(0.3)%	(0.7)%
Excess tax benefits on stock-based compensation	(0.3)%	(0.2)%	3.9 %
Federal and state research tax credits	— %	— %	4.5 %
Change in uncertain tax positions	— %	0.1 %	(1.1)%
Effect of investment in MHG	— %	(1.4)%	— %
Change in state rate	1.3 %	— %	— %
Change in indefinite reinvestment assertion for domestic subsidiaries	1.0 %	2.6 %	— %
Other, net	<u>(0.9)%</u>	<u>(0.8)%</u>	<u>(0.7)%</u>
Effective rate	<u>1.0 %</u>	<u>6.7 %</u>	<u>(0.1)%</u>

#### [Schedule of deferred tax assets and liabilities](#)

Significant components of the Company's deferred tax assets and liabilities (in thousands) were as follows:



	<b>As of December 31,</b>	
	<b>2020</b>	<b>2019</b>
<b>Deferred Tax Assets</b>		
Start-up and organizational costs	\$ 117	\$ 149
Goodwill	23,534	19,142
Operating lease liabilities	15,963	18,055
Accrued expenses	7,488	9,534
Stock based compensation	8,530	8,899
Net operating loss carryforwards	123,604	112,316
Federal and state research tax credits	1,828	1,828
Fixed assets	131	—
Interest deduction limitation	2,452	2,490
Outside basis differences	197	—
Other	8,640	1,451
Subtotal	192,484	173,864
Valuation allowance	(89,902)	(50,815)
Total deferred tax assets	102,582	123,049
<b>Deferred Tax Liabilities</b>		
Internally developed software costs	12,973	14,603
Intangible assets	48,857	58,655
Outside basis differences	—	5,865
Right-of-use assets - Operating	13,122	16,180
Contract fulfillment costs	6,375	9,510
Convertible debt	20,411	15,732
Fixed assets	—	796
Other	1,572	3,650
Total deferred tax liabilities	103,310	124,991
Net deferred tax assets (liabilities)	\$ (728)	\$ (1,942)

Changes in our valuation allowance (in thousands) were as follows:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Balance at beginning-of-year	\$ 50,815	\$ 37,037	\$ 53,201
Charged to costs and expenses	47,025	9,250	16,443
Charged to other accounts <sup>(1)</sup>	(7,938)	4,528	(32,607)
Balance at end-of-year	\$ 89,902	\$ 50,815	\$ 37,037

<sup>(1)</sup> Amounts charged to other accounts includes a decrease of \$7.9 million, an increase of \$4.5 million and a decrease of \$32.6 million charged to additional paid-in-capital for the years ended December 31, 2020, 2019 and 2018, respectively.

[Changes in unrecognized tax benefits](#)

Changes in our unrecognized tax benefits (in thousands) were as follows:

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
Balance at beginning-of-year	\$ 753	\$ 934	\$ 762
Gross increases - tax positions in prior period	—	—	934
Gross decreases - tax positions in prior period	—	—	(762)
Lapse of statute of limitations	(75)	(181)	—
Balance at end-of-year	\$ 678	\$ 753	\$ 934

**Investments In and  
Advances to Equity Method  
Investees (Tables)**

**12 Months Ended**

**Dec. 31, 2020**

**Equity Method Investments  
and Joint Ventures**

**[Abstract]**

**Schedule of carrying value of  
the associated assets and  
liabilities and the associated  
maximum loss exposure for  
the unconsolidated VIEs**

The following table represents the carrying value of the associated assets and liabilities and the associated maximum loss exposure for the unconsolidated VIEs indicated (in thousands):

	D E V H P a s s e s s
<b>Assets:</b>	
Current assets	\$ 271
Non current assets	
Total assets	\$ 272
<b>Liabilities:</b>	
Current liabilities	181
Non current liabilities	
Total liabilities	\$ 181
Investment carrying value	\$ 70
Loan and interest receivable	41
Guarantee	25
Maximum exposure	\$ 136

**Schedule of summarized  
equity method investees  
financial information**

The following table represents the aggregated summarized financial information as of and for the dates indicated (in thousands):

	Dec 2020	
Current assets	\$	69,
Non-current assets		3,
Current liabilities		54,
Non-current liabilities		20,
Non-controlling interests		2,
	<b>For the Year Ended</b>	
	<b>2020</b>	<b>2019</b>
Revenue	\$ 1,766,641	\$ 387
Operating income (loss)	8,112	(60)
Net income (loss)	6,606	(73)
Net income (loss) attributable to entity	5,632	(23)

**Non-controlling Interests  
(Tables)**

**12 Months Ended  
Dec. 31, 2020**

**[Noncontrolling Interest](#)**

**[\[Abstract\]](#)**

**[Schedule of changes in non-controlling interests](#)**

Changes in non-controlling interests (in thousands) for the periods presented were as follows:

	<b>For the Year Ended December 31,</b>	
	<b>2020</b>	<b>2019</b>
Non-controlling interests balance as of beginning of period	\$ 6,689	\$ 45,532
Decrease in non-controlling interests as a result of Class B Exchanges	—	(42,377)
Issuance of non-controlling interest	25,749	6,500
Net loss attributable to non-controlling interests	—	(3,609)
Disposal of assets	(6,689)	—
Redemption of Sponsor's equity	(25,749)	—
Reclassification of non-controlling interests	—	643
Non-controlling interests balance as of end of period	<u>\$ —</u>	<u>\$ 6,689</u>

**Fair Value Measurement  
(Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Fair Value Disclosures  
\[Abstract\]](#)

[Summary of assets at fair  
value on recurring basis](#)

The following table summarizes the Company's assets and liabilities measured at fair value on a recurring basis (in thousands):

	December 31, 2020			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 5,877	\$ —	\$ —	\$ 5,877
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 5,877</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 5,877</b>
<b>Liabilities</b>				
Warrants <sup>(3)</sup>	\$ —	\$ —	\$ 13,730	\$ 13,730
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 13,730</b>	<b>\$ 13,730</b>
<b>December 31, 2019</b>				
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 3,698	\$ —	\$ —	\$ 3,698
Restricted cash and restricted investments <sup>(1)</sup>	1,004	—	—	1,004
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 4,702</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 4,702</b>
<b>Liabilities</b>				
Contingent consideration <sup>(2)</sup>	\$ —	\$ —	\$ 9,883	\$ 9,883
Warrants <sup>(3)</sup>	—	—	7,092	7,092
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 16,975</b>	<b>\$ 16,975</b>

<sup>(1)</sup> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December 31, 2020 and December 31, 2019, as presented in the tables above.

<sup>(2)</sup> Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4.

<sup>(3)</sup> Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9.

[Summary of liabilities at fair  
value on recurring basis](#)

The following table summarizes the Company's assets and liabilities measured at fair value on a recurring basis (in thousands):

	December 31, 2020			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 5,877	\$ —	\$ —	\$ 5,877
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 5,877</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 5,877</b>
<b>Liabilities</b>				
Warrants <sup>(3)</sup>	\$ —	\$ —	\$ 13,730	\$ 13,730
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 13,730</b>	<b>\$ 13,730</b>

	December 31, 2019			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents <sup>(1)</sup>	\$ 3,698	\$ —	\$ —	\$ 3,698
Restricted cash and restricted investments <sup>(1)</sup>	1,004	—	—	1,004
<b>Total fair value of assets measured on a recurring basis</b>	<b>\$ 4,702</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 4,702</b>
<b>Liabilities</b>				
Contingent consideration <sup>(2)</sup>	\$ —	\$ —	\$ 9,883	\$ 9,883
Warrants <sup>(3)</sup>	—	—	7,092	7,092
<b>Total fair value of liabilities measured on a recurring basis</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 16,975</b>	<b>\$ 16,975</b>

<sup>(1)</sup> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December 31, 2020 and December 31, 2019, as presented in the tables above.

<sup>(2)</sup> Represents the fair value of earn-out consideration related to the Passport, GlobalHealth, Inc. and other transactions, as described in Note 4.

<sup>(3)</sup> Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 9.

[Changes in contingent consideration measured at fair value](#)

The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands):

	For the Year Ended December 31,	
	2020	2019
Balance as of beginning of period	\$ 16,975	\$ 8,800
Additions	—	12,992
Settlements	(3,500)	(800)
Realized and unrealized gains (losses), net	255	(4,017)
Balance as of end of period	<b>\$ 13,730</b>	<b>\$ 16,975</b>

[Valuation techniques and significant unobservable inputs of Level 3 fair value measurements](#)

The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:

	December 31, 2020			
	Fair Value	Valuation Technique	Significant Unobservable Inputs	Assumption or Input Ranges
Warrants	\$ 13,730	Black-Scholes	Stock price volatility	62.2 %
			Annual risk free rate	0.2 %
	December 31, 2019			
	Fair Value	Valuation Technique	Significant Unobservable Inputs	Assumption or Input Ranges
Passport contingent consideration	\$ 3,700	Real options approach	Risk-adjusted recurring revenue CAGR	93.9 % <sup>(1)</sup>
			Discount rate/time value	4.8% - 5.3%
GlobalHealth contingent consideration	\$ 5,200	Monte Carlo simulation	Stock price volatility	80.0 % <sup>(2)</sup>
Other contingent considerations	\$ 983	Management estimate	Adjusted EBITDA	\$ 19,235
Warrants	\$ 7,092	Black-Scholes	Stock price volatility	55.0 %
			Annual risk free rate	1.7 %

<sup>(1)</sup> The risk-adjusted recurring revenue CAGR is calculated over the five-year period 2017-2021. Given that there was no recurring revenue in 2016 and 2017, the calculation of the 2017 and 2018 growth rates is based on theoretical 2016 and 2017 recurring revenue of \$1.0 million, resulting in a higher growth rate.

<sup>(2)</sup> Equity volatility based on Evolent's daily stock price returns for a look-back period corresponding to the time until the second test date. The large one-day stock price drop on November 27, 2019, was excluded from the volatility calculation.

**Related Parties (Tables)****12 Months Ended  
Dec. 31, 2020****[Related Party Transactions](#)****[\[Abstract\]](#)****[Schedule of related parties](#)**

The following table presents assets and liabilities attributable to our related parties (in thousands):

	De
	2020
<b>Assets</b>	
Accounts receivable, net	\$ 9
Prepaid expenses and other current assets	
Customer advance for regulatory capital requirements, net of allowances	
Prepaid expenses and other noncurrent assets, net of allowances	4
<b>Liabilities</b>	
Accounts payable	\$ 2
Accrued liabilities	1
Reserve for claims and performance-based arrangements	

The following table presents revenues and expenses attributable to our related parties (in thousands):

	<b>For the Year Ended December 31,</b>		
	2020	2019	2018
<b>Revenue</b>			
Transformation services	\$ 5,416	\$ 4,009	\$ 10,540
Platform and operations services	226,339	60,325	37,490
<b>Expenses</b>			
Cost of revenue (exclusive of depreciation and amortization expenses)	2,863	28,954	9,451
Selling, general and administrative expenses	113	991	917

**Repositioning and Other  
Changes (Tables)**

**[Restructuring and Related  
Activities \[Abstract\]](#)**

**[Costs associated with the  
Repositioning Plan](#)**

**12 Months Ended  
Dec. 31, 2020**

The following tables provide a summary of our total costs associated with the Repositioning Plan for the year ended December 31, 2020, by major type of cost:

	<b>Incurred For the Year Ended December 31, 2020</b>	<b>Total Amount Expected to be Incurred in the Repositioning Plan</b>	<b>Cumulative through December 31, 2020</b>
Severance and termination benefits	\$ —	\$ 2,500	\$ 2,500
Office space consolidation	—	2,100	2,100
Professional services	1,275	4,200	4,200
Total	\$ 1,275	\$ 8,800	\$ 8,800

Segment Reporting (Tables)

12 Months Ended  
Dec. 31, 2020

[Segment Reporting](#)  
[\[Abstract\]](#)

[Reconciliation of revenue](#)  
[from segments to consolidated](#)

The following tables present our segment information (in thousands):

	Services	True Health	Intersegment Eliminations	Consolidated
<b>Revenue</b>				
<b>For the Year Ended December 31, 2020</b>				
Services:				
Transformation services	\$ 11,990	\$ —	\$ —	\$ 11,990
Platform and operations services	913,005	—	(19,939)	893,066
Services revenue	924,995	—	(19,939)	905,056
True Health:				
Premiums	—	117,579	(202)	117,377
Total revenue	\$ 924,995	\$ 117,579	\$ (20,141)	\$ 1,022,433
<b>For the Year Ended December 31, 2019</b>				
Services:				
Transformation services	\$ 15,203	\$ —	\$ —	\$ 15,203
Platform and operations services	671,919	—	(12,481)	659,438
Services revenue	687,122	—	(12,481)	674,641
True Health:				
Premiums	—	172,722	(980)	171,742
Total revenue	\$ 687,122	\$ 172,722	\$ (13,461)	\$ 846,383
<b>For the Year Ended December 31, 2018</b>				
Services:				
Transformation services	\$ 32,916	\$ —	\$ —	\$ 32,916
Platform and operations services	514,515	—	(14,325)	500,190
Services revenue	547,431	—	(14,325)	533,106
True Health:				
Premiums	—	94,763	(806)	93,957
Total revenue	\$ 547,431	\$ 94,763	\$ (15,131)	\$ 627,063
<b>For the Year Ended December 31, 2020</b>				
	Services	True Health	Segments Total	
Adjusted EBITDA	\$ 48,573	\$ (7,137)	\$ 41,436	
<b>For the Year Ended December 31, 2019</b>				
Adjusted EBITDA	\$ (14,667)	\$ 3,699	\$ (10,968)	
<b>For the Year Ended December 31, 2018</b>				
Adjusted EBITDA	\$ 21,310	\$ 1,915	\$ 23,225	

[Reconciliation of Adjusted EBITDA to net loss](#)

The following table presents our reconciliation of segments total Adjusted EBITDA to net loss attributable to Evolent Health, Inc. (in thousands):



	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Net loss attributable to common shareholders of Evolent Health, Inc.</b>	\$ (334,246)	\$ (301,971)	\$ (52,658)
Less:			
Interest income	3,164	3,987	3,440
Interest expense	(28,337)	(14,534)	(5,484)
(Provision) benefit for income taxes	3,553	21,536	(40)
Depreciation and amortization expenses	(61,475)	(60,913)	(44,515)
Equity method investment impairment	(47,133)	—	—
Loss on extinguishment of debt, net	(4,789)	—	—
Gain (loss) from equity method investees	10,039	(9,465)	(4,736)
Gain (loss) on disposal of assets and consolidation	(698)	9,600	—
Goodwill impairment	(215,100)	(199,800)	—
Change in fair value of contingent consideration and indemnification asset	(3,860)	3,997	4,104
Other income (expense), net	(119)	(492)	109
Net loss attributable to non-controlling interests	—	3,609	1,533
ASC 606 transition adjustments	—	—	(4,498)
Purchase accounting adjustments	—	(1,915)	(861)
Repositioning costs	(1,275)	—	—
Stock-based compensation expense	(14,606)	(15,618)	(17,609)
Severance costs	(8,986)	(17,350)	(2,205)
Amortization of contract cost assets	(3,944)	(2,876)	(2,456)
Acquisition costs	(2,116)	(10,769)	(2,665)
<b>Adjusted EBITDA</b>	<b>\$ 41,436</b>	<b>\$ (10,968)</b>	<b>\$ 23,225</b>

**Reserves for Claims and  
Performance-Based  
Arrangements (Tables)**

**12 Months Ended**

**Dec. 31, 2020**

[Insurance \[Abstract\]](#)

[Activity in claims reserves](#)

Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2020 and 2019, was as follows (in thousands):

	For the Year Ended December 31,					
	2020			2019		
	Services <sup>(1)(2)</sup>	True Health <sup>(2)</sup>	Total	Services <sup>(1)</sup>	True Health <sup>(2)</sup>	Total
Beginning balance	\$ 54,510	\$ 6,640	\$ 61,150	\$ 17,715	\$ 9,880	\$ 27,595
Incurring costs related to current year	420,597	89,008	509,605	\$ 267,064	\$ 136,303	\$ 403,367
Incurring costs related to prior year	2,878	799	3,677	(334)	(529)	(863)
Paid costs related to current year	464,571	79,640	544,211	220,050	61,621	281,671
Paid costs related to prior year	9,598	6,949	16,547	8,165	8,092	16,257
Change during the year	(50,694)	3,218	(47,476)	38,515	66,061	104,576
Impact of consolidation on reserves for claims and performance-based arrangements	164,297	—	164,297	—	—	—
Other adjustments <sup>(3)</sup>	10,714	—	10,714	(1,720)	(69,301)	(71,021)
Ending balance	\$ 178,827	\$ 9,858	\$ 188,685	\$ 54,510	\$ 6,640	\$ 61,150

<sup>(1)</sup> Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. EVH Passport operations are not included in 2019 activity.

<sup>(2)</sup> There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. The number of claims processed for the Services and True Health segments for years ended December 31, 2020 and 2019 were 2,279,228 and 317,187, respectively.

<sup>(3)</sup> Other adjustments to reserves for claims and performance-based arrangements for Services reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf. Other adjustments related to EVH Passport and our True Health segment represent premiums received less administrative expenses related to the reinsurance agreements. Refer to Note 10 for additional information about the reinsurance agreements.

Investments (Tables)

12 Months Ended  
Dec. 31, 2020

[Investments \[Abstract\]](#)

[Summary investment holdings](#)

The amortized cost, gross unrealized gains and losses, and fair value of our investments as measured using Level 2 inputs as of December 31, 2020 and 2019 (in thousands) were as follows:

	December 31, 2020				December 31, 2019			
	Amortized Cost	Gross Unrealized		Fair Value	Amortized Cost	Gross Unrealized		Fair Value
		Gains	Losses			Gains	Losses	
U.S. Treasury bills	\$ 8,909	\$ 384	\$ —	\$ 9,293	\$ 10,784	\$ 270	\$ —	\$ 11,054
Corporate bonds	1,707	132	—	1,839	1,705	70	—	1,775
Collateralized mortgage obligations	3,433	149	—	3,582	5,472	56	(5)	5,523
Corporate stock	130	—	—	130	—	—	—	—
Yankees	598	49	—	647	597	30	—	627
Total investments	\$ 14,777	\$ 714	\$ —	\$ 15,491	\$ 18,558	\$ 426	\$ (5)	\$ 18,979

[Investments classified by contractual maturity date](#)

The amortized cost and fair value of our investments by contractual maturities as of December 31, 2020 and 2019 (in thousands) were as follows:

	December 31, 2020		December 31, 2019	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Due in one year or less	\$ 3,858	\$ 3,915	\$ 1,807	\$ 1,810
Due after one year through five years	10,919	11,576	16,121	16,542
Due after five years through ten years	—	—	630	627
Total investments	\$ 14,777	\$ 15,491	\$ 18,558	\$ 18,979

Quarterly Results of  
Operations (unaudited)  
(Tables)

12 Months Ended

Dec. 31, 2020

[Quarterly Financial Data](#)

[\[Abstract\]](#)

[Unaudited consolidated  
quarterly results of operations](#)

The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:

	For the Three Months Ended		
	December 31	September 30	June 30
<b>2020</b>			
Total revenue	\$ 271,923	\$ 264,593	\$ 264,593
Total operating expenses	276,659	277,512	277,512
Net loss	(13,803)	(38,170)	(38,170)
Net loss attributable to non-controlling interests	822	(822)	(822)
Net loss attributable to common shareholders of Evolent Health, Inc.	(14,625)	(37,348)	(37,348)
<i>Loss per common share</i>			
Basic and Diluted	\$(0.17)	\$(0.44)	\$(0.44)
<b>2019</b>			
Total revenue	\$ 236,525	\$ 220,143	\$ 220,143
Total operating expenses <sup>(1)</sup>	451,120	240,281	240,281
Net loss	(199,293)	(25,738)	(25,738)
Net loss attributable to non-controlling interests	(1,197)	(217)	(217)
Net loss attributable to common shareholders	(198,096)	(25,521)	(25,521)
<i>Loss per common share</i>			
Basic and Diluted	\$(2.36)	\$(0.30)	\$(0.30)

<sup>(1)</sup> The Company recorded goodwill impairment of \$199.8 million during the three months ended December 31, 2019.

**Supplemental Cash Flow  
Information (Tables)**

**12 Months Ended  
Dec. 31, 2020**

[Supplemental Cash Flow  
Elements \[Abstract\]](#)  
[Schedule of cash flow,  
supplemental disclosures](#)

The following represents supplemental cash flow information (in thousands):

	<b>For the Year Ended December 31,</b>		
	<b>2020</b>	<b>2019</b>	<b>2018</b>
<b>Supplemental Disclosure of Non-cash Investing and Financing Activities</b>			
Class A and Class B common stock issued in connection with business combinations	\$ —	\$ 23,556	\$ 83,173
Change in goodwill from measurement period adjustments/business combinations	2,200	(351)	(117)
Acquisition consideration payable	4,185	800	—
Settlement of escrow related to asset acquisition	—	—	2,519
Settlement of indemnification asset	—	—	1,004
Accrued property and equipment purchases	11	(527)	368
Accrued deferred financing costs	—	—	607
Consideration for asset acquisitions or business combinations	—	16,000	500
<i>Effects of Leases</i>			
Operating cash flows from operating leases	13,708	12,330	—
Leased assets obtained in exchange for operating lease liabilities	(2,170)	30,463	—
<i>Effects of Class B Exchanges</i>			
Decrease in non-controlling interests as a result of Class B Exchanges	—	42,377	34,682
Decrease in deferred tax liability as a result of securities offerings and exchanges	—	(22)	652
<b>Supplemental Disclosures</b>			
Cash paid for interest	13,352	5,037	2,500
Cash paid for taxes, net	9,679	1,484	343

**Organization (Details)**  
**\$ in Thousands**

**12 Months  
Ended  
Dec. 31, 2020  
USD (\$)  
segment  
shares**

**Dec. 31,  
2019  
USD (\$)  
shares**

**Organization, Consolidation and Presentation of Financial Statements**

**[Abstract]**

Number of operating segments | segment

2

Cash and cash equivalents | \$

\$ 340,490

\$ 101,008

Class B Common Stock

**Class of Stock [Line Items]**

Common stock, shares outstanding (in shares) | shares

0

0

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Operating  
Segments (Details)**

**12 Months Ended**

**Dec. 31, 2020  
segment**

[Accounting Policies \[Abstract\]](#)

[Number of operating segments](#) 2

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Restricted Cash  
and Restricted Investments  
(Details) - USD (\$)  
\$ in Thousands**

**Restricted Cash and Cash Equivalents Items [Line Items]**

	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
<u>Total restricted cash and restricted investments</u>	\$ 21,707	\$ 28,340		
<u>Current restricted investments</u>	0	704		
<u>Current restricted cash</u>	14,437	19,376		
<u>Total current restricted cash and restricted investments</u>	14,437	20,080		
<u>Non-current restricted investments</u>	616	113		
<u>Non-current restricted cash</u>	6,654	8,147		
<u>Total non-current restricted cash and restricted investments</u>	7,270	8,260		
<u>Cash and cash equivalents</u>	340,490	101,008		
<u>Restricted cash and restricted investments</u>	21,707	28,340		
<u>Restricted investments included in restricted cash and restricted investments</u>	(616)	(817)		
<u>Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</u>	361,581	128,531	\$	\$
<u>Collateral for letters of credit for facility leases</u>			388,325	295,363

**Restricted Cash and Cash Equivalents Items [Line Items]**

<u>Total restricted cash and restricted investments</u>	3,510	3,610		
<u>Restricted cash and restricted investments</u>	3,510	3,610		
<u>Collateral with financial institutions</u>				

**Restricted Cash and Cash Equivalents Items [Line Items]**

<u>Total restricted cash and restricted investments</u>	4,743	5,742		
<u>Restricted cash and restricted investments</u>	4,743	5,742		
<u>Claims processing services</u>				

**Restricted Cash and Cash Equivalents Items [Line Items]**

<u>Total restricted cash and restricted investments</u>	12,127	18,171		
<u>Restricted cash and restricted investments</u>	12,127	18,171		
<u>Other</u>				

**Restricted Cash and Cash Equivalents Items [Line Items]**

<u>Total restricted cash and restricted investments</u>	1,327	817		
<u>Restricted cash and restricted investments</u>	\$ 1,327	817		
<u>Bank time deposits</u>				

**Restricted Cash and Cash Equivalents Items [Line Items]**

<u>Total restricted cash and restricted investments</u>		4,700		
<u>Restricted cash and restricted investments</u>		4,700		
<u>Collateral with financial institutions, money market funds</u>				

**Restricted Cash and Cash Equivalents Items [Line Items]**



Total restricted cash and restricted investments

1,000

Restricted cash and restricted investments

\$ 1,000

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Estimated Useful  
Life of Property, Plant and  
Equipment (Details)**

**12 Months Ended**

**Dec. 31, 2020**

Computer hardware

**Property and Equipment [Line Items]**

Useful life 3 years

Computer software

**Property and Equipment [Line Items]**

Useful life 1 year

Internal-use software development costs

**Property and Equipment [Line Items]**

Useful life 5 years

Minimum | Furniture and equipment

**Property and Equipment [Line Items]**

Useful life 3 years

Maximum | Furniture and equipment

**Property and Equipment [Line Items]**

Useful life 7 years

**Basis of Presentation,  
 Summary of Significant  
 Accounting Policies and  
 Change in Accounting  
 Principle - Research and  
 Development Costs (Details)**

**12 Months Ended**

**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**- USD (\$)**

**\$ in Millions**

**[Accounting Policies \[Abstract\]](#)**

**[Research and development costs](#) \$ 15.1      \$ 19.8      \$ 18.2**

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Notes Receivable  
(Details)**

**Jun. 30, 2019  
USD (\$)**

[Passport Note | Notes Receivable](#)

[Short-term Debt \[Line Items\]](#)

[Face amount](#) \$ 40,000,000.0

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Goodwill (Details)  
- reporting\_unit**

**1 Months Ended 12 Months Ended**

**Oct. 31, 2020 Oct. 31, 2019 May 31, 2020 Dec. 31, 2020**

**[Accounting Policies \[Abstract\]](#)**

**[Number of reporting units for goodwill testing](#) 3 3 3 4**

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Intangible Assets,  
Net (Details)**

**12 Months Ended**

**Dec. 31, 2020**

[Corporate trade name | Minimum](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 10 years

[Corporate trade name | Maximum](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 20 years

[Customer relationships | Minimum](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 10 years

[Customer relationships | Maximum](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 25 years

[Technology](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 5 years

[Provider network contracts | Minimum](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 4 years

[Provider network contracts | Maximum](#)

**[Finite-Lived Intangible Assets \[Line Items\]](#)**

[Useful life](#) 5 years

**Basis of Presentation,  
Summary of Significant  
Accounting Policies and  
Change in Accounting  
Principle - Stock-based  
Compensation (Details) -  
Stock options**

**12 Months Ended**

**Dec. 31, 2020**

**[Share-based Compensation Arrangement by Share-based Payment Award \[Line Items\]](#)**

[Vesting period](#)

4 years

[Expiration period](#)

10 years

Recently Issued Accounting Standards (Details) - USD (\$) \$ in Thousands	12 Months Ended			Jan.	Dec. 31,
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2017	01, 2019	2018
<a href="#">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</a>					
<a href="#">Operating lease, right-of-use asset</a>	\$ 57,799	\$ 72,173			
<a href="#">Present value of lease liabilities</a>	69,883				
<a href="#">Cumulative effect adjustment</a>	\$ (619,600)	\$ (929,047)	\$ (1,046,306)	\$	(1,189,356)
<a href="#">Accounting Standards Update [Extensible List]</a>	us- gaap:AccountingStandardsUpdate201613Member	us- gaap:AccountingStandardsUpdate201613Member	us- gaap:AccountingStandardsUpdate201409Member		
<a href="#">Cumulative Effect, Period of Adoption, Adjustment</a>					
<a href="#">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</a>					
<a href="#">Cumulative effect adjustment</a>		\$ 2,970	\$ (17,309)		
<a href="#">Retained Earnings (Accumulated Deficit)</a>					
<a href="#">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</a>					
<a href="#">Cumulative effect adjustment</a>	\$ 589,178	251,962	(85,952)		\$ (50,009)
<a href="#">Retained Earnings (Accumulated Deficit)</a>					
<a href="#">Cumulative Effect, Period of Adoption, Adjustment</a>					
<a href="#">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</a>					
<a href="#">Cumulative effect adjustment</a>		\$ 2,970	\$ (16,715)		
<a href="#">Accounting Standards Update 2016-02</a>					
<a href="#">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</a>					
<a href="#">Operating lease, right-of-use asset</a>				\$	51,400
<a href="#">Present value of lease liabilities</a>				\$	47,400



Transactions - Passport (Details) - USD (\$)	Dec. 31, 2020	Nov. 16, 2020	Sep. 01, 2020	Jun. 06, 2019	May 28, 2019	1 Months	3	12 Months Ended			Jun. 18, 2019
						Ended	Months	Dec. 31,	Dec. 31,	Dec. 31,	
						Jan. 31,	Dec. 31,	2020	2019	2018	
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Amount received from escrow in asset acquisition</a>								\$ 0	\$ 0	\$ 500,000	
<a href="#">Payments to redeem Sponsors' equity</a>								\$ 20,000,000 <sup>0</sup>		\$ 0	
<a href="#">Passport Asset Acquisition</a>											
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Cash and equivalents</a>			\$ 159,800,000								
<a href="#">Debt securities, available-for-sale</a>			88,600,000								
<a href="#">Receivables related to unsettled sales of securities</a>			43,000,000.0								
<a href="#">Other assets</a>			50,200,000								
<a href="#">Accrued medical expenses</a>			164,800,000								
<a href="#">Accrued liabilities</a>			50,000,000.0								
<a href="#">Molina</a>											
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Asset Purchase Agreement, escrow payments</a>			\$ 20,000,000.0								
<a href="#">Molina   Subsequent event</a>											
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Amount received from escrow in asset acquisition</a>						\$ 20,000,000.0					
<a href="#">Passport Note</a>											
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Interest rate</a>											6.50%
<a href="#">Proceeds from collection of notes receivable</a>	\$ 40,000,000.0										
<a href="#">Proceeds from interest received</a>	\$ 3,600,000										
<a href="#">Passport Note   Notes Receivable</a>											
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Notes receivable, net</a>											\$ 40,000,000.0
<a href="#">Passport   Variable Interest Entity</a>											
<a href="#">Business Acquisition [Line Items]</a>											
<a href="#">Payments to acquire interest</a>					\$ 70,000,000.0						
<a href="#">Interest in investment</a>	30.00%	30.00%			30.00%		30.00%				
<a href="#">Performance bond amount</a>				\$ 25,000,000.0							
<a href="#">Payments to acquire equity method investments, amount held back</a>								\$ 16,200,000			
<a href="#">Payments to redeem Sponsors' equity</a>	\$ 20,000,000.0										

Transactions - Gain (Loss) on Disposal of Assets and Consolidation (Details) - USD (\$) \$ in Thousands	3 Months Ended		12 Months Ended		
	Sep. 01, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<a href="#">Business Acquisition [Line Items]</a>					
<a href="#">Gain (loss) on disposal of assets and consolidation</a>			\$ (698)	\$ 9,600	\$ 0
<a href="#">Passport</a>					
<a href="#">Business Acquisition [Line Items]</a>					
<a href="#">Gain (loss) on disposal of assets and consolidation</a>	\$ 5,700				
<a href="#">Vivant</a>					
<a href="#">Business Acquisition [Line Items]</a>					
<a href="#">Gain (loss) on disposal of assets and consolidation</a>		\$ (6,400)			

Revenue Recognition - Disaggregation of Revenue (Details) - USD (\$) \$ in Thousands	3 Months Ended								12 Months Ended		
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<b>Disaggregation of Revenue</b> <b>[Line Items]</b>											
Total revenue	\$ 271,923	\$ 264,593	\$ 238,632	\$ 247,285	\$ 236,525	\$ 220,143	\$ 191,959	\$ 197,756	\$ 1,022,433	\$ 846,383	\$ 627,063
<b>Transformation services</b> <b>Disaggregation of Revenue</b> <b>[Line Items]</b>											
Total revenue	[1]								11,990	15,203	32,916
<b>Platform and operations services</b> <b>Disaggregation of Revenue</b> <b>[Line Items]</b>											
Total revenue	[1]								893,066	659,438	500,190
<b>Services   Transformation services</b> <b>Disaggregation of Revenue</b> <b>[Line Items]</b>											
Total revenue									11,990	15,203	32,916
<b>Services   Platform and operations services   Clinical solutions</b> <b>Disaggregation of Revenue</b> <b>[Line Items]</b>											
Total revenue									690,391	458,991	228,464
<b>Services   Platform and operations services   Administrative solutions</b> <b>Disaggregation of Revenue</b> <b>[Line Items]</b>											
Total revenue									\$ 202,547	\$ 198,618	\$ 264,104

[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

**Revenue Recognition -  
Transaction Price Allocated  
to the Remaining  
Performance Obligations  
(Details)  
\$ in Millions**

**Dec. 31,  
2020  
USD (\$)**

**Revenue from Contract with Customer [Abstract]**

Revenue, remaining performance obligation \$ 87.8

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]:  
2021-01-01

**Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]**

Revenue, remaining performance obligation, percentage 54.00%

Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]:  
2022-01-01

**Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]**

Revenue, remaining performance obligation, percentage 86.00%

Revenue, remaining performance obligation, expected timing of satisfaction, period 12 months

**Revenue Recognition -  
Contract Balances (Details) -  
USD (\$)  
\$ in Thousands**

**12 Months Ended  
Dec. 31, 2020 Dec. 31, 2019**

**Revenue from Contract with Customer [Abstract]**

<u>Short-term receivables</u>	\$ 122,167	\$ 71,707
<u>Long-term receivables</u>	4,554	709
<u>Short-term contract assets</u>	329	1,751
<u>Long-term contract assets</u>	0	999
<u>Short-term deferred revenue</u>	14,327	19,828
<u>Long-term deferred revenue</u>	3,593	1,330
<b><u>Contract Assets Rollforward</u></b>		
<u>Beginning balance</u>	2,750	
<u>Reclassification to receivables, as the right to consideration becomes unconditional</u>	(2,539)	
<u>Contract assets recognized, net of reclassification to receivables</u>	118	
<u>Ending balance</u>	329	2,750
<b><u>Deferred Revenue Rollforward</u></b>		
<u>Beginning balance</u>	21,158	
<u>Reclassification to revenue, as a result of performance obligations satisfied</u>	(18,481)	
<u>Cash received in advance of satisfaction of performance obligations</u>	15,243	
<u>Ending balance</u>	17,920	21,158
<u>Revenue recognized from performed obligations</u>	\$ 12,100	\$ 1,100

**Revenue Recognition -  
Contract Costs (Details) -  
USD (\$)  
\$ in Thousands**

**12 Months Ended**

**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**Capitalized Contract Cost [Line Items]**

<u>Contract cost amortization</u>	\$ 21,195	\$ 5,723	\$ 2,703
-----------------------------------	-----------	----------	----------

Capitalized contract cost, amortization period 5 years

Bonuses and Commissions

**Capitalized Contract Cost [Line Items]**

<u>Contract cost assets</u>	\$ 3,300	4,700	
-----------------------------	----------	-------	--

<u>Contract cost amortization</u>	1,900	1,000	300
-----------------------------------	-------	-------	-----

Contract Fulfillment Costs

**Capitalized Contract Cost [Line Items]**

<u>Contract cost assets</u>	23,400	31,800	
-----------------------------	--------	--------	--

<u>Contract cost amortization</u>	\$ 13,000	\$ 4,700	\$ 2,400
-----------------------------------	-----------	----------	----------

**Credit Losses - Accounts  
Receivable (Narrative)  
(Details) - USD (\$)  
\$ in Thousands**

**Dec. 31, 2020 Dec. 31, 2019**

**Accounts Receivable, Noncurrent, Past Due [Line Items]**

<u>Percentage of receivables, current</u>	59.00%	
<u>Accounts receivable, net</u>	\$ 173,700	
<u>Allowance for doubtful accounts</u>	\$ 7,056	\$ 41
<u>Past due less than 60 days</u>		

**Accounts Receivable, Noncurrent, Past Due [Line Items]**

<u>Percentage of receivables, past due</u>	24.00%	
<u>Past due less than 120 days</u>		

**Accounts Receivable, Noncurrent, Past Due [Line Items]**

<u>Percentage of receivables, past due</u>	37.00%	
--	--------	--

**Credit Losses - Schedule of  
Changes in Allowance for  
Accounts Receivable  
(Details)  
\$ in Thousands**

**12 Months Ended  
Dec. 31, 2020  
USD (\$)**

**Adjustment**

Allowance for doubtful accounts, beginning balance \$ (41)

Passport acquisition (2,582)

Provision for credit losses (3,283)

Charge-offs 1,665

Allowance for doubtful accounts, ending balance (7,056)

Cumulative Effect, Period of Adoption, Adjustment

**Adjustment**

Allowance for doubtful accounts, beginning balance \$ (2,815)



**Credit Losses - Investments  
Held at Amortized Cost  
(Details) - USD (\$)**

**12 Months Ended  
Dec. 31, 2020 Dec. 31, 2019**

<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Interest Income</u>	\$ 1,123,000	\$ 431,000
<u>U.S. Treasury bills</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Interest Income</u>	239,000	249,000
<u>Held-to-maturity, allowance for credit loss</u>	0	
<u>Corporate bonds</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Interest Income</u>	524,000	49,000
<u>Collateralized mortgage obligations</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Interest Income</u>	339,000	112,000
<u>Corporate stock</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Interest Income</u>	0	0
<u>Yankees</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Interest Income</u>	21,000	21,000
<u>Level 2</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Amortized Costs</u>	14,777,000	18,558,000
<u>Level 2   U.S. Treasury bills</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Amortized Costs</u>	8,909,000	10,784,000
<u>Level 2   Corporate bonds</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Amortized Costs</u>	1,707,000	1,705,000
<u>Level 2   Collateralized mortgage obligations</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Amortized Costs</u>	3,433,000	5,472,000
<u>Level 2   Corporate stock</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Amortized Costs</u>	130,000	0
<u>Level 2   Yankees</u>		
<b><u>Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]</u></b>		
<u>Amortized Costs</u>	\$ 598,000	\$ 597,000

**Property and Equipment,  
Net (Details) - USD (\$)  
\$ in Thousands**

**12 Months Ended**

**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**Property and Equipment [Line Items]**

<u>Total property and equipment</u>	\$ 175,096	\$ 140,169	
<u>Accumulated depreciation and amortization expenses</u>	(88,856)	(55,014)	
<u>Total property and equipment, net</u>	86,240	85,155	
<u>Depreciation expense</u>	28,300	23,300	\$ 17,300
<u>Capitalized computer software, amortization</u>	24,300	18,700	12,400

Computer hardware

**Property and Equipment [Line Items]**

<u>Total property and equipment</u>	18,866	11,604	
-------------------------------------	--------	--------	--

Furniture and equipment

**Property and Equipment [Line Items]**

<u>Total property and equipment</u>	3,559	3,649	
-------------------------------------	-------	-------	--

Internal-use software development costs

**Property and Equipment [Line Items]**

<u>Total property and equipment</u>	137,085	112,501	
<u>Total property and equipment, net</u>	75,300	74,900	
<u>Capitalized computer software additions</u>	24,600	30,900	\$ 33,100

Leasehold improvements

**Property and Equipment [Line Items]**

<u>Total property and equipment</u>	\$ 15,586	\$ 12,415	
-------------------------------------	-----------	-----------	--

Goodwill and Intangible Assets, Net - Impairment Testing (Details)	1 Months Ended			3 Months Ended			6 Months Ended			12 Months Ended		
	Oct. 31, 2020 reporting_unit	Oct. 31, 2019 reporting_unit	May 31, 2020 reporting_unit	Dec. 31, 2020 USD (\$)	Jun. 30, 2020 USD (\$)	Mar. 31, 2020 USD (\$)	Dec. 31, 2019 USD (\$)	Jun. 30, 2020 USD (\$)	Oct. 31, 2019 \$/ shares	Dec. 31, 2020 USD (\$) reporting_unit	Dec. 31, 2019 USD (\$)	Dec. 31, 2018 USD (\$)
<b>Finite-Lived Intangible Assets [Line Items]</b>												
<a href="#">Number of reporting units for goodwill testing   reporting_unit</a>	3	3	3							4		
<a href="#">Decrease in average closing price per share due to impairment (in dollars per share)   \$ / shares</a>									\$ 6.59			
<a href="#">Goodwill, impairment testing, percentage share price decrease</a>									43.50%			
<a href="#">Number of reporting units, fair value in excess of carrying amount   reporting_unit Impairment</a>	1	1	1	\$ 199,800,000	\$ 215,100,000	\$ 0	\$ 199,800,000	\$ 215,100,000		\$ 215,100,000	\$ 199,800,000	\$ 0
<a href="#">Goodwill</a>				354,734,000			572,064,000			354,734,000	572,064,000	\$ 768,124,000
<b>Valuation, Income Approach Finite-Lived Intangible Assets [Line Items]</b>												
<a href="#">Goodwill</a>				\$ 214,300,000			\$ 431,700,000			\$ 214,300,000	\$ 431,700,000	

Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) - USD (\$)	3 Months Ended			6 Months Ended		12 Months Ended		
	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<b>Goodwill [Roll Forward]</b>								
Balance as of beginning of period			\$ 572,064,000	\$ 572,064,000	\$ 572,064,000	\$ 572,064,000	\$ 768,124,000	
Goodwill acquired							3,416,000	
Measurement period adjustments							351,000	
Goodwill disposal						(2,200,000)		
Impairment	\$ (199,800,000)	\$ (215,100,000)	0	\$ (199,800,000)	(215,100,000)	(215,100,000)	(199,800,000)	\$ 0
Foreign currency translation						(30,000)	(27,000)	
Balance as of end of period	354,734,000			572,064,000		354,734,000	572,064,000	768,124,000
Cumulative inception to date impairment	575,500,000			360,400,000		575,500,000	360,400,000	
<b>Services</b>								
<b>Goodwill [Roll Forward]</b>								
Balance as of beginning of period			566,359,000	566,359,000	566,359,000	566,359,000	762,419,000	
Goodwill acquired							3,416,000	
Measurement period adjustments							351,000	
Goodwill disposal						(2,200,000)		
Impairment						(215,100,000)	(199,800,000)	
Foreign currency translation						(30,000)	(27,000)	
Balance as of end of period	349,029,000			566,359,000		349,029,000	566,359,000	762,419,000
<b>True Health</b>								
<b>Goodwill [Roll Forward]</b>								
Balance as of beginning of period			\$ 5,705,000	\$ 5,705,000	5,705,000	5,705,000	5,705,000	
Goodwill acquired							0	
Measurement period adjustments							0	
Goodwill disposal						0		
Impairment						0	0	
Foreign currency translation						0	0	
Balance as of end of period	\$ 5,705,000			\$ 5,705,000		\$ 5,705,000	\$ 5,705,000	\$ 5,705,000

**Goodwill and Intangible  
Assets, Net - Intangible  
Assets, Net (Details) - USD  
(\$)**

**12 Months Ended**

**Dec. 31, 2020**

**Dec. 31, 2019**

**Dec. 31,  
2018**

**\$ in Thousands**

**Finite-Lived Intangible Assets [Line  
Items]**

<u>Gross Carrying Amount</u>	\$ 403,034	\$ 412,514	
<u>Accumulated Amortization</u>	134,962	104,055	
<u>Total future amortization of intangible assets</u>	268,072	308,459	
<u>Amortization of intangible assets</u>	\$ 32,900	\$ 37,700	\$ 27,200

Corporate trade name

**Finite-Lived Intangible Assets [Line  
Items]**

<u>Weighted- Average Remaining Useful Life</u>	13 years 2 months 12 days	14 years 2 months 12 days	
<u>Gross Carrying Amount</u>	\$ 23,300	\$ 23,300	
<u>Accumulated Amortization</u>	6,271	4,891	
<u>Total future amortization of intangible assets</u>	\$ 17,029	\$ 18,409	

Customer relationships

**Finite-Lived Intangible Assets [Line  
Items]**

<u>Weighted- Average Remaining Useful Life</u>	16 years 1 month 6 days	16 years 9 months 18 days	
<u>Gross Carrying Amount</u>	\$ 281,219	\$ 291,519	
<u>Accumulated Amortization</u>	58,256	44,750	
<u>Total future amortization of intangible assets</u>	\$ 222,963	\$ 246,769	

Technology

**Finite-Lived Intangible Assets [Line  
Items]**

<u>Weighted- Average Remaining Useful Life</u>	1 year 9 months 18 days	2 years	
<u>Gross Carrying Amount</u>	\$ 82,922	\$ 82,922	
<u>Accumulated Amortization</u>	63,507	49,760	
<u>Total future amortization of intangible assets</u>	\$ 19,415	\$ 33,162	

Below market lease, net

**Finite-Lived Intangible Assets [Line  
Items]**

<u>Weighted- Average Remaining Useful Life</u>	2 years 3 months 18 days	2 years 2 months 12 days	
<u>Gross Carrying Amount</u>	\$ 1,118	\$ 2,048	
<u>Accumulated Amortization</u>	648	1,334	
<u>Total future amortization of intangible assets</u>	\$ 470	\$ 714	

Provider network contracts

**Finite-Lived Intangible Assets [Line  
Items]**

<u>Weighted- Average Remaining Useful Life</u>	2 years 9 months 18 days	3 years 8 months 12 days
<u>Gross Carrying Amount</u>	\$ 14,475	\$ 12,725
<u>Accumulated Amortization</u>	6,280	3,320
<u>Total future amortization of intangible assets</u>	\$ 8,195	\$ 9,405

**Goodwill and Intangible  
Assets, Net - Amortization of  
Intangible Assets (Details) -  
USD (\$)**

**Dec. 31, 2020 Dec. 31, 2019**

**\$ in Thousands**

**[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)**

<u><a href="#">2021</a></u>	\$ 28,701	
<u><a href="#">2022</a></u>	24,819	
<u><a href="#">2023</a></u>	22,055	
<u><a href="#">2024</a></u>	16,171	
<u><a href="#">2025</a></u>	15,916	
<u><a href="#">Thereafter</a></u>	160,410	
<u><a href="#">Total future amortization of intangible assets</a></u>	\$ 268,072	\$ 308,459

Long-term Debt - 2024 Notes (Details) - Senior Notes \$/ shares in Units, shares in Millions	1 Months Ended		12 Months Ended			
	Aug. 31, 2020 USD (\$) shares \$/ shares	Dec. 31, 2016 USD (\$) shares \$/ shares	Dec. 31, 2020 USD (\$) shares	Dec. 31, 2019 USD (\$) shares	Dec. 31, 2018 USD (\$) shares	Dec. 30, 2019 USD (\$) shares
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Payments of debt issuance costs 2024 Notes</a>	\$ 2,500,000					
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Face amount</a>	\$ 117,100,000		\$ 117,051,000	\$ 0		
<a href="#">Interest rate</a>	3.50%					
<a href="#">Debt conversion, converted instrument, amount</a>	\$ 84,200,000					
<a href="#">Debt issuance costs</a>	\$ 3,000,000.0					
<a href="#">Interest expense</a>			1,500,000			
<a href="#">Conversion price (in dollars per share)   \$/ shares</a>	\$ 18.23					
<a href="#">Initial conversion amount (in shares)   shares</a>	6.4					
<a href="#">Long-term debt, net of discount</a>	\$ 78,900,000					
<a href="#">Debt Issuance Costs, Net, Debt Component</a>	\$ 1,700,000					
<a href="#">Non-cash amortization of debt discount and debt issuance costs</a>			2,700,000			
<a href="#">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a>	100.00%					
<a href="#">Repurchase covenant, sale price as a percentage of conversion price</a>	130.00%					
<a href="#">Repurchase covenant, trading days, minimum</a>	20 days					
<a href="#">Repurchase covenant, consecutive trading days, minimum</a>	30 days					
<a href="#">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a>	100.00%					
2024 Notes   Common Stock						
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Debt issuance costs</a>	\$ 1,300,000					
<a href="#">Proceeds from issuance of debt</a>	\$ 38,100,000					



[2024 Notes | Common Stock | Class A](#)

[Common Stock](#)

**[Debt Instrument \[Line Items\]](#)**

[Initial conversion rate per \\$ 1000 principal amount](#) 0.0548667

[2021 Notes](#)

**[Debt Instrument \[Line Items\]](#)**

<a href="#">Face amount</a>	\$	125,000,000.0	26,737,000	125,000,000	
<a href="#">Interest rate</a>		2.00%			2.00%
<a href="#">Debt conversion, original debt, amount</a>	\$	84,200,000			
<a href="#">Debt issuance costs</a>		\$ 4,600,000			
<a href="#">Interest expense</a>			\$ 1,700,000	\$ 2,500,000	\$ 2,500,000
<a href="#">Proceeds from issuance of debt</a>		\$ 120,400,000			
<a href="#">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a>		100.00%			

[2021 Notes | Common Stock | Class A](#)

[Common Stock](#)

**[Debt Instrument \[Line Items\]](#)**

[Initial conversion rate per \\$ 1000 principal amount](#) 0.0416082

[Conversion price \(in dollars per share\) | \\$ / shares](#) \$ 24.03

[Initial conversion amount \(in shares\) | shares](#) 5.2

[New Notes](#)

**[Debt Instrument \[Line Items\]](#)**

[Debt conversion, converted instrument, amount](#) \$ 32,800,000

Long-term Debt - Credit Agreement (Details) - USD (\$)	12 Months Ended				
	Dec. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2016
<u>Initial Term Loan Facility   Secured Debt</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Face amount	\$ 75,000,000.0				
<u>Credit Agreement   Line of Credit   DDTL Facility</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Maximum borrowing capacity	\$ 50,000,000.0				
Commitment fee percentage	1.00%				
<u>2021 Notes   Senior Notes</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Face amount		\$ 26,737,000	\$ 125,000,000		\$ 125,000,000.0
Interest rate	2.00%				2.00%
Interest expense		1,700,000	\$ 2,500,000	\$ 2,500,000	
Debt issuance costs					\$ 4,600,000
<u>Senior Credit Facilities   Secured Debt</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Interest expense		8,000,000.0			
Debt issuance costs	\$ 4,700,000				
Non-cash amortization of debt discount and debt issuance costs		\$ 2,200,000			
<u>Senior Credit Facilities   Secured Debt   After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Redemption, call protection premium, percentage	4.00%				
<u>Senior Credit Facilities   Secured Debt   After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Redemption, call protection premium, percentage	3.00%				
<u>Senior Credit Facilities   Secured Debt   After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary</u>					
<b><u>Debt Instrument [Line Items]</u></b>					
Redemption, call protection premium, percentage	2.00%				

[Senior Credit Facilities | Secured Debt |  
Maximum](#)

**[Debt Instrument \[Line Items\]](#)**

[Term](#) 91 days

[Senior Credit Facilities | Secured Debt |  
Eurodollar](#)

**[Debt Instrument \[Line Items\]](#)**

[Basis spread on variable rate](#) 8.00%

[Senior Credit Facilities | Secured Debt | Base  
Rate](#)

**[Debt Instrument \[Line Items\]](#)**

[Basis spread on variable rate](#) 7.00%

**Long-term Debt - Warrant  
Agreement (Details) - Class  
A Common Stock**

**Dec. 30, 2019  
\$ / shares  
shares**

**Class of Warrant or Right [Line Items]**

<u>Warrants agreed to be sold (in shares)   shares</u>	1,513,786
<u>Exercise price of warrants or rights (in dollars per share)   \$ / shares</u>	\$ 8.05
<u>Period during which warrants or rights exercisable, after maturity of credit agreement</u>	30 days

Long-term Debt - 2025 Notes (Details) - 2025 Notes \$/ shares in Units, shares in Millions	1 Months Ended	12 Months Ended				Oct. 22, 2018 USD (\$)
	Oct. 31, 2018 USD (\$) shares \$/ shares	Dec. 31, 2020 USD (\$)	Dec. 31, 2019 USD (\$)	Dec. 31, 2018 USD (\$)	Oct. 24, 2018 USD (\$)	
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Debt issuance costs</u>	\$ 5,900,000					
<b><u>Senior Notes</u></b>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Face amount</u>	\$	\$	\$		\$	\$
	172,500,000	172,500,000	172,500,000		22,500,000	150,000,000.0
<u>Interest rate</u>	1.50%					
<u>Proceeds from issuance of debt</u>	\$					
	166,600,000					
<u>Debt issuance costs</u>	\$ 3,400,000					
<u>Interest expense</u>		2,600,000	2,600,000	\$ 500,000		
<u>Conversion price (in dollars per share)   \$ / shares</u>	\$ 33.43					
<u>Initial conversion amount (in shares)   shares</u>	5.2					
<u>Carrying amount</u>	\$					
	100,700,000					
<u>Non-cash amortization of debt discount and debt issuance costs</u>		\$ 9,200,000	\$ 8,500,000	\$	\$	\$
				1,500,000		
<u>Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</u>	100.00%					
<u>Repurchase covenant, sale price as a percentage of conversion price (at least)</u>	130.00%					
<u>Repurchase covenant, trading days, minimum</u>	20 days					
<u>Repurchase covenant, consecutive trading days, minimum</u>	30 days					
<u>Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</u>	100.00%					
<b><u>Senior Notes   Common Stock</u></b>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Proceeds from issuance of debt</u>	\$					
	71,800,000					
<u>Debt issuance costs</u>	\$ 2,500,000					

[Senior Notes | Class A Common](#)

[Stock | Common Stock](#)

**[Debt Instrument \[Line Items\]](#)**

[Initial conversion rate per \\$ 1000  
principal amount](#)

0.0299135

Long-term Debt - 2021 Notes (Details) \$ / shares in Units, shares in Millions	1 Months Ended		12 Months Ended			
	Aug. 31, 2020 USD (\$) shares \$/ shares	Dec. 31, 2016 USD (\$) shares \$/ shares	Dec. 31, 2020 USD (\$)	Dec. 31, 2019 USD (\$)	Dec. 31, 2018 USD (\$)	Dec. 30, 2019
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Amortization of deferred financing costs</a>			\$ 14,780,000	\$ 9,370,000	\$ 2,455,000	
<a href="#">Repayments of senior debt</a>			16,606,000	0	0	
<a href="#">Senior Notes</a>						
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Payments of debt issuance costs</a>	\$ 2,500,000					
<a href="#">Net loss on extinguishment of debt, including fees paid to lenders</a>	4,800,000					
<a href="#">Senior Notes   2021 Notes</a>						
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Face amount</a>			\$ 125,000,000.0	26,737,000	125,000,000	
<a href="#">Interest rate</a>			2.00%			2.00%
<a href="#">Proceeds from issuance of debt</a>			\$ 120,400,000			
<a href="#">Debt issuance costs</a>			\$ 4,600,000			
<a href="#">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a>			100.00%			
<a href="#">Interest expense</a>			1,700,000	2,500,000	2,500,000	
<a href="#">Amortization of deferred financing costs</a>			600,000	900,000	\$ 900,000	
<a href="#">Debt conversion, original debt, amount</a>	84,200,000					
<a href="#">Face amount of debt repaid</a>	14,000,000.0					
<a href="#">Repayments of senior debt</a>	13,900,000					
<a href="#">Senior Notes   2021 Notes   Class A Common Stock   Common Stock</a>						
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Initial conversion rate per \$ 1000 principal amount</a>			0.0416082			
<a href="#">Conversion price (in dollars per share)   \$ / shares</a>			\$ 24.03			
<a href="#">Initial conversion amount (in shares)   shares</a>			5.2			
<a href="#">Senior Notes   2024 Notes</a>						
<a href="#">Debt Instrument [Line Items]</a>						
<a href="#">Face amount</a>	\$ 117,100,000		117,051,000	\$ 0		
<a href="#">Interest rate</a>	3.50%					

<a href="#">Debt issuance costs</a>	\$	
		3,000,000.0
<a href="#">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a>	100.00%	
<a href="#">Interest expense</a>		\$ 1,500,000
<a href="#">Conversion price (in dollars per share)   \$ / shares</a>	\$ 18.23	
<a href="#">Initial conversion amount (in shares)   shares</a>	6.4	
<a href="#">Debt conversion, converted instrument, amount</a>	\$ 84,200,000	
<a href="#">Senior Notes   2024 Notes   Common Stock</a>		
<b><a href="#">Debt Instrument [Line Items]</a></b>		
<a href="#">Proceeds from issuance of debt</a>	38,100,000	
<a href="#">Debt issuance costs</a>	\$ 1,300,000	
<a href="#">Senior Notes   2024 Notes   Class A Common Stock   Common Stock</a>		
<b><a href="#">Debt Instrument [Line Items]</a></b>		
<a href="#">Initial conversion rate per \$ 1000 principal amount</a>	0.0548667	



Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD (\$)	12 Months Ended					
	Dec. 31, 2020	Dec. 31, 2019	Aug. 31, 2020	Oct. 31, 2018	Oct. 24, 2018	Oct. 22, 2018 Dec. 31, 2016
<u>2024 Notes</u>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Carrying value</u>	\$ 81,462,000	\$ 0				
<u>Unamortized debt discount and issuance costs</u>	35,589,000	0				
<u>Principal amount</u>	\$ 117,051,000	0	\$ 117,100,000			
<u>Remaining amortization period (years)</u>	3 years 10 months 24 days					
<u>2024 Notes   Level 2</u>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Fair value</u>	\$ 153,220,000	0				
<u>2025 Notes</u>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Carrying value</u>	116,349,000	107,169,000				
<u>Unamortized debt discount and issuance costs</u>	56,151,000	65,331,000				
<u>Principal amount</u>	\$ 172,500,000	\$ 172,500,000	\$ 172,500,000	\$ 22,500,000	\$ 150,000,000.0	
<u>Remaining amortization period (years)</u>	4 years 9 months 18 days	5 years 9 months 18 days				
<u>2025 Notes   Level 2</u>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Fair value</u>	\$ 147,488,000	\$ 122,048,000				
<u>2021 Notes</u>						
<b><u>Debt Instrument [Line Items]</u></b>						
<u>Carrying value</u>	26,557,000	123,237,000				
<u>Unamortized debt discount and issuance costs</u>	180,000	1,763,000				
<u>Principal amount</u>	\$ 26,737,000	\$ 125,000,000				\$ 125,000,000.0
<u>Remaining amortization period (years)</u>	10 months 24 days	1 year 10 months 24 days				
<u>2021 Notes   Level 2</u>						

**Debt Instrument [Line  
Items]**

Fair value

\$	\$
26,470,000	111,250,000

Commitments and Contingencies - Additional Information (Details) - USD (\$)	Nov. 16, 2020	Sep. 01, 2020	May 28, 2019	3 Months Ended							
				Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	
<u>Restricted Cash and Cash Equivalents Items [Line Items]</u>											
<u>Restricted funds</u>				\$ 21,707,000				\$ 28,340,000			
<u>Percent of tax savings to be paid</u>				85.00%							
<u>Passport   Variable Interest Entity</u>											
<u>Restricted Cash and Cash Equivalents Items [Line Items]</u>											
<u>Interest in investment</u>	30.00%	30.00%	30.00%	30.00%							
<u>Requirement to acquire ownership, consideration, amount</u>				\$ 20,000,000.0							
<u>Payments to acquire equity method investments, amount held back</u>								16,200,000			
<u>New Mexico Health Connections</u>											
<u>Restricted Cash and Cash Equivalents Items [Line Items]</u>											
<u>Reinsurance arrangement, capital amount</u>						\$ 10,000,000.0					
<u>Reinsurance arrangement, term</u>					15 months						
<u>Reinsurance arrangement, percentage of gross premiums ceded</u>					90.00%						
<u>Reinsurance arrangement, percentage of claims liability indemnified</u>					90.00%						
<u>Reinsurance arrangement, maximum amount of insurance risk as a percentage of premiums ceded</u>					105.00%						
<u>Surety Bond</u>											
<u>Restricted Cash and Cash Equivalents Items [Line Items]</u>											
<u>Loss contingency, estimate of possible loss</u>										\$ 25,000,000.0	
<u>Collateral with financial institutions</u>											
<u>Restricted Cash and Cash Equivalents Items [Line Items]</u>											
<u>Restricted funds</u>				4,743,000				5,742,000			
<u>Restricted cash and investments</u>				\$ 4,700,000				5,700,000			

<a href="#">Minimum risk-based capital requirement</a>	150.00%		
<a href="#">Letter of Credit   Line of Credit   Letter of Credit Expiring December 31, 2020</a>			
<b><a href="#">Restricted Cash and Cash Equivalents Items [Line Items]</a></b>			
<a href="#">Maximum borrowing capacity</a>			\$ 5,000,000.0
<a href="#">Letter of Credit   Line of Credit   Letter of Credit Expiring December 31, 2019</a>			
<b><a href="#">Restricted Cash and Cash Equivalents Items [Line Items]</a></b>			
<a href="#">Maximum borrowing capacity</a>			\$ 1,800,000
<a href="#">Letter of Credit   Line of Credit   Restricted Cash For Letters Of Credit   Letter of Credit Expiring December 31, 2019</a>			
<b><a href="#">Restricted Cash and Cash Equivalents Items [Line Items]</a></b>			
<a href="#">Restricted funds</a>	\$ 1,800,000	1,800,000	
<a href="#">Letter of Credit   Line of Credit   Collateral with financial institutions   Letter of Credit Expiring December 31, 2019</a>			
<b><a href="#">Restricted Cash and Cash Equivalents Items [Line Items]</a></b>			
<a href="#">Restricted funds</a>	\$ 1,800,000		\$ 1,800,000

**Commitments and  
Contingencies - Reinsurance  
Agreements (Details) - USD  
(\$)  
\$ in Thousands**

**12 Months Ended**

**Dec. 31, Dec. 31, Dec. 31,  
2020 2019 2018**

**Insurance Loss Reserves [Roll Forward]**

<u>Reinsurance premiums assumed</u>	\$ 19,130	\$ 83,325	\$ 3,242
<u>Reinsurance premiums ceded</u>	(3,275)	0	0
<u>Claims assumed</u>	14,812	72,594	3,934
<u>Claims ceded</u>	(422)	0	0
<u>Claims-related administrative expenses</u>	0	14,024	551
<u>Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</u>	1,465	(3,293)	(1,243)
<u>Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</u>	0	1,243	0
<u>Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</u>	(502)	0	0
<u>Reinsurance payments paid (received)</u>	(3,039)		
<u>Reinsurance payments paid (received)</u>		4,536	0
<u>Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</u>	\$ 4,002	\$ 0	\$ 1,243

**Commitments and  
Contingencies -  
Concentration Risk (Details)  
- USD (\$)  
\$ in Thousands**

<b>6 Months Ended</b>	<b>12 Months Ended</b>			
<b>Jun. 30, 2020</b>	<b>Dec. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>	<b>Dec. 31, 2017</b>

**Concentration Risk [Line Items]**

Percentage of cash and cash equivalents held with FDIC participating bank

98.20%

Cash and cash equivalents (including restricted cash)

\$	\$	\$	\$
361,581	128,531	388,325	295,363

Percentage of cash and cash equivalents held in money market funds

1.60%

Percentage of cash held in international banks (less than)

0.20%

Cook County Health and Hospitals System | Customer  
Concentration Risk | Accounts Receivable | Customer Receivable

**Concentration Risk [Line Items]**

Concentration risk

48.40% 61.50%

Cook County Health and Hospitals System | Customer  
Concentration Risk | Revenues

**Concentration Risk [Line Items]**

Concentration risk

20.30%

EVH Passport | Customer Concentration Risk | Revenues

**Concentration Risk [Line Items]**

Concentration risk

16.80% 18.70% 17.50%

New Mexico Health Connections | Customer Concentration Risk |  
Revenues

**Concentration Risk [Line Items]**

Concentration risk

10.90%

Molina | Customer Concentration Risk | Revenues

**Concentration Risk [Line Items]**

Concentration risk

8.80%

Leases - Narrative (Details) - USD (\$) \$ in Thousands	12 Months Ended		
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
<u>Lessee, Lease, Description [Line Items]</u>			
<u>Restricted funds</u>		\$ 21,707	\$ 28,340
<u>Operating leases, rent expense, net</u>	\$ 14,200		
<u>Lease Agreements</u>			
<u>Lessee, Lease, Description [Line Items]</u>			
<u>Letters of credit outstanding, amount</u>		3,500	
<u>Restricted funds</u>		\$ 3,500	\$ 3,600

**Leases - Material Office**  
**Leases (Details)**  
**\$ in Thousands**

**Dec. 31, 2020**  
**USD (\$)**

**Lessee, Lease, Description [Line Items]**

Future Minimum Lease Commitments \$ 94,889

Arlington, VA

**Lessee, Lease, Description [Line Items]**

Lease Termination Term (in years) 11 years 1 month 6 days

Future Minimum Lease Commitments \$ 38,675

Letter of Credit Amount Required \$ 1,579

Riverside, IL

**Lessee, Lease, Description [Line Items]**

Lease Termination Term (in years) 10 years 3 months 18 days

Future Minimum Lease Commitments \$ 44,605

Letter of Credit Amount Required \$ 232

Pune, India

**Lessee, Lease, Description [Line Items]**

Lease Termination Term (in years) 2 years 8 months 12 days

Future Minimum Lease Commitments \$ 2,318

Letter of Credit Amount Required \$ 0

Brea, CA

**Lessee, Lease, Description [Line Items]**

Lease Termination Term (in years) 1 year 4 months 24 days

Future Minimum Lease Commitments \$ 1,555

Letter of Credit Amount Required \$ 0



**Leases - Components of  
Lease Expense (Details) -  
USD (\$)  
\$ in Thousands**

**12 Months Ended  
Dec. 31, 2020 Dec. 31, 2019**

**Leases [Abstract]**

<u>Operating lease cost</u>	\$ 15,848	\$ 13,903
<u>Amortization of right-of-use assets</u>	299	598
<u>Interest expense</u>	3	26
<u>Variable lease cost</u>	5,097	4,177
<u>Total lease cost</u>	\$ 21,247	\$ 18,704

**Leases - Maturity of Lease  
Liabilities (Details)  
\$ in Thousands**

**Dec. 31, 2020  
USD (\$)**

Leases [Abstract]

<u>2021</u>	\$ 11,558
<u>2022</u>	9,562
<u>2023</u>	9,012
<u>2024</u>	8,733
<u>2025</u>	8,265
<u>Thereafter</u>	47,759
<u>Total lease payments</u>	94,889
<b><u>Less:</u></b>	
<u>Interest</u>	25,006
<u>Present value of lease liabilities</u>	69,883
<u>Lessee, operating lease, lease not yet commenced, undiscounted amount</u>	\$ 700

**Leases - Weighted-average  
Discount Rate and  
Weighted-remaining Lease  
Terms (Details)**

**Dec. 31, 2020**

**Dec. 31, 2019**

[Leases \[Abstract\]](#)

[Weighted average discount rate](#)

6.44%

6.25%

[Weighted average remaining lease term](#)

9 years 4 months 24 days

9 years 10 months 24 days

Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details) \$/ shares in Units, shares in Thousands, \$ in Thousands	3 Months Ended							12 Months Ended			
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
	USD	USD	USD (\$)	USD	USD (\$)	USD	USD	USD	USD (\$)	USD (\$)	USD
	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)
	\$/	\$/	\$/	\$/	\$/	\$/	\$/	\$/	\$/	\$/	\$/
	shares	shares	shares	shares	shares	shares	shares	shares	shares	shares	shares
<a href="#">Class of Stock [Line Items]</a>											
<a href="#">Net loss</a>	\$ (13,803)	\$ (38,170)	\$ (203,521)	\$ (78,752)	\$ (199,293)	\$ (25,738)	\$ (31,900)	\$ (48,649)	\$ (334,246)	\$ (305,580)	\$ (54,191)
<b>Less:</b>											
<a href="#">Net loss attributable to non-controlling interests</a>	822	(822)	0	0	(1,197)	(217)	(285)	(1,910)	0	(3,609)	(1,533)
<a href="#">Net loss attributable to common shareholders of Evolent Health, Inc.</a>	\$ (14,625)	\$ (37,348)	\$ (203,521)	\$ (78,752)	\$ (198,096)	\$ (25,521)	\$ (31,615)	\$ (46,739)	\$ (334,246)	\$ (301,971)	\$ (52,658)
<a href="#">Weighted-average common shares outstanding - basic and diluted (in shares)   shares</a>									84,928	82,364	77,338
<a href="#">Loss per common share Basic and diluted (in dollars per share)   \$ / shares</a>	\$ (0.17)	\$ (0.44)	\$ (2.38)	\$ (0.93)	\$ (2,360)	\$ (300)	\$ (380)	\$ (590)	\$ (3.94)	\$ (3.67)	\$ (0.68)
<a href="#">Class B Common Stock</a>											
<a href="#">Loss per common share Convertible preferred stock, conversion ratio</a>											

**Earnings (Loss) Per  
Common Share -  
Antidilutive Securities  
(Details) - shares  
shares in Thousands**

**12 Months Ended**

**Dec. 31,    Dec. 31,    Dec. 31,  
2020        2019        2018**

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Number of antidilutive securities excluded from the calculation of earning per share (in shares)</u>	13,144	13,897	11,551
---	--------	--------	--------

Exchangeable Class B common stock

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Number of antidilutive securities excluded from the calculation of earning per share (in shares)</u>	0	1,399	1,831
---	---	-------	-------

Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Number of antidilutive securities excluded from the calculation of earning per share (in shares)</u>	797	813	1,027
---	-----	-----	-------

Stock options

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Number of antidilutive securities excluded from the calculation of earning per share (in shares)</u>	1,141	1,324	2,517
---	-------	-------	-------

Convertible senior notes

**Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]**

<u>Number of antidilutive securities excluded from the calculation of earning per share (in shares)</u>	11,206	10,361	6,176
---	--------	--------	-------

**Stock-based Compensation -  
2011 and 2015 Equity  
Incentive Plans (Details) -  
shares  
shares in Thousands**

**Dec. 31, Dec. 31, Jun. 13, May 01, Sep. 23,  
2020 2019 2018 2015 2013**

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of options issued (in shares)  
RSUs 4,070 4,828

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of RSUs and shares of restricted stock issued (in  
shares)  
2011 Plan 1,737 1,493

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of options issued (in shares)  
2011 Plan | Restricted stock 4,800

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of RSUs and shares of restricted stock issued (in  
shares)  
2011 Plan | Class A Common Stock 3,800

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of shares authorized (in shares)  
2015 Plan 9,100

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of options issued (in shares)  
2015 Plan | RSUs 2,800 2,800

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of RSUs and shares of restricted stock issued (in  
shares)  
2015 Plan | Class A Common Stock 4,700 4,400

**Share-based Compensation Arrangement by Share-based  
Payment Award [Line Items]**

Number of shares authorized (in shares) 10,500 6,000

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD (\$)	12 Months Ended		
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	\$ 14,606,000	\$ 15,618,000	\$ 17,609,000
<u>Stock-based compensation capitalized as software development costs</u>	0	0	0
<u>Cost of revenue</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	1,811,000	2,673,000	1,475,000
<u>Selling, general and administrative expenses</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	12,795,000	12,945,000	16,134,000
<u>Stock options</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	2,927,000	4,237,000	9,008,000
<u>Performance-based stock options</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	75,000	448,000	447,000
<u>RSUs</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	7,763,000	8,877,000	7,766,000
<u>Performance-based RSUs</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	0	(388,000)	388,000
<u>LSUs</u>			
<b><u>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</u></b>			
<u>Share-based compensation expense</u>	\$ 3,841,000	\$ 2,444,000	\$ 0

**Stock-based Compensation -  
Unrecognized Compensation  
Expense (Details)  
\$ in Thousands**

**12 Months Ended  
Dec. 31, 2020  
USD (\$)**

**Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]**

Unrecognized Compensation Expense \$ 20,579

Stock options

**Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]**

Unrecognized Compensation Expense \$ 1,971

Weighted Average Period

1 year 6 months 18 days

RSUs

**Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]**

Unrecognized Compensation Expense \$ 11,914

Weighted Average Period

1 year 10 months 20 days

LSUs

**Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]**

Unrecognized Compensation Expense \$ 6,694

Weighted Average Period

1 year 9 months 7 days



**Stock-based Compensation -  
Stock Options (Details) -  
USD (\$)  
\$ / shares in Units, \$ in  
Millions**

**12 Months Ended**

**Dec. 31,      Dec. 31,      Dec. 31,  
2020            2019            2018**

**Share-based Compensation Arrangement by Share-based Payment  
Award [Line Items]**

<u>Weighted-average fair value per option granted (in dollars per share)</u>		\$ 6.52	\$ 6.30
<u>Expected term (in years)</u>		6 years 3 months	6 years 3 months
<u>Expected volatility</u>		51.60%	38.90%
<u>Dividend yield</u>		0.00%	0.00%
<u>Fair value of options vested</u>	\$ 3.6	\$ 5.9	\$ 11.3
<u>Intrinsic value of options exercised</u>	\$ 2.2	\$ 0.6	\$ 25.1

Stock options

**Share-based Compensation Arrangement by Share-based Payment  
Award [Line Items]**

<u>Vesting period</u>	4 years		
<u>Vesting percentage</u>	25.00%		
<u>Expiration period</u>	10 years		
<u>Risk-free interest rate, minimum</u>		1.90%	2.60%
<u>Risk-free interest rate, maximum</u>		2.70%	2.90%

**Stock-based Compensation -  
Stock Option Activity  
(Details) - USD (\$)  
\$/ shares in Units, shares in  
Thousands, \$ in Thousands**

**12 Months Ended**  
**Dec. 31, 2020**      **Dec.  
31,  
2019**

**Options**

<u>Outstanding at the beginning of the period (in shares)</u>	4,828	
<u>Granted (in shares)</u>	0	
<u>Exercised (in shares)</u>	(416)	
<u>Forfeited (in shares)</u>	(342)	
<u>Outstanding at the end of the period (in shares)</u>	4,070	4,828
<u>Vested and expected to vest at the end of the period (in shares)</u>	3,951	
<u>Exercisable at the end of the period (in shares)</u>	3,475	
<b><u>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</u></b>		
<u>Outstanding at the beginning of the period (in dollars per share)</u>	\$ 9.44	
<u>Granted (in dollars per share)</u>	0	
<u>Exercised (in dollars per share)</u>	4.75	
<u>Forfeited (in dollars per share)</u>	14.80	
<u>Outstanding at the end of the period (in dollars per share)</u>	9.32	\$ 9.44
<u>Vested and expected to vest at the end of the period (in dollars per share)</u>	9.17	
<u>Exercisable at the end of the period (in dollars per share)</u>	\$ 8.48	
<b><u>Weighted Average Remaining Contractual Term</u></b>		
<u>Outstanding</u>	5 years 3 months	6 years 3 days
<u>Vested and expected to vest</u>	4 years 11 months 12 days	
<u>Exercisable</u>	4 years 7 months 17 days	
<b><u>Aggregate Intrinsic Value</u></b>		
<u>Outstanding</u>	\$ 12,578	\$ (1,880)
<u>Vested and expected to vest</u>	27,095	
<u>Exercisable</u>	\$ 26,228	

<b>Stock-based Compensation - Performance-based Stock Option Awards (Details) - USD (\$) \$ / shares in Units, shares in Thousands, \$ in Thousands</b>	<b>1 Months Ended</b>	<b>12 Months Ended</b>		
	<b>Mar. 31, 2016</b>	<b>Dec. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>
<b><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></b>				
<u>Granted (in shares)</u>	0			
<u>Expected volatility</u>			51.60%	38.90%
<u>Expected term (in years)</u>			6 years 3 months	6 years 3 months
<u>Dividend yield</u>			0.00%	0.00%
<u>Weighted-average fair value per option granted (in dollars per share)</u>			\$ 6.52	\$ 6.30
<u>Outstanding at the end of the period (in shares)</u>	4,070		4,828	
<u>Vested and expected to vest at the end of the period (in shares)</u>	3,951			
<u>Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</u>	\$ 9.32		\$ 9.44	
<u>Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</u>	\$ 9.17			
<b><u>Weighted Average Remaining Contractual Term</u></b>				
<u>Outstanding</u>		5 years 3 months	6 years 3 days	
<u>Vested and expected to vest</u>		4 years 11 months 12 days		
<b><u>Aggregate Intrinsic Value</u></b>				
<u>Outstanding</u>		\$ 12,578	\$ (1,880)	
<u>Vested and expected to vest</u>		\$ 27,095		
<b><u>Performance-based stock options</u></b>				
<b><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></b>				
<u>Granted (in shares)</u>	300			
<u>Risk-free interest rate</u>	1.83%			
<u>Expected volatility</u>	65.00%			
<u>Expected term (in years)</u>	10 years			
<u>Dividend yield</u>	0.00%			
<u>Weighted-average fair value per option granted (in dollars per share)</u>	\$ 6.68			
<u>Outstanding at the end of the period (in shares)</u>		268	268	
<u>Vested and expected to vest at the end of the period (in shares)</u>		268		
<u>Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</u>		\$ 10.27	\$ 10.27	

<a href="#"><u>Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</u></a>		\$ 10.27	
<b><a href="#"><u>Weighted Average Remaining Contractual Term</u></a></b>			
<a href="#"><u>Outstanding</u></a>		6 years 2 months 1 day	6 years 2 months 1 day
<a href="#"><u>Vested and expected to vest</u></a>		6 years 2 months 1 day	
<b><a href="#"><u>Aggregate Intrinsic Value</u></a></b>			
<a href="#"><u>Outstanding</u></a>		\$ (326)	\$ (326)
<a href="#"><u>Vested and expected to vest</u></a>		\$ (326)	
<a href="#"><u>Performance-based stock options   Vest on March 1, 2019</u></a>			
<b><a href="#"><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></a></b>			
<a href="#"><u>Vesting percentage</u></a>	50.00%		
<a href="#"><u>Performance-based stock options   Vest on March 1, 2020</u></a>			
<b><a href="#"><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></a></b>			
<a href="#"><u>Vesting percentage</u></a>	50.00%		
<a href="#"><u>Performance-based stock options   Class A Common Stock   Tranche One</u></a>			
<b><a href="#"><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></a></b>			
<a href="#"><u>Vesting percentage</u></a>	33.33%		
<a href="#"><u>Award vesting rights, share price threshold (in dollars per share)</u></a>	\$ 13.35		
<a href="#"><u>Consecutive term</u></a>	90 days		
<a href="#"><u>Performance-based stock options   Class A Common Stock   Tranche Two</u></a>			
<b><a href="#"><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></a></b>			
<a href="#"><u>Vesting percentage</u></a>	33.33%		
<a href="#"><u>Award vesting rights, share price threshold (in dollars per share)</u></a>	\$ 16.43		
<a href="#"><u>Consecutive term</u></a>	90 days		
<a href="#"><u>Performance-based stock options   Class A Common Stock   Tranche Three</u></a>			
<b><a href="#"><u>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</u></a></b>			
<a href="#"><u>Vesting percentage</u></a>	33.33%		
<a href="#"><u>Award vesting rights, share price threshold (in dollars per share)</u></a>	\$ 19.51		
<a href="#"><u>Consecutive term</u></a>	90 days		

**Stock-based Compensation -  
Restricted Stock Units  
(Details) - RSUs - USD (\$)  
\$ / shares in Units, shares in  
Thousands, \$ in Millions**

**12 Months Ended**

**Dec. 31,    Dec. 31,    Dec. 31,  
2020        2019        2018**

**Share-based Compensation Arrangement by Share-based Payment  
Award [Line Items]**

Requisite service period for vesting 4 years  
Vesting percentage 25.00%

**Total RSUs**

Outstanding at the beginning of the period (in shares) 1,493  
Granted (in shares) 1,202  
Forfeited / Canceled (in shares) (304)  
Vested (in shares) (654)  
Outstanding at the end of the period (in shares) 1,737    1,493

**Weighted-Average Grant-Date Fair Value**

Outstanding at the beginning of the period (in dollars per share) \$ 12.23  
Weighted-average fair value per option granted (in dollars per share) 8.88    \$ 10.66    \$ 16.12  
Forfeited (in dollars per share) 11.38  
Vested (in dollars per share) 11.11  
Outstanding at the end of the period (in dollars per share) \$ 10.13    \$ 12.23  
Aggregate intrinsic value, vested \$ 6.1    \$ 7.3    \$ 4.8

New Century Health

**Share-based Compensation Arrangement by Share-based Payment  
Award [Line Items]**

Vesting period 1 year

Non-Employee Directors

**Share-based Compensation Arrangement by Share-based Payment  
Award [Line Items]**

Vesting period 1 year

**Stock-based Compensation -  
Leveraged Stock Units  
(Details) - \$ / shares  
shares in Millions**

**12 Months Ended**

**Dec. 31,      Dec. 31,      Dec. 31,  
2020            2019            2018**

**Share-based Compensation Arrangement by Share-based Payment**

**Award [Line Items]**

<u>Expected term</u>		6 years 3 months	6 years 3 months
<u>Expected volatility</u>		51.60%	38.90%
<u>Dividend yield</u>		0.00%	0.00%

LSUs

**Share-based Compensation Arrangement by Share-based Payment**

**Award [Line Items]**

<u>Granted (in shares)</u>	0.5	0.7	
<u>Weighted-average fair value per option granted (in dollars per share)</u>	\$ 8.90	\$ 6.52	
<u>Expected term</u>	10 years	10 years	
<u>Expected volatility</u>	62.10%	51.70%	
<u>Risk-free interest rate</u>	85.00%	254.00%	
<u>Dividend yield</u>	0.00%	0.00%	

LSUs | Tranche One

**Share-based Compensation Arrangement by Share-based Payment**

**Award [Line Items]**

<u>Award vesting rights, stock price increase, percentage</u>	33.30%		
<u>Vesting percentage</u>	75.00%		

LSUs | Tranche Two

**Share-based Compensation Arrangement by Share-based Payment**

**Award [Line Items]**

<u>Award vesting rights, stock price increase, percentage</u>	50.00%		
<u>Vesting percentage</u>	100.00%		

LSUs | Tranche Three

**Share-based Compensation Arrangement by Share-based Payment**

**Award [Line Items]**

<u>Award vesting rights, stock price increase, percentage</u>	100.00%		
<u>Vesting percentage</u>	150.00%		

LSUs | Tranche Four

**Share-based Compensation Arrangement by Share-based Payment**

**Award [Line Items]**

<u>Award vesting rights, stock price increase, percentage</u>	200.00%		
<u>Vesting percentage</u>	200.00%		

**Stock-based Compensation -  
Leveraged Stock Units  
Activity (Details) - LSUs  
\$/ shares in Units, shares in  
Thousands, \$ in Thousands**

**Dec. 31, 2020  
USD (\$)  
\$/ shares  
shares**

**Outstanding as of December 31, 2020**

<u>Leveraged Stock Units (in shares)   shares</u>	1,170
<u>Weighted Average Grant Date Fair Value (in dollars per share)   \$ / shares</u>	\$ 11.10
<u>Weighted Average Remaining Contractual Term</u>	8 years 7 months 24 days
<u>Aggregate Intrinsic Value   \$</u>	\$ 5,771

**Vested and expected to vest after December 31, 2020**

<u>Leveraged Stock Units (in shares)   shares</u>	1,170
<u>Weighted Average Grant Date Fair Value (in dollars per share)   \$ / shares</u>	\$ 11.10
<u>Weighted Average Remaining Contractual Term</u>	8 years 7 months 24 days
<u>Aggregate Intrinsic Value   \$</u>	\$ 5,771

Stock-based Compensation - Performance-based RSUs (Details) \$ in Millions	1 Months Ended	12 Months Ended	Dec. 31, 2019 USD (\$)
	Aug. 31, 2019 USD (\$)	Dec. 31, 2020	2019 USD (\$)
<a href="#">Performance-based RSUs</a>			
<a href="#">Share-based Compensation Arrangement by Share-based Payment Award</a>			
<a href="#">[Line Items]</a>			
<a href="#">Vesting period</a>		18 months	
<a href="#">Authorized amount</a>			\$ 8.6
<a href="#">Incremental cost</a>	\$ 4.7		
<a href="#">Risk-neutral probability exceeds threshold   Contingent Consideration Liability   Real options approach   New Century Health   Fair Value, Recurring   Level 3</a>			
<a href="#">Share-based Compensation Arrangement by Share-based Payment Award</a>			
<a href="#">[Line Items]</a>			
<a href="#">Measurement input</a>			0.39
<a href="#">Risk-neutral probability meets earn-out cap   Contingent Consideration Liability   Real options approach   New Century Health   Fair Value, Recurring   Level 3</a>			
<a href="#">Share-based Compensation Arrangement by Share-based Payment Award</a>			
<a href="#">[Line Items]</a>			
<a href="#">Measurement input</a>			0.24



Income Taxes - Narrative (Details) - USD (\$) \$ in Thousands	12 Months Ended			
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Provision (benefit) for income taxes</u>	\$ (3,553)	\$ (21,536)	\$ 40	
<u>Income taxes receivable</u>	\$ 3,900			
<u>Taxes payable</u>		\$ 600		
<u>Effective rate</u>	1.00%	6.70%	(0.10%)	
<u>Deferred tax liabilities, indefinite-lived intangible assets</u>		\$ 1,900		
<u>Federal and state research tax credits</u>	\$ 1,828	1,828		
<u>Unrecognized tax benefits that would not impact effective tax rate</u>	700			
<u>Unrecognized tax benefits</u>	\$ 678	\$ 753	\$ 934	\$ 762
<u>Tax receivable agreement, percent of cash savings paid to shareholders</u>	85.00%			
<u>Tax receivable agreement, percent of cash savings not paid to shareholders</u>	15.00%			
<u>Periods Prior to June 2015</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Net operating loss carryforwards</u>	\$ 79,300			
<u>Federal</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Federal and state research tax credits</u>	2,400			
<u>State and Local Jurisdiction</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Federal and state research tax credits</u>	300			
<u>Finite-lived Tax Credit Carryforward   Federal</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Net operating loss carryforwards</u>	203,100			
<u>Finite-lived Tax Credit Carryforward   State and Local Jurisdiction</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Net operating loss carryforwards</u>	253,400			
<u>Indefinite-lived Tax Credit Carryforward   Federal</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Net operating loss carryforwards</u>	288,500			
<u>Indefinite-lived Tax Credit Carryforward   State and Local Jurisdiction</u>				
<b><u>Income Tax Contingency [Line Items]</u></b>				
<u>Net operating loss carryforwards</u>	\$ 153,000			

**Income Taxes - Schedule of  
Loss Before Provision for  
Income Taxes (Details) -  
USD (\$)  
\$ in Thousands**

**12 Months Ended**

**Dec. 31, Dec. 31, Dec. 31,  
2020 2019 2018**

**Income (Loss) from Continuing Operations before Equity Method  
Investments, Income Taxes, Noncontrolling Interest [Abstract]**

Domestic

\$            \$            \$  
(339,632) (328,161) (54,681)

Foreign

1,833      1,045      530

Loss before income taxes and non-controlling interests

\$            \$            \$  
(337,799) (327,116) (54,151)

**Income Taxes - Income Tax  
Expense (Benefit) (Details) -**

**12 Months Ended**

**USD (\$)**

**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**\$ in Thousands**

**Current**

<u>Federal</u>	\$ (3,338)	\$ 1,175	\$ 458
<u>State and local</u>	200	14	9
<u>Foreign</u>	721	399	251
<u>Total current tax expense (benefit)</u>	(2,417)	1,588	718

**Deferred**

<u>Federal</u>	(38,312)	(27,334)	(14,820)
<u>State and local</u>	(9,546)	(5,046)	(2,252)
<u>Foreign</u>	(303)	6	(49)
<u>Total deferred tax expense (benefit)</u>	(48,161)	(32,374)	(17,121)
<u>Change in valuation allowance</u>	47,025	9,250	16,443
<u>Total tax expense (benefit)</u>	\$ (3,553)	\$ (21,536)	\$ 40

**Income Taxes -  
Reconciliation of Statutory  
Rate to Effective Tax Rate  
(Details)**

**12 Months Ended**

**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**Income Tax Disclosure [Abstract]**

<u>U.S. statutory tax rate</u>	21.00%	21.00%	21.00%
<u>U.S. state income taxes, net of U.S. federal tax benefit</u>	2.90%	4.40%	3.60%
<u>Foreign earnings at other than U.S. rates</u>	0.00%	(0.10%)	(0.20%)
<u>Change in valuation allowance</u>	(13.90%)	(2.80%)	(30.40%)
<u>Benefit of net operating loss carryback provision</u>	0.011	0	0
<u>Non-deductible goodwill impairment</u>	(11.20%)	(15.80%)	0.00%
<u>Non-controlling interest</u>	0.00%	(0.30%)	(0.70%)
<u>Excess tax benefits on stock-based compensation</u>	(0.30%)	(0.20%)	3.90%
<u>Federal and state research tax credits</u>	0.00%	0.00%	4.50%
<u>Change in uncertain tax positions</u>	0.00%	0.10%	(1.10%)
<u>Effect of investment in MHG</u>	0.00%	(1.40%)	0.00%
<u>Change in state rate</u>	1.30%	0.00%	0.00%
<u>Change in indefinite reinvestment assertion for domestic subsidiaries</u>	1.00%	2.60%	0.00%
<u>Other, net</u>	(0.90%)	(0.80%)	(0.70%)
<u>Effective rate</u>	1.00%	6.70%	(0.10%)

**Income Taxes - Deferred Tax  
Assets and Liabilities  
(Details) - USD (\$)  
\$ in Thousands**

**Dec. 31, 2020 Dec. 31, 2019**

**Deferred Tax Assets**

<u>Start-up and organizational costs</u>	\$ 117	\$ 149
<u>Goodwill</u>	23,534	19,142
<u>Operating lease liabilities</u>	15,963	18,055
<u>Accrued expenses</u>	7,488	9,534
<u>Stock based compensation</u>	8,530	8,899
<u>Net operating loss carryforwards</u>	123,604	112,316
<u>Federal and state research tax credits</u>	1,828	1,828
<u>Fixed assets</u>	131	0
<u>Interest deduction limitation</u>	2,452	2,490
<u>Outside basis differences</u>	197	0
<u>Other</u>	8,640	1,451
<u>Subtotal</u>	192,484	173,864
<u>Valuation allowance</u>	(89,902)	(50,815)
<u>Total deferred tax assets</u>	102,582	123,049

**Deferred Tax Liabilities**

<u>Internally developed software costs</u>	12,973	14,603
<u>Intangible assets</u>	48,857	58,655
<u>Outside basis differences</u>	0	5,865
<u>Right-of-use assets - Operating</u>	13,122	16,180
<u>Contract fulfillment costs</u>	6,375	9,510
<u>Convertible debt</u>	20,411	15,732
<u>Fixed assets</u>	0	796
<u>Other</u>	1,572	3,650
<u>Total deferred tax liabilities</u>	103,310	124,991
<u>Net deferred tax assets (liabilities)</u>	\$ (728)	\$ (1,942)

**Income Taxes - Changes in  
Valuation Allowance  
(Details) - Valuation  
Allowance of Deferred Tax  
Assets - USD (\$)  
\$ in Thousands**

**12 Months Ended**

	<b>Dec. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>
<b><u>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves</u></b>			
<b><u>[Roll Forward]</u></b>			
<u>Balance at beginning-of-year</u>	\$ 50,815	\$ 37,037	\$ 53,201
<u>Charged to costs and expenses</u>	47,025	9,250	16,443
<u>Charged to other accounts</u>	(7,938)	4,528	(32,607)
<u>Balance at end-of-year</u>	89,902	50,815	37,037
<u>Valuation allowance increase (decrease) charged to additional paid-in capital</u>	\$ (7,900)	\$ 4,500	\$ (32,600)

**Income Taxes - Changes In  
Unrecognized Tax Benefits  
(Details) - USD (\$)  
\$ in Thousands**

**12 Months Ended  
Dec. 31, Dec. 31, Dec. 31,  
2020 2019 2018**

**Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to  
Examined Tax Returns [Roll Forward]**

<u>Balance at beginning-of-year</u>	\$ 753	\$ 934	\$ 762
<u>Gross increases - tax positions in prior period</u>	0	0	934
<u>Gross decreases - tax positions in prior period</u>	0	0	(762)
<u>Lapse of statute of limitations</u>	(75)	(181)	0
<u>Balance at end-of-year</u>	\$ 678	\$ 753	\$ 934

**Employee Benefit Plans**  
**(Details) - USD (\$)**  
**\$ in Millions**

**12 Months Ended**  
**Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**Retirement Benefits [Abstract]**

<u>Employer discretionary contribution amount</u>	\$ 6.4	\$ 2.6	\$ 8.6
---	--------	--------	--------



Investments In and Advances to Equity Method Investees - Additional Information (Details) - USD (\$) \$ in Thousands					3 Months Ended	12 Months Ended			
	Nov. 16, 2020	Sep. 01, 2020	May 28, 2019	May 24, 2019	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<a href="#">Schedule of Equity Method Investments [Line Items]</a>									
<a href="#">Gain (loss) from equity method investees</a>						\$ (10,039)	\$ 9,465	\$ 4,736	
<a href="#">Gain on disposal of assets</a>						(698)	9,600	0	
<a href="#">Impairment of equity method investments</a>						47,133	0	0	
<a href="#">Passport</a>									
<a href="#">Schedule of Equity Method Investments [Line Items]</a>									
<a href="#">Gain on disposal of assets</a>		\$ 5,700							
<a href="#">Passport   Variable Interest Entity</a>									
<a href="#">Schedule of Equity Method Investments [Line Items]</a>									
<a href="#">Payments to acquire interest</a>			\$ 70,000						
<a href="#">Interest in investment</a>	30.00%	30.00%	30.00%		30.00%				
<a href="#">Global Health   Variable Interest Entity</a>									
<a href="#">Schedule of Equity Method Investments [Line Items]</a>									
<a href="#">Payments to acquire interest</a>					\$ 15,000				
<a href="#">Equity method investment, ownership percentage</a>					45.00%				
<a href="#">Business acquisition, equity interest issued or issuable, number of shares (in shares)</a>					1,577,841				
<a href="#">Gain on disposal of assets</a>					\$ 9,600				
<a href="#">Contingent consideration, liability</a>					\$ 5,900				
<a href="#">Equity method investment, ownership percentage</a>					29.00%				
<a href="#">Statutory capital reserves, liquidity guaranteed by investors</a>						300.00%			
<a href="#">Equity interest to be transferred</a>						100.00%			
<a href="#">Impairment of equity method investments</a>						\$ 47,100			
<a href="#">Equity Method Investee   Services Agreements</a>									

**Schedule of Equity Method**

**Investments [Line Items]**

Income from long-term services  
agreement

\$ \$ \$  
192,800 41,500 10,700

Minimum

**Schedule of Equity Method**

**Investments [Line Items]**

Economic interest percentage

4.00% 4.00% 4.00%

Voting interest percentage

25.00% 25.00% 25.00%

Maximum

**Schedule of Equity Method**

**Investments [Line Items]**

Economic interest percentage

38.00% 38.00% 70.00%

Voting interest percentage

40.00% 40.00% 57.00%

**Investments In and  
Advances to Equity Method  
Investees - Schedule of  
Assets and Liabilities and  
Maximum Loss Exposure of  
Unconsolidated VIEs  
(Details) - USD (\$)  
\$ in Thousands**

**ASSETS**

<u>Current assets</u>	\$ 546,134	\$ 228,801
<u>Total assets</u>	1,370,185	1,498,015

**Liabilities**

<u>Current liabilities</u>	401,779	192,769
<u>Total liabilities</u>	\$ 750,585	568,968

Passport | Variable Interest Entity

**ASSETS**

<u>Current assets</u>		271,894
<u>Non-current assets</u>		577
<u>Total assets</u>		272,471

**Liabilities**

<u>Current liabilities</u>		181,206
<u>Non-current liabilities</u>		40
<u>Total liabilities</u>		181,246

**Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure**

**[Abstract]**

<u>Investment carrying value</u>		70,000
<u>Loan and interest receivable</u>		41,387
<u>Guarantee</u>		25,000
<u>Maximum exposure</u>		136,387

Global Health | Variable Interest Entity

**ASSETS**

<u>Current assets</u>		50,729
<u>Non-current assets</u>		39,259
<u>Total assets</u>		89,988

**Liabilities**

<u>Current liabilities</u>		55,442
<u>Non-current liabilities</u>		44,650
<u>Total liabilities</u>		100,092

**Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure**

**[Abstract]**

<u>Investment carrying value</u>		46,456
<u>Loan and interest receivable</u>		0
<u>Guarantee</u>		0
<u>Maximum exposure</u>		\$ 46,456

Investments In and Advances to Equity Method Investees - Summarized Financial Information (Details) - USD (\$) \$ in Thousands	3 Months Ended								12 Months Ended		
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<b>Balance Sheet Related Disclosures [Abstract]</b>											
<u>Current assets</u>	\$				\$				\$ 546,134	\$	
	546,134				228,801					228,801	
<u>Current liabilities</u>	401,779				192,769				401,779	192,769	
<u>Non-controlling interests</u>	0				6,689				0	6,689	
<b>Income Statement Related Disclosures [Abstract]</b>											
<u>Operating income (loss)</u>									270,624	306,612	\$
											47,480
<u>Net loss</u>	13,803	\$	\$	\$	199,293	\$	\$	\$	334,246	305,580	54,191
		38,170	203,521	78,752		25,738	31,900	48,649			
<u>Net income (loss) attributable to entity</u>	14,625	\$	\$	\$	198,096	\$	\$	\$	334,246	301,971	52,658
		37,348	203,521	78,752		25,521	31,615	46,739			
<b>Balance Sheet Related Disclosures [Abstract]</b>											
<u>Current assets</u>	69,218				356,085				69,218	356,085	
<u>Non-current assets</u>	3,859				43,744				3,859	43,744	
<u>Current liabilities</u>	54,885				267,300				54,885	267,300	
<u>Non-current liabilities</u>	20,693				57,599				20,693	57,599	
<u>Non-controlling interests</u>	\$ 2,671				\$				2,671	70,535	
					70,535						
<b>Income Statement Related Disclosures [Abstract]</b>											
<u>Revenue</u>									1,766,641	387,960	3,591
<u>Operating income (loss)</u>									8,112	(60,572)	(13,085)
<u>Net loss</u>									6,606	(73,685)	(13,066)
<u>Net income (loss) attributable to entity</u>									\$ 5,632	\$	\$
										(23,348)	(4,099)

Non-controlling Interests (Details) - USD (\$) shares in Thousands, \$ in Thousands	1 Months Ended					3 Months Ended					12 Months Ended													
	Nov. 16, 2020	Sep. 01, 2020	May 28, 2019	May 31, 2019	Nov. 30, 2018	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Apr. 30, 2019	Oct. 31, 2018	Oct. 01, 2018	Sep. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	May 31, 2015	
<b>Stockholders' Equity</b>																								
<b>Attributable to Noncontrolling Interest [Roll Forward]</b>																								
Non-controlling interests balance as of beginning of period									\$ 6,689				\$ 6,689											
Net loss attributable to non-controlling interests						\$ (822)	\$ 822	\$ 0	\$ 0	\$ 1,197	\$ 217	\$ 285	\$ 1,910	0	\$ 3,609	\$ 1,533								
Non-controlling interests balance as of end of period						\$ 0			6,689				0	6,689										
Passport   Variable Interest Entity																								
<b>Noncontrolling Interest [Line Items]</b>																								
Issuance of non-controlling interest		\$ 25,700																						
Interest in investment	30.00%	30.00%	30.00%			30.00%																		
Requirement to acquire ownership, consideration amount						\$ 20,000							20,000											
Gain on consolidation													5,700											
<b>Stockholders' Equity</b>																								
<b>Attributable to Noncontrolling Interest [Roll Forward]</b>																								
Issuance of non-controlling interest		\$ 25,700																						
Non-controlling Interests																								
<b>Noncontrolling Interest [Line Items]</b>																								
Issuance of non-controlling interest													25,749	6,500										
<b>Stockholders' Equity</b>																								
<b>Attributable to Noncontrolling Interest [Roll Forward]</b>																								
Non-controlling interests balance as of beginning of period									\$ 6,689			\$ 45,532	6,689	45,532										
Decrease in non-controlling interests as a result of Class B Exchanges													0	(42,377)										
Issuance of non-controlling interest													25,749	6,500										
Net loss attributable to non-controlling interests													0	(3,609)										
Disposal of assets													(6,689)	0										
Redemption of Sponsor's equity													(25,749)	0										
Reclassification of non-controlling interests													0	643	2,939									
Non-controlling interests balance as of end of period						\$ 0			\$ 6,689			\$ 0	\$ 6,689	\$ 45,532										
Class A Common Stock   Common Stock																								
<b>Noncontrolling Interest [Line Items]</b>																								
Issuance of common stock (in shares)				1,600										3,100										
Class A Common Stock   Common Stock   The Advisory Board																								
<b>Noncontrolling Interest [Line Items]</b>																								
Issuance of common stock (in shares)																1,800								
Class A Common Stock   Common Stock   TPG																								
<b>Noncontrolling Interest [Line Items]</b>																								
Issuance of common stock (in shares)					700																			
Class A Common Stock   Common Stock   Evolent Health, Selling Stockholders																								
<b>Noncontrolling Interest [Line Items]</b>																								

<a href="#">Issuance of common stock (in shares)</a>	100			1,200
<a href="#">Class B Common Stock</a>				
<a href="#">Noncontrolling Interest</a>				
<a href="#">[Line Items]</a>				
<a href="#">Income tax expense, obligations related to exchanges</a>			\$ 1,300	
<a href="#">Class B Common Stock   New Century Health</a>				
<a href="#">Noncontrolling Interest</a>				
<a href="#">[Line Items]</a>				
<a href="#">Consideration transferred, equity interests issued and issuable, shares issued (in shares)</a>				3,100
<a href="#">Class B Common Stock   Common Stock</a>				
<a href="#">Noncontrolling Interest</a>				
<a href="#">[Line Items]</a>				
<a href="#">Issuance of common stock (in shares)</a>				3,120
<a href="#">Evolent Health LLC</a>				
<a href="#">Noncontrolling Interest</a>				
<a href="#">[Line Items]</a>				
<a href="#">Parent's ownership percentage</a>	99.20%	96.10%	100.00%	100.00%
				99.10% 95.30% 95.30% 99.00% 98.90% 96.60% 70.30%

**Fair Value Measurement -  
Assets and Liabilities on  
Recurring Basis (Details) -  
USD (\$)  
\$ in Thousands**

**Dec. 31, 2020 Dec. 31, 2019**

**Liabilities**

<u>Warrants and rights outstanding (in shares)</u>	1,513,786	1,513,786
<u>Fair Value, Recurring</u>		

**Assets**

<u>Cash and cash equivalents</u>	\$ 5,877	\$ 3,698
<u>Restricted cash and restricted investments</u>		1,004
<u>Total fair value of assets measured on a recurring basis</u>	5,877	4,702

**Liabilities**

<u>Contingent consideration</u>		9,883
<u>Warrants</u>	13,730	7,092
<u>Total fair value of liabilities measured on a recurring basis</u>	13,730	16,975

Level 1 | Fair Value, Recurring

**Assets**

<u>Cash and cash equivalents</u>	5,877	3,698
<u>Restricted cash and restricted investments</u>		1,004
<u>Total fair value of assets measured on a recurring basis</u>	5,877	4,702

**Liabilities**

<u>Contingent consideration</u>		0
<u>Warrants</u>	0	0
<u>Total fair value of liabilities measured on a recurring basis</u>	0	0

Level 2 | Fair Value, Recurring

**Assets**

<u>Cash and cash equivalents</u>	0	0
<u>Restricted cash and restricted investments</u>		0
<u>Total fair value of assets measured on a recurring basis</u>	0	0

**Liabilities**

<u>Contingent consideration</u>		0
<u>Warrants</u>	0	0
<u>Total fair value of liabilities measured on a recurring basis</u>	0	0

Level 3 | Fair Value, Recurring

**Assets**

<u>Cash and cash equivalents</u>	0	0
<u>Restricted cash and restricted investments</u>		0
<u>Total fair value of assets measured on a recurring basis</u>	0	0

**Liabilities**

<u>Contingent consideration</u>		9,883
<u>Warrants</u>	13,730	7,092
<u>Total fair value of liabilities measured on a recurring basis</u>	\$ 13,730	\$ 16,975

**Fair Value Measurement -  
Additional Information  
(Details)**

**Dec. 30, 2019  
shares**

[Class A Common Stock](#)

[Business Acquisition \[Line Items\]](#)

[Warrants agreed to be sold \(in shares\)](#) 1,513,786



**Fair Value Measurement -  
Changes in Contingent  
Consideration and Other  
(Details) - USD (\$)  
\$ in Thousands**

**12 Months Ended**

**Dec. 31, Dec. 31,  
2020 2019**

**Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input  
Reconciliation, Calculation [Roll Forward]**

<u>Balance as of beginning of period</u>	\$ 16,975	\$ 8,800
<u>Additions</u>	0	12,992
<u>Settlements</u>	(3,500)	(800)
<u>Realized and unrealized gains (losses), net</u>	255	(4,017)
<u>Balance as of end of period</u>	\$ 13,730	\$ 16,975

Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) \$ in Thousands	12 Months Ended	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2018
		USD (\$)	USD (\$)	USD (\$)
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Fair value</a>		\$ 16,975	\$ 13,730	\$ 8,800
<a href="#">Fair Value, Recurring</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Warrants</a>		7,092	13,730	
<a href="#">Fair Value, Recurring   Level 3</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Warrants</a>		7,092	13,730	
<a href="#">Fair Value, Recurring   Level 3   Warrants   Black-Scholes</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Warrants</a>		\$ 7,092	\$ 13,730	
<a href="#">Fair Value, Recurring   Level 3   Warrants   Black-Scholes   Stock price volatility</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Measurement input</a>		0.550	0.622	
<a href="#">Fair Value, Recurring   Level 3   Warrants   Black-Scholes   Annual risk free rate</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Measurement input</a>		0.017	0.002	
<a href="#">Fair Value, Recurring   Passport   Level 3   Contingent Consideration Liability   Real options approach</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Fair value</a>		\$ 3,700		
<a href="#">Fair Value, Recurring   Passport   Level 3   Contingent Consideration Liability   Real options approach   Risk-adjusted recurring revenue CAGR</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Measurement input</a>		0.939		
<a href="#">Fair Value, Recurring   Passport   Level 3   Contingent Consideration Liability   Real options approach   Discount rate/time value   Minimum</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Measurement input</a>		0.048		
<a href="#">Fair Value, Recurring   Passport   Level 3   Contingent Consideration Liability   Real options approach   Discount rate/time value   Maximum</a>				
<a href="#">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</a>				
<a href="#">Measurement input</a>		0.053		

[Fair Value, Recurring | Passport | Level 3 | Contingent Consideration Liability | Real Options Approach Valuation Technique 2017-2021 | Risk-adjusted recurring revenue CAGR](#)

**[Fair Value Measurement Inputs and Valuation Techniques \[Line Items\]](#)**

[Risk-adjusted recurring revenue compound annual growth rate, number of years](#) 5 years

[Theoretical recurring revenue](#) \$ 1,000

[Fair Value, Recurring | Global Health | Level 3 | Contingent Consideration Liability | Monte Carlo simulation | Stock price volatility](#)

**[Fair Value Measurement Inputs and Valuation Techniques \[Line Items\]](#)**

[Fair value](#) \$ 5,200

[Measurement input](#) 0.800

[Fair Value, Recurring | Other Transactions | Level 3 | Contingent Consideration Liability | Management estimate | Adjusted EBITDA](#)

**[Fair Value Measurement Inputs and Valuation Techniques \[Line Items\]](#)**

[Fair value](#) \$ 983

[Measurement input](#) 19,235,000

**Related Parties - Assets and  
Liabilities (Details) - USD (\$)  
\$ in Thousands**

	Dec. 31, 2020	Dec. 31, 2019
<b><u>ASSETS</u></b>		
<u>Accounts receivable, net</u>	[1] \$ 125,986	\$ 75,667
<u>Prepaid expenses and other current assets</u>	[1] 61,034	28,488
<u>Prepaid expenses and other noncurrent assets, net of allowances</u>	[1] 5,832	6,253
<b><u>Liabilities</u></b>		
<u>Accounts payable</u>	[1] 32,068	37,488
<u>Accrued liabilities</u>	[1] 84,507	33,343
<u>Affiliated Entity</u>		
<b><u>ASSETS</u></b>		
<u>Accounts receivable, net</u>	9,474	8,781
<u>Prepaid expenses and other current assets</u>	51	1,592
<u>Customer advance for regulatory capital requirements, net of allowances</u>	0	40,000
<u>Prepaid expenses and other noncurrent assets, net of allowances</u>	4,554	2,709
<b><u>Liabilities</u></b>		
<u>Accounts payable</u>	2,509	6,429
<u>Accrued liabilities</u>	1,520	2,583
<u>Reserve for claims and performance-based arrangements</u>	\$ 435	\$ 4,264

[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

Related Parties - Revenues and Expenses (Details) - USD (\$) \$ in Thousands	3 Months Ended								12 Months Ended		
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<b>Revenue</b>											
<u>Total revenue</u>	\$ 271,923	\$ 264,593	\$ 238,632	\$ 247,285	\$ 236,525	\$ 220,143	\$ 191,959	\$ 197,756	\$ 1,022,433	\$ 846,383	\$ 627,063
<b>Expenses</b>											
<u>Cost of revenue (exclusive of depreciation and amortization expenses)</u>									701,373	[1] 513,059	[1] 327,825
<u>Selling, general and administrative expenses</u>									222,600	[1] 257,046	[1] 235,418
<u>Affiliated Entity</u>											
<b>Expenses</b>											
<u>Cost of revenue (exclusive of depreciation and amortization expenses)</u>									2,863	28,954	9,451
<u>Selling, general and administrative expenses</u>									113	991	917
<u>Transformation services</u>											
<b>Revenue</b>											
<u>Total revenue</u>	[1]								11,990	15,203	32,916
<u>Transformation services  </u>											
<u>Affiliated Entity</u>											
<b>Revenue</b>											
<u>Total revenue</u>									5,416	4,009	10,540
<u>Platform and operations services</u>											
<b>Revenue</b>											
<u>Total revenue</u>	[1]								893,066	659,438	500,190
<u>Platform and operations services  </u>											
<u>Affiliated Entity</u>											
<b>Revenue</b>											
<u>Total revenue</u>									\$ 226,339	\$ 60,325	\$ 37,490

[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

**Repositioning and Other  
Changes (Details) - USD (\$)  
\$ in Thousands**

**12 Months Ended  
Dec. 31, 2020 Dec. 31, 2019 Dec. 31, 2018**

**Restructuring Cost and Reserve [Line Items]**

<u>Incurred For the Year Ended December 31, 2020</u>	\$ 1,275	\$ 0	\$ 0
<u>Total Amount Expected to be Incurred in the Repositioning Plan</u>	8,800		
<u>Cumulative Amount Incurred through December 31, 2020</u>	1,275		

Severance and termination benefits

**Restructuring Cost and Reserve [Line Items]**

<u>Incurred For the Year Ended December 31, 2020</u>	0		
<u>Total Amount Expected to be Incurred in the Repositioning Plan</u>	2,500		
<u>Cumulative Amount Incurred through December 31, 2020</u>	0		

Office space consolidation

**Restructuring Cost and Reserve [Line Items]**

<u>Incurred For the Year Ended December 31, 2020</u>	0		
<u>Total Amount Expected to be Incurred in the Repositioning Plan</u>	2,100		
<u>Cumulative Amount Incurred through December 31, 2020</u>	0		

Professional services

**Restructuring Cost and Reserve [Line Items]**

<u>Incurred For the Year Ended December 31, 2020</u>	1,275		
<u>Total Amount Expected to be Incurred in the Repositioning Plan</u>	4,200		
<u>Cumulative Amount Incurred through December 31, 2020</u>	\$ 1,275		

**Segment Reporting -  
Additional Information  
(Details)**

**12 Months Ended  
Dec. 31, 2020  
segment**

[Segment Reporting \[Abstract\]](#)

[Number of operating segments](#) 2

Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ( \$) \$ in Thousands	3 Months Ended								12 Months Ended		
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>	\$ 271,923	\$ 264,593	\$ 238,632	\$ 247,285	\$ 236,525	\$ 220,143	\$ 191,959	\$ 197,756	\$ 1,022,433	\$ 846,383	\$ 627,063
<a href="#">Adjusted EBITDA</a>									41,436	(10,968)	23,225
<a href="#">Operating segments   Services</a>											
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>									924,995	687,122	547,431
<a href="#">Adjusted EBITDA</a>									48,573	(14,667)	21,310
<a href="#">Operating segments   True Health</a>											
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>									117,579	172,722	94,763
<a href="#">Adjusted EBITDA</a>									(7,137)	3,699	1,915
<a href="#">Intersegment eliminations</a>											
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>									(20,141)	(13,461)	(15,131)
<a href="#">Adjusted EBITDA</a>									41,436	(10,968)	23,225
<a href="#">Transformation services</a>											
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>									11,990	15,203	32,916
<a href="#">Transformation services   Services</a>											
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>									11,990	15,203	32,916
<a href="#">Transformation services   Operating segments   Services</a>											
<a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a>											
<a href="#">Revenues</a>									11,990	15,203	32,916

[1]



<a href="#">Transformation services   Operating segments   True Health</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		0	0	0
<a href="#">Transformation services   Intersegment eliminations</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		0	0	0
<a href="#">Platform and operations services</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>	[1]	893,066	659,438	500,190
<a href="#">Platform and operations services   Operating segments   Services</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		913,005	671,919	514,515
<a href="#">Platform and operations services   Operating segments   True Health</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		0	0	0
<a href="#">Platform and operations services   Intersegment eliminations</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		(19,939)	(12,481)	(14,325)
<a href="#">Services revenue</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		905,056	674,641	533,106
<a href="#">Services revenue   Operating segments   Services</a>				
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>				
<a href="#">Revenues</a>		924,995	687,122	547,431

<a href="#">Services revenue   Operating segments   True Health</a>			
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>			
<a href="#">Revenues</a>	0	0	0
<a href="#">Services revenue   Intersegment eliminations</a>			
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>			
<a href="#">Revenues</a>	(19,939)	(12,481)	(14,325)
<a href="#">Premiums</a>			
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>			
<a href="#">Revenues</a>	117,377	171,742	93,957
<a href="#">Premiums   Operating segments   Services</a>			
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>			
<a href="#">Revenues</a>	0	0	0
<a href="#">Premiums   Operating segments   True Health</a>			
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>			
<a href="#">Revenues</a>	117,579	172,722	94,763
<a href="#">Premiums   Intersegment eliminations</a>			
<b><a href="#">Segment Reporting, Revenue Reconciling Item [Line Items]</a></b>			
<a href="#">Revenues</a>	\$ (202)	\$ (980)	\$ (806)

[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.

Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD (\$)	3 Months Ended							6 Months Ended	12 Months Ended			
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<b>Segment Reporting</b>												
<b>[Abstract]</b>												
Net loss attributable to common shareholders of Evolent Health, Inc.	\$ (14,625,000)	\$ (37,348,000)	\$ (203,521,000)	\$ (78,752,000)	\$ (198,096,000)	\$ (25,521,000)	\$ (31,615,000)	\$ (46,739,000)	\$ (334,246,000)	\$ (301,971,000)	\$ (52,658,000)	
Interest income									3,164,000	3,987,000	3,440,000	
Interest expense									(28,337,000)	(14,534,000)	(5,484,000)	
(Provision) benefit for income taxes									3,553,000	21,536,000	(40,000)	
Depreciation and amortization expenses									(61,475,000)	(60,913,000)	(44,515,000)	
Impairment of equity method investments									(47,133,000)	0	0	
Loss on extinguishment of debt, net									(4,789,000)	0	0	
Gain (loss) from equity method investees									10,039,000	(9,465,000)	(4,736,000)	
Gain (loss) on disposal of assets and consolidation									(698,000)	9,600,000	0	
Goodwill impairment	(199,800,000)		(215,100,000)	0	(199,800,000)				\$ (215,100,000)	(215,100,000)	(199,800,000)	0
Change in fair value of contingent consideration and indemnification asset									(3,860,000)	3,997,000	4,104,000	
Other income (expense), net									(119,000)	(492,000)	109,000	
Net loss attributable to non- controlling interests	\$ (822,000)	\$ 822,000	\$ 0	\$ 0	\$ 1,197,000	\$ 217,000	\$ 285,000	\$ 1,910,000	0	3,609,000	1,533,000	
ASC 606 transition adjustments									0	0	(4,498,000)	
Purchase accounting adjustments									0	(1,915,000)	(861,000)	
Repositioning costs									(1,275,000)	0	0	
Stock-based compensation expense									(14,606,000)	(15,618,000)	(17,609,000)	
Severance costs									(8,986,000)	(17,350,000)	(2,205,000)	
Amortization of contract cost assets									(3,944,000)	(2,876,000)	(2,456,000)	
Acquisition costs									(2,116,000)	(10,769,000)	(2,665,000)	
Adjusted EBITDA									\$ 41,436,000	\$ (10,968,000)	\$ 23,225,000	

**Reserves for Claims and  
Performance-Based  
Arrangements (Details)  
\$ in Thousands**

**12 Months Ended**  
**Dec. 31, Dec. 31,**  
**2020 2019**  
**USD (\$) USD (\$)**  
**claim claim**

**Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]**

<u>Beginning balance</u>	\$ 61,150	\$ 27,595
<u>Incurred costs related to current year</u>	509,605	403,367
<u>Incurred costs related to prior year</u>	3,677	(863)
<u>Paid costs related to current year</u>	544,211	281,671
<u>Paid costs related to prior year</u>	16,547	16,257
<u>Change during the year</u>	(47,476)	104,576
<u>Impact of consolidation on reserves for claims and performance-based arrangements</u>	164,297	0
<u>Other adjustments</u>	10,714	(71,021)
<u>Ending balance</u>	188,685	61,150

Services

**Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]**

<u>Beginning balance</u>	54,510	17,715
<u>Incurred costs related to current year</u>	420,597	267,064
<u>Incurred costs related to prior year</u>	2,878	(334)
<u>Paid costs related to current year</u>	464,571	220,050
<u>Paid costs related to prior year</u>	9,598	8,165
<u>Change during the year</u>	(50,694)	38,515
<u>Impact of consolidation on reserves for claims and performance-based arrangements</u>	164,297	0
<u>Other adjustments</u>	10,714	(1,720)
<u>Ending balance</u>	178,827	54,510

True Health

**Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]**

<u>Beginning balance</u>	6,640	9,880
<u>Incurred costs related to current year</u>	89,008	136,303
<u>Incurred costs related to prior year</u>	799	(529)
<u>Paid costs related to current year</u>	79,640	61,621
<u>Paid costs related to prior year</u>	6,949	8,092
<u>Change during the year</u>	3,218	66,061
<u>Impact of consolidation on reserves for claims and performance-based arrangements</u>	0	0
<u>Other adjustments</u>	0	(69,301)
<u>Ending balance</u>	\$ 9,858	\$ 6,640
<u>Number of claims processed, including denied claims   claim</u>	2,279,228	317,187

**Investments - Investment  
Summary (Details) - Level 2  
- USD (\$)  
\$ in Thousands**

**Dec. 31, 2020 Dec. 31, 2019**

**Schedule of Held-to-maturity Securities [Line Items]**

<u>Amortized Costs</u>	\$ 14,777	\$ 18,558
<u>Gross Unrealized Gains</u>	714	426
<u>Gross Unrealized Losses</u>	0	(5)
<u>Fair Value</u>	15,491	18,979

U.S. Treasury bills

**Schedule of Held-to-maturity Securities [Line Items]**

<u>Amortized Costs</u>	8,909	10,784
<u>Gross Unrealized Gains</u>	384	270
<u>Gross Unrealized Losses</u>	0	0
<u>Fair Value</u>	9,293	11,054

Corporate bonds

**Schedule of Held-to-maturity Securities [Line Items]**

<u>Amortized Costs</u>	1,707	1,705
<u>Gross Unrealized Gains</u>	132	70
<u>Gross Unrealized Losses</u>	0	0
<u>Fair Value</u>	1,839	1,775

Collateralized mortgage obligations

**Schedule of Held-to-maturity Securities [Line Items]**

<u>Amortized Costs</u>	3,433	5,472
<u>Gross Unrealized Gains</u>	149	56
<u>Gross Unrealized Losses</u>	0	(5)
<u>Fair Value</u>	3,582	5,523

Corporate stock

**Schedule of Held-to-maturity Securities [Line Items]**

<u>Amortized Costs</u>	130	0
<u>Gross Unrealized Gains</u>	0	0
<u>Gross Unrealized Losses</u>	0	0
<u>Fair Value</u>	130	0

Yankees

**Schedule of Held-to-maturity Securities [Line Items]**

<u>Amortized Costs</u>	598	597
<u>Gross Unrealized Gains</u>	49	30
<u>Gross Unrealized Losses</u>	0	0
<u>Fair Value</u>	\$ 647	\$ 627

**Investments - Contractual**  
**Maturity (Details) - USD (\$)**      **Dec. 31, 2020** **Dec. 31, 2019**  
**\$ in Thousands**

**Amortized Cost**

<u>Due in one year or less</u>	\$ 3,858	\$ 1,807
<u>Due after one year through five years</u>	10,919	16,121
<u>Due after five years through ten years</u>	0	630
<u>Total investments</u>	14,777	18,558

**Fair Value**

<u>Due in one year or less</u>	3,915	1,810
<u>Due after one year through five years</u>	11,576	16,542
<u>Due after five years through ten years</u>	0	627
<u>Total investments</u>	\$ 15,491	\$ 18,979

Quarterly Results of Operations (unaudited) (Details) - USD (\$) \$ / shares in Units, \$ in Thousands	3 Months Ended							12 Months Ended			
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
<a href="#">Quarterly Financial Data</a> <a href="#">[Abstract]</a>											
<a href="#">Total revenue</a>	\$ 271,923	\$ 264,593	\$ 238,632	\$ 247,285	\$ 236,525	\$ 220,143	\$ 191,959	\$ 197,756	\$ 1,022,433	\$ 846,383	\$ 627,063
<a href="#">Total operating expenses</a>	276,659	277,512	466,101	272,785	451,120	240,281	217,192	244,402	1,293,057	1,152,995	674,543
<a href="#">Net loss</a>	(13,803)	(38,170)	(203,521)	(78,752)	(199,293)	(25,738)	(31,900)	(48,649)	(334,246)	(305,580)	(54,191)
<a href="#">Net loss attributable to non-controlling interests</a>	822	(822)	0	0	(1,197)	(217)	(285)	(1,910)	0	(3,609)	(1,533)
<a href="#">Net loss attributable to common shareholders of Evolent Health, Inc.</a>	\$ (14,625)	\$ (37,348)	\$ (203,521)	\$ (78,752)	\$ (198,096)	\$ (25,521)	\$ (31,615)	\$ (46,739)	\$ (334,246)	\$ (301,971)	\$ (52,658)
<a href="#">Loss per common share</a>											
<a href="#">Basic and diluted (in dollars per share)</a>	\$ (0.17)	\$ (0.44)	\$ (2.38)	\$ (0.93)	\$ (2.360)	\$ (300)	\$ (380)	\$ (590)	\$ (3.94)	\$ (3.67)	\$ (0.68)

**Quarterly Results of Operations (unaudited) - Additional Information (Details) - USD (\$)**

	3 Months Ended			6 Months Ended		12 Months Ended		
	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018

[Quarterly Financial Data](#)

[\[Abstract\]](#)

[Impairment](#)

\$	\$	\$ 0	\$	\$	\$	\$	\$ 0
199,800,000	215,100,000		199,800,000	215,100,000	215,100,000	199,800,000	



**Supplemental Cash Flow  
Information (Details) - USD  
(\$)  
\$ in Thousands**

**12 Months Ended**

	<b>Dec. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>
<b><u>Supplemental Disclosure of Non-cash Investing and Financing Activities</u></b>			
<u>Class A and Class B common stock issued in connection with business combinations</u>	\$ 0	\$ 23,556	\$ 83,173
<u>Change in goodwill from measurement period adjustments/business combinations</u>	2,200	(351)	(117)
<u>Acquisition consideration payable</u>	4,185	800	0
<u>Settlement of escrow related to asset acquisition</u>	0	0	2,519
<u>Settlement of indemnification asset</u>	0	0	1,004
<u>Accrued property and equipment purchases</u>		(527)	
<u>Accrued property and equipment purchases</u>	11		368
<u>Accrued deferred financing costs</u>	0	0	607
<u>Consideration for asset acquisitions or business combinations</u>	0	16,000	500
<b><u>Effects of Leases</u></b>			
<u>Operating cash flows from operating leases</u>	13,708	12,330	
<u>Leased assets obtained in exchange for operating lease liabilities</u>	(2,170)		
<u>Leased assets obtained in exchange for operating lease liabilities</u>		30,463	
<b><u>Effects of Class B Exchanges</u></b>			
<u>Decrease in non-controlling interests as a result of Class B Exchanges</u>	0	42,377	34,682
<u>Stock Issued, Decrease In Deferred Tax Liability</u>	0	(22)	652
<b><u>Supplemental Disclosures</u></b>			
<u>Cash paid for interest</u>	13,352	5,037	2,500
<u>Cash paid for taxes, net</u>	\$ 9,679	\$ 1,484	\$ 343

Subsequent Events (Details) \$ in Thousands	3 Months Ended			12 Months Ended		
	Jan. 11, 2021 USD (\$)	Jan. 08, 2021 USD (\$)	Mar. 31, 2021 segment	Dec. 31, 2020 USD (\$)	Dec. 31, 2019 USD (\$)	Dec. 31, 2018 USD (\$)
<a href="#">Subsequent Event [Line Items]</a> <a href="#">Cash paid for interest</a>				\$ 13,352	\$ 5,037	\$ 2,500
<a href="#">Subsequent event   True Health Stock Purchase Agreement   Bright HealthCare</a>						
<a href="#">Subsequent Event [Line Items]</a> <a href="#">Purchase price</a>	\$ 22,000					
<a href="#">Subsequent event   Credit Agreement</a>						
<a href="#">Subsequent Event [Line Items]</a> <a href="#">Repayments of long-term lines of credit</a>				\$ 98,600		
<a href="#">Payments of make-whole premium</a>				9,700		
<a href="#">Cash paid for interest</a>				200		
<a href="#">Subsequent event   Credit Agreement   Class A Common Stock</a>						
<a href="#">Subsequent Event [Line Items]</a> <a href="#">Payments to settle outstanding warrants</a>				\$ 13,700		
<a href="#">Subsequent event   Forecast   Services</a>						
<a href="#">Subsequent Event [Line Items]</a> <a href="#">Number of reportable segments   segment</a>			2			

{ " } " }

... ..